tag:blogger.com,1999:blog-72945409444502393322024-03-05T11:48:23.605-08:00potter love milanluphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.comBlogger25125tag:blogger.com,1999:blog-7294540944450239332.post-45782656395739994822018-10-27T18:42:00.001-07:002018-10-27T18:43:08.280-07:00Kesan Pesan Mengikuti UKMPPD Batch 3 2018 (1)Hoollaaa... so here i am.. few months after CBT UKMMPD....<br />
oke, jadi sebelum mulai dengan kesan pesan after UKMPPD, saya akan menceritakan sedikit tentang apa itu UKMPPD.<br />
jadi, UKMPPD kepanjangannya adalah Ujian Kompetensi Mahasiswa Program Profesi Dokter. Dulunya UMPPD ini dikenal dengan UKDI (Ujian Kompetensi Dokter Indonesia). UKMPPD diselenggarakan oleh Kemenristekdikti sedangkan UKDI diselenggarkan oleh kolegium. Nah dari sini saja kelihatan kan bedanya? UKDI merupakan ujian kompetensi dokter sedangkan UKMPPD merupakan ujian kompetensi mahasiswa. Nah, sebelum lulus UKMPPD, ijazah kita tidak akan diberikan oleh kampus jadi bisa dibilang UKMPPD ini adalah exit exam nya mahasiswa program profesi dokter. Ini lah salah satu penyebab masih banyak mahasiswa program profesi dokter yang nasibnya jadi luntang lantung karena belum lulus UKMPPD ini. Bila tidak lulus UKMPPD, mereka masih berstatus mahasiswa dan masih harus membayar untuk bisa dihitung sebagai mahasiswa. Jujur saya gak tahu tentang kampus lain, tapi sebelum dinyatakan boleh mengikuti UKMPPD, ada yang namanya yudisium. Di yudisium ini lah kita ditentukan lulus atau tidak setelah melewati sekian banyak stase koass. jadi kalau sudah lulus yudisium berarti harusnya sudah lulus jadi dokter dong? nah ternyata belum, jadi harus tetap mengikuti UKMPPD ini biar bisa benar-benar lulus menjadi dokter. jadi tidak seperti Progam pendidikan kedokteran yang setelah lulus yudisium berarti udah sah mendapat gelar S.Ked. Panjang ya jalannya? iya, super panjang, tapi harus tetap dijalani.hehehehhhe<br />
<br />
Jeda dari Ujian UKMPPD tiap batch adalah 3 bulan. Mungkin buat beberapa orang tiga bulan ini bukan waktu yang lama. tapi untuk kita yang udah 6 tahun menjalani pendidikan rasanya tiap menunggu tiga bulan itu sesuatu.hahahhahaha<br />
<br />
okeh, di bawah ini beberapa sumber yang saya jadikan acuan menulis postingan kali ini: :)<br />
http://aktivasi.pnukmppd.dikti.go.id/<br />
file:///C:/Users/Userr/Downloads/SE%20Registrasi%20UKMPPD%20Periode%20Mei%202018.pdf<br />
https://tirto.id/gagal-paham-uji-kompetensi-dokter-cNaSluphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-65497483408750323262018-04-07T09:14:00.002-07:002018-04-07T09:16:41.939-07:00Friendship<br />
<div style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em; text-align: center;">
<img alt="Gambar terkait" height="223" src="https://media.giphy.com/media/ytyetVRJFT5sI/giphy.gif" width="400" /></div>
<br />
<div style="text-align: justify;">
Okeh, jadi postingan kali ini sebenarnya mau menceritakan masih hal yang sama, tentang kegalauan yang kemarin. Kegalauan karena tidak lulus.hahahhahah *iyeee, kelihatan sekali susah move on XD*</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Singkat cerita, dua hari lalu salah satu sahabat baiknya saya, let's call her "S" berulang tahun. Nah saya sama si S ini bisa dibilang model sahabatan yang sudah tinggal beda pulau, yang jarang berhubungan tapi sekali chating bisa lama terus nyambung, dan bisa otak kami itu connect,hahahha *oke, sekarang jadi tambah kangen đ*</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Nah terus ceritakan tentang kemaren tak lulus, terus ada fase dimana protes ke Tuhan sama Bunda Maria juga.. adihhh, langsung dinasihatin sama si S, katanya kemaren itu bunda lagi dalam proses berkabung, jadi mungkin terlalu fokus memikirkan Putranya, jangan ditambah dengan kedogeannya saya, kan kasihan... Tiba-tiba berasa jlebb.. Iya, jadi berasa jahat. Tapi ya ini hati memang sekeras batu, masih doge juga..hahahahaha setengah hati menyesal sudah marah-marah, setengah hati lagi masih keras kepala, jadi begitu deh, meskipun masih doge tapi agak melunak juga. Yah setelah dipikir-pikir setelah ngobrol sama si S, jadi berasa dia jadi lebih dewasa. iya si S sudah jadi lebih dewasa.hahahhahah đ€</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<img alt="Hasil gambar untuk sahabat quotes" height="228" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjl4A7mFfKmeKTG0V-e_8LlHOvEqfU7HPBEZCVQZzTO9SLd_BWvvmoznSPtmyvMPUVjZz6tDhKCBmn9YpIgcNMRKugjAhj8NrKVgaHoksuJToBLpEmBvHjt61f1TLZ7YueEe4WzrQ_Gd5I/s320/Screenshot_1.jpg" width="320" /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Oh iya selain membicarakan tentang itu, kita juga membicarakan tentang nikah. Iya, nikah. hahahhahaa, topik yang dulu kalau ngomong isinya lebih banyak imajinasi. Terus entah kenapa jadi bahas beginian, bahas kerjaan (okeh, baru dia yang kerja, sedangkan saya masih menapaki jalan menuju ke sana, wkwkwkkwkwk), bahas liburan (sekarang kita lagi butuh liburan sangat -,-"), dan ternyata setelah disadari, kita tahun depan sudah 1/4 abad, makin tua...hahahhaha</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: center;">
<img alt="Hasil gambar untuk labuan bajo" height="298" src="https://s3-ap-southeast-1.amazonaws.com/traveloka/imageResource/2017/12/07/1512631144617-03ad46f743f6c4b6ba8b325395ba9a32.jpeg" width="400" /></div>
<div style="text-align: center;">
<span style="font-size: x-small;">ini calon tempat liburan nanti ^^ </span><span style="text-align: justify;">đ</span></div>
<div style="text-align: center;">
<span style="font-size: x-small;">hayoo tebak di mana..hahahhaha</span></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Oke, dan inilah akhir dari postingan hari ini. Kurang berfaedah, tapi ya setidaknya ada pesan yang bisa dipetik:</div>
<div style="text-align: justify;">
1. Sahabat itu tidak selalu harus mereka yang ada dekatmu. Tapi juga mereka yang akan selalu bisa terhubung denganmu entah bagaimana caranya itu đ</div>
<div style="text-align: justify;">
2. Jangan terlalu fokus sama dirimu sendiri, karena saking fokus sama kesedihanmu bisa jadi kamu tidak bisa melihat ada orang lain yang juga lagi kesusahan đđđ</div>
<div style="text-align: justify;">
3. Kamu memang butuh waktu, tapi jangan lupa waktu juga terus berjalan, jadi jangan sia2kan waktumu. (Nah kalau ada waktu liburan, liburan lah đđ)</div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-7895550770883148102018-04-04T03:45:00.001-07:002018-08-16T01:59:14.888-07:00Gagal Ujian - Tidak Lulus Yudisium - Koas - Kuliah kedokteran - Krisis Kepercayaan<div style="text-align: justify;">
<span style="font-size: small;">Oke, jadi hari ini ceritanya adalah hari yudisium dan hasilnya adalah jreng jreng jreng, tidak lulus. Seperti yang sudah diduga sebelumnya. Yah, meskipun sudah diduga dan udah dikasih tahu sama mas-mas TU kalau jadi salah satu yang tidak lulus tapi tetap berharap ada keajaiban, tapi karena tidak ada keajaiban maka berakhir dengan kecewa dan sedih luar biasa. Kenapa luar biasa? karena hasil ini sukses bikin saya nangis sampai ini mata bengkak. Yeah, the last time mata bengkak karena menangis itu adalah 5 tahun lalu waktu mama harus balik ke Maumere.</span></div>
<div style="text-align: justify;">
<span style="font-size: small;"><br /></span></div>
<div style="text-align: justify;">
<span style="font-size: small;">Rasanya benar-benar down, kecewa, malu, sedih, marah, semua campur aduk jadi satu. Dan entah kenapa meskipun sudah disuruh jangan keluar, tapi ini air mata tetap keluar. Jadi ya begitulah, benar-benar sudah nangis dari sejak sebelum itu kertas dibuka (kertasnya disteples sebelumnya) sampai setelah kertas dibuka. Setelah lihat yang her apa saja jadi malah makin nangis. Satunya sih sesuai perkiraan, tapi tidak menyangka setengah koass. Yang satu lagi tidak sesuai perkiraan, tapi setelah diingat-ingat yah mungkin saja karena salah satu penguji terkenal banyak tidak meluluskan koass (yah atau mungkin memang sayanya yang bego...)</span></div>
<div style="text-align: justify;">
<span style="font-size: small;"><br /></span></div>
<div style="text-align: justify;">
<span style="font-size: small;">Kecewa? iya, sangat. Dari tadi nangis karena saking kecewanya. Bahkan langsung sms mama biar jangan telepon karena pasti tambah nangis. Rasanya malu, ke diri sendiri, ke teman-teman yang lulus, ke orang tua terutama. Iya, merasa sangat mengecewakan mereka. Mereka yang sudah berharap banyak, berdoa banyak, keluarkan biaya banyak, rindu mau ketemu mereka punya anak yang satu ini, tapi anaknya malah tidak lulus, buat kuliah tambah lama, buat mereka harus bayar uang her yang juga tidak sedikit. Bayangkan rasanya. Mengenai uang her, lumayan besar, bukan lumayan tapi memang besar apalagi untuk saya yang orang tua cuma PNS daerah (oke, ini harus tetap disyukuri, setidaknya dari pekerjaan ini bapak dan mama masih bisa membiayai hidup anaknya yang sering bikin repot ini). Bahkan teman-teman yang kebanyakan orang tuanya pengusaha pun bilang kalau biaya her ini mahal. terus kalau mereka saja merasa mahal apalagi saya. Rasanya down luar biasa. Tidak mau her, tidak mau lagi mengulang masa-masa koas. Tidak mau waktunya banyak terbuang juga, tidak mau duitnya terbuang juga. Yah terus nanti pasti dijawab makanya belajar baik-baik biar jangan her. Hahahhaha, iya, harusnya waktu ujian tidak usah tidur dari 3 hari sebelum ujian, biar pas ujian sekalian collapse. Kadang bahkan tidak tahu kenapa her, kenapa lulus. ada yang dirasa ujiannya bisa tapi tidak lulus, ada yang dirasa ujiannya tidak bisa tapi malah lulus. Untuk kasusnya saya yang menurut saya ujiannya bisa, malah tidak lulus. Dan itu adalah salah satu faktor kenapa super kecewa.</span></div>
<div style="text-align: justify;">
<span style="font-size: small;"><br /></span></div>
<div style="text-align: justify;">
<span style="font-size: small;">Salah satu yang juga bikin sedih adalah karena saya banyak berharap dengan keajaiban. iya, keajaiban yang bantu saya untuk lulus bedah, yang benar-benar awalnya bikin takut tidak lulus, justru akhirnya lulus. Yah, saya berdoa, dan saya minta semua orang yang saya kenal untuk berdoa, saya minta mama untuk novena, tapi yah tetap ini hasilnya, dan saya benar-benar berharap dengan keajaiban Tuhan yang ini. Saya bahkan minta kelulusan ini sebagai hadiah natal dan ulang tahun dari Tuhan. tapi ya begitu lah, tidak ada, tidak lulus. Rasanya kecewa, saking kecewa terus langsung sms mama untuk stop praying, God won't listen. stop buat baik, no one care, even God. Iya mama selalu bilang bahwa Tuhan juga melihat usaha kita, Tuhan juga lihat bahwa kita banyak berbuat baik, Tuhan pasti membantu. So yeah, my conclusion is my mother was wrong. Atau mungkin saya yang kurang baik, kurang banyak berdoa, harus benar-benar hidup selibat mungkin. yang pasti saya benar-benar kecewa. Dan mungkin saya bisa menjadi atheis karena ini.hahahhahahha.. oke, kedengarannya gila. tapi iya, ini titik di mana bisa dibilang adalah krisis kepercayaan saya. Titik dimana saya pikir sebanyak apapun saya berdoa tapi tetap mereka yang menentukan. This is what i feel right now. tak tau nanti. </span></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<span style="font-size: small;">Sebanyak apa belajar, sebanyak apa berusaha, yang dilihat cuma ketika ujian akhir. Attitude hanya menentukan apakah masih ada kemungkinan lulus atau tidak. Kalau attitude jelek yah pasti tidak lulus. tapi yah selama attitude jeleknya tertutupi yah tetap bisa lulus. Pas tau harus her rasanya benar-benar campur aduk, tapi tetap semuanya adalah negative feelings. Tak kepikiran yang lain. Cuma bisa menangis. Iya, nangis dari tadi pulang kampus ada 2 jam, terus diam sendiri, habis itu buka hp, beberapa teman berusaha menyemangati, makin sedih, jadi nangis lagi. ya gimana mata tak bengkak. Beberapa teman itu juga her, dan mereka masih bisa menyemangati saya. dan di sini saya merasa sangat egois, tapi ya tetap tidak bisa menghilangkan rasa sedih karena tidak lulus. Apalagi karena merasa yang tidak lulus itu harusnya bisa lulus. pas ditanya memangnya kenapa kira-kira bisa tidak lulus. sejujurnya saya pun tak tahu. karena kebanyakan setiap kali habis ujian itu kayak masuk labirin keluarnya tetap pusing, tidak dikasih jawaban, entah salah atau benar. </span></div>
<div style="text-align: justify;">
<span style="font-size: small;"><br /></span></div>
<div style="text-align: justify;">
<span style="font-size: small;">Memikirkan harus mengulang her itu sesuatu, bahkan salah satu stase yang tidak lulus adalah setengah koass, berarti kembali jaga malam. Rasanya itu sesuatu, sesuatu yang mungkin teman-teman lain juga tau rasanya. Kata salah satu teman yang sudah melewati her, "her itu tidak seburuk itu kok setelah dilewati", iya, tapi saat ini saya rasa itu adalah yang terburuk. Her yang berarti makin telat ikut UKMPPD, lulus makin lama, dan harus bayar lagi. seperti yang tadi saya bilang, her itu mahal. Uang tidak dipetik dari pohon. dan tidak semua mahasiswa orangtuanya pengusaha atau dokter dengan penghasilan 20juta/bulan atau lebih. Rasanya kasih kabar jelek plus minta duit tambahan untuk her itu bikin sesak sendiri, iya, itu yang saya rasa.</span></div>
<div style="text-align: justify;">
<span style="font-size: small;"><br /></span></div>
<div style="text-align: justify;">
<span style="font-size: small;">Akhirnya setelah mati-matian saya tidak mau ditelepon, mama akhirnya telepon juga, mau tak mau tetap diangkat, sesuai dugaan nangis lagi. rasanya menyedihkan. tapi justru bapa dan mama yang menguatkan. Punya orang tua seoptimis ini, anaknya malah nangis-nangis gak karuan, berantakin kamar gak jelas, gambar2 dicabut semua. Iya, i feel so useless. Sedih, kecewa, merasa sangat buruk. Tapi dengan tenang nya bapa dan mama menenangkan, dan mungkin karena mama juga sudah berpengalaman jadi pengajar, mama tetap berusaha membesarkan hati saya. Suruh keluar, jalan-jalan, makan, karena meskipun tanpa dikasih tahu, pasti mereka tahu anaknya yang satu ini seharian cuma nangis di kamar gelap-gelapan. Iya, because i feel so stressed. </span></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<span style="font-size: small;">My parents is my strength. They are the reason why i didn.t end my life eventhought that thought came and came again today. Iya, habis nangis berjam-jam, terus merasa useless, ingin mengakhiri hidup, tapi pengen ngasih sesuatu dulu ke orang tua, gak mau mati sia-sia, akhirnya nyari cara buat jual ginjal, ternyata gak nemu di internet dan sepertinya terlalu beresiko, bukan mati malah masuk penjara. tapi tetap sedih, akhirnya browsing cara buat suicide tapi ternyata suicide benar-benar harus pakai niat, kalau tidak mati malah risiko cacat otak. Kalau bunuh diri juga dosanya besar (wait, sedang krisis kepercayaan, jadi tak terlalu kepikiran tentang ini). Eh terus malah bikin orang tua tambah sedih, ditambah malu. Udah useless karena gagal ujian, tambah useless dan bakal jadi beban seumur hidup kalau do suicide. Bahkan setelah diingat-ingat dalam perjanjian beasiswa kalau bunuh diri maka harus mengganti semua biaya yang sudah keluar untuk kuliah, it means i will make my parents pay almost 500millions. Mau jadi anak macam apa saya kalau saya benar-benar melakukannya. Oke, jadi saya tetap tidak jadi melakukannya.</span></div>
<div style="text-align: justify;">
<span style="font-size: small;"><br /></span></div>
<div style="text-align: justify;">
<span style="font-size: small;">About my belief, i used to believe in God so much, that's why i felt so dissapointed. I really really put so much hope for His miracle, but yeah, i m not lucky enough. Dulu beberapa kali kalau membawa renungan, saya sering membawakan tentang doa. Tuhan akan menjawab doa kita dengan "yes, this is for u", atau "no, i have better plan", atau "not yet my child", iya, dan harsunya saya percaya ini. Sebagian hati kecil bilang untuk tetap percaya ke Tuhan, dan sebagian lagi bilang "kamu sudah lihat hasil doamu dan novena ibumu". Iya, sebagian hati kecil itu lagi protes ke Tuhan. Putar-putar lagi ke belakang, mikir-mikir lagi, apa karena saya kurang berdoa ya, apa karena saya jahat ke orang ya? tapi kyaknya tidak deh, yang lain juga begitu. apa kalau begitu tak ada gunanya saya berdoa dan baik ke orang yang kadang bahkan saya tak kenal, yah mungkin karena ini, ada harapan dibaliknya. Sebagian hati masih ingin percaya, dan sebagian masih protes, bahkan sudah ada ancang-ancang tak usah ke gereja ini minggu. Iya, sepertinya iman saya bahkan lebih kecil dari satu sel epitel. Tapi iya, mungkin saat ini sedang krisis kepercayaan dan saya sedang marah. Marah dengan kenyataan tidak lulus. Semoga tidak memburuk ke arah yang lebih buruk lagi.</span></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<span style="font-size: small;">Dan kenapa saya tak mau her? saya sudah melakukannya 2 tahun. saya tidak mau nambah, tapi inilah yang terjadi. harus nambah, yang artinya ujian-ujian ke depannya juga makin terlambat. Stress, bahkan kalau fase angry nya tidak bisa sampai ke tahap acceptance dan menetap di depression, saya takut jadi benar-benar depression. Yah, merasa useless tapi juga angry, at the same time feel sad. Ada tidak ya koass yang jadi gila karena masa koass atau karena tidak lulus ujian? Sejujurnya koass itu bukan sesuatu masa yang ingin saya ulangi meskipun harus diakui ada siklus-siklus atau saat-saat dimana koass itu sebenarnya menyenangkan dan lucu kalau diingat (kebanyakan masa-masa stase senior di luar). Tapi ini bukan periode yang tepat untuk mengingat saat-saat itu. tidak ada koass yang mau mengulang masa koassnya. sedih tidak lulus, tapi mau bagaimana lagi. sudah terjadi. Sejujurnya juga agak menyesal memilih jalan ini, iya, untuk kesekian kalinya menyesal. kemarin-kemarin akhirnya menemukan alasan untuk tidak menyesal. tapi saat ini yang bisa saya rasakan cuma sedih dan regret.</span><span style="font-size: small;"> Masih ingat sekali dulu pas masuk, ada senior yang bilang, masuk di kampus ini itu gampang masuknya, susah buat keluar. I feel it now. Susah buat lulus. At least kalau kampus lain bisa langsung tahu lulus atau
tidak, dan katanya sih pengujinya baik-baik jadi biasanya bisa lulus, juga bakal diusahain biar bisa lulus. </span><span style="font-size: small;">Nah saya, boro-boro..... Bahkan masih gak tau gak lulus kenapa :(</span></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<span style="font-size: small;">iya. sejujurnya ini jalan yang susah, masih menyesal mengambil jalan ini. dan sepertinya saya butuh psikiater, sayangnya sewa psikiater mahal. So i postpone this idea, mungkin nanti saat saya sudah punya cukup uang, saya akan konsultasi ke psikiater dan minta obat penenang. Sedih iya, merasa tidak sanggup kalau harus melewati masa-masa jaga malam itu, masa-masa menjadi keset, masa-masa tidak bisa apa-apa, masa-masa belajar sambil jaga, masa-masa ritual pagi harus tertunda. iya, saya sudah koass 2 tahun lamanya, dan harus ulang lagi, rasanya sedih, kecewa, marah, semua jadi satu. Satu-satunya pikiran baik yang bisa saya pikirkan adalah, oke, itu cuma dua stase, harus banyak-banyak sabar. iya, tapi tetap sedih. tetap kecewa. </span></div>
<div style="text-align: justify;">
<span style="font-size: small;"><br /></span></div>
<div style="text-align: justify;">
<span style="font-size: small;">Oh iya, tadi sebelum pembagian kertas, sudah diingatkan untuk tidak menulis apapun di social media. jadi ya cuma bisa cerita ke sini. waitt, ini social media bukan? tak tahu lah. Mungkin selama bukan nulis di fb atau instagram masih diterima. Saya masih kecewa, masih sedih, masih stress, tapi setelah menulis ini rasanya agak sedikit berkurang. tinggal menunggu mata yang bengkak ini mereda. Capek juga menangis. Yang pasti sekarang agak malu keluar dari kamar. Ini mata tidak bisa diajak kompromi. Oh iya, postingan kali ini tidak ada tips dan trik untuk menghadapi hasil yudisium atau ujian. Ini hanyalah secuil curhat dari salah seorang koass yang tidak lulus yudisium dan harus mengulang dan harus terlambat ikut UKMPPD dan ditambah harus tambah bayar her.</span></div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-17896969807110748072016-05-16T07:00:00.001-07:002016-05-16T07:06:43.342-07:00Curcol co-ass siklus pertama, radiologi.<span style="font-family: "georgia" , "times new roman" , serif;">Haloha...</span><br />
<span style="font-family: "georgia" , "times new roman" , serif;">Selamat kembali :)</span><br />
<br />
<span style="font-family: "georgia" , "times new roman" , serif;">Jadi, sejak postingan terakhir yang isinya curcol tentang belajar, diriku tiba-tiba kepikiran lagi buat menulis.hahahhaha</span><br />
<span style="font-family: "georgia" , "times new roman" , serif;">Nah ceritanya sekarang sudah jadi mahasiswa klinik. What's so special about it? idk.wkwkwkkwk...</span><br />
<span style="font-family: "georgia" , "times new roman" , serif;">Oke, sebenarnya mau curcol saja sih. Sedang belajar tapi yah begitulah tiba-tiba jenuh, daripada ngestalking insta orang mending tulis blog.hahahhaah</span><br />
<span style="font-family: "georgia" , "times new roman" , serif;">Berhubung ini adalah siklus pertama jadi tidak banyak yang bisa diceritakan. So far masih dibilang enak sih. Ya iyalah, siklus pertama dapatnya radiologi, siklus minor yang hari sabtu libur, yipieeeee :D.</span><br />
<span style="font-family: "georgia" , "times new roman" , serif;">Sebenarnya lagi mau menulis sesuatu yang lebih berguna, misalnya tips n trik baca hasil rontgen, tapi entah kenapa sampai minggu keempat ini masih susah bedakan infiltrat super halus dan corak vaskular yang ramai. Beberapa kasus memang kelihatan sekali bedanya, tapi ada juga yang kasusnya infiltratnya super tipis. Giliran yang saya bilang ada infiltrat malah di ekspertisenya normal @_@. Katanya sih kuncinya adalah ikuti percabangan hilus, kalau masih nyambung berarti itu vaskular. as simple as that but i can't. mati gak? mati....</span><br />
<span style="font-family: "georgia" , "times new roman" , serif;">Terus bedakan foto polos thorax AP (anteroposterior) dan PA (posteroanterior) katanya liat dari scapulanya. Kalau foto polos thorax PA seharusnya scapulanya <i>Absent</i> alias gak ada di lapang pandang thoraxnya. Nah tiba-tiba ketemu foto PA yang scapula nya kelihatan di rongga toraks. Tahu tak itu apa? foto PA TIDAK SEMPURNA. Okelah, katanya lihat saja dari usaha pasiennya. kalau cuma kelihatan sedikit scapulanya yah bisa jadi foto PA tidak sempurna. mati gak? mati...hahahhahah</span><br />
<span style="font-family: "georgia" , "times new roman" , serif;">But, terlepas dari susahnya bedakan yang normal dan patologis, siklus ini terasa surga. Jadwalnya gak membunuh, dokternya juga baik-baik. Yah harus dinikmati tidurnya, harus dinikmati hari sabtunya, harus dinikmati sebelum masuk siklus selanjutnya, salah satu siklus mayor yang mematikan.wkwkwkkwk</span><br />
<br />
<span style="font-family: "georgia" , "times new roman" , serif;">Sepertinya cukup dulu lah ya cerita tak penting ini. Semangat belajar saya sudah kembali. Selamat belajar. Ganbatte :)</span><br />
<br />
<span style="font-family: "georgia" , "times new roman" , serif;">oh iya, buat yang tertarik radiologi, ini ada bebe<span style="font-family: "georgia" , "times new roman" , serif;">rapa su<span style="font-family: "georgia" , "times new roman" , serif;">mber yang <span style="font-family: "georgia" , "times new roman" , serif;">bisa dijadikan bahan bela<span style="font-family: "georgia" , "times new roman" , serif;">jar:</span></span></span></span></span><br />
<span style="font-family: "georgia" , "times new roman" , serif;"><span style="font-family: "georgia" , "times new roman" , serif;"><span style="font-family: "georgia" , "times new roman" , serif;"><span style="font-family: "georgia" , "times new roman" , serif;"><span style="font-family: "georgia" , "times new roman" , serif;">www.radiopaedia.org</span></span></span></span></span><br />
<span style="font-family: "georgia" , "times new roman" , serif;"><span style="font-family: "georgia" , "times new roman" , serif;"><span style="font-family: "georgia" , "times new roman" , serif;"><span style="font-family: "georgia" , "times new roman" , serif;"><span style="font-family: "georgia" , "times new roman" , serif;">www.radiologymasterclass.co.uk</span></span></span></span> </span><br />
<span style="font-family: "georgia" , "times new roman" , serif;">buku: Learning Radio<span style="font-family: "georgia" , "times new roman" , serif;">logy-Herring</span></span>luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com1tag:blogger.com,1999:blog-7294540944450239332.post-82945646193524301402014-10-09T16:12:00.000-07:002014-10-09T16:12:05.237-07:00Lingkar Kepala dan Ukuran Fontanel Bayi<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><br />
<!--[if gte mso 9]><xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves>false</w:TrackMoves>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>IN</w:LidThemeOther>
<w:LidThemeAsian>X-NONE</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="267">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]--><br />
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoListParagraphCxSpFirst" style="mso-list: l0 level1 lfo1; text-align: justify; text-indent: -18.0pt;">
<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt "Times New Roman";"> </span></span></span>Berapa
cepat pertambahan lingkar kepala pada bayi?</div>
<div class="MsoListParagraphCxSpMiddle" style="mso-list: l0 level1 lfo1; text-align: justify; text-indent: -18.0pt;">
<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">2.<span style="font: 7.0pt "Times New Roman";"> </span></span></span>Bagaimana
anatomi ubun-ubun besar dan kecil?</div>
<div class="MsoListParagraphCxSpLast" style="mso-list: l0 level1 lfo1; text-align: justify; text-indent: -18.0pt;">
<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">3.<span style="font: 7.0pt "Times New Roman";"> </span></span></span>Berapa
ukuran fontanel normal?</div>
<div class="MsoNormal" style="text-align: justify;">
Jawab</div>
<div class="MsoListParagraphCxSpFirst" style="mso-list: l1 level1 lfo2; text-align: justify; text-indent: -18.0pt;">
<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt "Times New Roman";"> </span></span></span>Lingkar
kepala rata-rata 33-35,5 cm (13-14 inci), tetapi waktu lahir bisa lebih kecil
untuk menyesuaikan jika kelahiran terjadi pervaginam. Biasanya hari kedua atau
tiga ukuran sudah kembali normal. 6 bulan pertama lingkar kepala bertambah
1,5cm/bulan. 6 bulan berikutnya menurun jadi 0,5cm/bulan. Ukuran rata-rata 43cm
pada 6 bulan pertama, dan 46 cm pada usia 12 bulan. Pada usia 1 tahun, ukuran
kepala telah meningkat sampai 33%.</div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify;">
Fontanel
posterior menutup pada usia 6-8 minggu, sedangkan fontanel anterior menutup
pada usia 12-18 bulan (rata-rata pada usia 14 bulan). Berat otak bertambah
sekitar dua setengah kalinya pada akhir tahun pertama. Ditandai dengan reflek
volunter.</div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify;">
Lingkar kepala
diukur tiap bulan pada tahun pertama, per tiga bulan pada tahun kedua, dan
perenam bulan pada tahun ke 3-5. Grafik bayi dimulai dari 32-38cm, sedangkan
perempuan 31-37 (<a href="http://www.idai.org/">www.idai.org</a>). Disebut
mikrosefali jika kurang dari 2 sd, disebut makrosefali jika lebih dari 2 sd.
Menggunakan grafik kepala Nelhaus.</div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify;">
<img alt="" height="337" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAXkAAADICAIAAACCgAYOAAAgAElEQVR4nOy995Mkx3U/yP9CcSHdXUhxuh9OX8V9T1KEIk4hiQSDIEV+oS9FiTqGDEWJJCAQWG9m1i+A9d57v7O7M7M73nvT07a8r2o3PdPT43pMu3JZlZX3Q+4UemcX4IIkIIrCi4qOrKqstO998uXLl9lfQV/Sbxx5nod/Ma17VU0QwnURXpmaH+flBD/p4brsXs76F6vafwhBCF3X/c9V5pepuhNd133tr5CHfz30SzbAV36pr7+kXxvy5QEjiOM4cI38OPit67r4ueu6tm3bto3jVAMQTgETvgUAAABweB3X4ueu6/opV4MLvq0uT/XzdcVDVSLx60D/6WDxU8iviOM4tm2/9lfQcZ5HhtCpegMR+mwt8yXW/IaQ4zgYawAAmJkAALZtO46D1vgMQoifuK7rVBFGCvyhZVnVAuY4DgDAMAwcsCwLrBFOB2dULZCWZeE0cQQcwPH9T3B21SBVrf78R7Tffzl6TRj1PBchhyDD7R3NCKFQaPzkqWOZTBIhBCH4TDl+iTW/CeR5nmEYCCHbtnVdRwhBCFdXV23bNk3T5yqsnlTrz76ag6Udg1Q+n5+ens5kMolEAn/oum6pVMIRcHxfD8cPHccpl8vpdHpqasqyLJy4r7Ng6HllsdGLuv06velL+vzo9VU2G+j/93//v/7nd789NZ38xptf+9d/++E//tPfW5buuq+rHGH6Emt+EwgrDtFo9Ktf/WokEhEE4bvf/W53dzdCqFpP8THi1KlTO3bs2Lhx48TEBFoDBX/C9ezZsz/4gz/44z/+48OHDy8sLCwvL8uy/L3vfU+WZdd1l5eXDcPQdb1SqczMzCwvL2PQ+eijj77+9a//4R/+4c2bNyuVyuzsrOd52Ww2kUjs3LmToqiZmZnZ2VkAQCaTyeVyU1NTCwsLtm1rmpbNZv2Z2itR6Uv6ldNrY4138dKp/+8H392xc2Nff8f/eOubweDQG2/8eaGw4CHn539dRV9izW8OtbW1/e7v/i7DMCMjI7/zO78zNDSEELJtuxprsP7ye7/3e1/5yle+8pWv3L59GyGEwQJPdhBCAIAf/vCHDx48KBaLP/jBD/72b//26tWrv/Vbv/WNb3yju7v77bffbmlpOXr06NatW//8z//8rbfeKhaLCKG/+7u/O3jw4FtvvfXOO+/84z/+45/+6Z/euXPnq1/96j//8z//9m//9q1bt/7mb/7m29/+9o0bN954440/+ZM/+eu//utNmzZ1d3f/0R/90be+9a2VlRWc9W+AFfY/Bb0m1kxnJ/+P//N/f+fff/TVr/2/udn0hx/tefudH/33/+e/mWbBdb+cQ/1a0hezBPPOO+/09fUhhHbs2FFfX4/WcMQvA9Yafv/3fx9jzd27dxFCjuP49lqEULlc/qu/+itZlpubm994441vfvObNTU1Z8+erampOXfu3Ntvv93U1LRp06bvfOc7t27deuutt1ZXV4vF4h/8wR98//vfv3379ubNm//yL//ye9/73o9//ONLly49ffr0W9/6VnNz849+9KM333xzz549p06d+u53v/vo0aONGzd+8MEHb7zxxp/92Z9hwKo23Pxnpy9g9eoLaKiFhdm6R/fefudf/9f/7X+RFe7osQ9//JMf/c/vfsdxrS9tw7+mVG2V+JUnjnnaNM2NGzdirNmwYUNLSwtCCJtv/KyxeWXv3r1///d//0//9E8EQaC1uZU/h9I07Wtf+9rKyso//MM/fO1rX9u+ffu//Mu/dHd37969u6Gh4Tvf+c6bb75ZU1OzYcOGoaGhrVu3IoQikchbb721tLSEEDpz5sybb7554cKFPXv2jI2NNTU1fetb33rnnXe+/vWvb9iw4dSpU3fv3j18+HB3d3dtbe33v//9b3zjGxs2bPCL8StvnC+ecDv7xu/PKf0vYOjyaWZmqqOjVddLj588OnnyhKrJeOT6TIl8iTW/CeRbbWdnZ4vFouM4uVyuWCy+bAmutumiNduwDzRY2iuViiRJjuNkMhlRFAuFQiKRKJVK8/PzlUqFJEmWZRcWFubm5kql0vLysud5y8vLmUwGG1wMw2AYZnl5OZ/P67qu6/r8/PzMzEwulyuXy6VSqVKpFItFwzBM05ydnZ2ensYGbN9K/R/Wjr9S8tfXPo/EvzCrFgDAtk2swlSveUMIXPdLe82vK+FF6M8pcWweRlVmF3/VeZ1Ktc6lxTfW4ETwJ6hq8uV/Xq13+C45qGqZyffr8V/hpe7qcvrr6y9jirfmGfQra5T/UPr8lA4IoWmaXwwoQwgBsB0HQOhC6Lqu47qO4wDbNh3n19te85uhJP9iZFmWYRifH/9hrxlUtZL9Sl++dbqMt+ZWhwPVLnnYjoNRDPvmVPsB+gGcmu+zg3EE3/ro48fHroP++jqGNn/F/TeDPapX/T6n9C3L+mJUG583fMI85jifWWX7Emu+IPqCJ9hf0pf060ZfzqG+IPoSa76k/+L0hWKNr0t/kZl+SV/Sl/TrQF8E1vgjuWmalUrlN8b49yV9Sf8lyPuE6zPS62LNz1f+Py6E9+JG9PUbTD9Fr/mVTzReJ52fm50fYV3ZPv3D51VHnoc86EHouX7rvH7ZfuW0zs73Ev/4hwe8btlebpBPoc+tWq8wYVbV6BOF5XXE55NK/lLl4Otcz3lgLfCLVfYXbclPrPfP76aXG+jXAmugh6CH/Mb8LBOmz4kvPc8DAGDP1JdfrVusQa9gI2/dKz/8aZlWNwlCEEHoua7nQORWS/LLiXyuwvlKgYQIQeStuz49keqw33qvEPify8S/2uq8omq/INZ8Ssm9VxzHAz3PfZ0LIYgQDrjoU9nAz+LlsfkXtULAT7o+727C9FpY80l1fjHSS3CzFv48mO810/RvXdet9qB9zaR+mUJCD7meV83rELmu5zjQsYHtTyRfls9fLLtfrPyfaYSvzqX6yS9WyNf/6pNSwFS9Tv9CzNe+qhH20yv+crgqt0+U5JcE24XQ8bz1WPPKXntlh7ou/KQIn9p08CXU86/PC1+q6edgTXWPfvqoBV3oudBz4Zpe40HHxbcQfuyWuo4+JcFPp09KcF2amP98f7bqHlrHmutSWNcOsGpvi1elCn1a1h50oOsi6PO038+2bfv+Eevq8vPY5RO56jUbZH0zIg9n+Qqpe1Wb+14z1UVCVeL3+r326Yz3SbVeVzXXdS3L8ndRraua60HHc19W2dZdrgf9y2+sl5vXf/iqVn1dvQYDDb48z11L9gW+Wmufj2F/3Sv/WI+X2+RTG//jrHHuVdcLH75mX3x6zJfptbAGvnig0SvJAcCxgQscDDGeC4FlOzZA0KtyK/tEMYBrxx349PMa7nVFy3dFsywLW4sghP45UtXnxfkd+YraOQ72ZENr3rG+o5rvjYbj+GSYhm4ahm3aAAAHmhZYWS2trJYs24XQ8w+L8j3f/ESqb9f16Kd082s2iF9HTLYDbAcA13Gg60DX8VwccL1XND5cO/XKPyjL99zzK1Kdvn8Wl7/54JUehj+XPqXfHccxDKP6IK6qtoPAdXAFXQ++JtYA54VOgWsjCj4kDOeI+7eaUSF0IQSu+/EFofPKAJZz/9Y0dds2XRdUYxB+ZdsmANbLr3ARfLBY9+p1MO7lmH4h8fXpSlk1Qr1+J6JXYo235lfqP6m26Xovaq1+93sQF9hxgeO50DYto6Jj3MFiuY5l3bVdOZh8MfPjuK+CKNd1q8+ac9e83f2SrNM+qlVr/wQ530vVP8HAL5K3trGouhi4bP74WY2DPor5mGWaJt7poxsVE1i2AxzXNS1g2XC1UMkvFXXdAY7ry6pbdW6mZVm6rmMoxMhYfTbVy2BR3f4+4qwrf7Vs+yCFPwcA2A7w5c2BLkSe7QAcwAmuAz7s+lypVAzDgBD6ChoAwDTNalipPr7P72J865fWe9WsBL6oNMEq9Pcbyv/ErXJxxmHLsp7jAvIg8gzLNCxzTa+EeJaE6+sjrO0A07Zwa9rA9o80xF3guq5lWXgnl98IuCJV56K6AJgYAgCwALA8z/UDjmPbtokxAmMHfuU4tmFUTFP30QchiCNjrDGMCgAWvl0HLn7Ytk3bNl+JJjhH/5UfoRpTcLc4wKqGtk9BGR83f/VYA9fUjWq+r+5vP4znTRgioeOaulEplbFesw6eqmEFVh2PVD2S+9K1bjx0Xzx00vM8fLtumPXBq/q2GiwwTPh4t25Y9ivllxYLv19md02LwSdRFYvF1dVV/IlpmqZpWpatmxULmMAFwHUN0wYOKpXs5WXDNL11WONUHd+p6zo+TA8ztPfirO2VY/u6V9W19nvTr6mPp8/LD+zqsd1DCLgOcB3Xg9U9Vd0I+NcwDB87cMnxq3VDiF+2aubxgc/v7uqxza/LOm78FKypBixfwbGAbTugbFTKegVjimGZpm3hakLkAdexgG1Ypm4aumlgkAUO8KuMDznEgwfWnnxOq+470zQtyzRN3TR1LIcYU3DAcWzcYDiA8ch1AbAtACwb6NCzXWhBz0bI8ZBj2bpl6wg5jmvZwHChDRwTQhshByEHerbjmtCzPQQ8BKBnW7ZuWmUXWp4HoAc8BFxoOY4JPRt6AADDhRa+EHKrDUYvQpIFHBM4Bk6n+sL5IuTgHHFSawX4lWKNPwo5a0fG+sPpC1jjId9S47nQsYGpG8XVgqkbCHreGtdWD7m+0Pq7yF7Gmmpp98fw6q363trxun7H+/rFujkOFgb8yleGq0EEp79uUuOsHdzrb97xa+03CEIIAFCpVHAEXddxCo4LbMeqGBUbODaANvAKBTufN3XdA8CtLrCztmMIg9eaDIPqGq1TAWCVHueHffFbpztUg4IPDXjoNiwTz5iwBPrzDgc+lyL/SGCs2b28gwmTP9RXv8Wdi8XVqbKF+wNY9c6pdRVcxyTrwtXsWt2Vz9HHhRBCG9gYSkzbMm0LV8oCNsYgDKkWsPEr/1o35OBC+tM0XBFvTQPFDw3DAMB2XYABxdcgsFRj3MGgg9EHI45p6jYwgWNAz7aB/lzOEcBo4kLLgR8LP3AM29ExyrieVY01NtAtu+IDEP4cf4hRDKfmecA3GPpqFC4wQtCFtuOaz2MiAD27+sJ5vQprPtvmz9fSa/wAhNA3n+EORgh5EAIAHBtgM41jA2DZCHp6uWLqBvIQAMBxXehBZ00/qhYt27bdNeb7eHz2nluUvTW7MlbqYZW27LoutjtjnFqHEVho8StfSNDa+d7+UO+fyIvr7k8KqtUE9+OpE664P9p//E8A/mi/srKi67qhG4apm8Ao6yXdtHQD2AAVCiCft3QdARtWaTQO1kVxSXDZcBiLehW4fyyN1WIG12wK1YN/dW96nodP7UQf7+d2cYvpplGNNb7IOdAFAJTLZXysH24usHb4uWEYWKFz1sxYuHmxBOq6bltWNcwBAJyq3vGgV134NQRB62rnwec85qs51d1RXUEMcR+rHsBxHMd2gLUGNxVDB47jIWTaVjXcmLZVMXXDNv1olm1Vgzsug2mYhmE4a32B1url84zj2K5rA2BhNQGrD3ii5OsO/gylUimVSoVisQChA73nSgdwdODoHrI9ZLvQdKGFkGPZFcMsudD03/oqhq/muNCE0IKeBT0LIcdxDRea0LMc13Bcw0O2BSrANRByvI9X2Z+rNpVKybIMhDwIbQ/ZOBGMKQgBhID/sBrdqrDmlztTAkLorhlTPn64Nn/3PASrBpUXws7zT/SyaRk2dGCpUIKuixAyjeeLzQ5wTMME9lonWbZtWQ544R8koAuR5wEMSR60geVCB3rQcQFwgAtdG9iu60CI1XrHddzVlYKuv7B/GltMsBnFNM1yuYzFBq5ZhUHV8Q7VKpuu69VKwdpk5HlmrotjAscBANh4xMNiVi6XcTqVSsWybMuydEPXTV03KrphViqmh1C5hFZXXcNADkCuiwB4flkWsm3kOAgA5ACk626l4lYqwDRt3OYfdw1GOAgxBMC1/0Xwcd95yRqCsdcwdMPQ8YEACGHcdAGwK7pu2hbWZYDrGJaJgQaP7D72YXwxTRM9F63n6h6OgJERF8+ybdMysQMRcBwbq0XQddd0WMd1nLWpKKqaCmHAdVwHYHMWPrvAdVzoYoUGABsrWPhwAwhfZFHo+hW0LNMGtgPd52hi6MVyCdfRME3DMh3XdT3oQmg7AM+hAHQqhq6bhmkZOkYc1zEtAzi2C13g2BBCx3FN07Ys23EhbmbguKYFTMsulcqYH9Zw2XEcp1Qqmabpug62cZXLRaxeY/OKrpdt28LaBIS2DXTTLGMFBziG4xi2XbHtCgAVyyrbdgVjigMM1zFc9zn62HYZIcfzbHzhyC40XWg6jqHrBQAqllWy7bILTYQcAIxicdm2dMexXGjretG0ytC1PM+1LMM0dMsy1yDStW084wOOY7iuCaEJoWmDkuvqEOoeMiD87Gebvzg3hrZlGxWdiMaGB4dikShD0eViqbhamM5MIYSWlovNLe3jgVAylVlaWu3s6h0bD44HgoosDw8OB0aDwHI817NNYBkWTccSccmDLs/yNEkDywY2sExrIjDxrKHRqOgIei5w9HJlbGQ0Gopk0pOWYSKEgGUD20IIuZ6TzqRWiysIIeDaZb0EkesAEwADD48ugHE1tbiQLxdL3V3tkUhQUVSnanXJWzMWuGumBN/OQtP04uKiP6fAb7ElIhQKaZqGcWp2dkbXy9ghwrJMx7ER8tLpJM+zaO0vSvBX/qTGF3ist5XLBSLWszgvjo48S6cI152FMGdZUwDMILTogDkXzDogl5mk4vGwBxddd7ZSzlbKZrFQkSV1IhCen1tECHnec3DxJ03+DHRlZSWVSkEIS6VSb2/vwsLCwsJCKpVyXdfXMBDy8KiL/20DQte0rIqhY/uFDYALIXAdG4CyXlEUBf8jAm4uAEChUFBVFaMPBuVKpYIBbnZ2VpZlz/MM03SgS7OMpMgWsLHG5LhONjcjqwqEUDeNhfyiBWwXwkQqmUyncEMtLs1zAgscq6QXM9OTtmM5LkAILeTnJUlAHsQlx2fcYlMrQUT7+npIMjY9ncFrOtiu+VyDwEYZx7EdgHVCC9jO2tIbQsgCNrZMOa6LkRF6HnCBaRs2sFiBmQgFBocHgGM7EDgQ2ABYNrAAKJZKFV13XLejs6t/YNCwbMM0LctECE1OpimaQgjpeiUzlQHARghZlmGauj+NQsjDJlsMkr7BFV+WbUDorq4u52YyGC1FgenpbjfNcnY6zTKErhc9z6WpSFvr02gkwLEEQtDzbOQ5ssSKAu06husYyLMRAtA1IbQgtIBdSaXUqUzi9q2rK8vzCLkI2bZVxkZzhDxZlGdnch6EnuvZprUwt2DqJl5wRwhraq7rmNlsslTKe54JYeWXwhqEEADAg97K8srI0PCumtrNGzeNj46Vi6We7p4ffP/vEULlSuUv/vwvrl+7vn/fganM1E9/8tOmpubRkdHh4cFNGzaeOnEaech1XKOsO7ZVs3PLpUunEULnzpzdunkLzqJcLDU/a/rWm98cHxtHCHku1MuVUydOhiaCJ4+fSMYTC/MLtmktzM8lk3HLMiRJWFnOT09nVpbzplFJxNXJyQRCcDmf15SEaViL88sJLVUqlja8/+7IyOClS5eLxeLKysrs7GypVJqampqenp6entZ1nSRJhmEw7iwtLR0/flyS5Fwut7y8XCgUJEmemprCCsLly5fHx8cRQvn8kqrK8/OzsizOzEy7LlhYmMtkJiORUFtby/Ly8upqYXp6OpfLFQoFURRzuVwmk5mfn5+cnJQkKZ/P27Zr2/nmph+SxL5IeHdh9QEAjUtLN0ul+4uLN+Zmr9n207nZ64uLt7PTlycCO3T9yeLiNdNsRcgbGws1Nj7jBXFubn5hYTGTyRiGMTs7m8/ncZkBANlsdm5ubmpqKhaLIYSWl5d37969sLAwPT1N03Q+n0+lEtlsZm4ut7g4XyoVVlbyS0uL8/Ozk5Mp07KK5dLMbC6dmawYejY3s7yyYloWJ/BPnjzJ5/PxeBznAiHM5XLHjx/Hf36QTqcFQSiXy9lsdnZ2luf5pqam2dnZpZVlz/MePqobGBr0ECrrlcmpzNT0FMOxw6MjC/nFmdmcpMjAcRBCo+NjMZJYWFzMzmRFWWjraJ2dzy0uLahxxYEAeu7cwtx4YLSxsX5hYT4eV5eWFhmGCgTGSqUCQqitraW7uzMYDDx92rC4OE9RRDY7RRDR+fnZeFydmc3xgkCQJMXQkVg0m5uhWaavv29yKpOenJyeyc7kcloiQTH0zGwuFAnTDLOYz8uqZFg69Nz7D+919XQuryxNZTORWFiNK5mpdCQ2kZlJNbU0zMxlPOQ9qr8/PNrvuNZqcZHlohxPptPKrVuXRYmZyaUoOpSaVPr6O+fmZgCwJElIp5L5/AJFEbOzM6oqB4MBjmMmJsanpiYJIjo+Pjo1NZlOJeNxdW5uNhGXoWtDaC8u5IYGexcWcg31dZLIGkYJIYeIBTs7mkdH+rs6W2Zns9lsOpVUeY5k6Gg8LgkcOT83HQqOhkNjs7kMQp4scxxL8BzZ2FBXWF0cHOgWBTquiUNDvUQslMloXV1Nsdi4FufjCYHjorduXZqbnySIQDQ6lk5L4+P90eiYbVc4lohrEkLQdUzP++xzqGq9BrrQdVyjoiOEzp4+c+LYcfyiq6Pza3/xVYqIIeh+51tvfnRg/46tWyzT3L5l88afvUtEwgih2prt165ewUnplbLrgjt3rly5choh1N/bv6umFgCwuLBYKZURQieOHRd4ASHk2MCD3s3rNx7VPTp5/EQkFG54Ui9w/JVLl65fuURGI81PGwd6u4f6epsbGxgydvzwofrHDxmGaGluOnHshConPBeVixXbtjZvfv/SxXPnzp2bm5urr6+/fv3606dPz5w5E41G29ra7t2719ra2tvbgxBSFCUYDD569EjT1N7e3vb29ra2titXLre2tpZKJYRQY2Mjy7IIoWw229vb3dT09OzZ0+3trSQZ6+xsr6t7MDo6fO/eHUVRstlsNBptbGxsa2u7f/8+x7FtbW3DwyM3b15vaKjv6enxPA+hcnPzv1298j/KpXoPdgjisZaWfwsEakjy4OjoDpo+pKpnJOlUdvpaKLhnfv726OhWTbvseXB5eeXkydMtLa253FxnZ9fFixcjkUhPT08ymezs7BwYGOA4LhqNDgwMDAwMPH78GCFk2/bJkyd1XceoNzo62tDwpL7+0eBg/8BAH0FEBwf7+/p6OjvbAxPj0IOcwLd3dtx7cH8iFOzu7RkeHYkSsUBworm5WVGUrq4uiqKweUIUxdu3b09MTKyurtbX19++fTsWi3Ec9+TJE5Zlb926pShKpVJxofusuSlGEgih+YUFmmVa2lophn5c/2Qyk5EUubu3p1QuG4ZB0hTLc1oi0T/YPxEKPKi7L6tSbm6mubXJ9ZzV4grJEAQV6+rqyGanGhvrQ6GJtraWO3duqaqMEOrv771y5VIwGBgfHw0Exq5cudzQ8KSjo62/v7eu7kFXd9ez5qaGp43dPT09fb0UQ7e2tfX299U31g8ODQXDQZKmJqcyza0tw6Mjj548HhkbIWlqbn5WNyvQc6eymb379zS3Ni0t5weHB5tanuXmM4/q74yM97a01y+t5BByGpsejgcHLFDSzaXUpPC4/hYvRrp6GvsHWlgu2NXTOBboaW1v0PVSobDy8OH9ZDK+srI0NDQQDgdHRgZ7ero6O9vHx0dHRobGx0ej0XB3d+f0dKajo5Vl6cHBXs9zIASrK4ttrc8i4UBHezNJhHmOQghFI4GW5obHj+6FgqPRSCCZkEdH+kWBTqVUReZGhnoD40MdHc3RSEAQaIS8x4/uTWUSgwPd4+NDY6MDrS2N0UhgcLDnzOljN25clhXi/oMLPb0NwyMtz5pujwc6+weekuRQ49ObnV1PxgM9V66cePjwumGshENjFBlBCD33VP1lsMZ1XawsIoQOffgRxpp0Kt3d2bXx/fcP7tmFEPr2m19vanh8YHeNxFLbNr1/6uihhCIWVpf37N5x9cpFhFA6lSiXC4ZeuXv38vnzhxFCfT29O7Ztj6vahvfeFzg+rmqtzS0z2RnoutBxoQsvnDs/PDhkGEYuO9PW0jo2Onb/9u3g6MhwX19Hc/P44KDCcTcvX44EAn0dHYO9Xb09HTdvXI2EwnrZwMv8pVJh29YNDEOcP3+2vb311q0b+fzi0NBAW1uLrldiscjRo4eHhgZIMoYQ6unppihieHhQlsVYLPLo0cPu7k6KItraWufn5xBCjx/X4SmSJAmBwFh/f29PTxdBRMPhYF3dA1WVKYp47713KYool0skGbtx41p7e9vkZDqdTjY0POns7GhsrE8m4y0tTZYFbHupv39Dff0/93RvWMo/CAZ3zc1dn5u7LssnZmauTUzszmavscxRVTlLEB8sL98bHNwQjR5GyFtZWc3n81evXr169WogEMjnFzKZ9O3bNyVJGBjoGxzs5ziGJKOdnR2BQAAfZg4hPHr06MrKCv4/pkAgQJKxcDgoSUJvbzfDUGNjI4HAGEFEbdtCCNEsI0ji2Pj46PjY+ETgadOzpubm1GR6aHhYkqSWlpZwOIwQyufzzc3NXV1dFy9enJubGx0dHRwc7O3tzeVyDx484Dju8OHDmqY50IWe1/jsKcaaeDLB8tzd+/cisejxkye0RHx+YWFkbFSQxEgsOhEKCqIYTyabW5snQoHTZ09FYuGVwnJ7Z5vrOcl0ore/J5lKdHS0TU9nHj16ODDQF42G+/t7KYpACD192vD4cZ1pmooijY2N5POLY2MjDEN1dLSFw8FCcbW5tal/sD8wMR6NRQaHBiZCAS2hPmt+2jfQG46GxifGKYZqeFrf2d3xrOkpxZChSLCilw1TL5QK6Uxqembq4pULkVi4q0El1aUAACAASURBVKfzQd09mo3eunu14dmj9q7m3PwUQvDO/Rst7Y2lSlGQyGBoqO7RzbHx3uGRroGhDpYNt3c0jIx2R6LjCMFyZbV/oKe+oU6LSy2tTyeCo2PjQ2Pjw0NDfSxHdfe0k1Rkajo1MjJAM8TTZ08i0YmhwV7oWsDWDaPMsSTPUUQsxLFkLDqBEBofG+ztaU8m5PonD8LBUYoMj4z0k0SIJEKR8HhnR/PY6EAoOJqIS5HwuAdBa0tjZjL+5PH9vt6Oi+dPPaq7SxChR3V3nz193NvT3tvX1NNX39r24NbtMzdunuruqR8abr5z99yzptsdnXXtHXWdXfW3b18wzdWe7nZFFhBCDnBd55db83ZdiFeUHAB21e7avnWbbdttLa0MRTc9bfzB3/5NNpP69jfeuH/r+onDHyocvW3Dzx7fuz021P/g3s29e3YeO3poIjB2984tz3NNU9+3b+uBA1sdYN+7c++9d3+mV/S5ubmV5ZXanTV/9c1vPXpQ53meAxxg2adPnkolkgihtpbW40ePNT19dvv6jZH+vrHBwaHe3u7W1if379+9dm2wq7u1oaG+7j7LxC6cP93V0TEznXvW2AyAXSwu79tbMz4+dO/eHVWVz587OzIy3N/f+/RpgyQJDx/ev3jxfEtLU3t7K0KIZekHD+5dv361q6vj+rWrT548evjw/tDQwOPHjxYW5lzXuXLlUnd358jIUGNj/cBAX1PT0+bmZwMDfQxDXblyaWJiPBAYq69//Phx3ejocF3dg+vXrz54cE9R5La2lnPnzjx+XPew7l40Fuxob3Vdr1zO9vT8bHb2Zl3dP0SjB6LRfZHIrlzuyvj4Dpb9KJk8HwjUkuQHPHc0EKjl+cP9/e/HYkcQQhMTof7+/pGRkUAg0NraEgpNJBJac/OzUGiivb21ru7B0NDAo0d1PT094+Pj7e3tuBOHhoaGh4c5jiuVSqOjo+FwsL+/l2Go0dHhaDR89+7t7u7OsbGRpaW8hzw1rnX1dJM0NTg81N7Z0dnd1dnd9bTpWWtbW2tb2+PHj0mSdBxHURSs6D158qS/v394eDgYDHZ0dESj0cePH2Oka2pqyi/lXQibW1vaOtophm5qae7q6X7a9Kynr3doZLizu4sXhKGRYdOygOOMTwSiRKylrbW7t7u3v4diyMHhAZImOrraDUtfLaw0tzV1dXe0t7cGAmNtbS29vd0kGRsdHcYDxsjIUGdnO0JoaWmxra0lFosEAmMsSycS2uPHdfGkNjDUPzo+2j/YR1DE6PhId2/X+MRYZnoyGJ5ofNYQjoaGR4faO9vaO9ta2ppJmoiR0XAsVCwXynppcHggHA3FyCjLMS1tzR1d7b39fQODg/0D/YHgRGoy7ThO38BAe2fn+MRER2fH4GB/e3vr2NhIJBIKBMZlWQxHQjEiwvMMxhqCDNFMVBSZgcFuWeF4gWI5gmaiyZQSjoy3tT+TZDaRVCLRQN9AZywWpKmo61qWWWboWDKh2LY+lUlSZGR5ed5xTE0VxscGBZ5KxKXMZHx8bJAiw7LEaqoQi04QsWA0Ekin1HRK1VQBIcSxRDIhR6MTAk8NDfYM9HfhWVUyIfMceffuNUmiJyaGhoe7otExmg7JEhWLjY+P9zNMgBcm0pMcxwXn5jJjo4OWpePdDh58YTXwM2MNdF3nuRuhFVc1jmFty5YlubCyml9YVEVhcS4nC3xKU5eXFi29nJ1Mz05nFJGbTMenMsl0Mq4pylwuZ5nG8tKsolDZbNy29OnMdFzVbNNCCOnliqaoHMstLiyuGdzsTHqyVCgiz5ufnSNjxPzs3NzMzEp+MaWpTQ0NU6nkXHY6Pze7mMut5BeX8oujo/23b11raXkm8eJA34BlGQAYuZnJqanE8koeAHNmJpNOJwqF5dnZ6VJpdSY3tbCQW1peWMzPWZbuOOb8/Mzc/EyhsDQ3PzM7O52bnS4Ul/NL85atm2Z5fj43NzczOZnM5+dXVpaWl/NLS4ulUnFsbKS+/vHIyFAioRmGXi4X8ktz8wu5lZX8Yn6uVFpZXl7MzU4tLOTyS3Ol8spqIQ+hp+szxeJ9AJ4uLNxaXX1YLtcVCvfm5i53df10dfUuAI2VymPDqC+VHun6k0rlUaFwR9ebHcfSdX1ubnZpKQ+hMzeXm1/I6XoxNzttmOXl5YXFxblypbC4ODc3lyuVysViEVuOTdOcmppaXl52HKdYLOl6uVBY0fWyYVQKhZW5uVyhsFIsrupGGSFEc0xre1u5UlktFubm5xfyi6uFQmZ6qlQqra6uzs/PLy8vAwCWlpaWlpYAAMVicXFxcWFhoVgs4n/FnJmZyefzOH6hWNRNI7+8NDc/n83NrBYLi0v55ZWV1WKhVCkXy6VipVTWK8B1XOiWKuWKoZcqlUKpUNZLpm0Ypr68ulQorhZKq4Xian55cX5xTtfLpqmXy8VSqYBd5kxTB8A2Tb1SKeN1k6WlxUqlhJd7HMcul4umVSmUVsqVwsrqkmnry4V8d1/n5FQKIscGRqmyatoVw6pUjFKxvFrWC2W9qJtlw9JLlaJpG8VyoVBatR3LtI2yUTIsvaJbFd2ybHe1UKlU7FLZKpaMldVKoaRblmOZwLYdQ7cKqyXLtMtlvVTU9YplWaYNypZdLpWXAdA9zwaObphF4OguNHWjAD1rIZ8bGu4tlpYQAo5rWFbZNEuuYxp60bYqxcKSbVUAMBFyXMd0gFEuLztAdx3DMkvIs4FdAXbFssqOY5hGEdgVhIAHLeia0DWBXdErxXJpubC66EELeTbCfoPQQp5tmSWWiQUDY7Zl4tUD1wUedD3XWdtQChAqQ1hEyMnlUkv5Wc8DwDY9CL0Xt4D+IlgDXWgZpr+GjVe2XbyREiF37fmaw/fHn1anY+qGXim5roEQdIDluR5CyNANYAMXPDcp4a0MruPalo0QcoDjAgdBzzJMP46qSDRJoOdGew8+d+VGM9lUX19nJpN2gOMAxzQqwK4g5CBkOa5pWc/XDqEHILQQwg3neJ6N3Z8c18RulI5regg83+mPAEIu9iBAyEXIhZ5lWTr2xcJOE/n8QjgcnJ2dee5j4RgeAgghDwGEvLUPkecB6Nk464pesex5hHoB6ACgE6EBF3Yh1GMYz7IzNzzU5TodAHRA2ANhL0K9rtvpeZ0IjTiOAQDwPIhXH3EVHNfE2TmuiZCDEEDIKRSXy+WKYRjlchk71OPWe+4PgiDmIezEtdZFLgCWBez80tJUdhovAOMVYtfzF9Esy7Kwmw8O4/+BwetThmEUi0V3zXdW13XXdSu6rptGqVKGnmfalr/wjL0EIfIcCBFeEoKuzz2O6yDkQeS60EEIudAplguWbelmBaLqXdF4Hc3zF6RwvfCv/2SNHYELbYQg9GyEoOvZxdKKbpQgAjgpy9ZdzwauWTGKPj94COpmxYEAlwch5EBgO5brOS58Po4Dx7MBdFwPC8c6IbMt4HkI2I4DXISQh1yEcDFMhBzomR6yXGhAz0QIIOR6yELIgdBECEDPxJGxNHnQ9p19n4vi8yf4oQM/9gYGnov/WcWBrumtMTC+HICdTsBa47jPl66Qg1cjq4rvVbchrhBCls9p8DnXeQg5AJjVXqY/l16FNQ7E9ppPIe+lgH/vgufPgA3Wauu98IGHoOM+/8XP1nrMgx5+5TrYPcyu/sxxbRc6LnQcx0AIv/JcB0AIXcd2XQu6BgBl7DfpOCYAhucBCG0bVKBne95z50jgGAAYOIwdGdYe6mtemAaEtmGWLLsMPewmYhlGBXtGIISduRzLMnS9qBvFir5qWmXTLAHHMK0ycHTbrhhmqVxZMc2SYZYMs2jbpVJxqVhcLhaWDHPFslZMa8WF5XJ5sVBYKBbzhcJSubSqV1ZXVuYMY8UwVnWjtLKSN4yyaVZ0vaQbJcMs2aBSrqxU9FXLrlh2uVxZNYxisbi8uLiQy+V0XS8Wi+VyWdd1wzDxQYh6pWyaOt56Y1mGZRmuCwy9XNHLxVLJdoANQKFU1E3DArZuGlgHMXQDewCupWaUSmX8N97Ya65UKhUKBexbtLKysry8XKlUiqXSfH6xrFcqhlGqlEuVckXXF/L5YrlUKBWXV1eK5fLy6kqxXCpVyoVicbVQyC8trayuLC4tLOTnl1eXVour+eXFbC6bmc5MZTPzi3P5/OL8/OzcXG5uLrewMLe4OD89nZmZmV5cnJ+fn1tcnJ+fn52fn5ufn81mpzKZdDY7NZObzs5kpmfSybSaTKvpTHxyOpnNZbK5zORUIp5StKSsxkU1IWkJKZubzOYmk2ktlYlPZlKpdDKZSsSTWjqTmpyaVOOKllDjyXhqMp7KxBMpJZ6UtYSkxEVZExRNEGUunhDjSVHRuERKSqWVRFKKJ8R4QpRVVtG4eEJIJMV0Wk6lJE3jFZVRNU7VOC3OJ5IivtXivKpx8YSgxXktzqsql0yoqZQmS7ymismEoqqiporJhKoqgqoIiswrMpdIyLLEKjIni6wicwwdVWQOP08llWRClkRGFBlV4TmWwCviAk+JAv08IDIsE+NYQhRplo0xdIRhojQdEUWa44h4XJREWpFZTRUYJspzBM+RmsprmqAobKm06Lim8+Km/8+ANZ7nQddxHWcpnz95/MTP3n23ZmftrppdNTtra3bU1tbu3rZ9x+49+95+59333tvws/fe/+nb72zbtn3rth01tbu2b9u+ZdPWDe9v2r51Z+3OXVs2bd2+devWzRt2bNu0edP7WzZv2rxp467amu3btm7a+H5t7c53//3td9756Z7du/bs3rV7V83u2tq9e3Zt37b1pz/+8cYN7++q3blt2+at2zdt2vL++xvffW/Dv++o2bqjZuumze9t3b7pvfd+8rOf/eumTf++ZfN7mzb9rKZm6/79uza8//ZPfvLPGze+Xbtr66bN7/7kpz/csvW92l1ba2q2bNj4znvvv717z/YdOzdv2frejp2bd+/ZUbtr27btG7dt37ht24at2zbs3Vezecv723ds3rZ9446dm7fv2LRv/66dNVs2b3l/y5ZNu3fX1tbu3L27dvv2rbW1O3fu3F5bu3PLlk07a7bu3rNjy9b3N23+2cZN727fsammduuevTv37a99f8M7tbu27dq9o7Z2+5EjHx46dKimpnbTpi3bt9fs2Lm9ZteOd997Z+u2zQc/3L+zZvuBg/vOnD197vzZjRvf37Z9y6HDHxw5+tGevTU7arbU7tq+/8Duw0c+2Hdg16Yt7x38YM++A7t279lx7Pihgx/srd21bd/+2qPHP6rdtXPv3j379u2trd15+MihEyeO7d+/99ChDw8c3H/h4rljx48cOLhv/4G9e/ftPn7i6JUrF8+dP/Phhwf3Hzxw6Mjhgx9+sO/A/tNnz+w/eGDv/n37Dx44fvLEseNHz507e/7CucNHDh08eODipQuXLl08d/7syVMnjh07cvTokSNHD584cezs2dNHjx7Zv3/vkSOHT5068cFHB/ce2Hvk2JHzF8+dPH3izLnTx04cPXr86LETx46fPHbx8oULl86dPH3i2Imj5y6cvXr9ypFjhw9+eODDwx+cOnP88tULh45+cPTEobPnT504ffTI8Y8Ofrjv3IVTZ8+dPHb80Acf7qvdtf3Q4YMHP9i7e8/OPXtrjh776MTJI8eOHzp95vjhIx/sP7Bnz96a/ft319ZuP/jB3n37dx07cWj33p3HThw68OHe/Qd3Hz3+0aEjBz/4aN+uPTv27Ks5+NG+gx/tO33uxKmzx06dPbZr744PD+8/ceroR4c/PHX6xPkLZ48eP3zy1PETp459eOjgkWOHLlw8ffLUocNHDhw7/sHpM0dOnzly9tyxDz/au/9AzZmzR8+eP3Lm3JGTpz48f/HYqTOHDh/dd/L0Rwc+qDl24uCx4x+cPH34/MWT165fuHTlzNWr5y5eOn3t2vlLl89cvnzu6LEPP/po/8WLp8+fP3nh4qmzZ49dvHjq6rVzV6+ev3b1wuVLZy5ePHPr5tUrl8/fvHHl2pULt25evXr13PXrF+7evfbwwc1bty7funX51s3L9+9dv3b1/PVrF2/euHT71tW6h3ceP7p34/ql27eu3rp55cL5U3fvXL9z+9rZM8dv3bxy5/a1R3V37965fv3apevXL54/d/zy5ZMXLx6/efP8jRtnL148fvnS8Zu3zl29durc2WOXL509d/b4hQsnbtw4/+Dh9Zs3L9bX31tYmPY8x63aj/bZsMZ1oeMAx7FL5WJdXd2JEyevXbvx8MGjSxevXb50/fKlq7du3ayre3Dp0oWrVy7fuXP71q2bT548vnXr+p07t2/exNetuod1jx89un3zxr1bN+/fut746MGjunt1j+4/eHDnSf3D+w9u1zc8qm+oe1h3987dGx3tzR3tzc1NDY0Nj5ueNbS2PK17eLex4dGzp/WNjXUtrQ2Pn9y7d/9mc3P902ePnj571NxS397xDIebmh+3tT/t7mlrfFrX3dPa1t7Y1Pyko7Opp7e1o7Op8Vnds6bHT5/VdXY1NzU/aWh82Nb+tL2zqb2jqaOzubOrpa+/s6W1sa+/c3Cop639WUdnS2dX6+BQ7+BQ7/DIQFd32/BIf2dXa1NzY09v19DQQFdXx+Bgf29v99DQwMBAX19fz+Bg//Bw/8joYHdPe1NzQ3d3+/BI/1oK/U3NDX39XV3dHS0tTYOD/QMDg21tbU+eNAwMDHX3dD9rbmhqaWzvbB6bGBoNDPb0tw+OdA+MdD9tevKsuaGjq7W9s6WppbGnr3N0fKizu61vsGdkbLCnr7O3v7ujq7Wzu20sMDw43Nc/2DM8OjA8OtDX19XX393b1zU42BsKjw8N9w0O9Y2NDQ2PDERiweHRgZ6+roGh3v7Bnp6+zqGR/nB0YnR8uKevd3h0ZGRsdGhkeHwi8OjJ4ycN9R1dnWOB8a6ejrHA8NDoQCA4NjI2NDQyMBYYDgTHevo6OzpbBwZ7O7vaRkYGgsGx0dHB1ramgcHewMTo+MTo+MTI6PhQIDg6Oj40ERqfCI2Pjg+NBUYCwRGKiZJ0ZDQwFIyME1SYZmOB0GgoMj4RHo1RIVYgWIGIkUFOJCk2wgkkQYcYLkbTEUlmeJFiuRgvkKHwGEmFYsQEQQajsUBgYoggg5FYIBwdj8YCJBWimSgvUILAchwzOjZM02QsFolFwxzHMAzF8QxJxxiOFCQ2SoR4kWF5KkqEQ5EAw5G8QDNsjOVIggzzAq3FRZKKsBypqEI8LmuyKLCMyLESzzFkjKWIpKbKIi/LPMMQssJrcUnVxGRKTSYVLS6JEqsmJC0lyxovqVw8KafSalwTJ1OawJFxVdRUZTKVyk5NTqbjcU1MxKW4Jk5lEnGNVxQqlRKz2fjUlDYzk57KJNMpLZlQ0iktnZamppSZmfjMTDyZ5DMZeWpanZpScrnE1FRiJpueTGvJhJxKKqrCZybjU5lEZjKenU5lp1OKzKWSSmYyjuNMprVUUkkmpXRaSqfFyUkxm1Xm5hLzC4nMlDCdlVJpXtPYTEbKZpVkikkmWU3jstm0ZVSAbcHPcoTNC1gDoee6jmFUbNvOZrPxeFKSFFnWREFlGZFlBFmW4/EEx3GyLGcyGU2Lx+NxnhdiUUJV4yzLsywv8IIqKyLPsyTBUTGFZ5MJLZlKSJIgCDzHMTzPMQydSMTjcU1VZFkSZUnUVIVlaJokRJ5LJRKJuCqJHMfT8YRM0zEtLmmaJIgsx1G8QPMCIwisKHGKKsgKL4qsLPOCyPA8LckcwxCCwCQSCsMQPE9LMi9JnCixJBmVZF4QWUFkRYnjBSaVjiuqqGrSZCYpSixJRQSR0eKSFpcwe2lxSRAZVZUlSeA4JpVKqKrM86ymKZIkyLIoCJyqKqoqsyxN0xTPcwxDSZIg8FwkEhJFgePYWCxGklQwGI5FybHRYCgYo2gmSkZDkSDNkpzAkHSUpKOR2MREeEyQWEkWCYqMEpEYGY0RUZIhBYmnWZoX+UQqIUhCOBoiKILlGVmVtIQqygLLM6LACwIvSSJmW4ahFEUSRUHTFEWTZVUSJD6e1JLphKSIgsQn04nUZJITeEmRtURcjWuyqkiKzAk8LwqJVJJiSDx9SKTialwRJF5WJV7kBIlnWIrnGUkSVFWWZUEQOFkW43FVlkVZESVF4EVO0WSckSgLLE8LEs8JjBqXJIVX4xIvMrIqaAlZUnhFE0WZ40VGUvjUZDyeVBRNFCRWUnhZE7W4LEqcqklaXIrHJVUTJYnjeRrzg6zwDEPwAsMLNMMQosRyPE3RMVHkeJ7leZamyXA4SFFENBqmKIIkYyQZI+koxcQUTYyRYRzGF8tTnECTVITjKZYjOZ7ieEpRBZYjeYEWRY5lKEngeY7hOUZTZUUSE5qqyKIosqLE8gItSizmSUnmBJGRZE6NS4LCSirH8AQvUCQVpqmIpoqKyDBERBL5VDKeTiVSSVXgaUXmJic1VeHicT6Z5BMJHBAm06oi85LIJhNKMqGIIqlpjKYxGGjicTaR4Kan1XRamsrEkwk5ronJhJxMyJoqqAqfiEuTaQ1fqaQiCrQkMom4hNet4po4mVbicZ7joqpKp1KcqpLJFBNPUIkkrWm0prGTk1I6zfFCUBQjqsoszGdt23Cc1/23crwT5St+CFXt27ZtO5FIsCwXnIiMDAdYRqJInqYEgmBIkgkFo+FQLBImghORYDBKxOhohBYFNRwigsFIcCJMk3Q0HA6NjYUDY8GRUZqkYzFyYiIUDkcpimFZniCoUCgyOjpOxiiKoMOhSDQcZWkuEoqGJkIszVEEHY3GJiYCNE3HYjGCIEiSiITDgUBgbGyUIAiCIILBYCwWjcVigUBgbGxsYmIiFApFo5FYLEaSJEEQsVhMFEWGYViWJUlSEIRoNBKJhEmSoGmKpilRFGVZoihKEkVZ4Sk6GgqPU3QUMw1BhgWRYViC51lZFimKEEWe4xiKIhiGEkWeYahwOExRNE0zBEHGYiRFMbEYQVFMJBKjaZrneYIgCYIKBEJ9vUO9PUN9vcPDQ4FIlFDjWiQWicQiY4HxcDQSiUWC4eDI2MjQyAhBUqFwlKRolhfCkdhEKEwxbCRKRGOEIMqSrFA0y/ICSTPRGMGLkpZIsixPUywGFY7laZoVBEmS5HA4qqpaPKkpmswJLMszDEercSWe1CRF5EWOFwUMLpIi86KAfW1EWSIokqAIjCwUQ1IMyXA0yzMkTQgSLwicIHBYkgWB4zgGXzzPEmQ0EguzPKPGFYw1JE1wAsuLHM1SiibyIqPGJSzbGHR4kZEUgeU5RVPVuMYJPElTvCBIsiSrCsOxDMOoqppMJhVF4XleEASWZePxuCzLyWRCEARZlnmew71MEATDMCzLCAKL3aAmJsYFgWNZmmVpiiIoiiCoCEFFZFXAxSDpqChzgsTyIsNwJMMSDEvQTEwQGV6gGZag6CjNxHiOFgVOlgSeY9KpRCKuypIQjYQ4ls5kkhiSZIXHQxS+JJmTFB5jjaiwqiYoKq8oXFyTknFJ4EhFFpMJjWVIgac1VdBUIZPRpqfj8TgnSUQiwaVS0uxseno6GdfEzGRiNjc9k01rGp/JqNPT8XRazuVS09Pa9HQ8l0tNTWnTU4lEXEom5HRKTSWVVFJJxKWpTCI7ncLqzFQmocicKNCKzMU1EWs3isImEoKqsrJMJZN8MslOTgqpNDuTk6enFUVhBCGqaWR6ksvlNFVl0mm1Uil68HUnUBhYXsAahBDeOmTbjqYlYlGK5+RQMMbQYihIMLTIsXIoSI6OhMIhmiB4gdeiETYcohhaokguHCKiUYqh+UgoSkRig729Az1dHEGSMToSpmIxhmVEhhajEZqm+GiEDoxHKIKLBAmBlSMhMhqmYmGajDIMKfCMzFA8z0sUyZIEw9ACSbIMzZMEEwrFaJqPRIhgMEoQTDgUi0QIkmAYmmdoPhImiBhNkkwkQrCsIEsqw/CxKNXV2bt374GGhqcsyxMEyXFCIpHq6ur56KPDDMNms9l792/39nVKMtfb17lnbw3DEpLMZaaSzS2N58+fVRRJVeW7d2/39fXwPBuPqwQRZRgqlZpUFC0aJaJRkqZZimIEQeI4gSSZWIwUBImm2UiEIAmWIvmx0dDYaGR8LDo4ONLQ2Pikof7KtevRGBklyKHh0UiUICk2FqMpmp8IRmMEw3JSjGCCodjoWGg8EIlEaYJkGVYkSI4kuWiMiUQpmhFEKS5JCZaTeEGhGTEaY1hOkuQ4y8k0IypqQlYUXuQlRRZliWZpTuBEWdISGstzMYJkWE5RNUWLc7zIixJJMywvMCzPCbwgCWpcYziWoEiKoSmGphiKEzie52ialmVJUWSe5wWBj8WiJEmyLMuwLM3SDMeKssSLgiiL+JYTOIxWWMdhOJrhaFHmRVmQFEGNaywvcrykakmOlyiak+W4ICqKmmBYgWEFUVS1eFqSNf9S1IQka6KkMqyQSEzyvKyoCV6QGUZgOZEXJEEUKIYcGx8NR0MsRwsix/EMQUYpmmQ4kuFImiXC0QmWp2iW4AQ6HJ3gBJphCVFitbh0/8HtXbt3RGPBfft3jYwOYAc8LS6rmkjR0VRak2U+npDvP7gdjQWDoTFF5VVNSKVVhiVSaS09qSVTSjwhTc2kEpOqrPHJSTWVVrW4mEwqibikKXxcFTRVnMqkcjOZmexkdjqdnU7Oz2dIMsDzke7uZw0Nd+vr783NTU5PJWay6cxkIpXUpjLJzKSWTIpTU1oiIWQy6tSUNj0dV1VW0zgMMZNpDc+bEnGJ58hEXJrJpjGyxDURm43TKRXP2hSZ4zlCUbhUSpmaUjMZOR5nMhkpMyXOzKhTU4qi0BwX1jRqOivNzKiiSKRTarlUQB78RbCm+jGEnmHYPCeFgjGWkUiCIwkuFKQiYZoi5MA4OT4ai0Z4ipA5Jh4NcxMBFiFoRAAAIABJREFUKhbhghOxwYGx4aFxMsYQUSoaigWGR/u7u8lwNBahohGajHGRMBWN0PiXIvlImAoGYoHRMEdL4yOhzrbeaIhiSIGMcmSUJaIMy4hE7P8n7T2f48jTNLH/SIo46euFtLpd3d7t7q3Rzc7crJmZHdOeppsGoCfoQBLeEgQBGoAEQRCG8IXy6X/epM8sX/C0ze5mu2lSH3J2TqdThPZ2KjIqEllZqG9PvO/jklsmYdS2TEyw0DVQLOiaapkGUhVTVSxVMU0DKUWDEokRBxZl1CZYIMg01TJ0BCwiuJtJF/7tv/2jJ0+WbNuDEOu6xZiYmZn70Y9+oii6ZVl9/d3rqeVSOVC1/N/8X/9peWXBMJVcfmP01vDhwwc1TUmnU6OjI7lcZn191TA0QtDy8uLKylo+XySEKYq2sZEpFtUHDx7euzepKPrS0nImkzUMq1jUEGJK0VxdSW+kCkc+a71/f2pmbmb8zvjZ8+cxpZpmpjayhknWU7l8Qdd0qOnQAtQC1DCxaZF8Qc/lNcPECEuIOMIiOQBkmEjKHMocxl0hfYQFITZlDhdecsUPSp4fOJ7reK7tOq7v2a5DGGWCYUohIhARTJhpQcMEjusTyiEi0nYtCLkUAMGiqmiGjimxIFA0VTcNLoQUUkophEjGRgAA59xxHNf3/DBgkie/gilJZiUv8BHBhCFhc0RgMmFRTrhkfujajmM7QRhVo7gaRhXGHWn7YVRx3FBIj3NX2r7vl0rluufHQnqOG7puxLjjupHtBLYdOG7oebGQnutFEDFpe8IWiT0PYpBAGxMUEwgxoBwxgRGxdFNJgEbYlEviBTZlMNmbNtKr//iznzKOjrd8trg0p+kFQq3FxdlMdo0yMDc/Pb8wIwReXpnPFzYOHvpQ1bLpzHI2t+r5fGl51jALUewoanp5bX5ucYZJZEGtqGSkTTZSy8tLc/nseja96jo8l02pSi6f29hILRUKa4zp584dy+dXNG1jdXX2zp0be3v1Wi0qxV61EpVLwWazurVZrZSDWi3a3q5tNsul2G3U41o1rFaCaiWslINktEmwxnVYpRzUqlEY2IkyFYVO4MtKOfA9EUdus1Fu1EthYJdKXqMeNRphHMtGI2g0/HrdaTSCKBKlkmw03OamFwTIdXEp9r5+88W7d2//hZr3f8Wa/+bqu3fv3r774bdvXTs0DUywoMShxCXYQUBCIHMZXSlCgl2CXEYDTgMEbIJdBKWuwVxWwYgzItWCBnVAASYmNDQIAePMhYABi1JiYyQIlq4TOTIEBhHUlcyDJmXY9uyIE4dhG0NumRhYxDQQJZJgQYmNAEOQY8RNAxdyGgQUAgosaplYCo8SaeiQMwcjYZnY0KBlYl0Djh3mc+pPf/qPxaLiOE46nWlru3D69JmHD6d/9atf37o1pqrqsWOfTj2cWFyay2TXP/3swPSj+0PDfZ8c+ODB1L0zZ0+NjAyvra0cOnRgeXmxre3c4uLC5mbj+vWrH3zw/smTJ28MD586derKlSsXLlz4i7/4i76+vtbW1jNnTt+/P3ny5Ine3r6bN0dPnjx96NBn0w8fv//eR+O3x692XL43eefEqVaIoarrhgExEbm8lstrqgaSg3E3QROIuGkRyhxpB4Ta0g4ScKHMhYhDxBl3EZGEu0x4thsx4THhEeZgart+KYxLrucLaTMumJBC2lwm7zbClHGbUGkBLG3PdnwAiapZXDiYUGk7JoC6aeqmZQJQVNR8oagbprQd3w8wJgBAIWzOBQCQcxkEoW07EGEmhON6JgAIE4SJkLZ0EhIKCFtADJPxiksubOH6XhBFnh97folxx3HDMKq4XlSpNv2g5LiRdIO40ogr9ahcc7yICgcz2/ZC4fhuEDt+LJ3A8WPKHSpcJlwTEMwEEUw4gghiQIMIwmxmAANgIF2JGfz9RGNBnTAIsckEdjxBKBCSMI7ikn/23Mmu7mtPFmdPnjoOoF4opu9OjF28fFbV89c7L4/fGbk1PjwyOri8unCt46IFiiurcxcunlpcnJl+dE/VMvVGNDv/oH+oa2LqzoXLZ2+MDjyencrm1kdvDmbSq30914cGuu9P3u64fnl5aW5woOvWrYHR0b7Fxan+/nYAcjdudK2uPp6evru3Vw8D6dhss1lp1Mv1WqnZKO/uNCrlMGF8y6WgUS9vNavbW/Vmo5xATAIizUa5FHsJ9JRLfhQ6CUFTir16LU5OqpVws1mNIy8KnSh0qpWg0YhqNS+OeRSxRiMsl91q1YljVqmKSkVGkQgD++s3X7z7byvf/39f/x3WvH339od3P3z/LvDLlNiC+4L7lHgI2hi6pkGUokmJI4RvWQxBwZlHsC24D4EAFjMNDAFFgKqKoWSLZtHwhEMQ11QAAU1IH0NHEDBKbAiYYC4nDkWSIuGIgCBhc59ATpCQ3CNYQEgtExHCpXAZk5QICAghHEFaKKgQEAgpghRjDgFBkBaLGgTEMGCxqBsGhJACC0NAigXt3/0ff5xOp6LIn5y8d/r0yY8++mB0dORnP/uH99//jePKk6eO374zevTY4cn7d1paj0xM3h4Y7Pnlr342fvvmz372D3//9z/lnF682LawMDc7O2NZxtZWc2xs9PKVCwODPR9/8v6hw59ksxvXrl85dPiT3b2tkZtD73/wy7YLp0+fOZHJprq6O7q6Oo8c+ez+/QfHjh2bW5g5f/Hk1PS9lhNHLGiouqJoWiabNy2MiTQtompWUTEtQCFimEgAmW4gC1AAGcLCcSOEOWW2kB4XnpCeF5Qdv0SFJ9wwKNWIcDF3mO0z6UsvdL1A2q5te0I4mDDKhO14rhcQwlTNMkxEqNQNSKgkVELETIsI6UFEGJNc2NJ2LYBUzcjli4YJOLcxplI6jImEokpOGBOeF3BhmxZkXCY/5AcRJgwhyrj0ggBT7HguE5wJnjBEtusyKeJyOQhLrhcmeFcq1xw38IM4CEtBVHbDuFRr+nHZi0rSC7jjccd3w5ITRFS6VDpeVHLDEubSi0rc9Z0gcsPYiwIndAGF1GbUZtwVgEJAIXUYIgAgw/EEl8SCOhM4YYWdfyZ0ucDlSvhg6t6ly+cpgx9/8r7j8ExufeBGz5VrbSvrC3cnb62sL/QPdQ2N9D5Znmm7dGptbX5wqPN4y8HZ+fuF4rrj4uZWKZ1dunf/1uLq/NWOSxevnMvlU7l8auLe2N5uM5te7e+53nH9cmvLZ7ZNxseHFhYeLCzcn5m509t7qVBYHhrqmJgYGRzsfP16v1oJGvXyznajUS+XYj8MnP29rVo1rlXj/b2tZqNSr5V2thvbW/V6La7X4mRLqtfirc3qZrOSQE+55IeBXa/FyQKVbFu/l6gS1jm5srVZ2dwslctOqSQ3N6NmMy6XpeuCSlVsbgZxLKPIefPV62SH+hfONf8fWJPMNl+/+V5wDyOJkQQmN3SmFLBpsGQ88b2S4F4yOwCLIsgpsYHFIZCUOJZBoEk4tZGBLdV0mYMhhYBwZhPMIaRKUYeA2LYHITUNKKhtGVBTTE4lMBEChBFpC9dzA4QJhMiyAADIMEwAEYRIUTTDMIWQjuMSwkzT4lxQykzTMk2AECaUAYAsC2BMKGWE0CCI5uYW/uzP/uzm6ND1jssXLp756d/96NjxT6+0t124ePbylbYr7W2tJ46M374ZxV5ByRw89NHwjf6W1iOfHPigu6fjwoXzBw581NFxraena2Zm+oMP3ltcXNjd3e7p6fzxT/66p/dqNrd66PAH3T3twzd6f/PezwkzJu/funa97c7dkYuXz9ybuHXh4pnunmtHjx0eGRn65JMPr3W0HT/5ycUrJ8+2tahGzoIGxLCgKNlcUdWsfEHNFzXTwggzRTV0A0DEEGYAUt0AEFHGbQtgyiTjDhcOZZIJ2wlj5njc9aNqndoOFrbth04YuWEcx5UorpTKNS5sTLi0PccNXC80LZTNKapmUeZw4WIiLEAwEZgIxl3GHUyYbliECkwYgNi0oG4A00IIUc4kwQwjCgFmTCJEMaKc2xgzQgVEVNNNxm3b8X+Ha1RI20YEScdOVjnp2EnOGzNqu47nB47r+WFIGXc9Pzkc14tK5aBUCsol7rp+KcZCMMf2SyU/joXnYiGwEE4QSN+ntu3FMXMc7rjMsZ3QJZJqQKcORxxjQYRnS99mDk8IYC4xxCYiFpfE9WXCDYeR6/mSMui43HZYUcnGJX9jY6W5WV1ambtxq+/R3OTS2uzM/P10fmVq5u7tyZtEmI9mJyanRsfvDEzcH8kXV+ef3OfS3HtaXVx+2HLy8KO5qajszS5Mr6eWdKNw7+4tW5CNtaVCdl0KNDkxls+v5fNrudxysbhimhsrK9Op1OP19bnV1ZmlpUebm6Vmo7S1Wa3XSslRrUTbW/UkFbTZrCags73V2Nlu1mulzWalXosTyalSDra3agm+xJGbrFEJTZPI3o16qVoJm41yHHlh8Lupp16Lt7bKtZpXrbrVqler+c1mUCqxIET1uhtFol6Lv/v2zdv/Eaz5nQ71/3798O7bb35w7IASmxIHAgGBwMh2ZIQRh4AiSC0Tc+ZYJsaIM2onc4rrRJQ4poYYFhQyNasaBY0jBk0EADINoOsmhBghQimnhEOILQNgiKEFKWaCCQSQqZucck6567iUMQQhY1QIblkmZ4wQrCiKZZoYY8PQDcNgjDLGMEYQAk3TMMYYYwghIQRjBACAALiuY1lGPp9ZTy1vpFeFJAibAOqmpUJkYGIpSta0VExAXAoANHRDsR3OOJY2xRhgDIVgEFoAWJxThIAQrFSKL1w8/3d//yPCjCi2i2q6qKQdl0gbm1bRMArZ/KppFSxLAUBlHBIKFSWn66quaxAbqpHCTNPMnKLnTEsjDFvASqcziqrrhpUvKPmCgjEzTGBaECEKINF1K8EaC+CiogNIGLchogASJmwiJRbSwJjatvB8IiWglDmOG0Zc2I4bxKUqRNS0EKFC2r4fxABS3YCMu5iIhN9JZijTwgknjbCwAIGIWYAkNxeKhmEixw4SKYBRmxLpupHgLiWScxciRqhAiBEqmHCEdAnlCDNMOOMCIoIJwZQ4nks5gxgJW9quRARTzrmwhbSZEK7vRaW4VCknAhl3HTeKiBR24FNbSt93ozAol9wwcsKIux61bSIltQV3bSy5iaFFEJIECYI41pFhYgtLCjmGHFOHcZsCZJhAS7AGUYtLgtnveBzGsetLxnGjWZE2FZI6nvADOyr7cc2vNONSPXAj4Zcc6qC4FlSaUaUW1BtxueKXK57r0VLFLZXdKLZnZif7Bq83tkqlqluu+ZVaWKtF1WpUrYTVatisl2q1qNEo7e7Wnz3b3N+vb2+XGg2/3vDrdX+zGVer/tZmudGIS7G32axsNqtbm7Vmo7K3u9molxv18vZWvdmobG3VdrbrW5vV7e361mY1WaMa9VKyTCW4kxDDlXLg2DSRwxMkqlWjWjVqNqrVcimKvCh0S7HfqJfr9TgIRBzblYofhiKKRLkkKmVZLgvXxZvN+Lvvvnz77vs/LKPww9t3b9/99vu3tvQJFghSpWjkc6qmWghy00CaaiHICnlNUy1VMQkWGHGChSM9ghg0EQWUAgI1q5jKqht5ASiG1DAQggxYxDKxoUOChRQehBRBRBCmmDhSSi4wRAgAiomp69CyKEEQmARDy9QhMCEwKUGeIzGGmqZAaHFOpeSJlgmAqSgFTVOFELZtM8YgtDRNgcg0LRVAnXLo+x6EkBDsug6EgFIiBA8C33VtxgghSFEKhCDOmevaGEPOCedUCJ4Qn5xzxhhjjBDi+36xWFhbX2YcEwINQ0swTkobAAQB1g3VBBqEgLFEn/IR5ErRMnRKMPM8h3Gq65qua6ZpYox1XTcMQ1E0QwfAIqpiGjpEkDFqc+ZQIhXFNC1MqM24mzA4XLiE2oTahErKOOWCC9t2fdcLCOVMSOm4QRhTzmzXjUqxdJy4XBa2HURREIVcSAtAC2AAMWWCcVtIhzJpAWwBrBuQcYdxB0BqWljTQTpTSAQyIT1CJeOO7fiMO64XSdsnVNqOz7hNKBWJkU5wxrl0bCY4QAgiKqTPuA0RcTxPOpJLhgjwI1vaklDH80tRXPWDkueH0nbjctkLfS6FsN1ypRGXaptbe9X6ZlSqYirK1UajuVsqN4KwEoTluFSr1Brlai2IS9KxHd91I88OpB1I7rKg7Duh7UaOE9pBJYjLURgHwuZxOfRDO4idWjMOS3ap6kclP4j8Sq3sh97mdjO5MypFpUrc2KxWalGpEpSrYVwOqvWSF9jNrVqlFtfqtVq1XqvVNzc3N5vN7Z3NRrMSxV6pHGxuV7Z3S3FZbm3HW9vlRjMOI9sPZLkSNBrlvf2dV69evHr1/OXLpy9e7u0/3dzZrdeb0e5eY293c3en+fLF3quX+69ePn39+fPvvv0qaZn44vWL3Z3ms6c7z55uP3u2/fr1/hdfPH35cuvly+3nT7d3dxp7u82n+1u7O439vc3nz3b2dpvJ+auX+3u7zb3d5mazklzc3qrt7jTqtUqz3qhWylub9WdPd14833v+bCfZv3Z3mlubta3N2tZmZWensrNT3tmJnz2vfvfd8++///K/r5r/H8Oa337/7qsvvyVYQEATHLFMrCqmZeKEajV0qKmWoUPTQBBQXQPAIrZwlKJqqqZNBANYz6tKOl9cy3CLMMILBUXXTEXR8vliKpXWNEPXTV03s+lsMV/QFDWbzmysp9Siklpbz6YzxXxRKRay6ZSqFAr5bCadKhZy2cxG8md6Yz2VWkul1nK5zNraSjabzuUyqdTa2trKyspyKpXK5XL5fD4phVpdWyooGVXLq2o+n88XCoVcLre6urq6uprNZvP5vKIohUIhnd5Ip1PLy4uZzEY2m85kNjKZjY2NdUUpFItFXddVVc3lcoqiGIahaZppmqZpGIaaSq0qSiG9kUqn0ysrq6lUenU1lVrPrq2trK0trawsr6+vLy6urK9lc1lt9vHy4pPU0tLakyeLa2tr6+vrT548WV5e3thIp1KppaWl6elHS0srq6upubmFjY3M2lpqfv7J2loqlUpnswVVA7oBdQOurWeWltfzBa1Q1LM5pVDUTAvqhqUblgWQppuabpoWTKYkRVOLmpLJZXOFPBNcMzTN0A3LVA09nckVimpys25YpgUoE4RyxiXClDLpuD6AmFCOMFVU3bQQZcn+6nNhE8oxYQjTRL1iXCZfT65DRLiwHdcXtkMYx4Rz4TJuE8ocz4UYUU4px4iYiOBcXjdMDCA1TKRqZiqdUXUtXyxkcjmISFHR8nnFAmgjnc1kC6mNbC5fTG1k8wWtUDQKRT2TVTbSubX11FpqPZXeWE2tL60vL6w8efxkdmJqYurxwwePphaWnyQXH80+Wl5dWl1fefBwcvLBndmF6fX00tSjuw+m7ywszi6tLC4uP3n4aOrJ0sLy6tLcwuzjuZnV9dXl1cUnS/Oz848WlxdS6dV0NpVKr62sLc7OP5p5PLOysppKpVZWVpaXFtfWVh4/fjjzeCqdWcsXUrNz99dSC0VlI19IKWrW80W9Wf7qzeudnS3HkZ7rGIa2sbGaL2xksmtFJZ3Lr2Zza6ahIGg4NpOCODZzHS44ZhQ6NuMMGXpR1wrFQqZQSKnqhq5nisW1bHapkN9IrS+lN1YK+Y1iIV3Ib6ytPllZnl9dWVhanF1Znl+Yf/R45sHjmQezj6eS/pq52YcL84/nZh8/npmen5t5svD40fT9hflHK8vzqdRiemNlaXFu9vHUo+nJubkHKyszi4sPZmfvPn1a/uGHr/4grHn79u3bH969+eq7ZCqmRAruYsR/Dy75nLqRyiWqs6ZaCfpYJkKIEMwwwKZqFjZyHVeuf/ir908eaTnbcur40ZZPPz3y6adHDhw49OmnRz755GDriVOffHLoyNHjx48dP370WMux44cPHjr62ZFzZ85+9MGHx44cPdl6ouXYsdaWY5cutrW2HDt44OPjx44cPPDxp4cPHjzw8aGDn3z88Ycff/xhklE6derEyZOthw8fPHjw4wMHPj548ODhw4ePHDly+PDBY8eOtLYePXP2ROuJI8eOf/bRRx+dPn361KnTR48eO3ny1Llz51paWo4fP3769KnTp0+2tBw7e/b0+fNnW1qOtbYev3z54unTJ8+ePX3x4sW2trbW1tYzZ85cunTp/Pnz58+fv3jxYmtry/HjR06dar1w4fyFC22tra3nz7cdO9bS2nqq43r38ZZj59tOX7hwrrW19cSJE+fOXmhtOXPo4PFTJy+cO3ehtbXl+PHjbW1tly9fbmlpvXTp0unTp48ePXrgwMFPPz1y+PBnH3984Pz5C2fPnj9+vPX8+QttbRc6OrqvtHdeuNg+MHjzSnvH2XMXL1+5fu1699VrXdeud3V0dnf39F263H71Wkf/wFD/wFBXd29nV0//wFB3b09XT3dPX29vf19HV+fZ8+euXG2/1nHt0pUrl69c7erq7ezq6ezqab96/cbIqAVQGJU8P0SYmRYEEGu6KW3X80OIiAUQJowLG2FqAUQox4RjzBKIkbZLmUSYI8wYdzARjhtSZluAECq5SD5ljMuoVGKCO55jQXN4ZPDmrZu3xu7eGBm7OTo+euv2wOBwR2fnzVujo2Oj47dvP5iaHhgcHhy6cf/Bw8GhGzdHx+7cnRi9Nd7V3XdjZOzGyNjN0dujt24PDY30Dw4ODA0M3Rjq6eu9cevW8Ohoz0D/xfb29o6O693dN8fHx+9N3Lpze3hk+O7EnanpB/2Dvf1DPWN3Rmbmpm6O9Q+N9N6dGJ+afvDg4f07925PPph4+Gjq7sSd8TtjM7Mz0zNTkw/uPng4sbSyMDv/aHF5fnF5/uGj+1PTkw+npxaePFldXV1YWJibe7y88mR2bnpufnppeS6TXV148mh5ZT6dWUttrBSLOceR2ztbb9589eLF862tZqNRQwhsbKzm8ql0ZlXTc4XCejqzoql5y1A5QxiZEOiUAEYhRiajkGCLEpD0ZlFiOg52HCylRYhqS5KU1xBsmkZR1/K6li/kN3QtryrZ9MZKan1pI7Wcy65vpJbXVp8U8huZ9Iqq5IuFXCGfKRaySjGbzaxlM2uqmi4WU5qaNfSiqmZz2dVsdkXX04XCaiazsL9ffvfu2z98rnn71ZffOnZAiUSQJVuProFkitFUK59TVcVEkEFAGbVNIzEQm8CChmZaBmCQIh0AzbKp4JBpigYAtG0bIQQApJRSygghhBDHdiQXru0IxiUXFBMMkSNtgrBlGoRAShBnxJZcCgYsAwLTsQVnRNfVxIQOoYUxdByJEEhWKoyJYZiJ1RgAC2FL2tT1OIC6rmuqqjBGGaOWZbqunaxgrmuHoZ+4Sx1Hck4pxVEURFGQ/ArG0LIMx5Ge53LOpBRRFDqO7XrCcaXjSCmF4ziVSpUQBiGmVJqWLh3i+zbnFCEkhK0qZiatICgY5UIwAExd1xzHTnzMpmlQig3D0HWDMQYhRAhTShFCCQnlej6hwrSg4wa240vbpUxI23O9MAhLQjqeH3p+mAwdyRFFZT+Igiis1CpRKU7MNUxwL/C9wGOCMy79IJK26wdRFJeT/5CMJ4mf3zBN3TAAQpRz3TRVXQMIAYQIpYQxLqWwbUwIIhggKKRMsMYChHHHMJFuQAApRAxhTqgkjFPGmBCJ30fYAiAQxsHm9pYflIKwHMWVKC6XKhU/9IMoiErR1s5WtV4vVSpxuVyt10vlchjHcblcrlbDKHa9KIqrlWqjXKm5nh+V4rgch3Ho+m5QKrthJD2fSsf2A9sPS7WGG8ZRpeKHvuPZQRSEkR/GXhA71UbsBjSI7TD2KrVSuRoHkRfGflwOo5IfRG61Xq7WS8n51k4jyVLE5aDerMTloN6o1Wq1crlUKkVR5Ffrpc2taqNZLleC/afbzc1KtRZvbzebzdr29lYURWEYbW1tVyrlp0/3vvvum1evXuw/3d7b33z6bPvV5/vbu9XtneruTrJD7T97uvPyxf6rl08/f/Xsqy9fff7q2d7u5tP97Zcv9l++2P/qyxevX++/fr335s2zr79+/s3Xr7/5+vWrl/vPnm4/e7qdbEzbW7X9vc293WajXtreqiVUzmaz0myUEyJ5Z7tRr5W3txo7243dncbuTr1eC3f36ru71UYjbNSjvd369nZla6u8uRltbcX7+9Xvv//87dtv/rC55oe3v/3+3Zuvvgv8EsFCUy1dA5aJTQOZBkKQUSKBRRLOJfG/JDuUphkWQIZhmbpFMSMAEwsjAxKLUEwQwo7jQAgtyxJCIISEEJZlAQtACwjGE5RBAEILIAAZobbkUjLBKcEQI6AqBcvUCYaCU84IQoAQZJq6ohQQAlJyhABCgBCsqmqxqOi6rmmqohQQtjCxIDJ0vaCqRQgBACawzEIhxygRnOm6appG0qiWYAqleGNjnVIsJXcciTEElpn0ZmIMATAhtBglGEMLaLqhQmiZps4Yo5QyJgzDSqWypqVDpDOOMAaarpomKBa1xSerxYKhKpphaJZlFAo5CC2EQLGY1zRF05RCIa8oCsY4l8trmpYkMBRF0TQVQKgbVrIf6YaFMFW1RJ0jjEtNNxOZGSKSbDGUCWm7mDDCKBPcBJZhmbbrcPm7aEJRVQpF1bRg8pXkfmm7AGKIiAmspKYTEWwCCyCYLxaS5Sv5CCCom4YFgXRsiJGiqZqhcWEnXHLyrumAceef2WXMBLddJ7nfsEzCKKaYUIIJNU1EqGBcQIwJI45nh7HPJY1KoeO5YRw5nusFPuVM2NJ2Hdt1MCWM24mshgixoMUEo5zYrsAUaZaFuQSEGhBByqTnW5hYmEDKIIbS4ZQTiC2AdOEk0pmuW3nKge0xxxfSocKh3CaOx4VNbJfZLkvkquQgDLq+rNRi15d+4AaBLyTnHBMKuEDzh7NuAAAgAElEQVSuxx2XuB6LYy8uBbbDPc+pVEqVSqVcrgRB9PnnX0RR3GjUg8CL43B7p1Gvx/tPt3b3GvVGWK0G9VqpVo23t+r7e1tfvH7x6uXTF8/3dnea+3tbuzvNne3G7k5zb3fz2bOtp0+bu7vVp0/rz541nu5vJWRNwtdsb9USNIlCJ0GZJKwQ+DIM7EQar1bCeq1Uiv1aNW7US5WyH5cc24blsrO5GTUaQalkhyGvVNww5HEsw5DX68GbN89/+O03fyA3/MP3371789V3UnjAIsmRmHR1DSRUZULiYMSLBT3x7OoaABBbABUVLZvNU8IxJGpO0QsatjBGmAvGOdN1nXOmaaph6BACwzA0VeWEhX6AIQKmBS1QzBcKubyhGQQjBC0ELccWBEMITENXi4WcrimGriY5uqQAmDFCKU7QR9PUhEyBEJqmYZo645hQoGo5VcuZlmZaWj6fsSw9SW9CZAJgeJ6dzEemqUNoUYotywDARAgkuUoITSmZ60mILEoRgCbjuFQKKYMQmhBahGDLsjRNx5giRCAgpqlRZtkOpQxalqmqaqGgpNazhbxuWYAQCKBRVHK6rmAMIDKLxRyAZr6QLRaLqqqqqoIQ9H3PNA1FKZqmkc/ni6qaKxTyhaJhWgBhxgXCBCJMuUj2nYQ3+b2DxvNDyoTtOgBBE1gQIy6F7TpBFLq+5/re70mWxDrsuH6CVgAS1/dt1+aSI4IQQYqmZPPZfDGvGVrC5+umbliGCUxMsaqrEMOCUoAYI8wsgE0LWhAl2jyh3DAhJpgwJB3ph76qa1wKadsIk2Q18/zQ8TzHdV3f8wKPMFyplfzQ8UMHU8wlD+MwiELCaKlScn3P8RzHc7mwhW27vi9sySUjDBGGCIMW1DGnwnUAJQYC0nMBwappQkYRoxayEu+y40kmMbcxoqbjU8wM26PcxkRAKiCipuNzwoFwiONz1xdeYDueCGMvCY7G5SAuB+Vq5Aeu7ztB6LqeQNh0XBaEMoptIYHrs1LZ93xZrkTVaqlUjj3PtW3niy++2t/fbzbrjiMbjdrWdr1ai3Z2GvVG3Nws1Wph4p158Xzvqy9fffH6xbfffPn68+evXj5N4CbBoP29rZ2d2uef7z1/vvXy5ebTp/VGo7S1Wd3daSRzzfZW7dnT7S9eP9/daexs1xPQSXJSiRTVbJS3NquVclgph6XYazbK5bJXLjtxLMtlubtbrladnZ2S72PHgUFAG42wXg/r9ejLL5+/ffvdH9iV9cP33779+s33tvQNHUJAVcUsFvR8Ts1llUSQskwsuGsaaGU5pWtAKRpKUTdMoOqGYQLTBBAgVdHS6+litsgQpYTeu3fn4cMHiTCEMVTVYtKwbQvR293Tdu68qRvQAmpRMTRdU9TU2nohn+OMPJy6f7X9si25phYL+SzBEFiGaeoIgdnZmZs3byAEJifvjY/fKhbzpqkXiwUAgGEYqqpijNbWVgYHewHUpU0xMQHSVS2vG0Uu0MPpyXPnTxaVbL6wce78qYmJu1LyQiGn6yqEFmOEc7qxsd7X35Nko7hAlMFE0jItdfrR/ZbWI6O3hqenH3R0XNvYSGGMAQAYU4wpwdwC2tr6/OBQN6FASGoahmFY6XS+WNBWVpZPnDx2vOXT2bnph9MTLa1Hbt8ZBVAvKJn19ZVCIVcs5inFk5P3xsZGKUGapui6qqjFoqpgip8sLd4aH5t8cD9pgZi4PwExFtIBECeMLMJUSGfy/tRGOsuFTBYc6dgWBMn5o8cz6WwmKsUdXd1d3b2G+TtKGBMmbRcikisUr3Vcu3137N7kXYAszVB1U7OgiQgkDFNOfp/GpJxgiixo3rl3WzPUxApMGBE2RwRhgvzQY4LZrnR9m1Doh66whe06iGDTBBAR3YCUSYhxooJ393ZLh5ercVjyorLv+pIw7PpONp/p7u26cXMoSY16geuHPpdJbsuJStHo2M3x26PlWmS7zPGEGzlEEsiADvWh0aHpuWlq04mHE+MT45qhCpvbrpQO5zZhEgWxMzo+OLswFVc8JpHjs7DkchuVa2Emv9Z66sjtezfDktfZfa2z+1pU8uvNSrkaJdBTqkbVeun2nVHTUuuNcrUWVarh5mYpju0gYnFJjt+5sbb+BEB9+tH9B1P3PM/e3dv+5ps3Oztbvu9Wq+U4Du/cHfN8+erzp8+eb+/tN1++2kvmF0MvriwvmIays91YWV5wbPZ0f/vZ052n+9vPn+2+fLH36uXe/n5DUTaePWs8f7755RfPn+5vPX++u7Ndf/35M9Morq0+KRbSwFKXFmctU2k2ylHoJBCTqOMI6t1dVx2bhoHdqEebm6V63a/XPd9HCwuTE5PDhcIyhPnz548/eTK1uRmXy24QyK/ffP7DD38Y1rx9+/aH37776svvHDvI59T0Rj6TLhg6VBVTU61kzDF0aJkYI1bIawnWGDpQNKOgGwBhTTcNw4IIKwUlny0YuiElP3Dgo/b2S4pSQMja2FhbW1vBGDBGZqanP3jv/Z6ubskFTARYiBCAuqqpSjEK/YH+3r/5679E0Mpl07qmLMzPQmAyij3P6ey8/tOf/qRYzB86dKC19fiVK5eEoAhBy7IghIVCgTEyNXX/5z//e8NUVC1PqLW2vkgZ5ALrRnF1bfEX//QPff2dQ8N9La1HV1eXPc9R1SKlmBCUJJgVpfDrX/8y6bXhAq+tL5mWiollWsrpM62ffnZgeWWh7cK5q1evtLa22Lat64aum5YFTQMyjmbn7h89djCfT+ULaYTA/Px8KrVBsFhYmLvecfnoscPj4yPXrl8+fbpleWUBQF3Vcqal5vOZXD7DGOnp6WxpObaykjTgpJZXlrzAL1crp8+euXr9WndvT8uJ1o6uzo6uzon79xmXhPKEr7UdLwjjzq6eRzNzhaKq6lq+WCyqSrKMtF28MDxyo39wYHrm0cefHBwaHklcPBAR2/ESBUrazq9+88vJB/cOf3ZoZPSGohVX1pYTUebR42lMUS6fWV1fWUutZvOZXCFbVPNtF88/nH6g6oVMPpXKrKYyqxvZtbXU0sOZ+6qezxY2LKgTBpZWFjYyKYAAxMi0IMLMAsQCRDp2VIoBgi0njq+sLWZzKUStpdU5RctV65Vao9I/2Hf2/BnNUF3fphxLR0hHOL7rh4EX+NV6tf3apfZrl7KFDYD1gppZXJtzIuGXbebgDw78ZuLhnZmFh+1dl06cPT716IEfepRTw9QwtRyf1zfLHd2XR8cHs4U1JsHy2tziyuOt3WqlHkCiPZy513Ly08XluROnjqfSq/VmOYiccjUKIsfxuBfYtXqpp6dj6uFEUck4LgNQUbX085dbL15tzc5PnL/QIh14/8HY9PTE4FD3+sby56+fff3N63IljuOoXI63tprXrl1JZ9ZKZb9U9lyP+oH48ouX+3tbceSpSs40lNnHD48f+9Q0lGdPd7a36s+f7Sag8/mr/b29+t27I5RqlpVj1KLEMo3i68+fffnFi5Eb/fNz091d17o6r6Y3VsZGhxv1UuKySSLgSfl5+5U2CDQI1ExmKZ9fk9La2yuHIbl+/czdewODw+237/RdvnzCtsHubs2WJPDkt99++e7tv9Zf8/tHJv/2+7dvvvrOdX7HDRs6xIgrRQMCmgjhxYKuKiajDsESI5GMPyZAJkS6ARJtEkKSTeeBiaCJgsA7eOjDX//mF6trTx7PTn3w4a/PtZ1aTy2tri0tzM3/uz/6448++Mh3fU3RNEVHAFFMMcTZTBojMHbr5k//y4+HhwbmZmdajh89fOhAb09X8jyDBw8mP/rogydP5n/yk7+9dOnChx++jzHUda1YVIQQiqLoujY/P/uTn/zn4ZH+9dTyb977xYGDHwwO9aysLmykV+KSN3yjL5dPnTt/4o//5H9//PhRqRQVCjmEgONIw9A4p/l89he/+MfhG/1FJdPb19F64sidu6OZ7Nra+uLVaxf/6q//rLvn+omTLaOjI3/7tz8CACCEVEUzTYggwwTMLjw4dvzw7TujRTV/8uSJf/rlL8+duzA2di+1sW47dGCoJ1/YGBzu/dsf//WNmwOEA00vWEAFUFe1PMJmb1/ne+//cvz2zcWluc+OHDx46JOpRw/T2czFyxePt7a0nmz90//4H/oH+/sG+3v7+xJvrqabhgm4dMKo1NnV09s3kCsUHs8+PnvuzLm2s6n0hm4a1zs7rlxtbznROnF/8uix4y2tJxCmFoDSdsOolIQMgjA83nr00pW2kdGhsds3b42PDAz1njl38vTZEx8f+GB07EZPX+e5ttPjd0b7B3uGbvRf72zv6eu81nElr6Rv3R4eGum91H528EbPqbPHrlw9f3didOLBeGf31YKaPdd2tqunY+z2eLmS+JiFtAPp+I7nub7PpTh/4fy1jqsQW70DXS0nj/b0dy6tLKTSq3MLMwcOfTww1FuuRkxg6TDCMOMyCCM/DGuN6vDI4Icfv7ew9BgSvfXUkQvXzt5+MNrRd4XYZsuZT+9Nj43cGei90fHeJ/80dnc0LkVcUoBMKiDmICy71zovfnr0Y0jUbGH94KcfdvVenV14eHNsMKq4FlKLWtqPnMXlJ0M3BhCBXuA6nrRd4fp2pVaqN8vdPddbWo8YZnE99eR6x8Xhka75J1Mzs/e8gMw/eTBys7f92vnVtbnBoe7llYVavVSphp5vl0rx5mZjZ2ezu/v6ufMnG80yF3Dm8WQut/Zo+v7DqYnXnz/fSK1AoDfqleWl+Xt3x/Z2t/Z2Nxv10u5OY39va3e3vr1T7e1tHx8f2NyMph/ey+XWs5m1hflHCGqeywb6OwYHOsfHhoqFjbFbQ5WyH/gyCu1S7Aa+aDZK+/ubVy6fHx0dLJfdq1fbxscHi8W1gYGr8/OTCBVOnjw8MNjuB2xq6ta9eyNbW+XAt2vV+Juvv3j37l/qG/6vWJOU7/8/HkH/7vvvf+u6vmUiW/qWSUyDGDrWNZSkFnJZDVhc1zCwOEbSNKimQlW1MOSaCoBJTA1pRTObKmh5A6gwjoKDhz76X/7X/3louK9/oPvP/vzf35sYP992+uNPPigWtWxG+fD9A8tLKYwEwUIKnyBBkFCUou2wu/fG/s2/+Z9+9eufLzx5/Cf/5x9dv35laLjv8OFDCwsLfX19hw8fzufzP/7xj48ePXrx4kUpJYTIsiAhTNcN3/cWF5/8+z/94xMnj80vzPzxn/xvl6+cH7898vEn7z2auT82fuPU6ePzC48UNds/0D08PBDHIULAsgwpOWMkigJFKf7lX/35e+//k6rlfvbzn15pb3s0c//EyaMTk+MAapP3b7ddON124Uxn5/WjR49Ecey6HiUCAmaZxPHk4tr8f/qbv/j1B7/JK8VfvffesdZTfYMjhz87Mbe4uLy+fPnaZR3oqxurXX1d5y+dwxzllFwun9E0JZ1eZ4z09nb/+Z//x4MHP3n06OGPf/yj4eHBkbEbR08czanZ0Ts3j5082tHbcbWr/UJ726P5x6XaJsACMYm5hIS5QXjl+vV/+MXP+4YHJqfu/uMv/m7+yczQjf6bt0akIwaG+i9duaybRq6QHxm9mS8W/DBQdQ0g6PoelyKMo9+898ubo4PbO/XFpdm+/k5Vy3V2XZ1+NNl64ujEg9v9w923bt9I59ZujA509V47dbalp7/jNx/+cm5h+sHU3d7+jouXztwaGz57rhVTM1/YOHXm+AcfvZcrFK60X+3t7x8YHN7e2bMdjwtbSEe6vu2HXlSGhP3q/Q9+/cEHc4tPLrZfvtB+cXVjtbe/58HD+0W1kM1nRkaHHc9mgkIMKGec+9IOuXDLlUp3b+ef/+Wftp76NJNf/s2HP5tfnx9/ePts+zmNKD97/x+G7w4sZec7b1w7dvbTjeKaDLiBVAOrzEXEBtzDLWeO/NWP/vzK9QtzC48+PvhBOrs2/fjB5NTddG799NkTY7dH5hZmEaF3JyYM0wrjmHLOuHB9P4giabPOritHjx3o7bt2b2L0fNsJVcvk8qvpzLIJlEx2I5vNTNy7e+vW6MTE3Wq1UqtVS6W4Wi3XquV6rVQqBXduj/b0XJuZmURIXVufbzQipZjTNWWzWbt7Z5xgWMhnAt9hFH/11es4suv14MWL7WYzKpcd36dDQx2PHt1ZWZl5MHXn0cykH3Bdz9o23NyM7oz3uzZIr8/dGR+cn79frbpRJKpVr1r1ymW72YyEtM6dbe3suDI/Nz3Q3zXzaDIM5MLCtGnkA18MD/VSAjLpteXlx6nUk/39Rhy71Ur0r8xe7u/vv3jx4t27d4mC9dvfvv3m2+8SrMGQF/K6qgBdw6oCIeAQMFWxdA2l1vOGjgiWho4NHesaNHSoFA1VMSkWNneLGSW7nuOQ24IndpWTJ1smJu62th5fWJhFGEBoDQ+NXLzYvrKcQogjyDhzk0YIYBFN0ylF04+mTp8+8dlnhwYH+69fb79y5ZJhahgjIcTly5ePHj0KIezr62tra1tcXAQA6Lqu64au66ZpCMGmpx+0njh6pf1CT+/1js4r59tO5/IbjCOEzYOHPvrJf/nP1zuuXLx0bmCwRzeKhELTUhG2dEMBQPd8ubK6ePpM66nTLZ1dV4eG+zo62/OFdKnsC0nar168e28MYWN5ZX74xkAul6EUcy4AQKYJIcBM4KXV+evdV9uvX7nWce3OvXttFy8XFcNxoyCM7j+cmH8yW9Tyl9svjN0Z1YwixFZRK6hawdAVXStCYIyP3Ry9Odx+5cLU1MT1a5e7uq4BZFJO1jfWRsdv5opZyklPf/fwyKCwpZA+RBxhrhmWomkmBKNjo5NTk+3X21dSiz3915dWFoRN43JYVIt3JyaY4Kvra20XLyyvrjDBuRSJXAUxAggKW1y4ePbO3VuOy/OF9NBwXzaXmno4MTF5u7Pr6vBI/7HWz85fOLO6vnRv8nZn97XhkYHhkf4798Z6+jpXVhZ6ejvar16ceTx16fJ5Rc0tPHl8+kxr30BPOpu5NT7WPzh4a3y8sdlMUlFCStt1hXSDqGRYcHD4xvyThcHhwaWVxZFbw4al1pvVcjXqG+ieuH/HgkYYe8JmfuhKR3Dhce64nl+qlGfnZ8bujHT3Xc0Wlsfu3Ri/P8Y87pScvJFr7748fGeQBWj6yeTC+oz0ie0TbkPEdCJM7kDpkXv3b03PToyOD5tQnZy6OzM7VW2UGluV+cXHHV3tN8eGFhbn5+bnddMM4zgul6I49sMgjCPX922HLy7N5Avrk/fHLFBcWn5cVDYqVf/Lr57nC+lbozcZo1EUzM/PFov5ra1mHIe1WiWOgzBwfFdsNisI6UEgstllzs18fpVS49n+1tsfvm02Kr4nnj/bfTR9v5DfePXy6Tdff1GteW/ePH337s3Tp7Vq1Q1DZhiZOBammQ1Ce219yXHJ9k610YikNH3X+vxls1G1dTVVLsvNzahcsctlu9Hwo4jHMXddmEotYmRqas51WDGfjkJna7NarYS6lvc9sb+3tbQ4m8utbm5FjbpfLju7O43vvnvzr5lr9vb2KpXK7597/913v33z5hvPCywTWQYyDUywNHSKkQQW1jRL1yzDgLlsEUJKMDcNCCHRNF1VdU0zCvkiAphhpuVVvahB3fJcm1Ichn6SJGKMAGD+c8IIJK17tu0mpnpCGKWcMZG4cm1bJHrTP/fg6Y4jEbJczyYUEgotS7eArih5TVcIgQBYnDPT1HO5tG4UITIMswigoulZaRPKoKYXLKBRBhyXEwaSyjUhMSYmwgaAGiamBVRVy0OkJ0wwRDomluuJpIk2SeURaiFsckGDwHUcKSWnFLmexBhaQIfIRFiDSLEdgrGJCXBdx9ANpaiZhmUampSYUsA5ZAw6LnMcBoBmWUo+t2HpBU6AZRShqUqGMNQdQRgxETIxhowRyzKSYkDfcwiGlqX7vh+FJYyYoVuMcikEhEAI6jjcdpgX2OVq6AV2EHm2K7nkYRy5vkc5VzVN2IJyhilJCkABgpQzTDGAhm4UAdSYQIwjIQllUNpUSJLNbwwO93X1XF9cnqccOZ4wgUY5YpIISWyHEQqSekMANdthtsOEJEHkBJHnh67r27YrhWRMEC9wHM/mgrmuSzD2XMf37XI5iCKvXi9FkVNvlrxQCoeUKkFY8rxAeqF0PO6FktvY8WQY+24gXV/aHhMOKdeCSj0sVX1mk/+btPdqjiRLzzT/3N6soO31mO3N7hhnyJkm2WR1taoukZWZlQJIJBIqtI5AIAQCWkYghGv3c44f5dpDQ2ZmCbK7qrtEZtVeeHUtZwV3SLqFhYW5BRxwmPlnn3qfl9oEYF1UB5ZHTQ64bxIHeENqYtU0VcYQMjXT1AgxGEe+z3yfMQuN5/7sKiQcOD61Pcxs6A/5aOaPp8F4MpxdTi2HTWaj6WwcbeI4vu143HGJ49LR2JtfDl2PTqY+JrqJtdHYG408xvFkGt7eza+up+HQnc6GL19dj8f+ZOJNJ97d3ezubnJ7O3r9evr69eTubjibO8Oh/c03v//8s5uvvvr8u+++ur2dvn371Q8/fPvNN7///PObP/3pix9++ObLLz+dTJzJxL28DL788vX19eizz++++MdXN7ezydQfj+2729H1pXd347+6DV/ejkcj+9WreYSJmE7d0ciaTNybm9H19WQ88qOG8dXlOBqT31xPxyPvaj6+uZncXA+vrvzLS+fyyp3NnPnc//abP/zww5t/daz58ssvb29vfyqj3rx5+9VXfwrDEYIkYvH53phgj2CbUu44juO4hFBN0wEAkiSbJnZdj1CCsQkRYJSYCCIAgKoSAAmAmqp4nmuayLK457kIwSgxgRAwRhkjhGDPcxzHGg5D33eDwLdtCyFIKdU0FWPMOeOcBUHg+57rOphAypHnW9wyMQG6IUeA2Ghg5Lo8UlcSCgwgMQ4YNzBVTKwyZlJqImRgDC2bGUDjnDgOtx3KOHI9RhmMliMog5RBbpmEQt2Q/cDhFqXUhFBnDHu+bdmUMUIps23HsrjjWLZDw6Fj2SahGiYqAAPPQY4FXBvbFnY4ZdiUBUmTVE0WQ58DXbIY8mwCdQkaMtAlE6rE1HVlwLBhM8QJsBkiSBv6lk2hazND1xkhFmMmhBAYmqKMh0OLMYpJ6IejcGgz7tiW5zqOTRlFgW9jbIwnQTSjjR5sTEk4GmHKIDIjSI3jetyyTUJ5xGEmlDJuAB0hHUL9x3+RzQDUKTUtm3KLYoooxwDpJoGEma5vmwS6vs0sApHOLEIoAki3HIYwoMx0Pcv1uRfatku9wLJc6vrcdqnrc8ullJmc4TBwp5NwPPTCwAkDaxjaYcBdl7gBt1ziD+1g5PhD2/ap5WJqI8s1vZCMZ64/5I5Pw7EbjBxu42Dour7tuBwTiAkkFLoeoxxhagAkcQs4NuEMRR4mtoVdh1ICKAG2hR2PMNtwfDMc82DEghEbTW3uAH9I/aE1mQ+5Q0xqjKZ+OPZGE98LLM2QKIeWbRIKbm5ntkMsGzsutWwMkco44jaiHExnwdX1aDYPpjP/8mpkOdgP+GhsX10NLy+D6dSZzezxmN3dhXcvw/mlM5u5d3eTMGS3t+Mvv3x9fT28uRn98Y+fffnl65cv545r3tyMb28nYcg5B9Op9+WXn97eTYcj9+7l1Ww+tG08HFqTsX0991/djuZjezZxR2NnNvMi3Odk4kYfgoANQ8uxiecygo3J2I+2byL7l9k0CEPqecgPoOvprqf7PvB8+NVXr9++/ebf0huORN9v3rz55ptv/vjHP/3hD18eH58mk9lioVou1XLZcjyWSyXzuVw+nU5ls5lkMlmpVIrFwsrKytLS0sbGeiqViMXW1tdXi4VsIZ/NZ9OxlRfpeGyrVEzE4hsbG4lEIpFIZDKZRCKRzWYrlUqhUEgm46VSYXOzXCoVEolYKhVPJuO5XCaR2Egk4mtra6lUOpvNxuPxVCqVTqfz+Xwul4vHN1ZWltbWlx89vv98eSGbS6YzsZXVZ8svFp8vL+RyqWRqYyP2YvnFwsLiw43YcqGYiCWWll88jcfXYxvr6+ur6XQylUpks+l0OplIxFLpeCq9kc0l0plYLL6SycbzheTK6rNEcq1UzubzmVhsPfrD4vGNeDy2tbW5tbWZTidXV9dTqUwmk1lfX1189jgWX4nFX8Tiz2OJZ7GNhXRiOZNYqRRSlUI2vvYivra6trySiaUKmdTG6rPV5YV8Jl7MJUu5ZDa5nthYLmQTxVzy+eKj3/3mFyvPn66vPIuvPU/GVvKZeGx1Kb6+kojFc5lsIZffWFvPZbKb5crG2no+my3kCoVcvlqp5rO5TDqVSScL+XRru7ZVLZXLuWIpn82nk+nERnxjc6taLFeyuUKpXM0XyslUplAsF4rlrVqjWKo0mq1iqRKLJ7dq9VKpmM2mY7H1UqlQKORevHieSiVqtWqpVCiVi/liLpvPxJOxVCaZK2QTqfh6bC1fzFVrm5VqOZNLb9WrmVw6nU1l85lEKp4rZPPFTCafyOTj2WIymdkolDPFzWy2kEhmNpKp9WwmsVkpbFYK+Vxys5JLxFfS6bVMZq1cSWXyiXhqLZnZSGY3UtlYOhfP5BOrG8/XYkuJ9PNYailb2Ejn1uPp9dWNFyury4lUIpaIvVhefvLk8erq86XnCyurS0tLT54vP92ILT9berSy8iwRX03EV1deLC4/f7rw9JPFhU/SyY10OhZPvEjnVrOFWDKzGk+9SOfWE+mVZGYlW9jIFhKpXCxfTmfyifXEi1Q2tp548Xzl6cr6UrVWrNXKhWImk41vVoub1UK5kmvt1LZqpa1aKZF8kUiuJJIrze3K/kGjXMns7de3aoVqNd9sVhqNUrWazec3SqXE1lb6+Li2s1usbqVarXK1mimVEru7lVarXKmkstm1ZrN4etpqNsqVcnZ/r66q/YvO0eFBc2+v3ukciebBticAACAASURBVEJHVQUDqpounp0dnp3un5/t77U2c+m1VGwpk1qtVvP1ermQT5aK6VqtWClnioXU1lahuplPpzYy6dhmJV+vlZuNzUa9Uq+Vq5uFRqNYr+e3twu1erqyuVEqr2Wyz6vV5NWV/8N/n877py/8NwzQKNy8efP297//Qz5ffHD/0cLT5ZUXsfsfP/nde/cXni4vLS0/ffp0aen58vJyNptbW1tfXV17+PDho0ePFhcXPvnkQWQYFNtYW1td+eTjey+eLWYT8efPnmUy2UQiubj4bHV1NZfLp9OZdDq9vr6eTqcymVQ6nUymEvH4xurqi7W1lY2NtcXFhY3YRiqVjsfjqVQ6Foutr6+vrq6l05n19dja2urKyvNkMray8vzFi6VMJrmxsfrs2ZPl5WfLy0vFYj6bTadS8VQ6/mLlWSz+Iplai8WX44m1RCKezWbS6WQ8HkunU6lUMptNl0qFfD5bKucy2XihkN6qlTPZRL6QrmwWSuVsNpfM5TKVSrlSKZfLxWKxUKttNZuNer22tVUtlyu5XKFWq2cymUwmXW9Ua/VyvpAqb2Y2N7PlQqpaybWa1VI+Wy2Xq6XNUrZUypWrpVK5kN6qFKqVQq1a2tuplwuZQi7VqFV2tmuLTz/5X//if4ytv9huVIu5VKmQrpbzidhqMZ8tFoq7O3utViubyVbKle3mdqWyWd3cam3v7Gzvtbb36rVGo94oFUu1WvXs7OTs7PjoaL+x3WjttpqtRqW6uXdwuN3arTd2tlv7O7uHtfr2Vq1R3Wq0dvZaO3tn551Gs5UvlOuN7f39/UajXiwWGo365mY5l8u0Ws3Dw4OtrWqz1WxsNza3NuvNWqlS2tyqFEqFTC7TbDVau9uN7Ua9WW+0Gs2dZn270dxp7uzt7Ozv1JrV3YPto5O93f3m9m7t8GT35Pzg+HR//6i1u799eLjbaZ+ct4/39rfPz49OTvfPzw9Oz/ZOz/fPL07aF6fdfrvdPb3onV30zo9P9/cOW53u6eFJc/+43hNOuoOzw5P90/Pjbr8ryUq70+10OkdHh3t7u0fHB71+u31xet4+vuidXvTOLrpnqiKqqtTvd9rtk7OzI0HoAqAqijAQO4J8oRqiIHf7YkeQLgbShaINJLWnGqKiCwPpQpC7sjaQ1L6sDYCpMctkFlZVUZT6BlAirw7KkOtZfuD4gcUtyC3IOLAdzC2IiR4OLdsxfZ8PQ9fiiGDdtqHnYQiF0YgNh8RxDN/Ho5E1HPJobde2ASEK5zrnhm3hMHAiVnkYOGFgj0f+bDqcTcPpNJzORsORP5kE89nwaj4KPWaofaD2GDbC0LEt4rmcYMNipsWxxU3fszyX2xb2XBYRQoeh4zrUc1ngW0HAg4CMx8zzgGUr4RA5rj6Z8K+//vzNm/8fjcLbt2+/++6777777v9iZf3zWPP27dtvvvnum2++HY0mFnct7ttWgE0bGAxBHoZj2/YwZhgzSm1Z0gjhFnddx4/IVcCAwIAYYYqpJimGrPrcoZi5rs+YxbkdId0ioj9CmBDKGLcs23W9MByaJvY8fzgcQYhs2/X9EEIzDEec2wAgEJHiCDNNzBgnhCKIMCaWZVuWpeuGrukIYcYshEzGuGVx00SYQAA0iDTb+ZGPyzl3Xc/3fQghpdT3fdu2HcfiFnMcezgMIQKKIg9HQ893GWOO41iWzRhzXdc0Tc6553mO41BKObcty4nYdAiZGBNCia7rCEFMAOembRPOiGEYnNmcuYZmaoppImJbnBJMsOm6jq6pqqogCCIBBEQQAMMPPE1XFFWRZBEiQ9UUhLGs6sxyCLckRQMmocxy/ZByG1OLW4FJHEztYDghzIYmtl3P8X3KueXwYBiGo6Hj+bbtEWpxy3O9oesNI6XSP2NEeH4wNgA2AKaUmSaO7tc0seM4tm0zxhjjhFFMCbO4HwaE0UhLAk1EOTMpAdi0PFeDQAWAWNxklNoWtS1EEGEmswjlmFnEcn7EU7m+zW1GLMYszhzOHcYdantsPA9tnwZDdzwdh6PQdu1gGAzHw2AYWI7FOA2GP8L8wpHrDyMXCcfxgvFk7vujYDQyEFQNnVh0OAm5yzBH1EYmg5hjy7Vs3+YOxwwTTrzQ8wKPWdRy2HDsT+ajYOSNpiG3iRc4tsuHYz8YeuHI9wInGHqUY4SB41mYouE4mM0nhJjR7PLycjadjCeT0eXl7O7u5tPPXn32+d1nn7+8vZvf3s1n8+HV9eTu5eV0Ft7ezq+vZpNxOB4F00n46uXl7e30s0+vP/308uZ6NJv547Hz+vXV1eXw+no0mwV3t9Pb26ltmbPp8OXdVSRiuL2Zv3p588Xnr17eXb16efPZZ68uL2fzy8nNzez2Zn59NXl5M7uc+pcT7+ZyMp0OCQaBb4eBMxkH00kYvV/Of7SUitxdoh2cCHMzGfuTsTuZOqMRm8/tm1t/NrPv7iZv3nz15rt/KdZ8//333/35+P+MNX/849dffvlHxixVNXQN/XnmjUTBUGQoiTowKIJMVWCvK4uCJgw0VYaqAhRZFwVVElRxoCiipgxUua9ABekqANAUBpKuA001IqckSvlgICqyDg0MAQEG1lTQ6wq6BhEkoqAaOiKEi6KMEAEASZIqy1qkJpdEVVN/nHwBA4uCKsu6qgBZ0lUFaiqSRE1RDFXRJUkdDERJkjTtRwaEJEkImYwxTdNkWZYkKdr9i/xkMKaqqquqrigaAEjXAYQmQogQoiiKrusIIQhhhLAxjGi4rvb7oigq/Z7U60qKDCDgkmgMBoJqKKquAmgik2k6lmV0fiYKA6ioUDfgRW+gA6gDeHbekRRV1YxefyDIiqwbXUGUDdCX5Z4knXYuDIxl3dCQKRpAMgwJAAkCDWNkWappQs4ViBEPIA1EjUDmGsRWEYXMIo5nchsgZEAATRNTRqil6QiZnHHfxJYgqpKs60ZExiLIZIy7umEqqgEhijRrsqyoqirLsmEYhmEoiqJqarR/DBCUVUVSZEESJUU2ILA918CmbOgaBIgS3UQqMGRdk3WNWhyaUNFUk2BkImYxhE1FUzVDhwQjywKU8iDAjoU4QRYhHmc+s0OXMotzZziahMOx6wUR0jSisjuuSygzMSGUYUIBNDGxHDdklgsIxbZFXbsj9DQMTAsDDmQoq6aqmrpBEXGZaVMNGzqByCLOyOe+TThzPNfxXMKo47nM4pZjU86G41EwDMfTiRf4keYDmojbFre55/uu53ieE/Ucx+Oh77u+7w6HwXAYXF9f3b28+eKLz25ur25uLieTke3wcOjPL2dXV5fDMPQcdxQOR8NwNh1Hu8Lz+TAM7OkkDHxrPPI8l03GfmS3cn01HYZuFGV8z7qcjz99fRftEL96eX17M7+7u55MxldX88v5JGL33V5NPnt1/ent7OX1PAyc8ci3LeLYNLrOZBz4nhV5KkTA8/HIm8+GV5fjn1xfxiP/6nI8DPlkzMdjPhrx0dD56qt/iqqgfyGv+f7Px/97DfX27ds3b95+990b1/U1FWgq0lSkqaYiI0VBqoJkCcgSQJADg0HAsekIA10UDU1Fho5VBWoy1BWky0DuKWJXVvqq0JcjAIWuI0ZtSVR1DVJiQUAosQ2dWNzjzIs4xMCgqgw01YzknYZuKrKBEFVkXZF1Rm1DRxBQQyeSaBDs6JrJqAcBNZGlqaYw0GQJaCoUBuqgLyuyruvIMKCq6hBAzrmiKKZpcs5EUYAASJIIIVAUVVF002QEW4aOAPhRYvqjlxQ2BUGI9NYAAEJI5FqlKEq/PwAQGQZUFUOVIdAJBJau8n5XHwiygaAGoA5N1cCSaqo6Pe+ovQE0qSvIqoGwgcjFQOyLyvnFoC8qPUEWNdBXdRmaF5LSlRRRhzJAR+0LQLmgwwtF7ciKCE0Zk66qCwBC29WZpVFLMR3qzfsakZEFLR+7IeAOtF3AbAMhk2CTUFnRICKCqOqGqahQEDVZARHMWNWQAYiqQUHUIGIQMU3TDUNHCClKtEOgqqoa3XgUa6IoEz11fWHQG/QRNjUENRNpJtRNOFDlgSJDRiRD6wh9HcBIKRohKSizzB8pOZTYLnI8Fg5pEADbGhiawQkNPejQC2mAqRWGE0y4ohq2ExBqEWpT5kTvjhtadkCZAyDhlkuZPRBkZrsKhNuHB/vnpzI0NAx66uC4d4JsE3tEIYZk6jo3kctUCoFNgIV1jpDLAMayotqOiwk9Oj5BGFu2wyxb1Q0DwHA4YtxCGGPKLPtHvKnteJhgRrFtc8aJYWjT6Xg49C+6bcumlsWuri4ppYzRTz/99PJyPhwOR6PRZDIZj8ahFzqWMwzCwPPHo1HkOTUZDyNE3GQcDkN/Mg41VaYEXc6nr17eXs6nl/Px7c385e3lp69v724vIxHmF5+/nE4C33dfvXo5mYwB0IahOxn7N5djzyaeReaTMMpTppNwPPIn42A88sPA9j3r+moym4ay1NM18epyPBq6JtI8l11djl2HyVKfERiGlh+Q0cgKAjafDr/5+qu3b777V+u8/9t+zdu3b3/46quvI1sCWQLAoIbO+l1dGBiKbEBAI6UCgsziHqOOJOrCQJUlQ5Z0UVA1FRDMDRV0zzqDTq972tYVvd3uxGLxSmWzVCr/wz+88/Of/32v24MAVau1hYWlYqHi2D4wTAQJMExJVDU1SlIMgqmiaAcHh7lcvlgs1Gq1WGy9XCnrGoDQTCRS//E//uXBwZHjeJpmmAiLomwY0DRJvy8IgmgYwPeDVmsnlUolEol+/yKbTW1srMqKYNu03T699/EHCOmGoRsGUBRV03RdNyBEECIAoK4bAMCdnVa1WtncrPT73U8+efDrX//SNKFt82p188HDe9Wtiu1Yiqqquo5MqulIlgGEXJJlRZM5583t7Uwml8sXDGDWGzu/e/8+IQyaoNvtFkulbq8HoCkrWq8nKIqhqFBUgajowGSioqkGjKfTuVIxXy7HUpnfffTxxw8fAUxlzcgWS+lcoSuIOjJVgFSDIOJAbOmIQMJtP5B1QzfNfKlYqhR393fLm6Xtndbu3p7j+v2B+OTp0ocfPWhu71Jmm5gZwISIEGoZABFqCaL8+OmjVCaRyiQif04DaoSZlGPC8MHRQeTiYkAQ6TkNCGRVMQk2KdEhQMSE2BRkCZjI9lzCGbVYJC4fjsde4OsAWI7DbZtyZjk25baOiD8aA0w36/Xj87PmXgsQWK5VDFN3PIswnM1nDo8P2xed0WTMLItxizAe7Toz7jBuuZ7v+UFrd7fb72/V68VyYXX9xYNPPkbYkBQhmY7Vm9XD4z1/6OimriHDZJjY1DANQCAkCBBEbJrJJyV1cHS6VyhnOr3TzVpxdjU6Pt2vNSt7B62B2BtPR8HQtxzOrB81n5bjcIuNx0OEQKvV7A86/UHH9Vg6sxEO7YiPomny0fH+bD6ezyejUTCbj6+uZtPpeBj6vud4rj2djBybnRztYxMQDAmBiipYFrm8mg5HvqIKvX778mpy9/Lq9u7y9evbzz5/+fnnL1+9un796vrVy/mrm+l0ZDscAkN2bKppoqaKEeUTGHKjVp5O/MnYpVQnWB8NvfEomIwD28KOjcOQX1+N+7326cl+o14xkXZ+dohNPUptBv02wcbhQdOywHjMJxPbddF8Hvzxqy++/fZP/65Y8+23b77+05tvvv7OhEwSdUk0gMEwcoBuQYPrmmnoJjYZwVa0cRexJjQVSqIuDJRBXxIGEgImpxyommkAAhAl5ODg4Gc/+9nz58+Pj4/6/f7i4qKmaaqqPnz46OTk7P33P5RlxTQxxhRChDGF0FRkXdOALKuM8a2trb/9279JpRLNZv3vfv6zldVlwzB6vZ6iKLXa1rNnz3zfj4oaVVUNQ9c0Tdf1iMlAKf3ggw92dnYWFxfeeefvLy7OV9eWE4mN0TiAUP/Z3/wXCHXGCKU0onBSSimliiJDCGzbtiz+9Onj8/PTRCIW6TMXF58eHR1E+z7ZXCqTS1KOVV3VDB1TohvAANjEXNc1WRFME3744fvHx8fZbKbR2E6ns/c+ekApwRjcu/fh4uKCKIqmaUZ7SYOB1OvJoqRrGpQVoz8QT07Pf/HLd1Vd++jjexfdbn8gJVMZZJJGs5XPF8/OO4vPniOEAcQm5rqBACSYMMOAtuMABDvdi4efPJAUoVqrPHu++PGDj/cPDzClJqaO67d2DnQDRhwcSVY1HegGlBXNAEhW1N+89+vzzumThUeJVCydTR6dHuYKmaXlxfbF+cHR/kWvW61t1Rr1nb3d1fW1XCGv6lqlurm2sS4pMqaEMrZ3sJ9IJeuNeqW62e33GtuNfLFQqpQTqeTp+Rm3OTQRNBFAUNMNjLllu64XFEvFTx4/Oj49qtWrDx/dP28fXd1Od/e3K9Wi7VnJdGI4HlqODU0UFTgRp4LbViSMqta2HnzysNnaHo9DWRbK5UIQuNVqeXOz1O22V1dfhKFHGY5MoygnJoaYmpRh27UJMx8v3H/4+AMDiZu13KOnH+3s167vxtlCPFuIHZ/tHRztjibB/GrCLGpA3fFcP/QdzyWUjEbhYNBbXl7CGFS3ikFoVzazk6k3nnhB6BhAOTs/urmdT2fD8SSYzoaTaTCdhqOh57nc8/h45Fsc7+9tM4pURbi+niqq4Pn8s89f3t5dXt/MbIf+4z99+ur1zfXN7PMvXr369PbzL169fnVzdTn6/T+9/MfPboY+hnqPYh1B1eLmwf72MHQ+fX1TLKTzudTJ8e5oZAcBDQMr8B1GSRi4gW95LvZ9PB67B/vb3YvTeq1cyKf295qd9nHk8bLTqk0n/v5+zXXR5aUbhngysa6uwq+++vzt22//vXnNN1+/+fIPX5uIS6KOTQdBSxKAKlNdo6KoGboZyS8V2ej3pAgoMejLF51BJASXJVWVNUVS5IGgSTIBiFMqCMLPfvazd955hzHWbrfX19c9z9N1/d69+5Tyd9/91cnJGSEMIRzBUQwDairUNaiqGkK40+n85//8nxYXn4ri4K/++i9/9/5vo9YJY2x7e3swGFBKDcMQBAEhJEmSKIqapkW8TghhuVyOx+M///nP3333HVEcxOMb6+urQeBBaPz617+M8BERLTjq6aiqqmladAZC2Go1k8n4e+/95vT0WNOUWq3qunbkZp1Mx1bWnlsOFyRBkERV1wyATMxUDSiqjDEgxKzVqsVicWFh4b333n///Q/feedXA2EAoPbrX/+yVtva2NhQVVWWVdMkqmJ0L8T+QNF0JEqaKKm9vlCpVhOp5INPHkLT3G7tptLZyXS+3dpNJNPtTvfxkwUTU91AJrYoc1QNRthgA8DIFyWdTa+uL2dy6Vpj651338kXCwjjCLK3VduOzOcimqfj+pHUG5lEB+Dv/v7vcoXs3sHO0clhJLBOpOKr6yvbO81KdfPo5LjZ2k5nM2sb68VyaW1jvVAqxpOJxaVnkUOm47k7e7vJdGptY73WqFeqm4lUcv/wIJPL1hr1WqMeWfpGKByTUIw5odwPhsenJ08XF3KFXCyxcXJ29MFH7zk+3zto1RqbzCLLK8+5zX+y1nN9z/W90WRMOcOUeIF/cHT4ZOFpvli4vbnKZFL7+7u+71arlXw+i00Yj2+MRiGhP8YaZlGAjOgDwpByUtkqbCRe7B40Lvqn6/Hlnf36/HqkQ2mzVrj34P1O72wyG9ouNwkyCeK2Zbuu7bmO64SBRynudM6b21vn7SPLxqVyZjxxJ1N/Nh9HDpmMm69e31xeTYLQcT0+mw0vZ+MwcMLAcR02HvkQqAf7LUOX5/ORKPWQqd/czq9vZtEi5aef3c0vx7P56O7l1avXN59+dvfq1fWrV5eff3b9+eur+cRxuXF+emAi/dtvvhQGHdvCr19d17ZKwFC2toqM6WHIHBsPAzfwvTBww8B2HNP3cRhwxyaDfjuTjp2e7ANDPj3ZPz7affXyimCj3T5qNErzuTccEtvWgwBfXgbffPOH77//d9dQX//puzfffR8GE0nUDZ1AwGUR9bt690IRBe0nlk1EyTJ0M+IQQ0BVBQoDRVUMQwOKpEj9vipIQNE45ZXKZjyeWFx81m53stlcoVAUBLFery8vr+RyhadPF6PCJ/L5VhTNMCAEhJgs6s4Wi8VKpfLo0YOFhScrq0vr6yuNRmN/f//p06fvvvtuPB6PIossyxHYIWr3yrIsCELUalleXl5fX9/crKytrT58+KBa3Wy3z/v93l/91X+WZck0kWEYhBAAgCiKkR8DpVRRVAghY2R19cXS0qIkCe+//97CwpPNzXK7fbazs12uFFq725hiSZE73QtJkXUDAIg0HfQHPcZMVZUNQ0+n07lc7vDw+NGjp//wD79s7bRarXoiEcvnc8lkUpblwUCUJEUSVU0zVQ0NBGUgKL2+oBtwIApPFxfqzQa37WyucHbeaXe6ze2dQrGczuQy2TxllqLqEDHGXVWDES0YYawBnduWpIjPXzzr9i8WlxaarWZ5s7Ld2lE1Y3fvsFZvUWZFGIqIfRO9Isbwh/c+6gt9P/QTqcT9h/cXni3UGrVsPptMJ7fqtWK5tB7bWFx6th7bODo5jiXi+WLh3v2Pd/Z2+8Lg8PiIWbzebBTLpZW11d39vSgMnXfasUQ8V8hnctk/u4ZDyimmDJksCnb5YuG8006k4sl0YnOrvLr+/KxzvLu/HUusNVv1erPmBR7lzHYdhM3Iydfx3GAY+mGgAyNXyB+fnqzHNgjFG7F1QrEoiUfHh8+Xlzarm3v7e9xiBtAUTY5oGAAZ3GbMorZr6YaaSK2fnB9k8olas3LRPzs63euLHUSN84vjfCkdLQp6gf1nx043oh1ajnV5OR2Ph6YJD492uWXqhrQRW+YWOG8filKv3TnpXJxOpuHN7Xw2H/mB7flWGDqBb4+GXoSPmU2HEKh7u03bIrLU13TJcVm3dx6lRdzCdy+vLq8m88vxze389u7y+nZ+dTW5uhpdzoKXN5Obue87yITqfDYSBh1dE2fTUJH7mip0L87qtVJEpRkO7cB3PNeejINh6AyH1mjEPY96Ljs/O+z3zmfTMMIS93vnmiromthpH1GqzedeGOLRiIYhHY3tr7/+/ds3/3oG6P+tN/ztN9+/ffOD64SGjhHkukZkEYkDaGjURDxim0dRJmJN9HuSriET8UgUDgyTmBQjrMsyUDRiQEa4JCn5fLFWawCA6vWmphmDgdhstgYDsVAoSZICAFJV3TBgvy/oOtA0Q5Z1XYOYUEXRer1eLpfb3W31+91ypXB8ctjv97e3txOJxLNnz6rVqud5UVUVJTWDwSDyPAAAMMZOT08bjQYAQJblYrF4fHys6/r+/kGv1ysUCpIkYUwYYxhjTdNEUYz4pFEhpmlau31Wr2+ZJpRlcX19NXLalSSh1Wpk81kdGNA0AYKKpkbMuh8daXVZ11XGyOHhQalUUhTFMKAgSBed/mDQ3z/Y6XTa1Wrl7OxM07TI96p93hUEtT9QLrpCtycMBMkw0Hmns7O3iynRDaO1s0cob+3snbcvTs/a263dCNCn6YBQx8TcxJxQS5LVCAeDKTk9PxWkvh96F71OY7uhGXq73Yn4fgBiiHCEEI48aCOGue14Jqb1ZiOSSu3u77V2d+rNxla9tnewX6qU09nM3sF+lJ6UNysnZ6fV2lYilVxcera6vtZsbW9uVS3Hbl90Do4OT8/Puv3eRa+7d7AvKfJZ+/yi1x2IAuVM0VTCqBt4AJmYWFFlF31H1VXHs8/aJwCpsjYwCZCUwXnnLBj63ObRxD2qniJ+DabEJDiygon4gYTRvjCwXeei16WcibLU6V7YrgNNpAMNmoBZ1HI4QEaE49GBRjkZiBcDqev6HDMgawPMAMQaZkDVRcdnrs8th5oEEIYdz7Yc2/U9L/A5Z7bNXNe2HT4cefPLURDalIFwyF2PUgZNbMzmo9l8NBx5QegEoTOa+L5v2xaJ2rSjoRcGDjaN8cifz0YQao7Hr66njsvuXl5NpmEUZe5eXt29vLq+md3czl++vnl5dzWfh69ezq5mwWxs310Pv/jsZj4bMgrHI28y9m0LX12OEVQty5xMHMdBnkstjh2be649HnmTset5JmfAc5nFzfHIi6zsIuhEdHI4dCJ0lmVpngeDgHge+erLL/4tec0/P96+/f67b3/4+k9vsMl1DUHAgMGAwaHhEOwJA0UYKBCQnyJOZN4CATF0jE0ODGxoUJU1TdZUURp0LnRJBjrUdIAxJYQbBmTUkkRlZ2cfY4oxpZQTwqJAE0WcKLVRZB0AjEwsy0pULhmGpusq47jdOVtZWRkMBjj6ec4RQoPBoNvtAgAAAFFiEtH5ooERYwwAELVjbNuuVCqdzkWEIjVNM2Jr/TQFjwbbuq6LoqgoimFolOIIAMg5dV17f38XQsNxLMf1NN1QdV3RVEVXBUlUdVWQBFEWZWUgCL1O59wwdF3XVVXt94Wzs3a3K7Ra24oiXFy0I8MWRVF+uuXBQNk/OFVUcN7udi56oqiYGEMTYUpkRUEmkWS1Vm8SyhVVj1gziqorqmFiCxPLxJxxW5JVAwADAs3QLceyHApNw/FsZtGz9nmz1eKWE4Qjxw0MYMqKpmqG54d+MIxIoLoBdQMCCGVVMSAECEUbNDoAJsG1Rn0jHjMg4LYV9U0Io5Zj15uNWCK+Va+puoawSTkjjBJGTYKjWZWqa9EOTuR7GVl9a4YOTRTlNZRZmLAIh0w5CUdBMPQkpZ/JJ3SgeIEdjgLbtbjNCaMAwQhmGqnSoyASzaG9wGcWx4wSRkVZ3qxt6RAAEzHLilSmmqFBE5gEWQ5nFoUmwNSM6F8IG9wmzCIIG5RjL3C8wHE87voWtZBJDIQNhI0IEoawySyLWZxQHOFi/cAdT4Jw6AxH3nTmz+a+57Moyswvx+HQHY48xk3GTc+3gsCxLWJxHFlZei6/FaEM7QAAIABJREFUu72cTYeuwwLfjuqsy6vJcORF4WY2H11dT6ezYTh0owvOZ6Ory9Hd7fTl9fj2Knx9N/n01XXkLTcZ+6JwcXy0OwwdSoDrkMnEDQLqONi2iOtYjs08lyEke57p2KbnMIINQ5csboaBfXc7325WdU28nI9ub6aTiTOfu0FghiG2bWM8tr/5+vff/5v5NdHx5s3337/94btv35qIGbqJTVuSwKCnySJG0JZErd+TREHtXgiSqEWmLlExJQqaIhu6hgjm2CRCTzg9POqdtylECGCCLccOICCqAhw7kCX9wf3H/Z5kW26vN1BVXZZVhDCEpqYZqqpDaALDlCUNACTLKgDAsqyLi7aqyZQiVZV+85vfrq+vR1EGAIAQirKYfr8vSZKu61GkiPZiOOeUUkmSCGG27VqWs7S0fHJyRim3bVdRNFlWbdumlPZ6vQgnHo3GTdNUVTUCnsuyaFksohHHYutnZyeEYMt2DQMpqq5omg6MgTgQpIGkiLIqSnJf02RFkQDQJUk2DINS3u32ez3x2bPF4+MDAHRZFlVVlSQpWurZ2zvsdIROVxwIykBQJVnVDYgJIZzqwBiIoucPj0/Oni48i9BWiqpLshqZvQFITcwhotFEWdV1AwJMieM5lJuyKlkOJ4z2Bv0PP7oHoOkHI0JtA6DoUlFSo2oGgGb0rgMIIBIlJXJ0iX6XqhmaDqBpRkTRaMsGUyLKkqKpAEGTYFGWAIJRNIm+IMrSn/syOBpdGRBEYyyAoGbo0eKP5wWW7UZPL7MYpia3qQ6UhaXHB0e742mIMGQWdX0XIIQpQdiM+sEIm1GUsRwbYTNKdnRkWp4/kJWNZMowsck4JFQF0GTMgAZA+k+MwQhSQRhGGEYR56f2jUmQ6zuaoY4mQ8dnktKHpu54POryUM4i2SomJmPEtnkQeH5gB6ENkWbZ5vwyHE/88SSMUpLxJAhCx3ao47LhyPN9G5sGJXA09HzPivbrxiN/NPTC0L29uxxPAs+3Lq8mo7E/m48m0/Dqenp1PZ1Mw+HIm1+Or6+nl5fD25vJzeVw6JPJkL9+eTUZ+2FgX12OKQGFfOrqchz4lmOZnodd1xyPXc4wZ8TixLGpiRRKVcc2EVR1TSTYCHyLM3R9NTk53kNQHY881yHTqTubuY5jjEbUto0gYF9//ft/i877/xlr3r75nmALGJgzXxjovQtFlSkwuG35mgr7PanTHkSml9ELQaprpiIDVQGGjlRZ01Vd7PWlXr99dHqwd3zvo4erKzFKbF1DjfqOidijTxZMxFVFL5c3IyfM3d19SrkkKboOOLc0FWgq2Ns7ODg4unfvXiKe0DS1e9GpbBZME9br9SdPnsiysrm5GT2ujUbDsqxovKXruiAIhmEcHx+fnp4uLCysrKx4np/N5j/88J6ug2Qyoyga53apVDF0qOtga2sr6tFExZSu6xjj09PTTqcTj28kEjHb5qI4KBbzjJFiMd/tdhijjUaLcU+U1FqjKUiiAY2B2Bflvg4UHSidztnJydGTJ49jsdjR0dFvf/vef/2vf9Nq7T99+qTdPpVlcWurGtlO1esNSVJOT9r9nqyosNsTIaInp+dHx2fPX7w4PT87OjkulkrHJ2cX3f7is+eaDvYPjvYPjiizzs47F90BZW5UQymqYWKq6cZZ+3xnb3dtY01SBFVXDo72zjvtYBjef/hwIEiaDiRZ/8lMijIrgqVHliyR1ZQBEGVWRBWOKFyCqMiKpgMQDZsuet3D46PT8zNV16KHv95s9gb9KMpEFWXUlInOIGwCBKPUxiQ4qnps13H9wPVCUVT6A3E9tiFIEkDGRnx9d781nQ/z5cxZ+1hWhYteezgOoQn3Dw+ZxRE2CaNRfmQSvLO32+leLDxbPD49mcym+8cnBydnkNBEJmv7YV+UTztdarsqgLv7exAZOtBMgqLIwm0WhQ/btfYOdiVFfP5i6fT8hHJaKOW3d5p9oQeQZnuMchMgXTNUaAKE0Y8IDkYjboFhaEfHe7ohFYrpeqM8HNm9/jlEmiT3IdI++/zleBIwbprY8HzLdTnBgFEUFVDD0OXM1FSx32u3WnXdkM/Oj0rl/HarBqBqO/Tqenp9M7u+mV1eTa6up3cvr66uJuOR6zqmzYAqtU+PmgjIzcZmuZTtXpwOQ+fs9MBzWfv8aBja47FtGAMTqZxhgpHr8DCwPY9I0rmuDfZ2m7lsQpZ652eHhwctWeodH+0qcp9go14vv3w5mc+98/OWaQ6GQ+Z55Kuvvvj3xpq3b7///u0Pb777Hpu8eyGqCtJULEtQ6BuqggmxAcCqAiIWX2R9GRGIo5m3KGiioFy0u+JA1CW5Wd3KxJMX7f6L5Y0H958gyFZX4v/H//6fEGT3P36MAKvVmrlcQVE0UZRLpUqz2TIMOBiImmaYiFarjXQ6e3HRXVlZefDgvq6ricTGe7/71dnZcb1ev+h0UqlUuVyOsphMJlMqlTDGkbecJElHR0eJRAIAEIvF7t27hxD6D//hf7t376Ft+Zl0Xpa0arWxsZHsdPqqauRyuXw+TwjRNE1RFIzx4eFhOp1WVTWfz7377judzvl77/2mWq1wTtfXVy8u2vv7u8+evTBNjhCp1Rsb8TjCSAeaKPc1Qzo7P4rF17rddj6f/dWvftVutwuF0jvvvLu3d7S6utLvd3Z2tvP5bDT8KpXKpVLF0FG3K7Y7/f5Abm7vZbL5i14/m89n89l0NvP46dO19VjnopdIpmVFS2dyu3sHyCSKqpfK1dOzrok5gMQAyHH9rVr96OS4Lwgraytb9UqukK03a81WQ5DEar0GEa5u1TUd9QeiAWBzewcijAnTdBA1bgaCpKggMtvVDVMQVVUDoqTKit4fSBfdrg4MRVOr9a2Ts5PWTkuUpVKlfNY+P++0N7eqmBJZVWRVicJNZLcQZTERvCJKZ6LNY9t1GLea23sHh8eyokaDKspJrpAtb5Z6g87e4TazcK6QGYg9ZlHKabO1fXh8FO3vGhC4vpfJZU/Pz7htlSrl1u5uMAw/WVgsbTWI7WZKZcSsXLmqIdwVFUhZtb51dHIY1U3QBKquRC0bwnC1tnl4vO8Fzla92tiuG1D76OMPDo4OwpG/s9eklsksU9VlVVc0Q1U0NaoKKSOqIjFGKpXSyenBze3s8Gin1aru7dWWXzwNQscP7JPTgwgoETEJxpMgCBxKoMVMx6aRbuDs5FCRB4Fvn5zst3bqw5Hvenz/oMW4eXi0+/rT2/nlKAjd8SSYzUfT2XAyCTyPKnJ3PvGuZt52rWBCZTYNDUM6PzsQBh2MdVG4kKSu5zEIJcdBta2ixbHFietwzpCm9s7OdsYjF0E1mViDQM7nkrlsQpH7qjLwPd4+Pzo52Z3NPM51xpRyOe44YDhkf/zqi39vDfX2zfdvvvvh22/eMuqIgqapSNewMNAGfXXQU/r9niyLURcDIRNBYuimIgNNRWJflSVDElShL0mCDHWoK+q9Dz9qNben42mpVL5//8Hu7t79+w/e/cW7EEadYLC2tipJwosXS/l8rtvt/u53v8MYC4Kk6wAiEIuvlit51+Ob1cKjx/f39psLi5/cf/BBb9DudtsIGQsLjzVdLhSy5Urx/PzkF7/4e1mWe10RGKZpmhsbG/V61fX4zm79/Q9+BZFaKGY/+PA9RRGRaRCKVlaXu7326tpyNptGCN2/fz9akDUMw3GcxcXFra2t0Wi0s9P89W9+USrnPr7/wePHD3Z2m6Zp2A598vSTs9Oj3Z3tcjkvCL2PPv5QlHqaocqqSC3yYnUxnVkfjpxma+uv/uovATD6/cH9+w90HYqiqOvq2vqKKPUSyfVms3Z8fPzwwSOhr15cDERZ1nT93v17ze3GZDbOF7Mv1p6ftY//+md//WJljTJrIEiCKCeSaRPT+w8+UTWjtbO3Wa1HdiuEckL52kZMlBXb9eLJRL6Uaba2fv3bX27VKzpQMTUVTdnb3x+NJ0+ePiPU3m7t7x+cGMBUVAARNTHXDRMiSxCAoiBFBZ2LgaYbsiormixIg77QM6BRKBXqza2d/WZxM1eu5j558lG2kMAUrW1sRMqDKJH5ydpF0TRkEhMTZOLIB0KJgMOUIWwuLS9FhV6pUkpnk8NxUKkWV9eXvcD2fBsiPV9IDUf20vJjA0i9fjuRjNuOJSkiwtBy+KMnjyyHu77b2G6ks6n9w/2VjfXNRt3yXUhxTx4kc2nuWWvJdWLTw+ODYjnv+k6UzmiGqgMtGkV98vgBMFXbY9u79WQmFo7cg+Pdx08f2C5LZ5OiLFgOxxTpQAPIMGDU2jIAMqAJJtNxIhXXgRKO3PPOcSyxXKqkO93j6laJULhVK2u6xLgZhM5o7N+9vAoChzHkeVYQjaWG7s5uA2Mwmw0PDnfKldynn90MhHZ/cH55Na43ypdXo8nUm0yDYeiOx/5kEl5ejjlDpyf707F/czVpNjYNQ3j5ctrtHls2nIydycQ5P99zHKSqvUajOJ8HqdQqMETHxo5NphOv2z0+Pdudz4aUwHhsRdekSjm3sb5kW2g+C4ZD6/Bw23NJr3dydNS8vAwymTXfx5OJ+/XX//jfqfP+F/KaH96++eHrP701Eb/oCN0LURQ0YaD2e4owkGVZlGWh3++JooQQjlrFoqB12oNBV1ZErdsZtM8uup2eKmuaov7q3V/VNrcwNo+Pjz766MPl5efvvffbv/iL/+X09IQQs90+X36x2O2dffzgw2Kx0G6ff/TRR6ZpyrKKTQKhvrT8eLu1BaDc7Z89X36ytv78wcMP/6f/+X9oNKuWRQ8Od58/X9zerj94eC+Vjgti7ze//aVh6BedvmlSw4BPnjzaqpU1Xej2jh8//eiiewSRsrL67Phkz3ZIrV5+/OQ+ZVA3xLOzQ8ex79+//5Ovtud5Kysr+XzecRxRHGRzqfWNlXwhs7S0sLb+wrLoyenR04VH/c7pr979eWzjRRA4T558oiiiKItHJyc6gssriytrTw0gSXLv3r33Ly7aKyurT548U2Rd07TDw4NnSwsnpwd//w9/UyhmTk9Pnj9bAQYVBOWs3VY05cN7HxweH0DTuOidP19ZWHrxtNmqP1tavuj2ueVsVmvFUuXo+PRv/vbnh0cnu3sH261dxu3+QIxEAIvPniuqjkwyEIVkJpbNJyW1//jpJ4oqUk6qterewcHR8cnqWlzT0Wa1sbt3pGoQIqqowABYUSGEtqoSRUH9gdK56KuaNhD7vUGnL3RUXdaBvrq+sr1T7w7Oq/ViZStX2y5kCxsQGxvxuKTIUQ8l8pZSNFVSZFXXMWEQ4chLEyJsADMagRFGF5eedvsdbtNuv5PNp6FpIAzKm0XCsOvam5ulw6OWIJz/7oNfDITzs/OjRGLDsnhf6OlAw9R89nyRckIYbl+cv1h5fnx69PDJ44dPHusIQALXk+tH54fNvcbDp/cVIO8f7tUaW9xmUTpjEhSt29iutbS80B20tf+TtffqjS3LzgR/4Tyo0Rh1AzN6UA9kymVmVZqb5nrH6+i9JyMYEWR4747d+2y/jzdhSF6XJakhAaNWuaz087CzEg09Vg0RuCDBYAAELz+u9bkl0HDcPTrdc31GubO1sxal/knuiAk6mWVxGkdJGES+ksy5ZMLlTNA4jfrD3vxqEkTSsMfFi5NKvWDaw/39bQdZF+WCdGmc+LN5+vmvX71+cxXFnuJu4sT3Q3l1Pe32mkredn3e7lRn83j/YDObBJdXaaN58ebt5ef/dP327dV8lr68nr15dfn525dx5NmWfjnPOEOcodksvLyMOp3yZOJFEcsydzisuy7c21vd31ufTaOT493JJLicx5MsuL7KINQsc5ilgSvpaNg19GGnXTOMnmH0Xr1KERqNRs35PN7aWioWj2ez6Ohoaz6PptPgN7/517/4Zsu333/z9fd/+P03UoQQUFdGDmSjoamNbRV0DILY92J1hU6KIAozQwcQEAw5RcKBlFOpjXRP+gjCVqOZOzm9uCjfu/dgf+8wjlPHwfv7hwgRx0HVSq10Xiyd5//+H/6fO3duVyqV7e0dQhhyKEIUIVQsne3t7+Ryx8+eP+l2W2kauZ7I50+l5K4rWq1Gp9O6uCi9//4vX7x4VioVzs5yhKDhcOh5nu979Xo1lzvudBu3bn/SalcHw87duzfz+VPbNoWg1erF0fEBANbTpwu1WrVUKh0eHipWWHn5ms3m5uZmoVB48OB+s9mklObz+d3dXbX1VCqV8/Nz4oCf/eTvb9/6dNDvHR4eTqczLl3DBJaD2p3m4tKTg8Pt23c+29/bJYSur2+fnhR1DQRB3Go1i8V8s1X7yU//7vmLhXKlXK00omCKsbAAAhDnC8VCsdhoNVfWlqv1i9zZ8dbOZv6sSCh3vSCXL1RrjeFI+8U7723v7BWK5wCiy6uXaqVyvSB/Vuz2Bien+d39vZE2LJbyJ7mj3NkpE9wPw2q92e0NC8WLW7fvl86rhWLZBtjzY9eLHMQIlQASTCRlrmECALFu2AgTTdcNy6ScUM5czxuNx6e5k3a3sbO3lS+e5gpHRyd71Xrl6OT4R/kJEayIYUQw5dz1AsYldDB0sDqAp3w96WRaKBVbnXa721lcXhqOR+fli539XUxJkmZZltXrNUxAtVZ875c/29xaabVquq57nk8YFi6fX80uKuf5Qi53drp3sCtc9ubzN53BsN7uhukEYJQrFiwEzmulz+5+VmvXCqUzTNF0PlHit3qo+ajRqh8e79ca1e3dLcqJYekbW+uVWhkiWGtUs2k6mWV+6CnP8Y+Mj+tLddAGEUczhhfVwtHpHpOOG+Dzcr5eLzvI6vVbr15fXl5NJtP46nqapEEQSrVPZZMojNzpLDHMUafbaDQrw1FvMo2ns7jbb15eTR1kGcbo+np29XL65u1LFaF8/epSRbQxsidZ1GpWMbL/6devZtOQMXB1lc7ncZb6QjiX87jTruZODwiGpjGazzIpSBS6aRImsc8ZSmLfNEaMOi+vZ4zC8bidpu71dcyY4brOq1eTbrfaaJQ0rdPr1WazMIr4b37zr3/pLbrvvv3+u2+//+rL73wvETxwZTQeWZaJgE0cyKNgzmmCoAdsBgEjWHpuqGzEkoecuK4ICGKmbjkAWYbpAFgqlMYjw9Chcv0hh1HqAkAcyAgWUrrqQApjtNlsIUQwohAQz42ydOY4zulJzrYBhMj3Q4Kp6/qE0DAMMXYwdoJAJa7lYNArFPK2bVGKHQQoxeok5uHhvmHotm1yTqMwklKGYeQ4jq4blmV7nt/v9xcXl8rlytHRkWVZlFLF1yhbYLFYHAwGGFPOXSl91w2ybCalJ4RHCCOEC0od27ZNq1qpAdvxvZBQFxM51G2InFa7NtaGAAA/CB1ItLE9HtqGhiAkjgMxcRhHEJmWrQ0G/X5v1O8ZvZ4+GpsIc90AjWZH000HE4gciMBY14MgBhBJ17eBgzANwljTTQCRblhKSKJMEAUGXI7GupAeoYxLjrBjQ+B6gesGlEnF7MTJDDp0MNT7A831Is+PVcUEFz5jnoOIDRwLQEKZg0gQxg6iDqKUCcqkdP0gTOqNlmkDJqSS+ZmgtUatN+gTRpVQhSlRxI1wJcJEHSx0EAEQ/aivq2GHC7c/GKtvIQiTIIy59PwgSpKJ50aUsiDw5/NJGHkYw9FoRKlwHOoFHpcUU4QpqtYralSJklC4wg2TIJl6YWojEiQZd/3scu5GgelYuqUFkR9EvooaSE8Eka+kqCAKW51OFMfpZKIehDEmxGA0opykkySbporl8UNPKVlMUC4ZpsgCJkSgP+z4kZzM42TihYl4+Wb+8tWcceQHQrn4VAfoy1dzVZbqB+LyajKdJVHs+YGAjplmQZZF8/k0zZI3b17P5zMp+XSSTSZZFAVXV/Ory8mP4cl/+vXrJPbjyFPtEPNZmqXh61eX00l8dTmNI+/1q8ssDV+9vPz87av5dHp9dTmdZJIzz5VpHM0mWRJHWRrNZ0kYyOkkfv1qPpuF83l0fR2/fp3967++ubpK37yZJYn0PPzmzSzLvCjiv/3Nv3355e//Iqz5+utvf/ubP/7+d18JHlgmsi1sW5hRD9iEEZ+iGNoBsFx9THQNEewCm0gZci459RBkoZ8gSGwTOMAZDYaGpnvSE9x3ZYQcrnrRDR0q8BI8EFwahuZ5ruf9IHgDG5sGxIhDgAnmyh/IqBsGKSUSAkKIcF1f5Q+EEIwx0zRN01TnIjFGCAPLMghBCEEAoOMghDCEiDFJKXccDIDDuTQMu98fCuH5fuh5viKYFV+jDMfqIjAAkDHXthAlEgIKAYU2YdS1TIQcSh3CCJPc9d1IPQcTybgPsBxrOsZQSuG6rgMxJZ5poGZ9ZOrMMuFoNDRNTV1oAdDQtLGh28O+2W6PHYdjInUD6gYYjU1NN0djvdVuAwgZk9DBNnAsG47GuhKnoYMpE9DBACIAkTq8q5TvIIy5cL3At2yICVP7kbpg7HoxFwEmgjKXUKkKJaBDCZWUuZ4fYUpNYAlPEsYwYVGcChk4iNmAUOpG8QRAwrjvepHrRTZElg0JFcBxKGeKrEEEm7alLI5REjMhHESVLQg6WEhPyfZcuNINpBu5XkSZq5p0GPfieOr7SRRPMBJS+K7rMUoYI57nSuEy6iGHeYGnmF1l/8UUccm8wBWujLOrKJ0j4gLE3DCh0kOMe1EsPJdJZRclCnHUXMMEFS7zgzDNZn4Q+X7keqHnh8oT4GDKBIMI+KGngEYJWH7oqZciDHPJXF8Kl0qfeiGPUhnELE495RKeTOPJNL5+Obu8miRpcP1ylmZhFHuTaawGnDjx/UBkkyibRFHse56XJImUMkmS2Ww2mUyDIMiy7PJyPpumynCsGOXrq6mCiekknmRxliqUCaLQT5MoCr1JlkjBf/355//863/69dvPJ2kWh1HoBZEfBp4/SdMkDpPYj0I3S4JJFkynQZq6ScI7nYt8fk8I+Pr19NWrSRiyLPOyzJtOgy+++Pcvv/rDX6p5f/3Vt1/84SvOfF0DnPmCBxgJXQMQcMknnGa2KYElHCAcyBj1ICSEME48RiR2mGUA2wTYIYamAcsWTAgeAJuoJ2MkDB1iJA0d6mMQ+BFjjFIWBDFjUsWs1JMdyJSLR4pAxSC0sWVoQNdszl3GGOdcCKkClhhjXddt28YYQ2hjjAAAEEI1kjAmhfAgwJ7nWxbAmDImECIAOOp0HMZUrU4q6KDcw8p/TCn9UdpP4ikEhBKp1kbkUE9IV7icCn1s9rojjIWDOCYSII4wNk2dUoIxtkwAAaXY0zVs6NTQge+7EFqGNdL0Qa/fGo/H45HRbg07bc20sGVj03IAJABiTLiDCBMcEaJmDQcR6GDDtKGDwyihTFAmMGGMS2WEUQBEKA/CJJvMpOdSxj0vBBBz4RMqHcSlG6fZFXSY58cI8zSb+0GitCfoUEwEZVwhBSJEoZtCJcY8VXYDHeoghjAbaxZ0qGVjB3GEmXClss8oSlh9SBjFhDiIKpRRQEOZUE5Cxl2EeRCmyo7oB4l0wzDKpBty7sfRNAyTIAg4Z1JyjBxKfgjHQAQxRdITarQRLhcuD2M/jEMvzOLsksmQySBMp1S6bhjPX75EjBJOgshXjmFF1qivjdPID0PVd3F59dIPoiCM1Xk/Qrnrq6KvQDlxVExBHQVVu9ifQg90epkkkyCbBUFMr19Ns0nkB+L65ezV68s0C5M08AMRhDKKvSCUceILSRTWpFk4v8zevL2+up75vi+ljON4Pp9nWTafz6+vryeT6WSSKlh5++b69atLtU/FkZfE/uV8Mpum//xPb2fT1PfkJEvCwAsDN4nD2TR9+/r19eXVr99+Pp/OBOOB57tCSiGiMJxN05fXM89lvsdfv5q/fj19/XoaBHhh4dbDh58ZRu/6On37dp4kMsu8ycS/ukr++Mf/+O7P6xv+8e3bb7//7rvvv/jDVxDQfk+zTFQqVk+OC8AmzUavVukyEmDHbTb6puEQLFwZ2aZjmY6pwchPoY1N3bZN4AqXYgJtIBgfDrRuZwBs3O+N67U2JcK2EcHccWi32w+C0POCer2lLt4hh5mGY1tEcJ9RV2WvxiMTAtJpDzrtAbQJwdxBWNOMfn9ICG23u/3+0LYhAI5hWAA4jkMcB2NMAHBM09Y0g1Le7fbPz8855+oIr+vKwWCAMW61mtVqjVKquloUYGGMAQBqVhqPNSk9w7CGwzFChBDGmTQMq15vjfr9i1Ihd3pqmRaECCGCMMNE2ojawBKSAGD0+11KmWWCWq3dag16XQ0AfHFxfnCwOxx3643yaNxzHMeBpNsZj0aWaTmabo/GJnDwcKxZti1c0Rt084U8ZQJArBvWcKRpujkYjivVen8wUnYYhKkabQjlygeo6RblQnpCN7X+cOBg7PqBZcNefxwnU8OExVJlrFlBmKrxxPNjTIQNMMIcYWZDpJw1lg1L5+V2p9fq9AB0oIMIY6ZlmxbUDdu0HOgwBwnPT4T0pOc6GI20saJslIUPIgdhovY7IT21NNnAYVyq2UHJOQ4ipgX8MBoMx6121wvCJJ2aJqjVat1e2/P4aNzVtKGU0nN9ziVhRLjchpYNLS5Zt9+xoeX6stvvjU2be6EM4pFhFssVImQ8zTqDrht5al0SLg/jQNn2CMOE4cGojymO06RSqw5GwzCO/MC3gN1oNb3AY4I2WnXFB1NOVG7TwVAxNUzQVqfpYMglqdRLEJuzq2R2FXkBHWt9z+eux/qDtuux6SwJIzeMXNdjXGDXY2HkSpeOtX4QSi5wq13T9GGShMrtaZpaEHqM4XL5nFJ8eTW7mmeTLJpkUZaGWRrOpkkUur1u03PZ61eXjDqmMYojz/c4ckzLHHku5Qx5Lvv87ZuXV/Pp5AckCnyXUxxHAcFA1wZR6KZJ0G5XMTZevZrMZkGtlnec8dsW/P1PAAAgAElEQVS3c0qtdrvsumg+j2azcDYL//DFv/85dxT+97evv/7266+++8PvvyJYEixNw3n44Ok7v3i/VKzevfPwycKzfO4sy+b37j48OT5TN78pkZx6jk0Nze51hvrYtAxbchdBxzJMT7pLi0s3b97y/WBzc+sXv3hHShch7Lre1tb2J598lqaTQqH0s5++S7F0IEMOBzbFjrQtRClP4uzg4OjGjU+n0/nm5s5nn92W0k+SST5feP58sVg8Pz8vb2xsra1tNBotABzTgLZFgU0xEggxIbxypXL37l3btp48WfjpT/9hY3M1CKRujDY2Vjvdpm6Mjo72Hjy4a5qmEMK2bU3TFMSoJrp6vb6wsJAkca/XffDg/vl5CULAGH3x4nm9Xh32Os+fPvrlez8vnOUYJUJKB2MhfYcyG5qYWLX6+YsXTyjFGJP//t//r6PDU4KFYVh/93d/92LxKRf4k08/PDzapZTomq1rUNeBpptj3bQhRAQ9X3xePD/DFN668+nT508chBmXYZQ8efp8e2fvolxdePLs9p17mm6qX2NMGCZMzT7S9e/ee9Dp9SjHN29/sn+4i4iDCFpdXyuWzgvF84PDk/sPFp48XVQDiyJx/tTU5zHu6wZEmANIdMP+8MbHubP8nXt3TFunP8wFAlNsQwggQpi3O8PR2GJcQuQABz578dwPAwcj1drnBT7CBGGmKJsfT4/7QRQnmR+EwuVBFByfHp/mTwknu3u7xVKx2+96gZ/P51+8ePb02cN6o7Szu1Y6z3GOheCcc+FywjAiDpcsjIPl1aVqvTKdZxtbGydnBTeMiJBnF8Wni89XN9fiafz4+SPuc8oJ5US5kF1fKsVauHx7d0szhojA0/zxw8cPHAz8QI714fPFp37ojrTh/Yf31JpGOYnTiEtGGFZfG0T+6vqKbmqGNc4Xj5++eEQ4SKd+rXkuJW21a3HilytF3Rhev5wpmsb1mJBE7U1h5O7ubRIKPZ93e82j470k9SE0NrdWATQuymdBKHL5I8bR/DILfBFH3iSLZtNkNk2uLidhINdWF32PX16mu7tr9Xrx8jJmDOTzB63mBcaGbQ3L5bP/+S+fv3l9OZsmUSjVv66ks2mCHCt3eng5z8oXhScL932fvHo1mU59XW8XCgfX1+na2rPDw82XL7NXryYvX2azWfiHP/y/fynWfPPNd99/9/0Xf/jKtohlYka9bmd05/bDm5/dv3PnQaNZffjonuvK999//6//+r/du/doaXFte+vg/r0Fx6aWAaGNLd22DJtTMewPxsOR73rFwtnjhUdpGudyJ++99y4hyLZN09SXl5cWF5dtGx4dnd6/99i2sQOZaSBgU4xc23Icx/E8r91uf/TRjaurq4uL8o0bH08mE88LRkPjb/7mb5eX1h49enqWL+3uHKysbDAmHciNMQY2dyDXNTvwQ9u2nj17IiRlAlWqxb39zTQLOt363/6P/3t55ZmCg5u3bjBGfN9Xq5NhGLZtq4D4cDBcXln0A0EovHfvVr1ens3T45P9v/0ff/P8+WNTH8yn8Vn+SAVzGcc2tEzbhAQ72ATOaDhqra49j2JvMOi988475+dlCFClUv3pT3967/6dKPYWnjw4Ot4LAh/YyNSR43AuBURAM8auL/YPd87LZ0Ek7z289dmtTywbKhFndW1je2dvMp0jTLe2dzFhCNMoThGm6gmWDf0gevrsRbPVQsT+5Qe/WHj2IIxd3Rx9eON9wsjaxloQxr3++ODw1EGMMlfIABMBINF0G2EhRGLbglDfsjHj7seffrK5vXH/0R0m0dLKs3sPbh0e792689ni8tL2zs7W9u6jR09L51U/jKXvUs4Wnj5ptluNVrPVaW9sbZ7kTpmQSkRTS596cOEK6QVRwATxAtHs1Aul/EnusN6sGtZ4Z28rTsIoDDRtWDo/7fVr/+d/+z/OiodCYoQB45QwDBwbIsAE8QK5ub3RaNUvry9LF8Vi+SKapNyX0STSgHZSOM4uk73jHSwcL5Rq5VHcsBKtkyzeO9jt9JrZNIpTf/9wGxE7Sj0/FA8W7gSxZIKubaw5GHqBqzgaJqjrSy6pg50oCQ+PD4Bjzy6zOAt29je8kGFu7e5vEAr3D7alS7e214ql3Ju312qu8XzOOFJkzeXVJJc/Qth+9fpyOOquri3GiWuD0ZOn97q92v7BxqvX0/WNF4Nh8/XreRx5aRJEoTubJur9y3l2fLx/Oc8Mo9fpXDQahcvL6PWrbH9/9e7dG5OJ63lOpZJ/82b+6uUkSWSWem9ez5NYxrFMYul7rFg4nU4Sz2X53EG7Xf71r6+yzDWMzsrKwmTia1pne3uZUuvyMlaszR//+L/+Uqz59tvvv/n629/99o8ES+Qwla68e+fhO++8f/v2vUaz9vz5E9/37t69UywWHz58+O67v9zc3Ll5887BweHNz242m63xUBsPNUHdfntgjq3LyfXJ8cnC48dRFJZKxffee3cyySAEBwf7T58++cUvfv7ZZ5/evXv3V++/3+l0DcPWNFPXbMEDALBpAim9i4vKhx9+NJvNLy4u7ty5E8cJQk6n037vvXfv3r1z48YNdT1mbW1NSm6ZQNcgBBRCYtswCILhcHDr1qeuy6LYPSucQGhOZ8lp7nB3b/PR43vHx/u+Lz/97Ear1VI7lOM4juPYtm1ZFue83+s/e7YgBIWOtb6xurm15gfu+vpKoZDb2Fw9OdkHUN/cWpMus2zDApYFbN00MWWmpUNolMvFtfVlXR/fvn3rnXfeWVhYABBCCHzf/eijDyxLf7H47Pj4yDQtXTehTWwb2RCM9fFwPKScLC6/OMkdza9m2TS5//B+s9Xhwn367MWLxeWbt+5EcZrLF84vKmGUECo8P8JEGCawbEgoj5N0c3v7vHyRTbMkTR88ejjWdD8I84XCk6fP1jY2s8n08Oik0exkk5llOwhTADGAimMmlk3GGrBt4iAahNGnNz/b3d+5ffez0/zhnXufFS9yJ/mDja2VkdY/PNl/tPBgfXPdsHQvkNylYRz87Bc/ebH0TLhsa2fzJHdYKJ25nqd4VoUy0vUxYep9VcQhPXlevrioXBTPC+flYn/YPTzem87SJA63t9dH495w1Ll3/+bCk/vSpYxhCAFhHFNKGGOChXF4cLTfaNVnl5PzcvG8ch4kARV0bIzOSjk/9pJJtLT6gnBHcTSEYUyR4nS5ZJNZdnx6ZFjj2WXa7jXqrQp3iR/JMPFu3/1UeJRLvPD0kXAZExQRxwvcMA5d38UUQ2THSZDLH+vGKJtGzXa1UivFqZdNA8Lg1vba/sH27DLTzdHB0W42jb1AKLJGnUKULr28muzubZrWWJn99g+2GYOTLKAUbG4ut1qVf/mX17Y9zuX2Ly/T2SxJ0yCOvSwLo1AmsTufRmenB55EZ2c7GxsLjxc+8QMQhk6xtFso7iA8oHR0drYzncrpNJhOQ9VnPJvGr15OP//8Mo7dw8OdNAvfvLmKItloXly/nEyn0cuXWaFwiLHxb//2+WDQMIzebBYqyuaLL/79L/fyfff1V999+cdvVKFns9E9PsqXipXjo7OHD54sLa0UCkUp3YePHq2vbxSLxZWV1Q8//Ogf//Ef251G6bwAIBj0B6Zuc+JC3Rl19VimG2ub7733XhzHtVrtww8/pJSWy+XBYJDL5W7c+KDRrBwc7n7wwa9U7lHVjDMmICSmDrN0vr93/POfv5Mk2fn5xaeffsq5qNdrhcLpwpOHu7ub+bOTtfXl3d1NwxxThjRtbBpgPNZN06KUep6bz+du3vwUIfDzX/zjz372k3q92um0Go3a6ury0tKLUqlwcVFaXl4yTVMtTa7r/ihIeZ5XrpTv37sLoZ3LnaytrdTr1Xq9ure3u7u7s7W10e42SheF0kWRCQYciCkBEGm6pekWxtR13YuL8q1bt4QQlUrlV7/61fLy8sHB/tra8trayv7+Lufs448/WV9fN01L0wzTBLph2RAalgmRYwH70cLj49OTwWj45PnTk9OcbljlSk3TzWLp4vmLJen69+4/BBAFYQIgpcyDzg85JgfhKIlX19dKFxdjzShXGq12r9Md1uot6NDdvSPdsB1EHz1eUL/8mDDDtAF0MKGKe0aY64Y11gxMKMTOz37x83L14tnzpye5o0cL9+rN8tbO2s7+xnn57MGjO4+f3N/cWb2oFl4sPVVtocurL569WChXz9c3V+4/vNvttymnf0qQe6rUggs3TjIhXUKlg6h0/dPc2eHxERN8d3/38PiwUrvIF044pwcH+0Kw09Pjg4P9g4M92zYBsAAAjHuECs5dLwgo53sH++flYpyGu/tbpYsCRKDWqK6sLb/3q3ePTg4JRUsrizYw/dBjgv3oGFaMsh96u/s7g1FvrA8+vXljZW2x1ii3uw3gWJ/d+hg6FuXOoyf3uv2W9JiDofQE5dTBmHLm+twP2PLKM9MaGebw/v1bK6vPG80ywhYm4KJS5JK0u41WtzHWB1Hie4EgDDGBhSQKbhhHa+tL0DGhY9bqF612DSPLc6lljlvNShJ77Wa1Ub8w9MEkC4UkmIAo9tI04ByGAXU5ONxbZVi7vvI0vVarHwupcaGVznc73QKhQ8NsHJ+sXl8HV1fxdBJdX80u59NXL+evX83fvJlHscyfHaeToFY/t+xxNglH4y6h4Lx85iCDc1AqHbdaF1HE1e065Rv+S/01Kg/1xy++Mg2o+j3PS9VBXyNY9LqjSrmOHNrrjZqNzvl5dTw2bBs1G51atQkhgMB2HAdYYDzUMaS2BsY9nTui3x2USiXGmK7rtVoNAGCa5nw+T9PUtk3GMeeYc2bbNqWMUoYxcxziOEx1AI5GRrvdZUwMBoNKpeI4jqZphOB+v6frOmO01WoNh0MppWWZlmWbJjQMCyGCEKaUmqYxGPRMUysUTqvVsq6PAbA4p6b5g++mWq1o2ti2bSGEavZTtTWKQh6Px8NhXwhWq1VarYbvu6PRQEo+Hg87nRYTGCIgXI4IgshxMFKahW7YhFBKqWVZFxcXqjNwNBq1Wq3BYNDptM4Kp6apIwQrlepwOJTSY0xYFhyOxoZljnXNhgAipz8cVOv1/nBwVixYAEAHd3sDFc62gUMob3d6XLhC+obpAEgME6pPIUy4FO1uZ6SNCeWNZlsIV7q+4pURpmGYMC4bzbay6qgRQ80dqqeCUCmkZ1oAE8okL12cF0png1FfuKzTa5arpcGoW29WeoN2rVEejns2NAxrvH+4Z1i6cLlh6YalN1r1haePd/d3Do/3KWNS/lCXowKfSuJRBmI/iP0gMkxbkTsWsIBjC5dpxlC5pTxPuq4YDvsqOo+xQwghVCDMKBOu50nPtYBl2rrrS8MaA8f2Qw84tm5quqlpxtgLXAdDiIAihqMkDOMAU0Q5UXI1REC4LIjckda3gM4lGesD4JhjfeCH0gu5aY9taAiXKt2KMKp+TIxj16MOMj2fuR5F2LKBxrjjepQJhJlzeT21oUE5ml9N/FD6oQxjL4w96JhCkmwSqavEQhLpUi5wmoVx5FIChoN2lgaTLGQUSoGT2HMlUbdeg1DGsccoEBx4wnGZNc/cl1fh5aWfTYTrWnGMGdddz45jHMfY9czpTE4m3mwaz2fpbJpdX01n0zjLvOuXk/llenU9IRSEkcwmIRdISOwgK029+TxyHG0y8dUjCOj8Mvryy7+4U+Lbb7779pvv//D7r1TFpza2OPME9y3TsS3EqQdsMhqaroylCIFNBA+jcBIGGSEMYzwYDGwLAAsKJvvNgTmyJHYppq4rR6ORqoaJosg0zcXFRYyxlFxVcDoOZIy5ru84GDlU8ODHeCdyGBcSAEcJ0pZlIYQ8N2BMAOAA4Ejpu65vmjZCJPBjRl2MCWPC9wOMMYQgCDzOCeMojkPXFRg7a2sr7XZTtdIEgSclNwwDAGAYBoRQtfkpuFGdElEUIASl5JZlAGBtbq4bhgaA5YfyTzE8bENAOcOEMe5ChwDgqOIu1YajOCDLsizL4pxKySC0TVPXdd2yLMsCtg1NA4w1w7BM1S+lOrcgclQ8mnL+o4nGBg4mjFCuKmwIFdBhmAjLRpRJANFY01WyMUriNJsK6TEugjDuD0aVaj3NJly4UZy6XqD8OGrc+HHG+VMnTmjZ0IbQDwPhCtM2CMO6OZYeg8iygE4YgsgWLoPIkh6THuOSOdhxsAMcQBiRnsgXcvlCDjiACUGZUPudEuYVPaz8NYQKJUVJz8WUMkHVDbFOt7m8vGiauudJddmdUowQDEOfEBzFmXQDAFEQhpgS4Yo4jfzQlR5zfTmdT87Lpf3DPZV1Uv1YykqjPDWKFQ4i/8ecd5yGUeK7PpceI8xptmsbW6tMYOCYTCI34IQ5XiBtaFFOgigQrksYFS6LE88PeJL6rkelS6az+Op60u7UypViEHtMYIUvUeJHiY8I8EPp+txBloMsz+fZJErSgAvsByJOgyCUgc/7veb+3uYkC32PeS6VAoeB8FzqeUwNRFHopokX+IQ4Whaz61kwm3hxzCcTN4qYrndq1fx06iWJyDJ3NnMvL735PPRcGofeJEviyItCOZuGs1n05u1VEIogFJdXWTYJ/YAXS6edbn0+j9PUdV00m4Wui9LUTVP37dv5V1/99v+HHeq7777/3W+/MA2oMty2hWwLEcwhoAR7GLkOFBBwSnzfyzw3HY+gaSBChEr1WqZNMSMOMQa6NbYZoNCGQRCoDUVdPqGUfvLJJ5xzSjEAFiGIEKKKspDDDB2oSOefCCOoaYbjYFUrBQDAmBIsLRMBG0NA1HkpB1IHUIw4xpwxgTEVQjLGkiSSkvuBm6ShEBxC2/fdvb2dg4O92WzCOWUMm6auqj+V5g0htCyLEPKnRlEsJZeSQ2ir/+VLSy+azbqUHFNoQYNyYtoml4JQqhsWodxB1DAs9ToKxTDG5XK53++bhgGhLSQ1DE3TRgrgRiPNNG1gI003TdtS1cWUMwvYiGAmuEOQbpoOomqoUdMBoVyRwZbtUOYpz4vCIBtC6ckwjqTnJlnKpXAw8gJf1XGGccQE9wJfgZcCGkyYMvJaNmRccuEjzABEmDIlSWOKRtpQN0d/6uhxLGACxyYMa8YYEQdTZAFLNWOpDLR6R8nehDLVhqM2Ken6qlHwT3ATKphDBHNXqhcXLgtjb319td1uCsEIQZxT9VPgnHDO/SCmTLXRCN0yhCsU6ev6HBFHZQievXg61kdB5APHlp5QI4yCU+WsUX2gQeRLTwLHjBJPuBQRoLpBnr1Y0IwhE9iGOiI2E5jyHzwG6s8ApgQRKCRWs0yS+kEoCAXTWazp/fOLszgNvEAIl7o+B45JOaIcCZc62OYCez73fK5kb8ocz+cI24Y5SmLPAfrS4pMk9jhzfI+lic+ZE0dunPhqrknTIPCZ7+EkZKGHXGZfzWMpsAONy3kKgH58tDufJ55Lk9h1PYDQIE1lGMgwkFkaB76IIzdN3Ok09ANOGZzNEyExZXAyjQxzWCydXl4mnNtxLDwPK807Td2rq+R3v/u3Pwdr/lMH6LfffPfHL75WO5Shg/v3Ho+GhqrjI9jzvcz3MkNHho4o8YHNDB1BwGwb6ZrtOMQybUY4AkgfaOPuMH+U29vd+/u///vl5WVK6YMHD+7cuYMxvn//vuu6mqblcjnX9YIgOj8vWyZU0KYCn4x6BAvLQrYNq9V6q9V6/PjxRx99JKVXKTf2do8uzms72weC+6qFC9gYOdy2HAgRpcw0zVar1e/37ty5tbT8vNdv3b5966OPPuh228Xi2f7+rmUZ29ubnBNK8cHBwXA4JIRYlqXrutK8m82mpo03N9cXF59j7BwfH25srHFODw/3R6MB53T/cEel7za3N3uDPpfCsqFhAky4ZQHLslQtab1ePz8/X15efvfdd5uNxuLi8w8+/OXFRensLKcmNcsCpmmbJhhrRn+oOoX1sa6pToZ2t9NoNbd2do6OT6I4bbW7K6vrw5HW7Q003TRM27SggzjC3AYYOkS6vmnb9WY9d5ZfWVvtDwc2BE+ePa3Wa7pp7B3sJ1labzbGukYoH4314Ujz/FARPYRyAJGD1A0pDiBCmBiWSRgFjq0ZY+CYmjGGCFBO+sPe/uHeWTF/kjtWu8lF5aI/HKrUpQI4ByNEMHCgZQOEqRK8FSWsRirVmGOY8PgkV6s3F5eWLirlsT5a21it1MpCsq2tzVarUa2Wm82677uU4mazHgQe55xxj3Hp+9FgNDrJnbY6rdt3bzVa9cvr6f7hXrVe8QJ3e3dLN7Xc2Wmn11Yu4d6gCxGACLi+VD5j4Nj9Ya/Vad68/WmhdOr6/DR/ZNoaYc7y6ov+sHNRKdZblWwaacaweJ5Xtj3gQGUg6g06o3E3f3Z07/7Naq3U7tRq9fN2pzYcdSrVYpKFrU6dMOfyempY40rtPIjcOA24JIyjyTRWNI1la/sH29AxL8qF0nm+Vi0xCs9LOcFRq1nxPfbyemoaQwca01nyg9U49rLMh2AUuGjQrZTy+wyDZqPy4vlCr9sEtl6tlBh1quVSEvvTqdvpFE2jO5vGUehOsiRNwjhyARhhYg1HnZPTfYSt4ahzUT4jFFAGx1qPc9jplNPUnc8jw+gJAafTYDLxf/Obf/1zdKj/HWu+/vqbb77+7os/fMmZF/iJ78WffXqnUm7kc6VqpVmvdZ4/XVl8sUawhICqWKZtEeQIXQOGDrSx1e+NoO0wzCxNzx+dnB4ct5utZqN5//79g4ODv/qrv9rc3JRSLi8vAwCOjg6Pj08gdDwvOC9V87lSFE5sC2MkDd1RBaOcuRCiw8PjarWq4CaXy//DP/zk+Pg0DOPFF8vn52WMqWFYlgUsC0JAOJdSerlcrlQq9fu9waB389YnlWoJAGt9fbVSudjcXAfA2t3dLhTyKjlVr9cPDw993zcMwzAMhNDZ2dnm5qaU4vy8eO/eHcUib2ys5XInh4f7lmVUq+WzUk5li1ud1uLyEuXMsqEy+0IHqVxVr9dbXFwEAFQqlZ/85CeVSkXXRw8f3svnTzc316vVKkJIRSxs29ENtU6Bsa4BB3IpGq3m0ckxYSR3dnb33oMoTg+PTj67eTuMkly+YNkQQEe6gZAhwsIGmAsvjJLTXP6iUkEEn+ZPVSf5Bx99ABEYacOVtWUu2cHRPmFkrBnQwTu7+zZwVFGWZUPF4AD4Q3wJEaKbBnAARMDB0AK6BUwv8Ma6dnB0eFY8O82frq6vPnz8yAK2DUAuXwjCmIsf4hTQwWr4UrV+aoFSdmElzyNMXS88PjlrtjqYsEareZrPhXGYOzvNnZ10+61qtcwYWVh4pIi2LEsOD/cLhbzneZjw0dgQ0tve2TEskwnW6bUPj/f9UP705z+pNaqNVr1ar1BONrbW1QLlBW6hdNbqNFXzHqYoTqP9w71uvwMR0Izh9u7Gaf5oaeV5nAadXrPWKBPmrKwtQmz1h+0w9nJnJ91+J4h8L/Cl54VxdJo70o2BkLjZquTPjqq10tb2arlSGGu9drceRO5p/qjVqTfbtXQS5c6OLaAzgV2fM44oc84KJ6puot4oD4ad45P96TTe3Fgej7pSYIysUvF0PktGw04cufXauZLM/UBkWSglajUvXl0mSUCO99cdoM+myXDQ7rRrhj4IA2Hog0G/nSY+xiMhzVLpyPdY4Is48mfTxLbG/V49ST2Era3tVbVG5c+OCAVC4sk06nZrptlTjuE4Fsplc32dfv31b/4c3/B/uqPw/Xff/+Y/fq/4GkbdJwsvDg9Ot7f2P75x8/bt+x+8f+O//te/rlaaCDHOXWAjy4LjkTkeWcAmAJDR0NBGhmNDl/Fnjx9fnJ0Fnm8Yxvb2Nuf84uLi3XfftW3b8zzG2OLiEmPi2dMXhcJFu9W/d/exK6PxyIaAM+obOgA2ljKo1Ro7O7tZlhFCzs7Odna2b9y4sbKynMudnp6evHjx3Pe9waBv25am6drYVNGqzc3NVquVprFtm9s7m34gbdvc2dnyfTcMfSHY/v4uIWhnZ2tlZTkIgoWFJwihHwWpe/fu5fP5ly+v9/Z2Pvzw/efPn1ar5WIx//z5U0XxvHjxjDK0s7e5sbVOOf305meIYISpYdqYcAiRImt2dnaWl5ellMfHx//lv/yXdrvtumJ7e0NKvre3u729HQSBrpuablgm0HRTM3S1Rqng4vLqSqVWjdPk6fPnv3r/QzXU3H/waDq73NndHwzHhDIhfT9IVSOEdAPPD7d2dmwIoiR++vzZzt62cpo9ebaQTdMg8nuDbqF0FiXRJ5/dBBDtHxxVqnXLhqopHUDEhcu4ByBCmBHKDMsEDlTZQsIcC1iE0d39vbNiYTAali4u9g8P7j988ODxQwCdxaUVteXZwFFYo2zBPzJB6rPqQxXmokw+e75kWmA2vzIss9luZdPJ2sbq2sZKkoXTaQaAtbT0IsuSlZUlzmmr1VhZWfI8zwbYsqFlwyfPnoVxFMbhebk00obV+sXjJ48OjvYVKdMf9i4q52EcbO1scsma7Ua+kEuyWAUvVSUFEzTJ4ma7PtL6O3ububPjx08eJFk4mSXNdm17d8MN2Cc3P+KSdPvtcvWCS8YEU/nS5dVFLlCaBa121bRGmt7/5NMPDg63p7NoMovH+uA0fzQYdVfXlzCFpYuzav0iSnwH24wjG+jbO+tR7F1dT09zhzu7G3v7W9NZcny0q9p/67Xzfq9JsL2xvjSfJfv7W9KlUey5HkuTYDBo1muFq1k4y9zC6Q6GWhSJZvMiikQSS88j5+enCBm9Xm3/YPnyyt/dXXGAHgZuHAVXl5NOu1Yp5//5X15T5mzvrPkBn82Tvf1NhK3LqyxJg0q1MJuFvV6t36+/eTMrFo+Uo+/LL//X939Gp8R/wprvvvn+d7/90pORbSHfix8+eLK0uLa9tf+rX35048bHtVr95z1gdvcAACAASURBVD//xelpTkgJAEAIa5ruOOiHiCYg0CYIEsd2HMt6cPv2xVl+PBx++OGHBwcH/X4fAPv+/fuNRiOO40qlsry8cn5Rfv9XHx3sn3Y7w/W1ncDPdM1BjhQ8VBkFKfxCobS4uDyZTJaXl7e2tvb2dp+/eFIs5o6O9irV87X15TgOIDQ5x5QSzj3bdhAia2trrVaLMbq8vHh4uIcxODzc39vbCQLPsoxSqbC3t22a+jvv/Hx1dVlKefv2bSmlomyyLHv27FmxWBRCmKa+s7O1trZSLJ7t7GxdXJTSNO73u9vbG7o5+tUH7y2vLjnYefDoIRMcEzbWDEwEQkQ5dDY3N5eWljDG7XZ7YWEhn88vLT2/c/fmaNg/PNwvlUppmuq6YZq2adijka6bhmGZNrQtYDPBt3a2K7Uql1w3zYUnz/f2D+/df/gP//hTB5HNrZ3+YKSs/UKGKhuptKT1jU3N0NXv7frmKkCW9NhJ7ohL4gXiJH/UbNdqjcpHH3/cH4zWN7Yq1bqibPwg4sKVru960Z8aQrFDEBMcU8eGlutzTLH03L2D/Xa30+q0d/f3cmf5drezu7+HMFlaXiNUOIiqHj/oENcLwyhVtTWKIcKEen7IhQsgYlz4QbyyukEoH460B48eFUolTPFwPDg8PmACTybJ4eF+r9cZjwYff/zRaDSo16u53EkcR5hwIX2E6Or6epKl5Wr53oO75er50cn+L99/7/niMxV62t3bHoz6+ULu409vIAxbnWa1XgkiX7VzSU/ce3BXSF5v1p69eFJrlNc3l9vdxoulp34oJ7Nkd3+z3izniyc/f/cnhjUe64PeoBvGgfpjwKXY2d2MYvfgcPvF4kK7U8ufHZUrhc2tlTASaRbuHWxpxvDyeqqbw3QSnRVPu/1WGHt+IKRLXY8VSzkhsWVr/UG722ts76z3+61i4SQMRBy5xbNjyxxtb64uLT6JQtluVaezJMnCNAvn8xQ5Rq9bDT2CwRDZA991jk+29vZWHWecptK2+0dHG6bZ3dx8cXy8Ll0rn9vlHEWhF/judBIb+qDZPI8TORx1ao1zC4xtoDnIRNh68/YKE6Dp3ShkhcJhrVaQ0mm3y7NZ+Pbt/M/01/wnvua7777/3e++IETomo0Rz50WD/ZPnj5ZevF89emTFxfn1ZXl9cJZCWOGEPY8z7JsByIACGeBZSIHEEYEI4xAp3h6enpwcFG6+OSTW3t7h6VSeW1ts1QqE8IZk5VyvdFojsf6hx/cWF3dyp0Wi4WqFJFtEQcKy8SeG3PmSeGbpr2xsTUcDu/fv//48eNut7O/v7O+vgqhvba2YhiG60rGGCGUc+E4SNP0OE7K5fLOzs54PH7w4P7KyjKhuNVqNho1KYXrynq91mjUMUb379998eL56empKgxVlPBsNuv1emtra/V6fXl5pd8fYEy2t3fOzs445wjhRqPZ7Xa5FEsrSytrq812+/D42PUD6GDTAkL6CBGMCRcCQHDv/r1KtfJ4YWFra7fZ7D569PjuvTvFUuE0l9MNE2Fi2w4hHEI6HOmmbZm2NdI0w7Qpk7V6a//g5OS0sLq2Wa7UVK7yNHdmA+fkNK/oYUI5ZR7jHsIcEx7FWem83O72zgrFQvHctO1cPl88P7eAHacJRE6r0zEss95ofvjRJ6Xzcum8Qpl0vdDzIxs4DqJC+kL6jLtCetBBlHGIkIORbhqEYQcj4crBaHh4fFSt1w6ODtWJy7GunV+UD49PwyjFhLte4PohgEhxwKYFEWbqxbnwuPCCMOHCgw5hXLY7XQvY3X7v/sP7xfNip9euN2s2tLikURxq+phSYtnm0vJisVTc3tmCDmScI0Kl54dRXLo47/Q6jVZja2ez1qhEiQ8Q0C1DeIJJflEtc1dopr68ttwb9s8r50xS4XFEHTdwJ/MsV8iVa+VOv5MvnDZaVdPWj08PLWBN59MgChqthnSlCbQnzx7WGuXT/BGmmEtGuboMEdab1WrtvN6snJfPOt2mDYxytWhDI0kDz5cjbeBgcHx6uLTyvNNrFUp5wpwkC7kgXJA0izqd5nDY63SblqVPpomD7Hanzhj0fR7HnmmOsiwwzeHGxtJw2O73m3HsxYmfpkGWhVEoRsO2bQ4toxd4OIpYu1MeDpu+T9LUJcS0wTBNXdPsV6u5Vqs0GrVm0zgKJWdOmgSuJL1uHUKj329Z1jgMhKb1/YBdXqavXs/CkCWJm6YuAKN+v67rXc7B1VUym4VffPHv3/+lmve333755df/8R+/ZUwwKgmWnhvH0Uzw2HPTwMsEjzkLKHEZdR2HAgABcDCmtoUVO2uZgGJGEEG2jWzQa7RdHkThxIEsDidShGGQMephxAUPPC+cTKZxnGhj4/SkYFsY2AQ5AgJuW0RdaAA2cl2/0WiNRuMsy5SMxblACA8Go2azxajLuYccjhwhZUAIVqUQURQ1m01CyGQySdNUnXNRTRE/XmsJw1BKCQAoFAqO46gCUIU4cRwXCoVerxdFaRSmlAop/ChMKf3/WHuz58jP8zz0/zsXvkjqlFOOU8eJQjuSZWkkUhIpitSQM5x9HwCDfd+XbjTQjd5++7fv32/rbgAzJC1LsZJ4lyhRFIc6Fy855VT5wmW5CtXVABsgyAIevO/zPovGmGvtOVOcK21dhukwiF6xEnGSxUmWpERqy6QQSjSOj07aJ3GSpRmNEz4aXxpnMaWwthy3OmlGGTeYyF4/6AfDDBPGJRcGE9nrJUdHZ/0+kqp4tY9o44ZBdNbtg82SCy2kpUxBRkRejAiVcYLzYlTV53kxEdI5XxtbOl9TpuFJUU4GwxhMCc5XxhZVfZ6kJM0oF1+qbGC0YVxGcZqkOIySDJEUZdDe3To9SVFW1hU4wpXRB0eHwJjC/Rq4YaUVZTROMucr6wqf11IBLCqpLONKKl1UBSJZUeWTi0lRFaPJ6KswYAZ1ulIrKF1JUXbSPi3rijD4BqUvcuPMWa/jC+dyZZwUivq6UM6mBGeU6Nyb3I8uzsvxKMF4mIT5qNC5UV4nNFNeS6dOuqfVeT2ejHzhjDO+8HlZMiHAhq6055IZJwZBN4wHoAPEFGLAWJIlvcEZmB6+rO71BlQ82qqyLrRV3f7ZIOhjiphg0BUjFNdaSsmdM4yRyWRcFLnWUghWVt564bzMCz2a5OcX1XhSaMOUpnmhneFlYcpcC47qynknhcCXF/V4lD+/HF1e1JcXdVmY3GtnRVmYIte5V2VpOMvguTXcaKYVhSdG8/GoqApXV76uXV2bPOfPn5fn53Yy8caQ0cj+7Gcvfv7zj//6rz/6+OPJaGR/9au/h1y+fyXQ/ItY88Vnn33+i1984lzOqBLcxhFGmRgOMjh1o0xRojES8NMVx2kUJVGUhkGGEY8jxKkkiEbDCMUJx4QkWRIhlLFeN4AoP1Akg2BHKSulNsZRwtOEYCRQxq2pMVIYSQis4UxV1YgxkaYZBHRijCHAnFLKuQzD9CtUYggxjDGI6KAnF0QuEFpujIEnhBBoStBae++rqqKUQpsdyIUhKwvq65QyRVFZ66HFCUQ9UASMCQuj5JXNGhiKOMnSDCcpwURQzobhIErC3qA3GIaDYRyGFGGeolQoSRlLMxyEaRCmg2GapDSM0ihOCOFxgsIoCyMURSSOWZapNOVhlAipQZzyymOZIUKZdL5iXBMqhbTa5M5XSntwOWmTC2m5MEJaYwsIjoCYGEjho0x9FWCu4ZjFuAZWBS5HgGjwH5ghQhgjjCRZChnmUivCKGiduRRxmoDoGREMsRJQ20Ioy4sKgi8Yl8Y6OHgxeIXW2lqX59Z7Y50yhguprdXWcikgSBQqE+DMnKIMPggSSuBlKMeYpspwZTmVjAiOGE0JxpwhRoXRwmiTe+U0N0JYCY8AOsJKqsCxzSgnxhmooxFSh1HKuKacEJYygaMkgMAaymmSpZRzlztlpNQSkQzO6soocEtpq1KUAO6ARbMalXnppZZSi7ouQUVR1yXn1BhljDJaUYacl1Vti9IUpbFOAMqMJ0U98rlXzooi19CyUpW2yPV4lAO/A//UO2k0s4YzmipBlCRFrotcW8MJjjnLzielVtRo5p2sSldXXgrCWeasAMFeWYqqEnVtqkpfXBR///d//cknf/s3f/PTjz+eXF6Wn37691/87re/L9Z88cXvPvnk14Sw7hkcQ4Q1VRjgOKKUmDThUYgxEmlMBPsyJijLcDBM4giHQYpSkiWIEZYE4bDbS4OQIEawiCOkpGNMpQkhmIOOBmNmjJNSJwkiWApujS6ULABroHOKM00pT1MIVDdSKiE4xhnnglLGmEgzFAYJJTIKM6WsUhrQhHMOARHwrlKKcz4ajYwxw+EQoracc1CtyxiL41hKiRCSUlproXCKUoox9b7wviCEQhEw5xIhwrn0eQExVAjTfw46GSIZosMgJowG0TDDaYbS/iA46wb9fiaVFYpjSoxzAExRjPqDqNcPe/0gTlNCeRDGCPM4wRniUnnOLSYSgs3h9xO6dPOiAjmM0l5pL6QF7GBcC2kBaOrReVGOi3IMCTWYCMgwH40vKFOESqkcQEySEoS5NrmxpdKOMuF8aWwOJQoZokmKkxRhygijTIgkyzKMuZSY0gRcAxhJLeFU/woUMCVcCiYESGmUtmGcEMpBvJchQpgIo8zYvCjHXJiiHNejcyFtUY6V9oRSwigU8mFKKGdwoaOcwaNQkgnqcisUYwJpJ3yhuZauLKQ1ADd5XRWjWhjNlORGMM2U/xJxpFNMc1d5ZoQ0gkssNS/rwjjtixygllDuckNFluGYcowpklpwKUBvmeEMU5ThlHJirAIhMugDtVWIZJOLsfVaag5tDYBB2irGCMaZlFwpUZa51rIovDHaOlWPvPMCxMdSEW0Y49n5RVVWVnAkBQZ1n5KkrpxWdDIuJuMChpqqtDDv5F4VuYY6OmeFVpSzDCYakAjmXgmOrBFlYYvcjkdF7tV47KpK17UajfTz5yUcuX/2sxfACkPe8C9/+Te//exX//oF6l/Ams8/f/ny5e9+85vfEsKSGDGqKVGCO0Yt6PcwUv1ezKgW3GLMvvo7T+IYxxFOE5LEKEsQpxyABscpQRS0bf3+0Pui2WyFYSy4yjKcJFmrdUoILctRlgJB4wjWnDkpPMpYGKQYMc6lUiYIAiFEs9kMgiF0YColgiDIMmSttyYPhikhTCnNGIOCOhhMIGpvOBwaY9rt9tnZmTHGWss5bzabzjkYgmD8AUWf1hpyzq21xhhrXRzHRVEeHBwEQVDXtZSq2+3u7O7FScaFquoxXF4yRL5yMDtMuFDSON0bdput5jCIDo9OTk6GUZxSTiinZ73OIAjiJEtSBHATRmmaYSjYRphmiKWI7e03Tts9bfLWSRu4W6Ut1OxmiBDK04xA/4GxhdIe0jylcsYWRTmO4gw4nebxCReqrEZSmWEQSWWMLQiVUGIHS42QNk7IWTfgQhvrM0SENJhwxhVkD3OhojjBlNTjESI4RVmUJogQoRRhLMPpMOxTTsI4gCsyCOdArweziTIGYALWH6m1VJZxIyQ06lXwJEP8qNFuHreV1lIrKOqFOFEIMIZELmiPYYJJLQjD1qveoM0VORt0t/f3TrtnVAoieKvTPm6f2iIXRmtvXk00VDHlNRZE50YXNq9ckoXaCi7pzt42IpnzXhvXOmk3W0faCS6J1AwOWFIrqL5LUQJSvclFHaeB1JxLOgi6TOB6XLpcR8kQvmxZ+7L2vjDGKUwzhOO8MD43RWnPL+rxpEyzMC8M47jXP1WaasOsE9qwbu9kNM6r2tW1z70CiAEEAUCZjAuj2fbWqlaU0TQYnk3GRVkYo1m/d0pwPBkXdeXKwoxHeVVagB74iDWirnz37OSkdTQe5UnSC8POxYUvCs55nGUDxuKPP55cXBR5LspSjUb2k0/+9te//sXvhTUvX778/PMvPv30MyGU4IZ9mSmjCNaM2iwVGKks5VI4rTwhHCYOhOirrqgsJeCMS4IwDcIsjCVXeVE9ezZ348attfXNGzduzc8vYsKEUPfuPbh79/7t23es8YxKowvBrdGVkgUlGiNOicxSWpb1zMzs48dPdnZ2bt269eDBfWMEF4Rg9NprX9vZ2S2KinOFMTPGgrwYMrFgIcrzfHp6+oc//GGj0VhbW7t27VqWZaPRqN1uf/vb3wZYAWUzjEJpmsIiBjHmUsq5ubk7d+60Wq35+fmbN28GQWCtvXv37tr65tz8IliWIan7lYFAKse4klqdtFt//hffWFlbzhC58p3vz86uKW2YwA8e3VvbWF3fXOdSpBkaBtFgGGHCozgllCcpipOsrMaNRuu1P/sfjePjDOHv/+CtOMmM9cMguv/g0Xdf/97W9m5ZjTJEpfJCWsAXn9dSOYR5UY43t/Zu3rqDMF1cXHn7R+8uLa+OJxdphufnl3749jtJSghV2uQ+rylTPq/L6sXa+nudzhsffbQ+niwkybXxeN75J/Votqqf5cXU5eVyEL7bbH2nqKbKetrnT4pqqiifOv9A6kAo/fDx/cbx0dTM0+OTJvyF11ZRjimneVkCNIB5wjgLdQtFOXK+ZtwonZfV+d17j1fXto8apw8fTb/3/o3RZJxhNLcwv765sbm9VY9HMDdB2SYTPIwjwohQXCgmNfvxe29v7a5v7m7fvHv37sMHwuiU4N3DgzsP7nOthNFYUm4EVYxpbgrrKh+h2BS2vhhJQ59MPzjtNKefPdne3VxaWaxG5Wmn/XR6emb26f7RTlE5yjEk4ADecSms11zhauStl7fuXj9s7j2bf7qzv7GxvSI0HYRns/NTW7vriMTlyLlC+dIITQhLlWZSkbKy1om8MErTx0/uDYOzre3Vdqe5u7cxnhSjcX5yerSwOPPiw0lRmqpydeWEQLlXdeVGtfdO1pWrSru8NLu1uZJ71T5ttI4Pmo29y4saBIFrqwvnk7IsjJIE1i7vJCxiF+fV+aSKwv79e7e6ZyeCZ91u8+Bgo9s9+vDD6uBgo99v9futi4uiLFVZqqrSH300fvnyV793tvkXX7x8+cWvf/0bIZWUFiPBqJbCRSGhxMB2Q7AEYgUhhhBJU0QpzxJKicKIB4MojTOcIhwnQbfHUmSUGQyH9+7dX1hYPD4+/sM//MN79+7ned7r9a5efd9a/5//838hhAtuINCXUatVmaU8S5lW3miPMb1378Hs7Gyv1/sP/+E/3L9/t6w8F/j09PiHP3zz8HDfe59liDEhhCyKwloLATQAGVEUTU9P37hxY3V1dWNj4zvf+c7+/n5d11rr119//ZVtgnOeZRlMTwA0kJyeJPH6+urDh/dXVpY2Ntbv3r29sbHuvbty5dtn3d4HN27/86BfGEm4UEJaJpS2Zv9w73s/eOPh44d5Ub3z7rWpqaVqNO4Pz974/ncoJx/cvM4Eo5xlGHd7/SjOIEK8PwiSFBnn9g72r3z325vbm+cX59eu3wjC2FhPKK9Hk9m5hTTDZTVKUsT4l0NKhpiQtqwmmIjJ+YuNzZ33rl3b2dsrqiqIot39faGUsfb84vzJ1FQQprA9+bxGmBMqf/JXf3fUuDYc/o+f/6+FsroRJ98Nw28ft752fPzfjL2Kyff39/9Lhl7vnP1pGH+7KK8F0bcw+V6SXNk//E8IHxfV+O7929/81jfA8tM4Prxz79bC0tz84rPbd2/u7u92+2fLq8tC8XpcCyWMM1JLob7ktq0r04w+nZrb3Ws8f/GTXj9snXQ+/Pjjg6PDze0tqdXjp098kQNTAzpBl3suBRyGhGL9YWdm7mn77PjDn3x8ctbZOzpUziJGu8PB9Vs3uVYm9ynNXq1ORFJbOqCHTWE6vdaz+acZidc2lr7xzT9rto4uX1wsry7t7O12++3Z+amicsqIOI2E4ojgr8qFBZNIGtobthdXZgnPtvc3rrz+zZNOQ1mmHX/n6lvXb14tRs54SUWW17aorfFCaZqkQ6Wpz1VRmm7vZHtnLYr7a+uLJ6eNZ7NPzi8qhKPWyWGjuffhR+fOS+vEqPYANDC5wKiSe9U6PlhcmDk9ORoOOoKjpcVn41GuFV1emn1w/9bzyxHwxLBb5V4BThW5LnJjNG829nd3NvZ2NyiNouhsa2vh5z//sN0+vH79RxgHH300Lks1HrvLy/KnP33+xctPXv6eGaBffPHFF1/87le/+pQQhhHDiEvhOLNhgBm1acKzVKQJy1KWJjSOUZqhMIzjOJPCAuk76IcoxQSRsD8YnHVpmkku3nnnndde++/f+MY3VlZW3nrrzTfffBMh1O/3rl37QCnz31/7UyG0Vl5wK4XDSIUBiUKMMjhF8Q8+uPkf/+P/+8d//McbGxs//OEPb92+QVm6tb32+htX/uRP/vjtt99ijIVh0O/3KWXAB1NKvfcwlTx69Oi11177gz/4g7Ozs9XV1T/5kz8Jw7Cu6yRJrly5UhTFqwsUYwxACop6jTGEkLt3b1+58q0/+qP/1O12FhbmXnvta8Nh/+JisrOz9cEHN27eugt8DRyh4DkmNIpRmpEMI8opl+y9a1eTFP346vW5uXWfF51u6/tvve4Lc+PW9TiNkyzlklPO+4NwMIwR5mGUIIwpp9WozHB8++7NalTdvnsvjBKpTFWPhdRz84vgloyTjFCpTQ6Ei1SOC8OFkcp9/Jc/3T84ePTk8Wgy3jvYg4LtejzCFA/DwLoyTjDCHOL4lPZF+eKocX04/Ob//OvForzd7f1Fv/9txt4Jwu8myfcHwZV258+lvjoz+//UoztVfavb/+YwvDIMvjUMvml9YH3+dPrRd9/49sraosv11Mzj45Ojk3Zze3e9fXZy9/6dMA4eP320tbM5NfO0fXYK9xqXO6m0dTmm7Padu2++9fY7P76qjdvY2o6TdHJxvri8tLi8xAR//PQJE/yV74EJXlSl9Y5L7gvX7Xfu3Lv5g7feuH3vxsWHl4+mngZJzLVKMKom47mlxZOzTl5XKc24EaawVLGUZhlDRFJX+dNe+96j299/6zu37l7fP9xeWp1/Njf1/MOLrZ2NvYO9/cPdlfVFcGlTTjBFsEJqa1yuq7GN0t6T6ftvv/u9lfX5heWZje3llfX58UURJr2V9bn7j26FSa8cWUQjrpArpLJUKsxFZiyrR24YdO7cvf72j95YW18YT/z8wvTJ6dGHH533+qePHt+9+t7bXCAwdlalLXMzHuWwIsEOVVfuwxeTYHh2sL8VBt00GTYbe4BHUuB7d29cnFd15c4nJUAV2MelwEYzZyUE/a2vLe3srIZhp99v9XrN0Uj1es1Wa29vb+2nP31+cVG8eFG/eFF//PH4t7/9d/Bevvz008/+8R9/gRBhVGUpVOiaNOGUmDDAcI0GzphSiTEFcwAlCmU8ilAcZQRRxVXY7we9PkdEchEEwdLS0s2bN+fm5qamns7OPpudnT042H/yZOpHP3r3xo2bjMk0IQRLKbzRFcE6CjEQw5zpOEmfPJm6evW99fX1hw8frq0t7+yubWwuU5b94M3XV1eXCcG9XjeOY855HMdRFEIsOcZYCBEEwfz8/Ne//nVjzNOnTzc2Nnq9XqPRYIxduXIF5hrwWwNJHEUR0MmMMYRQlsWLS3NvvvW9vLBbW+vbOxtJGh4e7cVJcPfevdZJx+dlkuIoTiGdFyId4gQHYUIoWV5dWlpZfPDovpD6je/9cHZu7ajROGhszcw+fjL1cG1jOc6iIAqY4FzyME7CCGWIIUyBV15eXVpdX9zYXnG5/fHV9/qD4PCo2R8EjWZra3tPSJ1mJAhjQhW0L3BhCJWYCGNLytTK6sbyykqnezY1M/2Dt95snZ7sHezv7u+9f/39R0+e7B80Ie381fJVjz7e3Hrn5PRrYfT6weF/7Xb/ot35BkJvnXX/gpC3Dw7/K6U/0ua9rZ0/6px9PUXf2z/8/7r9b552/ixOrpSjNC/Lew9vnXaa9x/e3t7bWFie3dxZ5RJv7qzuHmzv7m/PLTx7//rVg6O9JIsoxymKMc2MU1ILl7tqVMZp/OjJI7BQLC4vFlXR6Z4dn7QeP32ysbW5f3jABNwAlbYGstOFkoRhIGIxTVfWFo9Pj7gWB81GfT45Oes0T0+OWseHx024RmUMATvENMeSwnRjCsuNIDydXXi8ubO8tbt62mmCxrc36M7Oz0w/e9zpnVCOKMdf/evMV93BXOjM5lw7srI+e9DYmp59eHy632jtNk/2uoPW0fH29t5qmHSVI0KjjARExFyl2hBCI6Wxz3leSGXw1vZykva6veNGcy8vVPN4fzwpMIl3dtfL6suzVJFrZ3lVWmu4s2JU+yJXlCTds1YwPKsr12zsNY52c6/SJOietZqNvTjqn09KuKoXueYsg4uVkqQsTFValEXbW2uDfjv36vBw8+hoS4ik0zk4Pt7p9Y6hFgoaFKpKTyb+00//4d9hrvnss8//8R9/SSnnTGUpI1hQoqKQ9HtJHBGUCYJlEhNKlOAmTXEUJiijUYjgRE0wxxkhiAzOzrqnbc04zhCljBCGMbXWtVonURhHUZymSErTarWHwzDPK6jQTGJMsKREUyyzlKQJ1spxLpMky7KMUtZsHodhwAXpnJ1oreI4LMuCUsIYyzIUhmEQBAjhNM3SNP1K4CelVEmSIIS63S6ctIfDobW20+lA8xxCCECHMQbZo1JKKaXWuqxyLkiWxUkatdutqs6HQa/X6xy3GoNgKKSWSgPEMC7hXpMhGsWIUK6MPmwcrm+uxWkcxcn6xm7nLDptd4dBnzK8tbMVxWEYR4jgDOP+cBhEKZyfEKaAPls764eNvTgbUkH2D44yRM56fahtApmvkCrNMGUSE4EwB1UeF4YLnRej1kknCMNqVHe6Z3sH+0EUhnHUbB3vHx7sHezD6Qou4l89rylblPJNjH/g/Ht5cU3pd5x7z+fXwujKafu15vF/S7PvGb391wAAIABJREFUFuU1qd52+XtcvMX4m4S96fyPizKR2rdOW0orRFAQBUmWHDYOCSMPHj047ZyUdT4IelESZDhxuQWDlXHKOKONY1xp61yeMyEyjK2zTLB6PIqSWGqFCIqSyDgDzoAUZcZZYGe1NYQRwohQwhdWKEZYFqFEGJ1RMoyjGGXtXpcIrr3jWimnpJXCCJMbk1vtNRFEOUUEUVb40tTjggmcZLHUIk4jbVWGsjgNuSRUYCZIihImqFACGmmkFlwR46Vx0niZl5pJhFlCRRqnA18qyhPMYqEwV5k0BLOYilRqQkgkJXZecJ5WlRmNvFLEe5kkA+uklASTxHkF1S5laZ1T5+cVELqjOi8LWxa2LAzwvkrS3CvAICUJJYnRLPeSkrgstbWsyKVWpCoNygIQ19SVe/F88uL5pMgNRnFd+VHtv7p5y6Lgec6NIXkuikIC1pSlurwsf/Obf/y9+qG++OKL3/3ui88//+KTT379Zf8kEkr6NGEE6ySmjGpGFVjAjc618lLYJCZZQtOEpgmxpmBECCYposNuL+j2BKYEMXgloxJlTEmX+1pwI4W1pqirc628kl4Kq5WnRBIslHQI0SzDCGEodSKEWeuTJJPSCKGEUBhTIZSUmjERBBFCBJpYkiRLkizPSym1UgYKobR2ShlCCFyd7t27B6QMCPyMMQghay0sXxhjQoj3HqJnjNavvAuQfz43NzsYDJxzQklXeF/klPH+IBDSwD5CqALvojI6SiPKSYazYRCmGc0yRYjCmBMqva8yRIMwIVTECYriLAjT/iCEvCvKGSh1hOJBNBiGfcxo67S1sbVZj0dSq6/IAp1kGReK8S/ZIm2c87mQOi/qejT2ZU45y8tifD5pn3UOG0ejyfjDjz+qRjUUQqUZBXlOGGVJqibn3efP5y9fLE/O56rRTFFOjc9n6/Ez6x4icl3I2/Vo5vLFUllNF+V0PZqtR3M+n6qqacbDDGmli6I8L6sLLhzjVkjv/OjgoIUw41KABdwXubYGkAJTjDBLEomQNXbEmOXCMq64UM4XGcbrm2vGaeO0cYoJKhQPoiHEdwoli6pURoNSB/I34IMm974qB1G4srGuvdPeMSWpFCb3cIeGwhYID6acGKet00xw5wtjvc9LbSxlXGnDhRRSWW8gNjRFCaYoRQkiGeWEcMwlV8YSxoVSeZkLyRBOXW5ap43Do11r5auyhLwwSjNMEkJTa4XRvC49ziLOUF05o3lZmLrKrRHnk+pgfycYdsejosxt7k2R21FdjOq8yHVdeXgzmudej0fFi+eTy4tRVbqL89FkXOZetduNnZ2VFy/q83NnDK4qWdfKOVqWSilcVy73usjhy+ZlYeFd0PIZQyYTD683hnjPoUHh8rKEx08++dtPfvkPXwDn8m/Dmpcvv/j885effPLrLMOUSIxEEpNgmBKs04RJYaWwwTBhVEGQFUAPrD9xhAQ3cZTGYYISlARhEoSANShjUCanlSdYCm4YUf/8i3CmMeJ1de5sKbjBiMNBHUJtjHFQ5KS1BSo6DBPOlVKAO/rLvhTypcMbQAchYq3nXBZFpbX1viCEGGPOz89v3rxJKYXkPeccHMW990AYAzEMQhshBIiMi6KAuK+iKB4+fLi0tFyWpQbpldGUcaWtdYVUbjCMgxClGY1TxASXWsKPJiZsMIzjmEcxBmsC44IJ2R8Mh0GUZohQlqQ4TjA0zwIxEcZhXnqpeZyGeVn0Bv2pmemvFgcK0hUhJeROUSbgCv5Vx5sTUvsid7mXWuVl0emebe/uWO+0NcbZKEFxgilTSntCJbxBrcKXJXZZyoRgQsATXxRSK0SItkYohSnLEGVcS+nCCFGmQd1jbAEVmsYWcOcqypHSVmplvQOLAwANVNYxLpOUE2qsqxg3yuRc6DhJtTWY4rWN1XpcQV4ndBhAd0KGU2CIldGAXIRRypnLvXE2o8RXZZgms4sLviqlNVSKlGBb5Da3cB2DphcgX74KA1Xaam2N0opylpe5MjpFqbZaGQUvgzfCMJdMW5WRVGqpjPJFDgE6mGYpisYX5Vn/pHG8X9Ue4Vgq6nMtJBGSOKfA4Q2VTEZzeFSS1pXPveYs+9lPP+qetaKw9+L5+HxSVl+uTnI8ysejoiodxNA4K+vKOyuL3OReX16MRnVujfj5X/9k0D+dm3t8fu7Lkuc5855i3LeWGEOcY2VhvFOv3qDjxRphLXeOnZ/nVSW9p3nOtcaXl+VHH41hjapr8+JF/dln//T7zjUvX74E3XCSZBgxjEQUou5ZGAYYxA1FPkIZg9w4kP8O+lEYpIxqJX0UZgSxOEzSOE3DKOwPaZqhlCQx2dk+6HWDWzfvbW/tD/rR3OzSg/tP+r3wYL8JYuI0IRDNBbMPozJJMik1qHUPDxsIkadPp3d39+M4XVpamZtbaDZbOzt7zuUYU85lFCVCKMZEmsJNSp2d9TCmd+7c63b7nc7Z/fv3FxYWnHPvvvuulLLT6aytrZVlyTlfWVnhnIOAOEkSGGSGw2Ecx7du3QrDsN/vz8/Pb25uWmu3t7ePjo4wxrv7e9CCtLi0DNdoqCLARAZhiimPklhb1Tg+ahw3bty89b3vv93vZ3Pzi7Pzs8cnza2d7RSlGU7DOEyyOMNZnKSECoRpkqH9w4Pt3Z03vv/Gxtb6IOhNzTw5bBwGUXjn3l1f5I3j5t7B/mgyjpJ472A/LypQ9yYp0sYhTDe3dja3du7cvT8Mg2breGVtdf/wALKyRpPx2sa61Go0uez2gl4/lMpliJXVxLqScSOV93kJmt75xcVOt8uEIIxRziGCRigplKJcWFeW1fj84iOfj4S0Qmkm+Gm73ev3W6cnZVVVo3o0GSdZFsYxYBx4F2DGAZa3qsdxgvcOjrjUCwuLZV0fHB3ML841W404jW7fvXX54uKwcRDGweRiHKdR4/gIAMJ6F0ShMjqIQgg8fTY363K/vbe7vr01jKPucHDnwf36fLLfOEowyutKGN04PoJ6XMAvKHhSRgolMM1O2k2h2MPH90aTqj88Ozja3d3f7vY7g6AHiehQ8/IKdPLSD4JekkWHjf3pZ4/L2m3vrW/trnZ6zVZ7f2tn9fJytL2zHsWDyXmVZmHz+MA6WZRWSqok9U6hLEJZdNI6WltdtEacnjT2dzcpiRqNrV7vuCzU0dGWc3wy8UnSQyh48XwyqvMiN2VhR3WepWFZ2NbxYbOxn3t93DxonzZxFmEU7u6uGkNOT/erSuY5aza3MB5aS7X+khL2TgFm1ZVPkyBNgtbxwezsoywbNJvb/X4zijpB0HaOwWJVFLIo5MVF8Zvf/H5ddPBpL19+8ctf/goi8rKUCm4oUYN+2u9FgAJwb2JUQZN3GCTBMMFIUKLCIOVMUcw44WkY9TtnJEmNcv1eeP/e47IY37n9YG52aWF+ZXfncHlpfW52aX1teziIjc6hfA52KIIEowIKKqXUx8cnT55MFUX14MGj5eXVqamZra2dw8PG8vLqs2dzrdYpwI2UGiYajGlZ1vv7h5ub29b6a9c+ODlpX736/vLy8vT09GAwWF5ezvN8amqq2WxqrRFCx8fHm5ubVVXB8ds5t76+fnBwUFXVo0ePoiiamppqtVqzs7OHh4d7e3tVVc3Pz+/t7wPWHDUa8wtLZTVS2jOuGTdcWEwYYfTg6GB2/tkwHLZO2z965/0HD59t7exs7awDMXzY2BeKpiiK0wDyXggR2rjFpZWtne3+cHDW67zz4x99cPP9OA1v371zcHQ4v7hQVOXUzHSGUZKlUsvVtbX+INDGcaGsy31eLi2vnnX7QZictjvP5mann81wISAua2tnWxk9v7jQG/Q7ZwNC5ezcEuMaOifB2WBd4YtSalWN6kdPHp+0T1unJ43jJqaEMOZyRzlttpqr66vHJycHh43NrZ3Do1Z/EOVlEafhwdEeIunO3tYg6O0d7LROG4iku/u7MH3kZQG6GJi2hJJFWezu7w6CQV7m9x7ctV7PLcy8d+3dZuuICbyxtcEle/z0UafbPmwc+MItLM33hz2huMu9MppLMTP7DDJYp2am87J48Ojh9Vs3e8Ewweig2RBGP1uY74dBq9O2Rb62sdbpticXY9AZgoTX5bYeV0src4PwbHxR3rxzLa/M7MJUlA6eTj8Mot7e4S44DzBFxmmILpZaaKvnFma4xIPw7PqNq9KQ6dkHXCVTz+52h0fd/jETeHll3joJOr3llfkMRePzyljhnaIk3VhfLguLsmhm+nGaBNNTj4vCbG8vZVmX8wjjwdbWwnDYipMz58jJyd7FeTWq89zrUZ1rxVrHh5cXoyQeHh7sxNHg6HAXZdH6+lKSDKpaMxYRMlQqpTTgPDo83Mhz4RyXAhe5GY8K2LwEx3u7m1XpLi/qIGhvbCxsbMxbixuNLYyDbrdZ14bzZDSyl5flZOL/4R9+/m/hhv/vTInPP/vs5aeffialpkRwZjjTBMskZnGE4whBNSUMIJRIo3OCBaMqDLIspUmMMWJZgkhG+p2zLIoVZWU+WlxYvXf30f/82f9eWlx7+uRZs3F688bdb3/r9fW17fW17ZnpeWfLLKWvvhpGHCGaZgghUlWj2dn5ubmF8/PL5eVVGGfefvudr3/9zxcWlpaWVu7ff1hVoyTJqmqkte12+0KoPC9nZmZbrVPvi9u37zYazd3d/atXr165cuX4+LiqKsbY/fv3nz9/fv/+/WfPnhljfvzjH4/HY9inqqq6ceNGp9N5/vz57OxskiQHBwfPnj27cuVKGIawUt27dy8v8qfTU3uH+0Kpm7fuGPtl86xUHhOZIZqXxdPpp3MLs2VdWJ+vrG6ure3t7O+3To9u3fngsLG3tDJPeZaiMIj6iCSE0iyjCNMfX33vrNetx6MwDrd3t+49uKOtfPTkcev0JC8LRDCMJ1e++x3C2Pbu7vrGFty/fV5SJu4/eEQo/+jjn0RxsnewP/1s5vmHL27duZ2ibDQZn7RPV9ZWTjvt+w8e9wfR3Pxyu9PPixHU2hIqpbLO55iSyfn5zOyzbr+3d7B/49bNTvdMam29aRwfNltHSRY/mXq8sLT06PHUk6czs3OLk4vJaae5ub3GBHo6/XB9c3ltY/nGrWvWy6mZp1ESg7MCUwJCPpd7l3sm2YPHd4yXTOInUw/H51V/ePatK99YXJ4bTarx+fis11ldXwmi4f2H9xDJNrbWp2aeuvzLKYkweu/B/RcffUg5m342U9bV/uHBt1//7vr2li1yrtXZoL+5uzOIwsXVFWF067S1vbsFxZXQ32K9Mc5MLkb3H972pc4r82T6gfHipNOYmXvyxptXjOczc1MIZ9WoRCSDwFPo5EMku/fgdjGyXOHHU/fPn5e7B6uPnt68fe/H9bmsJ3YYdBvNfWPF/Qe3n7+YLC7NDoNuWTljBDCy62tLH390qRVbmJ+5vBh12sfLy7OLi08//Kgcj02zuRXHnTxnW1sLeU6bze26crDyTMZlMOxurC//5cfPvVPNxv54VATD7trqYr93+rOffnh+kTebO3nO2+39RmPzr/7qfGlpylrqHPdOQrdUVboXzydZGi4uPKtKV1dWyiyOu3t7K3nODg7Wi0Kur8+PRvb8PB+PHfQo/OIX/+ffouX7v3P5fvub33z+61//BrhhrXKCZRwRCJQBd+VXBI1IExJHKAqzJMZRiGAV4lTijAgqsigOen2aotyVS4trt2/d/9//6+8+uH771s1755MXx832d7/zfe+qleWNhfkVawpAsTQhUNVMCAeCxrl8cXF5YWHpxYuPnjyZevz46Wg02dnZ+9a3rihllpZWZmfn87yEIQgscUmSKWUeP37aap0+f/7hW2+9vbW1a4ydnZ19//33GWPGmMPDw5WVFUrp1772tenpaYzxe++9B3V08IKnT592u92//Mu/vH79+snJycXFxc7OzoMHD4qiqKqq2WzOzc0RRr/5rb/Y3d/Txt6998DYPEOMUBknJM1YmpGiKlfWVhaX55VR71/74MnTZ/v7p4tLK0+nH23tbDRbRxtba0wQoViUBnEaEkbTjGrj7j942D7rdLpn71595/ikef/h3cbx4fvXr2NKxueT7d2dvYP9br/32p/96Un7tHV6enjULMoaUu+syx89fsq43Nndv3nrdqd7NjP7bBAMHz15zASvx6PHT580jpt/9bOfnpyeESqnpudO2z0AGiBrjM2l0nGa5GUxM/tsd3/v2dzsj959Z3d/r9M9K+tidX3p4eN79bhcXV9ptpobm5tLy8vTM8+KKj842t3cXpOazcw+3d3fitPg6vvvYJqub67ChRjGGZhotDW+yPPSP3xyF/OkqO3N29eFoovL81s7Gw8fPzi/nNTjamllsTfoXr64OGm3xuejo+bh1s7m+eW5L/KiKoWSd+/fq0Z1EIU3bt2UWs3Oz23t7kzPzRajmgg+PTebEjx5ftnu9YpR3TptnbRbeelhorHeQIRYNSqnnz1FJM5Lc/vuB1Sgixfjze3Vtc3lj3/yfGllQVvtcgs7FNQwWG+45FMzT7QTXOLb9z6YXJbFyCyuTPeDk8ml+/Dj8crqwjDo7u5tvvPuW8aKg8MdyrK8MFozZ6USdGd7va48Z+jJ4/sX57WS9OBgazg8LQrhPN3dXalrTUjQbh+8eFEdH++dT0rYej768MIasbO9/vxyPOh3tjZXLy9GguNO+9go9tGHE87j3d1VQoZLS093d5eNQTs7y1Wly1JDo+6ozuvKn08qztDW5mqZm431pY2NhTDsNJvb3e4BY1GWDY6Oti4uCmiGGo/dRx+Nf/n7Y83nn798+fLLOxRnSknHmcFIYKQYNZxpKWwUZowq7ypGVRLjMEiHgziJiZI+iTFBDGeEYkoz1GmdkDilWFAiZ6bnCRarK5sryxtJjFdXNsGcPT01ByIa4IlhumFUYcwIoUoZSnkYxvPzi8NhuLKytrW1c3bWW1paAUBZXFwmhGltwzDOMgztuIA7m5vbz57NKWVmZmaB7tnf34/jGI7fp6enaZpGUXTt2rWZmZlGowHeqDiOIY+i0+lMT08rpebn5weDAUJof3+fMQa65JOTkyiKpFaPnjze2No8aja3tnfzoooTjIkgVGEiEGa+yBFBT6Yet89Ob9+5d/W9D/b2Tja39paWl+I02dja7A36mJIgCiHaahhGwyDWxh01jrd2tg8bR7Pzz1bWlvvD7vSzp5vb277IjbP7hwfDMOgN+j946831zY31zY00Iz4vgbIpq9Fx67TRbK2srj9+MrV3sN8+62xub6Uoc7kHrkdqtbWzc/3G7aPG6dr6NohrwLrJhSFUcCEhu3tnb7fTPVvbWF/f3FhdX3v4+FFRuSQLHj251zptnLSPTzsnWzvbp532UaPpC0cY2j/cO2m3Ot12b9BtnR5vbK1v7WyubayfX15wKcCTCd4oJjgTQlu1vbfeajeMEzt7W0LxOI2XV1fPej2X58qqYThQRu4d7N66c/Ok3VpaWcQUUU6td3DVOmwcnbRPKWc7e7tcigRlh8fNYRyZ3CcYtXtdW+Tb+3v3Hj3sDgc7eztQkgtWA6CcrTcut0E0PDjaV0aedk4oJ5TjZqtRVP60c3JwtJ+XkCyhy7pwuYXnLrennZPe4IxLtr27aZwI4n6Y9OuJzyvtchmEPZ/rJA0eP7l/2m72+m3rpM81F5jgREvWbOyfnjRQFnXax9aI4eBMcFyVhvO0KBRjiVZkdvbx2up8EHSiqJd7LTguCwvVlyetI0pS71QcDXKv0ySQgpSF9V5qjcKwUxQ8TbswH6Vpbzx2zjKge4rcOCuVpEVuTlpHUdgfDjrt9qEQqXOk329WlTo5ORAiBax5/ryaTPzlZfmrX/3dv0cG6O9+96tffcq5JJgzqrXKCVbDQTYcJMDXwOWIEokRBxtUEmOMBMGi3wvDYRwMQpziaDDsd85wnGLEvKsgRAJCyOHTKZGNo5NOu6+kA6yxpgBTVRyhMEwwJlmGwzCmlLfbZ43GMaAJMMFCqJOTdhynnEsghhEi0AwFzgnGxOFhIwgipUyGcBhGcGCSUkKzZZqmRVHAwfvs7KwsSziEgwLQOdfpdNI0BScnRFKAMAckf5xzyr78cR8GwVd+KIaJ0KbIEEeYJVkqFD/tnLS7bZ+XQZgOBqjXj0CPMwxjTHh/ELY7PXBRtTu9s94Q7JdBFBJGyzo3TqcoGoZ9bY3QMsnSMI4oZ77IM4yYYEEUQiy5VAbutYzLYRApba3LYXyAR2V0URWQyN0+6+zsHhy3Ou1OHwzWzlfgpUpSkiE8DANEsFDSOAO4QDkL4wjTNCWh0ASKTTBFxhkmGPyvYIIPgiFhBJhgALizXjeMY0CZV+UK8G6GUYZTwtI4DShHXDLjndJWaVuUY20ceLiN02EcnJweh3GASJZkcZLFxlkuJXxjEMBe1hXkTgijlbNE8JTgBCNwRYHcBpHMFzYvfV56OGMDBWO9GU1GhDEuZVnXvii4lIxzwtggCCAjIi+9MhImGmi/tN74wmNKi7LKy0Jb5QvrCyM1pQKVI++9looKSbTh1kmpqFQ0L4z3muCkrpyzst9rw6gCZK01QnAkBakr550SHHOGOEPhsFvkxjtljYAjVFlYawSj2WRc1pUHF2VZWO9kkUsps8nEGYMmE+sc9p4WhfCeCwFub/bqZD4Zl1oxwfH5pCxK6RwrS5HnDF4/mfg8F3kuJhMPdXSffvoPX/yeGaC//e3nrzIlYDNCGU8TFkeUUZ2l7FVHHSRjDQdxEuPhIE4TGgbpoB+hlKYxklylYRT1B5JQTgXocbyrAFOMzqMwi8KMYAE9UHV1Dh8HSOJMR1GKMU1TFEVJGMaMCYxpGMZBEGUZhiM3MMGEMMYEKGsGgyCKUimNkpYxKYUmmAuhCRH9/jDLMiGE1hpCheHYBBsTaG2g9/JVqlaee6VUkqSMC0IoYzyOE85FliEI64riiHImtcSUcqEyRDARUYwwkULaJM2+qh8IUpTFSRaEaRyzXi8CZwDnBhORIY6JpEwnKTlt9866w8EwTDMkpEyzjEuOCcYki9NYak0YjdMkjCPKWJKlICoxzkFIOLS7VfUYip8yRBiXmBDCmDYGYayMxoQwIShnXCqQC8OhGmFuXel8BeYGbSyXAjMqtRZKYkJShDKMuJSE4SAeEEZeGTOkVjBNYsoyjCnnyugkS4MwzBDKMKIMkMhAog2XklBKGMOUujzPy1wocDMSTDGmLEkRoVIq73wJ00eGM5e7vPQut5QTJhhhBDhmwEGIzgL8wpRklFApqBRcK8Soyb20RnsnrYGSFmBqoFWuqHLYjDKEAOa4VMZ6+AOgtK1GYy5h9nHGGWiDgV4wEBDXo4lUhnJunHl1Hc9L5wujNHVeQR+L88p55XOtLZeSacmV5HWVK8mclYITZyUlqTWCc2K0VIp7pxnDo1FZFk4rkXszqvOqdEpSeDIZl94pIHrLwjKaKknzXHknQHpXFELKpCjEeOyKQiqFoWoK7lCTcVmVDvCryE3uFXgsi0KUpchzDnFZcIGCuL+Li+LTX//976sbBqz5p3/6JWNCCgseSyU9RooSTbDMUhoME4w4AEcwTM46gzBI0xTHUYYyRrAU1KCEBL1Bv9PBcUQQhesSJRJUfLArwQgDJy1ny1cqG0okwZIQztiXPnJAEyl1EESEsDRFcZyCeA8UfaCsUcqkKaZEMaqNLjDiSUwwklkKQEkRwoxRMGRCgDnEboGcz1oLNij4CAw4lFJKhVIuyyhjSkqrpONMeVdq7SCeDsJcoIQERHEIC6lMnMawI0RxCl0u7U5/MEzCEEnhMBJZyqRwUjiUcYJllrIwTBEioD/MMowxRYgkSQbrJFxZodEJQlUI4UJqyIKBqE0hdVHW2jiItvpnBUwOsq8wYQpa46TGRBAqIYkCsrKgZIoLo7SDujjoVIEuF6jBlMoOgwSEM5Qp6yoYhaIIMa6cLwjlSrtXCVvGemieYlxCFOErh2qGiM/LoqpA1QLz11eQwSnnXMoMI4Az4JJBLgwJFVwKCOhigsMYCFjDpRBGA7IQwTNKlLPw5srCFc7l5lUNprYK8qu0VSD8AT8nZGX5IocPKqPzsgCHOgiFQOUEKiFQJ/oiz8sCLOyQmFFUeV6YorTa8LJyRWmtk/Uo14ZLyY0yggktVeHz3Dvv9KjOy9xaK5xXxkpQDFd17ryCS7nPNZy6laRV6UZ1DockmGguzsuq0qPalqVyjk0mvq7NeOzyXDorRnU+GRfOSimINQLImiI38HVA41OVpir1eOxGIz0aqfNzf3FRVJV+/ry6uCiKQlaVfvGi/u1vfwE71L8SaP4FrIFP/qd/+oWU2mgvuMVISOEFz6XwEDZOiQRcABIXrAnDYZilBCNOsUoCnIQoDeKw30uCPsw18FnA0Wjljc7hKwhuONNKujBIOdNG50bnUjjBFcYEBhYYYUA4A/UsGFOYdIRQoPeDRymN4DZLKcBWMEziCCUx/qqjTlJKQb8Hy9SrOl2EEIj6wLppjGGMhWEopQQZIXwP1nitLaVcayulRhhD3mWKEAh2y2ri8zrNWJqhFGVccqkU/KImKWl3+mfdYDhMYAOF6z4lEmWcM0OJwogRQrMMAwmVpigM4yTJsgwzJjBhCDOoqYT8S2iYRZgKqa3LX3HDPi/hlxmAhgsFf6618VIZ63JAECENRFKV1UQqB2YFsEcBNORFVZS18wVU32HCCGWEyjDKIFULsiwwkZjIDHFCBaCY8wUXGr436/JXsTvQo/Cq2BuyOIx12hr4TYY5RWoltMzLAq7aEEnFpYDNCwaZV7/nMN2A9DEvC9ihlLO2yJWzmLOMkv+ftfd8juy80jz/zo3oD7u9E7G9IXJkWoYSRYkUTZEsBxQK3nuTSAekz+vN682973VpgCqSknp2pnt7p2VIiayi9sOpQnTMx2YjEIgsVMKSaAJeAAAgAElEQVRUReDgnOec5/eEGHGtgJWlUwVZl0JxuMdLsyQrTFaYoiqhXlDOoOjAtgsKnEo0EzwxKYjcoJ2ZPLv7PhOTlpMqMalKtEp0mpk0S0ym80JLRSHUCcQapZmSXAutpVZCMkIYJWXx6kiPMwRJu9AE5UWiE15NspvbSZIKIXBmVJ7pzKjpJL+ZV1oxSqI800DMqsq0KPRsmpcFELNYmvDM6DxL8iwxqYQbQvgM4LosC/hHiESzJCFpSrOM5jmbz810moIN6va2KEslRDSZJC9e/Olv35HL9+LFy2++efnHP/4ZE+q5YeChQd/uda1ux3Ls0HXCfm8MknAcUQjhHQ2cbmdoWY7vx9bYd+1w2LPtkWcPxqNe1x0P7LFjjT3HDmBpZVs+lB7XCQd9y3Mj1wlty4fHnhtByxPHxLbd8diGFsa2XVBkfD+ElEj4IYwiNBpZ/f4QZqjh0IJN2aBv+V48Hrm25b/Kz/SC8Xhs269ibYHXF4ahbdvj8Xg0GkF6LyHEsqwgCMIwRCgmhMAQB69QBUAwcl3fdp3BaOgFvu26nh9FMR6OHNeLYsSCMI4QCqLQCwLXC/qDUavdbbY6g6FjWT7cB7hOOBo6ve6o2xn2e1avOxoMxv3+0LbdOMau649GFlhb4Uu/JmNF0J54fjgcWY7rA68LYF2eH44tx3a8seVA2BPkNDmuz4WCbug1ZIf5QdztjcaWB8MUwtz1oiDECHMulO14rhcEYWw7nuP6QDju9YeuF3l+PLZ8x408P4bHnh87bmTZ3nBkwXdo2S58uOsFlu3ajncHLQV2quP68DaMYtBcgB8aodj1PT8MwKWBKQmicGxbY9vyAh9YfyNrbLuOHwbQ9diu4wU+CExhHGFKgPgZUxIRzLUigmPOvCh0Ah+ufu+SvP/9W+D+xRjgnhiQnOAphxkN2KN38xq0P9CLQaixSjSmkBTKKWeME51wxmM/sBEOINwS4YBxxDlBEfJdD8cojkKMQoJDwXEUOpJjqaiQhAusE84FJjTSCU+NTFLBaAw6C8GhFCQzSgrCaJxnOs+04DgKXYLDzCjBMUY+oxF0PYnm8CUIDlHsMxqDPJRozhmCz2aMyDLOeShEaAyZz40QkVJIKWQMUwrBXd9f/vI//xNqzcuXf/vzn7+CeOnAx64TBT6xrci2QlCFfS+GSMy7Q5s4Au+tIliGPmFYKZ76ljvqdQNnHPohJYpRBX0NdDEY8TDAYKGSIoXBCroerTJGFUI0jjGIwZxL3w/vZgqMKYjB0F9As3Mn2VAqgiDudgdxjBGiQRDD2ziGlpzdOZ4gVxdIoNDmcM6B1wfj1euMXYIxoZQRQihloApLqcIwwoQQRoMo5FJCBwHwTcYTzw/9MHB9zw9D+Iny/KjXH4/GnutGCJEgiB3HD0PkON5waI1GlmW5tu2NRhb8W0CWcl0fRkXXCwCRA1lud4Rj0GXuYiTh24BiFMUYWhhoUqCPiGIMMjahPEYsjAisnwB8AxyZKKZghgTJGTinQRhDaYsRYVx5fvQ6IVNGMfGDOIqxkBro7ncZ4fDh8ExCeWpy+A6lSl5/P0TqBGYQcBsQRuH3O/QsYOn2Ah/uAOFp0MVgSmC6gRIAf0QERxjJNEmLXJmUKcmU5FoxJRXgWwRFJAbNBWjkJk8hyhJsColJdKowxWmWQu+jEnln7ICpKity6ARMnqlEccmzIktMIrVMs9TkJs1SlSguqclUUaYmU3mRVJMMupW8SFKjYHRSgmcmKfJUK2pSDpiIokylolJRiIJiHME8VU0yYxRskbRiBIeJ5qDUFHmSZ2mihUk1pLLkWSIF0woMYZySyPcsKC6CY5NKUJSh4oBJIjMSYucmE11Vsiyl1vjOewlcvpub/Ouv//AfYZv/L9rwN9+8AD8UeBRsKxDc2FY0HvmQZut7MWd6NHSikEiRRhFhVMUxpkRQokKfhB5mWMZeaA0GVr8beGEcMVhXUSJhEItCAvc4Shq434M7Hc+NGFVxxHw/IoRCERFCwQXN3e0MQmQwGIVhLKWGDXccY84l1KM4xtAEwU8sQgRhEkUIqgnnPAxDYPdprSmlQK6BuQkkG9g0UUqVUgA5hxqEMYZRCyoO5SzNjNSKcQ5yieOGY8tjPIkRcXzAfTMhNMKUUOkHyPXi8fhVRwYmUpCfoJ2BkmrbbrfbR4gQwqDHEUIFQQR9CgxKIFsCJxyY6rC94kIlaaZ0CgWimsykShiX1WQG0olUCWRp50XFuIb0hTAithNgIgBvzriGRCf52qFoO95dJ8K54kJFMY5jEoSxVAnC1HH9MEJCKCiFoNRAG3UnD+nE5EUF5Q8mO3icZhloMSrR4CYFujBMIrBBuzvMgSELfuDvmBJQkqArkVr5YeDHkUwTZdKIYMyZKQtl0lcMUCXAmgAccvAowA3xXemZzKrZzRSOaJigidFMMKl1VuTggEvMqwWf1FqnGkpSXmbT+WQyq+4+A5dUKjqblzAHQb1IUpHlOsuTIjNKchT7guPMSC1pkStjeJKwvEiUZtDXpEaCtJwXidY8y7RJJZQbKBBK0qo0VWnSRBZ5CrNSWZgiT9NECk7SRIIATEkEiyoQfWCrlRk1qTJGUaL5fFYUhSxLdXNjpAyTBJelNobBBsoYBmupr//6hxfffPWdas2LFy9evPj2yy//EoaxY/tSpJQo30Oei+OIgzYseHK36saI+26MYuZ5ge9Fnhs7VmgNPRKzyA0CxyahL5ikRI1H7t0SKk0KmJviiI5HLmypAE4OfCzONIoJflUghOcFw+EYTvscxxNCYUzhhxBKiW27QC8mhMJrGEYY3/UjtNcbEEKTJAGSOWMsCALf90ejEbQ5wBiOoiiKItd1QdOBOUsIPhj0oygUgmutbdv2fU8ILgR3PNdybMJojBD8lna9qD+wPR+FEfJD3/U9hPHVdRcTRpkajpzrzhCitaIoHg5HURTHMXJdbzAYuq4fhhGI354XWJbTbl8Ph2PO5WhkjUYWZWJsOVBfAGmOCYMBChJyQVUBDRhcUaAWw4qdC2XZrpA6y0tMmE6MHyCAEwPyBqDoQqZCpn4QjS0bqobSKYxUYYQc1w/C2A/DGGGdpJRxTGgQRl4QIEws24X/B5CQoC0CkBjUwVe2UsKg1jAuKZM6MZgSlWjwr9uuA6VkZI1BJYGEFjikBrnk7kjnznIJ/c5gNLRdhwkeEWx5bkQweLu9KBzaFpWCKQm1Q6dKJRLSV2AJJbW46rTD2M/LLEJBb9BNjJKaM0GYIFyKOxlYagV1MC+Loqq45FKzcpJTjh3PKqosK0xv0HE8KzUyz/X8poIBCipIXiRlZapJPqnyNFGJ5ozG00nGWTwYtLVGCLmdbguTEGpNEDqMIyg9aSrmsxLufSdVBmYFwfFw0CnyhLPYsYewlrLGPcASV0Ua+NZVuwEajeAYRqo7VVgKMhp2wSfR67aMYbe3hef1jCFZxmazjPNwNLriPMwyrhSqKv3NN3/8T6g133zz8k9/+jNCJI5eCZauE4UBG4/8MMAEC9goQSdiW75jB1FIhFCQJ4UiFriIxNwd2Z41xqFnkuzJ4grYoDjTH7z/caN+BevtjfWdH3z/x1ube2lSBP6rdVUUEpOWjAqECGQYLC+vPnq0sLu7f3Fx+bOf/fzBg0cwVRHCvve9N6+uOoQwy3Jc148ixDmnlEL5wBgTgg8PDw8ODu7du5dl2c7OzuPHj4uiIISsra396Ec/2t3dBYIfxhiW4tDRIISCIBCCHx8fHh7ur6w8FYLt7m63Wg1KcZrq1dXlN958Y2SNEcFj2w4j5Aex58eOGwYhsWwXMpJWNzZ29w62tndPTmtb2/uffPrI80PLsh4+fLi4uLi3t2uM8X3f87woinw/AAm83x+GYfzw4eOjo5PRyFpf39ze2bMdb2//cP/gCIpFXlSbWzsPHy2YrIDiApMLoP8pE2//8ldjyxkMxyur6w8fLfQHo8UnT1fXNrK8JJT3+sN3fvUbiFvI8gmhMi+mSmdKZ93e6Mc/+dnu3sGjx4sg7kJgQxTj1OTdXi/GCLQSuKABgSPGcYQwhFjBDgtUaliT6cRA8IOQGvRmmKe40FwquBtMTAq4z5Oz08tGHa4HTZ55gb+xtbm7vwflBpQREE2gvwB7t+O5m9tbZxfnvUG/Px598vBBVpUyTYa2tby+tnd0OLDGSZ5xyUAJhtYGpGJYpS8tL1w2zmv1szD2lpYX6s2LojJC0acrCwdHB5PZFBEM2jP0Vq/FYC01wzTaO9hutGq2O+z02h99/L7jjYFYflk/i2Lv5nZSTbLUyOmsMJnKcz2pMimIknRSmTQVtdpRvX48HLbOzvbaV/XRuJcXCRd4a3vNdoZFmaZG6lTAxARDU5qIPNMmlUtPHqeJ6PWa49G16/R7vWa/17y+uhQ81grvbK82GxfdTivRHL4i+MKhYIWBs721piRdWV7s9Vqu23ec3qefvldVMk1JWaqLi4Nm81RrPJsZrfF8nr18+We4G/6P1xrIvfzqq7+CH8pz4/HIw0g6NvJcBBMQ5GGmSQGra8hgYUxqlUmRapkpbhJhAsfzbRv5bm6KH/7gp5e11m/e+4hg8fjR0snxBaMqDEii88OD06Unq5mpAh9FAYGjYUoko4JxEQSRTtKf/vSter351lu/gN/wH354D5IVBoPRm29+H6ATsIqKY4wQil+/hGHoed4777wzGAx+8Ytf2La9vr5+dHQ0m80opVVVXV5eLiwsGGOg1vi+D3MWKDVKKWPMu+/+ipB4bW15bX3l3r0Pjo72J5OirPKPP/7we2++4QW+1Mp2XNAjXpEZYuYHUYTiEEX/+OMfB2H8ZGn58Oj0//qHN977zT0hk+vr67//+7/vdDr3798XQnie5/u+67qWZcMYBZkwT5+uXF93a7X64eFxvd7aPzhqNNrHJ2dKp5TyKMZPlpaXni7P5rdcKFBhUpND41BW09+8/+HYcnb3DoYj6+T0vN5oNZrtBw8fl9VUykSq5N33PoSgKMiQApuCTnLHjd59730/iD788OOLWv3o+HRsuTu7B48XnkQxbrSaY9s6r100Ws1a/XJp+enB0WGMUa1x+fDRY8f1dWLKatrtDTY2t58urx4cHo/G9uHRye7uwcHB8eHRie14SZrrxEAxElIBkyGMoydPlyIU/+aD95dXVxKTPlp4bPJsfXOj3mwAAzQvC5iSYEqD3bPjuULJkTV++PgRE/zpyjJTcuHp0vT2pphOVjc3Rq7jhsFp7SKfVCpRUGKkFjA0SS2qaTmyhk+XF7NCH58e3D6fLq8uNq8upzdlUaWtq/rp+XFRVYTRclLB5hvuBrMi55KWk6w3uLr/8F4Qu/uHO9t7G/c++YAJ/NnnN5Y9uPfx++2relbosjIg3whJskzNpoVJpUn5dJLZVnd9fcF1u+326c7OytPlBeDdzG+q2uUpWKhMplIjM6PKPJlOcjj8VZLOZ1Xt4jRNRK22f/vM7O4+XVj86Le/m17UduN47HmdjY3Hkyo9PtoDbAV8IMAo4I/HR3so9tdWn0yq9OxsL8/FysrDNEWzWVoUanX18fn5/mxmvvhiludiPs+++eaPf/uOes3Lly9fvvzbV199Tal0nSDwESVKq9xzMYo5wQJ6meHAhh6EUQU9DsYsSXKMROBhQROji9gLUeDTKEi1uWr3P7734M03fjibPnuyuHx+VqdUEiIYlefn9cBHrhOimAFAC/ZQlIgoxHFETJo3m+0HDx69+eb3P/vsi15vcH3dpZS329fvv//B3//9f9na2k7TjBCWJAZjAnl1oPUCFfT8/PzBgwff//739/f333vvvZ/97GdSyrIsjTF7e3txHBtjgiAAGhb0NTA9gfXp8Ojg/oOPf/nOz9//4N1Go/bxxx867vh3v/u8mhTNVnN5dRVYWa4XUCYQYjFiCIswQl7g+6G/tb39yacPfvqzn7fa3Tfe/OH/+V/+7yCIEUKLiwtvvvnmw4cPOecAPPY8zxrbIDn5fsiYWF/fuLrqHB0d1+uNi4vLhcWl84vL7Z09kGDW1jc/+PDer9/9TZJmMCthwqGtMFlRVtOPP7nvev7m1o4fRL3+sNW+HlvO2798RyqdF6VO0o/u3RcylSplXEcxhSs+LhKE+S/f+fXG5tbIskaW9dG9j0/Ozi4uLx88fFRvNvcO9ju97nntYn1zY2tnu9luLS49OTo53tnbXV1b51yFEUrS7PjkbP/g8Onyaqfbr13WHz1ehOzwo+PTZutqMp2DoMOEhBvFLM8iFJ+en+0fHDxaeLy49GR+M3/w6GGM0fHpyVXnGlOy8GRxMptC4h3c42BKQEKGfVCz3VpeXXm8uJBk5snKclrkWVUur69Znjt2nZ2D/bwqq1kF93s6VaAHp1mSl9lkVrWu6qsbS6sbS9Pb4vzy5PjsYH5bZWVy1Wm0r5vVpCSMZkWuUw1VJs2MUEIqLhSVCWu0a2uby8en+7//fz7vDa72DreefzHv9tr1xvnZ+VHt8nQyzXUisiwpCmOMBhJNZmSaMJOyXq++sbHYbp9dXh4tLD7oD66ns0InHGrNbF6CdmNSmaUShiA4lskzfbC/xWh0drY9mYq9vacrq5/+/vfT8/OtOB6EUX97eyEz/Ohw16RScASXe3eYYSnI2ekhZ+jwYOeLz+eHh5vTabq1taRUOJulacqyjJ+f7yPk3N4WsJD685/+5bvuoV6+/Ntf//LtX756wahGsWBU+x4iWKJYwEkIFALAZWHEQd+NI4IxBS15NHAFTRKZRV6IAp+jyLG8Ip+Dw3s2vf31r9+7rNV7/f5wNHr06NE777zTaDSC4JXzwPdiMGFSrHAkIp8Klkiu73/y4PzkrN1s/uiHPzg7PW00GpeXl61W6+/+7u9WVlam0yljXCkVhuHdDR4QPAFyvrm5eXJy4rruRx999MYbb0Bl+dWvfvXuu+8OBoM4jn3fv0tTANUG5Jssy27mzzbWt3d3DxqNdrN5tfRkpXbRcGx/OLSazfb5eS1JDELEdX0QrQlhhHLX94DSIrXe2t7d2d1/ury+sbn7eGFlb28/DD1C0Pvvv3dxcRHHyPMCENdtKwgDFEXIsmxC6Pr6erPZGAz6GxtrDx7ePz0/397dXXzylAt13RnULlu/ePvX33vjB1IZyjQkXoJGgwhJM/Pg0UPH8y5q9YtafXfvoDcYIIJ39/cs1wJo5q9+/R4c3UEcFeMKFOXR2H73N++mmS6q7MnThQ/vvf/k6cLB0d7y6tLp+fHZxfnB0eH27s7TleVHC4+b7dbS8tONrc1fv/fudbcTobg/HBRleXJ6enZxvrK2Orasvf39jc3NGKODo6PD46PT8/M0y2KEEMYxxkJJyOEymSnL8vT0NI7jo6Oj66urpadPMSWNVvPisgbc0mo6geM9whiY2qMYRyhmgs9v50ywB4/uIxJRzn75q18lJrVdp95sAL5nMBrqNNFGM0FB9wWvNvAlqmmpEr65vYZphEg4HPfrzYYXeFLpo+Pj49ODapoLRRPzqiFKM5MVeV7mUqk8K6qq4pzt7e2OxgPHHfUH155vJUb4gd2+ql/UTmx79OzZjdY6TU2WF4nWRZ7CVkgrejMvOUNnp4ecxcdHu/3e1WjYtcb9zKjzsyNr3H/+bAZnNSaVjMZaMZOKIldVmUiJnj69H0Xjfr/Rub5oNk+azRPLuq7XjxynG8fjo6ON/uCy0znPM5EmXHDCKCrypCrTIteB7+xsb6SJqF2c9Hvt8ag7n2f7+2tKIdftY+z2+81+vyllPJ9nWmMp46+++tfvfsv3t6++fPHHP/w1jphtBWFAbCvw3BiStgkWgY+GA9u2fOhowAnFmY4iNB67KGZxSJ1xEAcEB3HsexxFoY8616OT4xpGnFK5ubnV6/f6/f719fX6+vr7779/cXGB0KtLWdigRyFlJNEi9x3EsGrVr44PTwqTXZyf/ea9Xx/s79m23ev1fvvb3zqOEwQBxigMQ8uybNsOgmA8HodhGAQBZOkOh8NarQYA0DiObdtGCNXr9YWFhYcPH56fnzPG4JlKqSzLYAoTQiiliqKwxs7x8VmiDWeyXm9dX/d8P3Ic//j47PT0PI6x1ikkYVLK4eovipDn+67vUc7Oa7W9/UMu9GjsPllavai1O92OHzi12nmz2RBChmEIJi9KpedGo6EN59EIoYuLi9PTYyl5o1k7PNoXSl426ue1mmW75xfN+c1nQpqx5QtpKNNwjBdGGBMWIYQpOa9dBFGoE3N2XusNBiNrfHB0GMZRhKKRNYxxtL655fkhLMtBA6ZMcKEdz9vYWnc8Syh2fHp4XjvdP9xrtC67/evz2tny6vLZxfnp+dnp+Vm92bi4rF026otLT+598vHCk8XWVfvs4nw6n/WHg3qzcXp+Zjn2Vee6ddWOUNzt9+rNerffzcsC1FzKGRccNn1pmjqOMx6Pq6pyXbfVasVxDHkJlmO3rtp5WQCVgjBKOddJTpmgXBLGKGeU0+vuVRB5t89nEUIXl5eA0aKcXXc7tutkRS61yooM5OGsMK+92jgxOjHacoYRCm6fTxut2nA8KCeF63tCadcPbHecZFIlXKfiNWeL5WVRVIVO0jTNptPZeDwWgk+n1XWnhXCQF4mQZDItYuQ77qiq8klV5nlmjMmyoipLmGLgfq8s0kH/Wkk2neRh4LjOqMgSxx5+8fltHHmcIRiaijyZz0qwRyWaZZmYTBJj6GjUShI0mxlC/DwX83kehuMs44R4VZUIERJqpWmUJrjINSUxwXFmlFa0KBSjkeuMMqMIjuLIzVJRFCoIBmUpOA/yXNp2F+h8RSGLQk6n6X9Qr/n3L99++7e/fPXiX//fP0IKHcESSOauE4UBoURixO8YWncXMZRIzqXvx4GPcSxcKyQxpxG2h0MceJxKgqXgiedGCJEkSV9vgnxKXxkafd8nhCFEopBEAXHswHfjyMcoZIxIgpjkGsfI9zwlxXg8Wl5evls8Qwh3EASj0chxHMuyut0uKDWWZfm+D6ByCEWAiEvYXidJYowBO0Icx/BXQD6HRXiSJIyxMIyTxBDKtU6NyRkThLA0zYRQWVYAzSuOEdSLu8Bvy7Zd3yOMji0LLm7BdmQ7IUII4dD3XcYofN3XDi/quZHnhnAxaNs2pVRr5fsuY5hyFEQ+OAxf3+PFCIsopn6AEBaQ2RLFRKqECQHL48SkQkouJGiZnV53MBpmZW5ywwSPYwIi7p2ZAOqOUDoxies7jmfDlHF3ftJsN/YP9/PXJ65ws5uY9PT8bO9gv9vvgW4qtUozA9m4hFGdJpPZdDqfZUUObgP4cDi9S9JEaw0dpVJaKcU5n0wmX3zxBeO8PxxMZtM0MwAzhQdMcKW1TvIYUYQpZGNKLfMyTzPNJTG5md/ednrdze0tLkU5maSZ8YKAcmZyAzMUSMKwhAKshNBsMs+1EYmR5SR3fbfRak5mU21SnUrCY8qRyTVIy0JJk2cmz/KiSNI0TU2e59NppRNpMnVzOxkMr687jWqSTWe5VLSa5HlutNbGmPl8Pp/Pp5OcMwT+yTzTs2kBly9K0vmsHI96nKGqNLNpAQsjGJpAURYca820JlnOwSo5majZzNyVg/H4mvPw9raAY5nb29SYWMpISWJSVZV5nuk8U3kuivwVcjjP9HSSP39eaY3KUiYJynNuDH/2rAR+TVkqwGV9++2X37XWvHz5ty//9PW//PO/warbGvtRSOOIgVsn8BG4E2CScuwAzn99D6xJBCEeBcy1QhRSSYVv2+5okKhU6xzFjDHJuYQzFs4ZNCMQfoAx9rwgjkkY4DiiccRwzKIAoYgywhOV4BjFYUQQxnHc7/d++KMfQa6Tbdta6zRNwzAcj8eO44Bp27Zt13WHw6Ft21BZCCEQmyul1FpnWWaMgffcIc2FEPBOeA4hBCGkdSKlUkrneZGmhnNRVZMkSRnjSmkoLuDYCoLIshzwnbueF0RhEIWu58WIhBGSyozGbn9g244TRl4QeGEYwLKMMR4EkWV5w4Ht2L5tO7btgtjkOA7GcRh6MQowRWEcqkTFGCNMIZmXUBnFFGEBYXJgR1BJAmsanSZ5matEmdyUk3J3f2//8CAvyte76nhsObDShiU6LLkRpq7v+qHPJXd9VyWKchrjGAwGcNUGmyNQSWzXsWAfyWheFmBTgqtfRHBW5HCqB6tiypnJstcOgIQryTjTWhVFLgQvy1xrSQjO8+yLLz73fX91fS0r8rws4PlQtqRWlLG8mGLCMWZSKS4F8K4Sk3BJEqOn86kf+qvrq1LLxCRMMCZYmqVplsQ4YoJCzAt4FKbzyWRWJkYITfIqzcu0nGS2O643G0wwpZXJtU75ZFbMbqrJrKqmJbilTJ6ZLJtOp7PZdDKpJtNyflNluYYYudrlye2zSTUxYGWqJnlRZFqr6XSS51lmtFb0Zl5NJ/l8VppUzmfldJIrSW9vJpe10+GgA8RP6IDKIoUlNyi7mVFlqU3G0pTOZklVSSkjKWMoB5eXR53OJdgvtcaTiTAmDsMRo1GiRZ4lmVFlkWiN81yZVJpUCB5LgapK39yY58/zLCNChK9bJwbWKmBKvPjmj19//eV3qzUvvv3yyxd/+Lev0qREMR8OHN9DSmYEqzDAUGJAx4WKA4tqSmQcE2vsxRGjWMYBRSGNvNAdj5xRX0udpkUYok63d3R0vLa2qrUcDLtHR3ud606r1SIEY4xdN8CYwleJQsqp8F2vdnFxdnL6ZGGx3Wxlqbm8qNXOLoaDwVtvvVUURafTubq6SpIkDMPLy0sYoOCtEML3/fF4DKNTu92GgN2Dg4PhcPjpp5/eu3fv7OwMUi7v9GBQlMEVlaYpmKem02m/3x+Nhhsb68fHx1rrZrPZarUIIY7jMiaiCAFEHYoOHDSHcWQ5tuM5QRh2uv1W+3ptffv45ML14qPjo+B6BJMAACAASURBVFbr0nXt4bAPtQbaIoyY76Hx2O31BsPhyLIs2NlfXJwhHI6s/tHJYYT89c21i8sLPwyHIyuMMCYcE0GZpkyHESGUSZVwIYMo1Gliu06EgiDyLi7PYhz3Bv2Dw6PJZD4c2WGEYfPdH4zucOh3rk4IsQWwJjx2fQ88BGAg4FIMx6NOr+sFPngjEcHD8eju+UAdhz0REDCKqnzVCJTFHeZCp4mQgnOaJiqKgnq9FgRekqiTk6Pr61YUBavra7ObeafXjTGqphM4EVaJxoxKZTDhqckTY1zfczzn+PSIckw52t3fHlmjxOiFJ4+9wB1ZwzAO5rezMA4sZ5wY/dps+crkHeOoP+w22jVlmExop9dCJEiM3D/cQyT2fA+RqJgYRELHG2eFUYkC51Q5nWCCCcGuazebl1LR4ah7cLht2T2l6cbm02qSchHrhBVlUlSp0twYnedZVRVQO5SkUej6ntW5bgIgYjjomFS2mrVet/3sdurYw7JIJ1XGGZKCQA8CBTxNWRiOEXJ6vcurqzOEHM8beN6gqnS9fjwctqtKj0ZXUkZFSX2/kyQ4TThnKNHCpDIzsiiUViTPdBy7GLvTadrt1iYTNR43u90zQhzGAoi7hIV3kpDpNP3mmz+++K477xff/uWrl//fv/6JswRM3pQooPNhJKKQOHYQ+AjyVQCUhWIWBti23cCP44gRJCKf4Ih5lhs4No8jyUUUxYeHR4PB4PDw4N13f23Zw3/88fcvaidC8IWFxSgKldJwrwtnO4GPGeX7ezsnx4fWeLS7vX10cNDv9t783huu7Qa+/9Zbb0kpnzx50ul0gCyztLTUbrfjOB6NRq7r3l3ZEEKur683Nzdt2z49Pb13797+/v7Gxsa7775br9f39/eHwyHYLwEzLKWEoqOUIoQqpSxrvLm5iTE6OztdXl6mlKyurmxvb9m2fXJyNhyO4aCZMXE3RjmO1+v3LdeOUNzpdtfWNj0/3Ns/+vT+4+OT2unZ2dLS43a7ub+/4ziO67qDwch1fRRT1wk9D9wYMFsF/X53a2szNerx4oPHiw8ardrZxeni0sJ57Xzv4CBGOEZYKaN0LmQaIw7L73qj2R8OhBIPHz88ONo9Otnr9q+frizXm43dvf3UFHv7x5gILnR/MNre2QN7wZ2hIUaEck4598MwCEPKOWXMCwLLtsMoCqIQuDM7e7uAIgZfGCK40+teda65FCCy3MHM4QpOKAlqC1zewMEel6Ioi3a7EceB41pra8v9Qff6uv3zn/80CFxC8fbuznQ+29zeshxbp0k5qY5PTyhniTGuF0UxzouqVr8cWeMwDje21gej/u7+1tvv/JxL2h92a/WL6XyyvrmqEpkVRmpxXjujnEznk7zMTJ7ePr85Ojm0XUtqcXy6R0V4Vjtc31quZpnlDK+77cTovYNtk6uiSpnAZxfHUsvJrII9VFGVtcsL33cow9s7655vcYEu6ycHh5sxcoJoPJ9nZ+f7QqK80Hmhu702ZUgpYYy+mVeZUacnB3HkwQPfszbWl8/PjqLQHQ27rjNSkl6168DHEhxfXzXg2BeMBZQG/X6TEG84bNbrh71e4+xsj1J/NLrqduvX17UgGDUaJ1WlsgwHQbfTqU0qkyYyM4ng2KSiLHWRqyJXpye7ZamMIRsbj2376qK2Y9st1+0MBi3X7UNUy/PnFbDNv/nmj9/1vubF61pDsHSdyPcQEA9gkgLhVqvszt5tWz6Ym6DWhAHBMedES5ZEbmAPBhzHBOGzs/Pt7e0vvvj8+Pjwxz/50ZOlR+/86uf3H3xk2+ONjY12u62UemXmRjzwkeBpovWnn3zgOsOySB/c/3hjffXD9z+4/+mnDz99OOgPHdfxPG99fb3RaPz85z+HtdSHH36Ypqnv+8DxhHKjtd7a2lpZWamq6uzs7Ic//CHGOM9zuLI5ODhYX1+HKAXYW4GJARxSlLKyLA8O9lqtxuefP2+1Gv/4jz8scvPrX7/zwQe/efbsptFo7uzsVdUUDAdgPRdCgTYcRIFK9JOnT3f3DlKT1y5bP/7Jz5dXNje3tt76xU8vLs4ODvYuLy8ppbDnjkI86FmuE2BMMX5VKB89etBuN/3AWVl7srO3eXx2gGm0ub2+f7i3trE2ti0uhJAJZRqSUuA8d21jg3JWq9fXNlY3tlb2DreKyvzmg3cRwVzosRVs7xy2r/r3Hyxgwra2d4cjCzwWkE0O8g2gWzw/BE0nCGPI9qSMmTzb3N7q9nvNduvo5Hh9c2Nx6cnB0SGmZG1j/a6+gDsRBh9APYBlCSxOYG5Sic5ys7y8GMVeUaZPlxcODndSI58uP77uNGfzyuQZYbTZbvlhsL65gQi+bNSPTo6ryUQqk5o8NfnS8tP57Q2X/NMHnwxGvaIyG1url41zwmKpWX/Y2dhand9ODo52i8p0+9eDUX8yq/IyywoTRP7K2nI5Kabzyc7+2nX38uB46/zycO9wK6+SrEgcb3x2cXTzfPJ0ZWEyK667reF4+NkXz/OyyMsCU7K9s/W733+WpOKje7+pN87++V/+qdO9jJGjUzS7SQlzzy8OhIwfL3x6+2xSb5xZ9mA6K7JcA/Hz4vz4f/z33//ut8+3t9ZQ7F/WTt/55Vso9m9vJrNp0e9dDfrXBIdnp4eURKcnB5DNkhlVZBojz7a7k4nm3D893fa8/uHhZqt1dnKyM5kkNzd5t1sPw7GSqN0+Lkq6uvqIM1TkaVXmIP3kuZxOE4zdRuNYiOjq6nQwuGw0DwbDS6X9i4vdIBidne09e1ZOp+nNTW4Me6XX/Af2UP9Lrfn6r3/74x/+QokKfOy5MViirLHvewjKCgQecKah1sAlMcY0CgmKue+iOKCcqNgLh52ONeiWeb6xsbGysqy1ZgxvbK68+97bZ+eHe/ubh0f7Z6dn5+fnxmSEsDjCUUhwzJXMlOQP7n/Q77XShPd7V+trK7959z1rZH34/r3RcJzn+fn5+eHhYZqm19fX19fXl5eXDx8+zLIM0rhBX6SUZlm2vr6+v7+fpimldHFxsdfrdjqdtbW13/3ud/V6fW1tLU3TIAjAuACxUOCTgnu/9fXVbvf65mamlFhcfDQY9Dqd9tLSouva47F1fl7TOgX2KJgngiAihEGmkkr14tLS3v6h0inC/P6DhVa7V7u8/MEP3pCS1+u1g4MDzjkwa6II93tj0IaHw/FoNKKUfvLJvevr9v7Bzvd/+L1/+N5/WVl/YrvDx4sPrrvt7d0d1/fT3FAuGIf8BpGkWRihpafLiOD7Dx/85K2fvP2rn+4fbauUf/rg46Isnz3/Yv/gpNuz8ny+vLIRRmhndx+2UeDkBO+SVAmQbgjlQIfAhAUh8oOYS3n7/NnCk8XBaFhvNlpX7ctG/fj0ZP/wIC+L5dUVLkU5qeAOWCX6jv9g8gwOYbjksMRBBMc45oI+XrgvJH7+2Zyy+OBw5/MvbsPIPT7Zy4v0+eef1eqXnV7n5vmzq861SnS92djY2ri5vS3KWVlNGZcLi4tpZiazycganJwd/49/+W9je7C1s6YSbnK9svbEcodeYC08eZiXafu61e13pvNJVpiiyjFFK2vLs5tpUWVeMNraXTqr7csEL68tTG+Kz357s7G16nhjN7AeLXw6mRW9wfXYHk1mVZqZyWwaY/R0+cnN7WR+UyHsn5zu//6fnm1sLs3m6e3z/OZZdtk4jNCYUO/p8sPPPp83mudB6ExmhU44+ANOTw6++Pz2i89vr9r187OjXrcdR97x0R6kzbWaNSXpF5/feu54OskPD3a0Yq9Ph6XrDFqts9kszTKKsa1UPJ9nT58+cN0ejDz1+rEQ0fX1xdXVyfxGr68vJJpVpZlOSjgahlrj+8NW6zQIBhsbjxcWPtjYfFi73A7Dbqt1LETUap3d3hZVpfNcQIPz9dd//K7eyxfffPuXr15CrYlCCtsojATsoSCtBWAIINwAexgjDmbGMCD97jhwUeTjwHbd8Sh0rDLPm83W+vr6ycnx+++/d3J6aNvDzc2VpaVHo9EAphutNcY0RkRJ4zph4BMp+N7uWq12fHK8v/x0cdDvDrq9Tz/+dH/nACPCGDs/P+/3+wjh+/fv9/v9zc2tWu1SSgm1Bq7+4U4PslYsy1paWtrd3TPGnJycXFxc5Hn++PFCp9MBaRnu9+7ydmGqEkJ0Ou29/W3Xs3Z2NhqNmpT04GD36Gjf952VldVW60pKDT7PO3hgFKIwilzfk4mqNxqb29u1y8bT5bWDw1PbCY+OjjqddhyH29tblmURQl3X9/0IbghcJxgOx5bljMdWFEX7+3tbWxtKi3rz4snyo97weml5cWNrNcLRzt4OEwxTwqWW8hVeD2EqpN7d3x+OR2lmTs5O+qN2vXW6vbt+dHKY5TnjamNzl7L0ujN6urzmuP7C4hLYOMEaDi4HQiXCIkYMYR7FBGGGCQ9C5LhBGEdZkZ/XLmDtfVY73zvYX9tY397dsV1n//AAdkwwN4FDEkzYr/ZHiQbHdl4W8LepSdbWnwah0+m2jo73gtBptS/PL44su19Ncm2SvYMDiCG+uKxlRb65vdUd9IRUSVoAiOfg6CiIwtZV6+jk0HLGp+dHK+tLfmhLTQmPd/c300ye145//LMfju1Bp3cdRH41LQEbXE3Li8vzMA7OLk7rrTOhY9vr7R6sX/fq5SxNMrG1sy4UPb88eeO//kMQuf1hB3I475Cjl/VaGLntq/pl/ZTxkFC/1T6b36TlRBaVqDePELHPLvbe/uWPhYwbzTOTqaxIlGZFlsxnZb93xWh8fnY0HHQSza/a9fGoFwZOZlSiea/bLvJkNOx2Oy3O0OnJgVZsOsknVTYpjVKk2TwTIm40jn1/YAzr9ZqDQcsYphRmNOj1mhi5x8fbm5uPHafdap3OZ4VgOE1UkSdFruez7OYmy3NWrx+nhtzcpqNR02TIdtqX9d0sw53OpecNgGIDMbvPn1d//eu//Uf8UP/+5cWLb//y1Yt/+ef/eceLgMUTMGuikHCmgUQFdQeOhj0XsgxT8GSiiDDMSRh5li0w0TJFMbs4b7Rb3W5niBFDMfPcMI5J4AXNRpNRghHmTEiuBdO+G5FYSJ5YltNqtj0veOW9Ztz3fUJoFMUI0SjEGLF2u7O4+PTivN5qXkch9jwfFBDYW8dx7DiO7/vNZiOKoijClMg4IkJoIXSvO9zY2KFEMCro6xe4HoY1OdAkhFDNZjuOMCVc6zSKMPjLr6+7h4fHsLgBPRWAD4BosWzPcf0gDP3Qv2zUhuOR6wW2EwxH/mBgSSlbrfbZWY1zRYnw3Mj3kOfGcEI9HrlhgFwniELkOn7tou7YHsYMEYowdbwAYXJeq3e6fXBgx4hxoQkVCDPXCxiXtuOdnV9wIVWiJ7MsJr7ljJighFJCOSY8NdXxSe3xwtOT0wvL9iAWigvAZUHN4lwkYOCUWscYRyhigmOKCCWYYEpp+6oNPlWEkeu6mJB6owFmVOhfAC0Mr5RxqRPYeYURyouSCymVTlKT5aUfhIdHJ1zIKMY3t8/hPzPLyyTNhNCMiaIo+/3O1va6bVuu583nt0mSK50xLrO8DMLw4rJGGJFacEkJiykjcBkcoTDGsclTk6cjawiW+KLK7yzdJk+ZoEHkZ4VJjJrfTtJMCUV1KhKjykke44hxbHI1snqExTEOIO8FxJq8KhFGnmvrRKVGVROT5UontCgVF5HJeZLSopRZLsdWVypiWYPJpJzNJtNpWeTJbFpAVK4UpMgTAF8Jjm/mFTiwp5O8LNJG/bzduvQ9C6jm00lelebZ7XQ2K16BIIpXh3lKkpubyqQiM3I6yTKjZtO8LFOMnSgacR5OJ1lVZibVZZGmCXv+vMwzOZ3knGNKwrJI0lRMJ1mRayVxmrLx+FprnOcCFupZxp8/r/72ty//I33Nv395+fLbr7785g//9qWSBjBOEEd5B5GAdgbewoEvWBbCgFIipUgJYp7jc8pxGI77g8gNogDDhfFo6L5icQbY9xCKeOCFoR+Evk8Q4VQ4lutYHo5Z5GMlMtCMUMyE0J4XBEEI5/wIYYI5pSIKsdaGc5UmmZQJxsxxPMsa27YNbQZc+gVBQAgOwxAhghGzLS/wI0ZFHOHJZM65Ykx4ngfFxfd9yFHgnBtjCCEIUYyYUqmUCefK80LOlTEFRgz4eH4QvSb7YmBWUSZcLxqNHUyJ6zsxjiIUYsL6A/vqauy6oW1bURRiTCkRUYQ9J3KswHXCwI+BYuO6QRjEYYgQogQzjBnGzHEDz4+ETAAfw7gCQIzt+JgwTChws+AIGJgPXIqYhH7o6FTqVBNGlU4gCzhJC4Q5odLz4yimQYgp05ClB64uOClGmHApbNchDEUoQCQihFDKCQHIThhFMcbE90NKWWrMHdvhVfrwa4y51JoLDbUmiglY0sHAlZq8msyDEElldJIlaS5kopNcaUOIUMJwLouimE4LpamQNE3SIq+kSIVM4ckmz1+7NzWXVCVCJVpIxYWMEUaYSJ2U1bSsJklqMEVwwkc5AbY5hChA3QErptISmOpcsvAVPFiV04xLIhSD52dFDhQ+negkkXlu5vNpWRmdsCTlRamyXKSG6YQkKZOKVBNTTfLnz2+FYHluZrMK2pPZtJhOcvBGFXkSBg7BIdwH3x0K3xmXgDiTGTWflVqxNJGwvYZrQDAfwNMAcKMV04pnqSoLmaY0z2VVZrNp9YqFrtBkqtOEATeLMzSblq/CdiWbVPnNvACNBtSf6TTNMj6bmZcv//xda823L7/9+q8vv/zz17APgnA4UGeikGiVAW4GDm2AYgk4G9B3woDEEUYRxhF2x9a4P+AxTnUGtFDBEwhmecWpYZoS5jluHEZZaijmFLPQR64d2COPEdCkiVZZlhVxjKMoCsPAdd0oim3b5VwqlSSJkVIjTMAU7vsBHOnBiTDoL/C71/d9xoTjeEEQcSGVSqRKgFORJFBTkJQyTVMgnMPZDudcCAkc0iwrksQAUybLijTNgJ6rEwOUPMf14aedC8WF9vzQ8dyRNUQktl3rst7o9sZxrPwgvLpqttp133fb7dZoNI5jPB47ju33+yPwK7iuHwQRONfHY9txfR/ieIMIMOZ3ZCwg4L3CDyNyh6GKEREy4VJSjglDeZlRTpngXMosK6VKlc4geQ5wWTFiEKIQIwbjGGUyRoSLV/DNGEeu73iBE8cxQsxxfBSDPYWHAQr82LY8LoTUSiUJ3OwRRuHMhwlOGQdMKlwng/kblGylU85fYXeE0IzL1ORKp0qnRTklRCRJmiRaa15NsixPpJTGFJxBZHiKCQOA3h38XCcSExaEOElyQoXSJssqk5W3zz6/ffa51K/y57LC3FHNoXykWZIYXU3L19weqVMllJCaq5SbQidGMkHgncCUSDOjtExTnecmy1KTKTioSQ3PC1lWejJNy0rrhFUTU02yPE/LMk9TPZmUcDgzmxbzWQl3NPNZmWgOG25Alz9/Nks0zzMNKImySKeT/M45Cec2WrHbm4lJJYqDNBFlYeDTAqkPEBO3N7nJaJGr6aRIE51nSVmkVaXBzI2Rm2eyyJVSmLHQGF7kKvDHvV5jOk1vb4skIc+fV0lCsozf3hYvX/7pu9aab7558c3X3/71L99YY388crXKaxfNy1oLeHqOHYyGThzRq3av2xk6dgCRu74XC54Cx9P3IsEkjrE7tpzRWDMehXG3O6REtNudo6MzJVPfi6IQ1+stx3aUkIzQ7nUnCmIlNI5ZFGAcMRRxjITnRrbljcd2HOPr6+teryeE8P0gimLHccdjixA6Go0ty8aYeF4At3xAurIsC/oax3GUUs1mazgcMSbgyb1ev1a7pJS5rj8eWyDTAPAc3AlQeqIosm2nKEo454uiOAhCISRj3LIcx/V7/SGQHCzbvXuVKhEyJZSvrq+trK0IxT998MmHH93r9a04VtfXnXd+9VazdVFvnB0fH3z44fvD0cDzvPHYchzX9wPbBrEmbjSarutRysIw6vX6rucHYUQoI5T1B0PKhev53V4fE/oKXoUIcLBgo2Q7HmWMCXLVuXJ9FzhSTIgwim+fPU/S3PUiQiWwsqQyYUQAbC6VIVS+cq5j7AW+63sja0gYJgy5rk+xCjwUBiQKiO8h1wkB8yyUSkxCGAE83eu0AxRjhAmFWqMTAz/H8IAywbhIjMmLUqdpYrJqOuNSciFNlqcmT9OMEBpG/mSaARg8TROtUylSxjUXymSFShKdJJTTrDAqEY5nIcyStFQ6CyMyGNqQ6jkau2GE87IAtFWMo7uTaJikYDN1l7qbZgnlpNvvCMWKiQmRV06ycpIDZAs29+VkMp1NyiKjFKdGm0zZzsBksij1dGaUxq43qCZplivKorzQaZaUZX57O09TuKCTkGQQhS7UGoJD37OkIDfzSivqueM0EfAgz3RVpjfzCioIBCFAKUGxD13MaNgJA8ek8mZeMRozGk8qQ0kUhmPG/CIHunBWFoYznOfi2bOc8+DkZPuzz6per37duZjPzWyWMuavrj1qtc6ePSt9f7i6+vgutuX58+rFi/+MWvPyxbd//MOXcUSfP/vtP/3+vzfqV+/88j3HDjbWd7Y294Dd+8u3391Y35EizbMJRHGnSWmNPd+LAy8iMeWUB45rD0eS0MWFJ4uLS0ol9+59/Mab//XyspHn5dbWzk9+8rO3fvqWazsfffBhq9ESTHIq4pDgmIUeQhGnRGWm+uTjhw8fPrYs+/333//e9743HA7BNfPJJ5/4vn90dHR6enr//qeu6yql4CYFRiE4ET46OlpYWGCMra2t3bv3Ub/fT9PUtu133nlnd3f36upqd3d3a2sLbpcBoIUxLooCIZTn+c7OzsLCQp7nCKG33377+voaDBYrKyu2bbWvOrt7Bzu7+3dn/kEYW7YbRohQYbLy4rK2vbtNOXnw6P4v3v7laOx5Pru6bv/v/8f/trO7vrr2/5P2Xk1yntmd5+fab7Ebu9qZi5F2NVJPt6TupuluEiRB2AJQhfLem8ysysxK7/3r38eb16cpVAHsbrU0s7sjadSOhONePCBCE6sLzRJRFwxEFAtgRB6e55z/+f02Or3G5198sre/47qWYeimaapbUHWtvrS0lM/nKaXra2uXl3nFtW22W9u7O8pdt7G12eq0HeAqIJZaJ6nzSwDxnbv3bdutNepf3r1z595dFSM+S6duff5ZsVw6z2YvC5XMeV6BzZVKQY1pAGSOi20HcuG5ACrp3eHxwd7BrhdwF0DBgzCYKLGXJyOChNKHCSm9QBqWvrm9oVoM6Qs/9ITHMaVceO9Bf54fqjcUF56QnmLu7R3sXxYvb148Pzw+yuZz0TiOkphSvre3B5Hd6zdPTvdr9dKLF9dBEJB3A2zieaEXBJiSR08ed3rt/rB778Gde/cfSi8Ko+lFtnh6ep45z+cvy4+fLC4urUVxpLJ8ijH8rhUK5GnqBCDXcszN7Y31zTX1mMoXcofHB8VywXK0RquSypzMnk2YUIB0nwk+no6ns2kY+gcHe4SgOPFz+fTp2cHVs9jzcbF03u3VypWsH7B05rg/aCfjKAz9IPA8j6s+RWWFH83dU0eV21trzUblqxezKBJbm8uFwvlo1MHIOjrcNo3+i+cz1Uup7macBFezJPD55saKJ2mv21xZmW+3q5NJIASqVvKddrXfa7Rblb29VU1rzWZhGEgpWBhIRmEY0MlERhEpFlO+D1dXH6VSu6bZfv48Zszc3JwvFlN/93fPLaufz58liXj2LLq5SX75y9nLl//89u33u718+fLVq5dv//EffitF+PKbN99++60U4drqVrlU/1/+5z/Z3NjttAem4d769PZf/egnC/PL+Vwply0uLa7pmus62HGwbbqO5WKALU3Xev1QeIcHRysra5QyzuXW1s7W1o7vh7btEMK2NrYezz36qx/+KHt+gQC2TVcbmrYJMGCOhS0LBn6ysb6ztrbhOG4QBKurq41G4/nz53fu3Pnggw8MQ79z506r1Xrw4EG/36eU9no90zQVn0FNbcrl8tLSUhAEw+Hw7t07vV7v6mo2GAx++MMfXlxctFrNH/zgB9vb277vY0xUMMfzPCmlYRie52Wz2ZWV5clkcnx8fPv2bQDAL3/51f7+3q1btwzDWFvfuCyUlpZX+4ORiqXYDnBcaJi2ZcMgTMrVSiqTkr749W9+9fjJwu7ukWVT6XmOq33y6UflyuXh0d5/+NN/32zWbdtSk+xWq6XYgBjjw8PDbrfbbrc/+uijSqWscv13799bWHxKOdve3b595/ZgNPR8X5E31ZNKZWQI5fcfzA1HhueHiJCjk5P3K+dOr5PKpNY31xeeLl9kC6qLUQ0OgJRQadnQsiFEVHqB9H3pe7/49JPcZfazL24xQbLZ/GW+1Gx0jo7Oet3hxfllo95+8uRpo94OosgLpO1aaxurvUF3MOrVm9Wjk8Ns/lz6UjFA36tg1BtQPbqY4EEUpM8zp6mzX/76V4VSsdaoJZMx43xra2t9fTUIxd7+JoDmxuYyxoBzJqUfhGMlkBCel0zGewd7zXYDIAdTeHR8atkAE76yuhEl04dzTzw/cgGp1VtX11fCY8pFF8ZBMon90BtPk2z+woWOanB29rbVX2Rnb5ty8vntz45PDyBxnizMPbuZqvZHhRL9MJhdTV+8uDk42IPQuXk+a3dqm1srv/7ba4iMw6Ot8cTb3Vu9epZkzk8Gw87V1eT6+urqaioEVak8T9K//fWLtdVFKYhtaYtPH7dbtdks7HarW1tL47E8O9sLQ3qW2rPt/vPnE99n4XdMiSiUrmNMJ5HakVfK+fv3PxsMGr/61VWvVzs42NC0drGY+c1vbkajhuMMopCHgfCkkIJ6UnnmJOf22dlOGOKDgzVKzdPT7TDEv/717KuvxoVCqtutXVwc7++vM+bMZkEY0ufPB0BoEQAAIABJREFUxy9f/vPbt6/+7XKof6XWfPPNy6//+OZ3v/2aUe/m+pfX11/ZFlxaXHtw//GdLx+cnZ5/8fldT0ZPF1ayF4W5h/N37zzM50pffH43e1HY3NgdDU3oYtt0CCJaf9CuN0LhpVOp/f396XSKECoUClJKdX42Go0MXZ9//KRRq9+7c69WqXMqDM0miNsmNHXg2FiKcHfnYG1t4/r6uW3b9Xo9DMOrq9kHH/ykUMhvbq6fn6cPD/d/9rOPLMtgjJimoYjlyriCMc7lcouLi+PxGAB3bu5BLncxm02ur68IQYuLC5ZlfPnl7fn5xyo6rER0KtdHCAnDMJ/Pn54eD4f9O3duf/jhT6vV8vX11erqcrfbfvLk8VkqfXB4/NMPPlLgcTVJ+W5ea1MmL3LZ9c11gNyjk6PTs3S50tzfT2fS5/nL84PDHULhwcHe8dEhJsQ0LdOwbdsejQaWZQwGPSn49vZmu928vMydnh5vbm2kz1PSl/cf3hvpw0dP5uafPmm2G198+bkikGLCVGujPn6UiaXlVcN04mTWbHXPL3KzZ8+EJ+NxUqmVuWT5Qu4Xn9xKZ/JRPHVcrIyd7x9Qlg0RZhARwpj0vVuf39rd33k8/6hULSyvLJVKxc3Nze3t7eFwmMlktre3Dw8PXdedTBMvYNJnP//ko8zFGeXo+PTg8HgvX7jwAg8h4gfR+yqj/swQESElQECpbC9y51/96kW33+kPe8+/ugnj8NGjR7Va+cn8w/WNp+OJ3NhcclxDCCaEJ2T4jpGOcTxOUpl0u9u6up5Kn3f7XaVe2dreCqLw7r27z66vM+cZgECUhH7oIQJd6Pihp/g1z26ucpdZysnNi2smaLffmV5NxtNkMOpv7Wyubazo5mBnf3NpZWH2bKz6IC6F+o/j+d7NzbNi8ZIQ+NUvryGy5hfmwohPpn6rXb4spLK50//r//5Nf9DKX57fPH82mSTT6TgI3vkPKAFfvXh2sL8tOP7bX79IYn9tdVEKOBw2t7eXnz2Ljo+3X7yYNJuFRuNyMvEnk1DVmukkUjaFJPYPD3bCgH/1Ysq5c3y8rVbUjUZhZ2fFcYZxzLPZYyHBZOxzhsPA8yTzJIkjPpkISq1M5sjzcLGYGQwaw2HLNHsYm91uVdc7rjsaDptHR1vK1kKpPZ36b978/ttvX3+vWvPy5auv//j65TdvCOa6Zl+cX66ubO5sH+Rzpdtf3Ft8urq0uEawWF3ZXF3ZXFpc21jf+eLzu3/xH39YKtarleZwYEAXI4AFFcZwVL4sMIg21teXl5d93//Rj35069atUqmk6/rR0dFf/uVfPp57dHRweHp0vLay1uv043CMANVHlqm5tolsG3kymns4/+TJgmnaP/7xjx8/flwsFsvl0sbG2uLiwtPFeU0bbm1tKEAnY8R1Hcuy1B2TaZpCiHQ6/fDhQ8Mw0ulUqVQolQrF4mW32z4+Pjw9Pe50WqnU6cbG2mAweE8v13VddTdJkhwfH9+5cxshkM9nP/zwp6VSoVotF4uX6fTZwsLjXq+/vLK+t39ImVDEX8XQZVz0B7oLsGGZvUEPYnCRO+/1B7rhVKrdbndQKOSEYAjBYrEkhKdkJJYJhkNtNBpo2tC2TSn5wsKT3d3tdrt5fHy4uPR0d3+nN+hu7WwWSpepzNnB0f55NvNofs6FrsIMKzeLumlCmN5/MFetNYNwvLGxa1quC+FQGy2tLN17cDebT2/vbp5f5DY2dynzbAeZFmDcZ9xXWgWlnQEAMylM2/rgow8vcue373xRqRYezN0pVworq4vpzGmhmFtann8yP/d08UmzVR1qPeFRF1qf3PrZg7m7jVb1wdzdu/dvA2T7oa/CAcpUpaqhqhSIYAWU2T/cOzo5/Pv/8pv0eWp3f8d2zVq9ls1m0+mTg8PteuMynTk8ONzyA8YYDoIAE66ceULKIArnHj8qlgsudD7++Qdbu+v5wkWpcnlydnR4vHdydsgEPksfA+T8y8t14XHlopO+WF5dUure+w/vbW5vlCrFoTawHHN9c80BFqLuzt5Gf9hJJqGa5niB54dBPE6ScRyF/traiqYNGEfNVqXTrdvOsNurWfbg6HgbIrPXbzaaZdMaxUno+zIMg+l0rHCc6oB7fW3JsXXH1kvFXLGYdd2hpjUzmf1q9aLbLQ8GtcGg5jh930eeZIJjVW4UOZhROP/koWWO6vXLTqc8GNRGowalljpcuL4OHaefSu1EEZ2MfU9SShAlMAy4lFBKN4qYWpxzBjGyp5Mwib3JOKAEzGbhzfPk2bPI9/HVVTiZeIptrvxQ36vWvHn95uU3b775+o3gvmUCbWSlU9l6rU2wKBVr6VT2vcXpPJNXW/BSsdZsdAUPPRk5NkKAGJpJMXVNa9DpEhcOer1Ktarrei6XS6VShmHout7v94+Oji4y556QnWZrNBgxwlwbWIYLXYIh14Y2gtwyQbvVGw41y3LOzs6Oj497vb6mjQiFpfJlf9DW9H6v1yIUAmhZtm5ZBsaIUooxMk2TMaZpo26367puoVAwzREmbqtdH416+ctzhN0gEPVGeTDoqmtvtfYmhPi+L4RIksQwjFarLiT1Az7S+gBajmvGsd9sVnV94AJQrtS58EzLUclaxqXysQ1HhuMiTIkXeJZjIAKV7bvbNbPZAiHEdQHnnm1Dx4bayNY1ByNh266uD2zHsGwdE7feqOQvLzB2u71Wo1UzbU03RwA55WrRAZbtmpel3FDrCY9x6b33ExDKVcomf1noDzQuwl5fY1xqhjEYDevN+nk20x+2u/1mLl/UDQciZtnQcXEQjpX3EiJGqASQQEyYEJqhp88zZ5mzTq/tB+L4dK9au2y2ysNRWzf6pXK21280mqVev3GaPgTIshytWMn3R+2z9NHT5SeHx7uFco5LpgwQaslNqODC97yQC0/6UvosiLxWp6HY4O1us9NvAeQYphZFQafX4AJNpv5gWKfUkR5B2E2SOE6m35khRBhH5WpZNzXpi9T5SbNTNeyhA3UmYbVRED72Quoigwqosopq5aTKjdo39QZdRKAfeuVqqTfoEoYtx9SMkR96URKM9D5hMEo84VEFu4mS6N31uS8n48QyjTD0w0j2By0/YGHEIDIQtuJEXD2L+4MWgMbsKokin1ISx+E4iXxJA5/NpnES+4Y+UFtnx9bjSHLuBAFizLLt3vV1SKnJuR2GmHP3O46nJwVRQt4wELalcYZMszcc1uOYEmIQYth2bzqV4zGn1CTEiGMehZwzhCAQnMSRF0c8CLAnyTgJlQFwMg6j0PclazaqYSCf30zHYyklnM2Cq6swivh4LCcT7//nG+q/v7188+b1t7//7deWCdViO/ATwQN1CaWkThhxCCijHqOeSt9IEVomHA5MXbMtw8GQuLarZsMMIoqpYVqapsdxMpnMHMcdDIYAwChKCKaMcka5JwMIqKE5pu5iKPSR69hE7dQZ81wXGobleT6llDEeRaGUwg88TRsC6CrCy2DYHw77KsWHkLK4QKAc14xDiAAAGAOMAUSuEFRKxhiG0HFcEyFXobbCMJRSKriEaZqO42BMgsCHCJimAYCDEGCcZjIpSjHjlDFBKDdN2zRtw7Qty0GIDBVWgjJM6WA0rDVqiBDbcS0bGCYYDM0n80suwAgTytlwNNANzQXAdkCrNTBN23EsFzi9XtcwdC4YIbjX61KKGWeUs3qjvn94oNQlyo2tDspVoEZNiCkTI81wAfKDSCFpuPAAhLbrWo5NOWOCEUakLwAkCHMVrlEGBco8xaaA6J3qwDAsy3aCMJK+jzCGGHmBiMch5cTzBSKAcuwFgnIMkGO7lmoZKMfxOALIOT49qjdrlmNg+s6ZK33v3arP9zGlDgCYEsM0pSfH0wlh1IVAnVCpg6lSpRTFYRj5ni+i2I+TECCHMiKkDMIkjBKMqW6awpOT2SSIfExhEEnhsXgc9gadcrUoA8EkRQQwQeJxyAQlDDNBHWCrcI0DbOmL96bdKAnH0yRKwm6/k81feIFEBCqnghcIyonwuBdIhbwRvmCcR1E8Ho+n07Ef8PEk5IJwTtvtVq/fmcyiIBSEAunTIJLJJPR8LiQNQkkJQtBNkjBJgsk0ZAwKiaXEvk/HY69Sydn2cDYLfQ9LicKA+j5OEs+TRCEgfI9JgQOfx5FUX56HfR+HAYsiXipeOM4oCpknEcG2JwmlrsoHepIFPv8uqsMDn2HkMIrUETnBruDo5HgfuKbvMUadJOFRRJKEJQmbzfznz8cvv/nnt29e/tsLzb9Sa169ev361be//90flblJ4WmASzDiBAt1damyfOr8UgWI+z1N4fsw4ggQTgVwgD4YWppOAXRtFwAkpS+Ep1hTlHIIMcZM000IMQAQuMi2EKM+gtx1mGVi16GmARwbOQ4CAEGIOefvgQ+O4+i6/s6UgDDGeDTSDMMAQFl3peOA0Ui3bVfXTSl9jBkhRNNGpql7nuCcQggAcKIocF2HkHfYLcaY7/uq1nDO30mgCIEQMsYghC9evKCUPnjwQEldlP1ORXuUpkqlbyjlEKF8MV8sF3/xySd7+0e+H2VzxYPDU9MCD+cWKJPlauX49MiFlm4OTtMnmm70B5phWLbtuK6rzJyUMpVddhzX9wPVsHx5554KKCt1r5pJq0Kj1mHqQee4ECIqPF/6nhJUq8GwYllxKaTnKVWu7SDdcBwXq6KjG45huiqwo56ECDPpBYbpjDQDE44IgQQrrriLoELkAYRs12VCqNNKJjhA7+J837kikfq5Knfz3t7NBGOCU8YRIclkIj1/Mp35YeiH4fTqqtvvn6VT6pQBIKiuH5RVMowiTAQXngswpupWg11dz8LYpxyFURREYbff39jaVH9lZV9wgKsMc6pkqJhlMonVyoxyMpmNmaDqHwxLf7q0oN5ZwuOEEUyxAt8ohChhKErCyXQ6mz2L44gxNJ3Fk2k4nkSz2QwCtLO7E40DRFwuifSZFwo/FGHsqR40SSLfl1EUxkngB4xQdzzxGXeDgN5cT/K5dKddm4wDgh1PksBnjADBURhwT2JPEk8SKfB0EnIGBUeeJEnsBT6jxL2axcdHu/VaMYk9wVEcSYJdwXEYSEWxUAa7OPL6vZZtjeq1Qjp1lMServUsc3hzPSmXsp7Ejq1VK/n//J9f3NyE1WomDGEU4efPx69f/eHt21ffq9a8fv3m9atv/9s//V45sC0T3L/3qFioqjif78XKoKBwfO9kuO+uGSBwCaOe4L5rA0MzoO30Wm2Pcl/6jgPa7e7lZfHRoycPHsxdXhZv3fr8iy++zOcL+XxBSp8xIUVIiYcgpySgJEBQaCNb12zbhq4Li8Vys9n67LPP5ubm6vX61tbG/v5uqVSoVEqMEUKRYWi2bWqa5jggDGPlwFU0GYxpPl/o9XpLS4tHRweMkb29nf393X6/2+22KcXfWeophDAIAnWgYNt2JpNpNpsrKyutVns0Gt25c+fk5OTm5mZhYSGO40ajUa3WgiCyLKdSqUnpqyNMw7Ck9A+OjlKZNJdid3//8OgkGU+XlteWltcwkds7h4x7G1ub59lMtV4KIrm9u5k5v0CY6brZbDY1TXMcp1qtFovFBw8eZLNZIUQqndYMiwvv4dzjbm+QyxcazTahvNPtt9pd1YMoeZMai9gOYFwiTGzX6fZ7+4cHjVZzpGvlaqU36Hd6Hc0wACSWDQ3THQwNy4YqLqzGw1x4jgsYl0qqGcVjx0Wm5SDMECGIIOHJWqN+lk5ValUFeYiSuFytGJZJObNdR3hSqV0QwZgS3TSUqVJFilU9wpSoPZcLnWa7MRj17z+8p2CAT5cWuv0OxPD49GQ8nRTLJdO2Zs+uTNvKXeajJOZCQMRMy6FMGqbZ7nYuctk7977UjCHlKJVJY0o6ve727o70/d6gb7tOMploht7qNBGBtmspER2myHat/rBXrVeWV5ccYBuWnrvM9gbdMA4OjvaFx1udpmHpV9ezbr/TG3SlL9QaizDsBdIFzmg0rFQLh0c7CJvtTqVWLxjmaDxOsrkLLxCtTh0g+/lXz7gknV4zSvww9sLIE4IxRtrt5mDYLZVzqfSR7YyareL+/gZwzWaj3GyUx4lfrxUxsgOfdTv1Rr0UhcKTJAx4HMlx4mujbq/b6Hbq6dTRZBzksqmjwx3O4OnJfrtV9SQpl3KcwTjydK2vAIDvqaOGPmzUy5zB4aB9erJvW6OnC3PdTn0yDlrNCqOgVMwOB23GnCBAltW+vDz+6qvx9XX05s0fvv2etebVq9cvv3n7T//4O9dRALb4y9v3zzP57EVhf++4WKienZ5vb+1TIh0HqcNLjLgUIUaCs4ASiSF1LNc2bEGopenAtDEizWZ7b++g0+kZhnXnzr1c7tKynHv3HrRanbW1DdO0OZOugxHktoUQlK7DGQ0gYKbhcuaXy9V0+rzX69VqtcePH6+uLj96dG9za3U46j6cu2taI8ZRf9gmFCAEIUTKQ6CwMoyJdrubSmUQwtVqZW9vR32dnBypHVa325JSqD7l/e2llPLw8LBcLkspDw4OTk9PXdfN5XKPHj2ybXthYcH3/YWFhWq1Vq3WOZfp9Hk2m5fS1zTDNG0p/dt37miGfvPi+UU2++TJ0/xlcW//eH5hGWGBsDAt9/H8fLffuffgy5Ozw0qttLm97bhoMNA0TaOUnp2dnZyc2La9urp6eHh4dnb22WefG6ZdqdaPT84wYWvrm5puqo5mb/9QQSGU8Ft9KZduqVxttlvCkwdHh4VS8Syd2tzeKpSKjVbz5OxUpYTVSBgToS4tVbTPBXikGaqTIpT7QcS4VDt1VSza3U7uMp/KpMvVysbW5mnqTDeNWqOeyqSD6N2lgqK7K5KWuldQtuz3SmwHuJSzKAnT56fdQas/bJ+cHabPT3OX57+49bFhjSjH27s7wpOb21uK9ZdMxmfplAPcMI4Jleoe6jSV0k2j2+8enx4VSoWTs8PV9TXK+VAb7R3s+2Gws7dLOYMYXz+/KVdLLnQIwxAD1c7s7u9oxkj6olqvnKZOeoNuoXRZb9b6w95QG8Tj6OBonzDMJZO+qNTKLnRU5jgeR37oFYp5xjGhbiq9V6mdp8/3pjM/nTnJ5y9s24gSP1+4mMxi4dHpVXKeTWEKKEeEoSDwIHRzuQvKoJD4snCu6V3poYPDLUPvdzt1Q+8D16hWLqNQYGRjZF+cn04noe9RT5IoFAQ77VYVQUsKnL04kwIvLT4+PtodJ34+l1bf0u81x4lPsAtcs1jIPr+ZqQusF8+vWs1qo16ejEPH1tKpo+zF2dnpQT6XrlULN9eTJPayF2e2NazVcpbVmU55NntwcxP96lezN6//8O23r79vX/Pm9beq1iiF7uNHT88z+YP9k48+/MXcw/mD/ZOf/+xWrdrizO92hu+1uRAwRj3BA4K5bTqWbkHbHna6w05XMLm6tnF0dDKdXlHKs9m8EuPOzz9Nksnu7n4+XwiD2NBd4FLLhK7DCPYxksqKmcSztfWNfL4wHo91Xa/X65o2+OGP/uKjj398fTOdX5g7ONwJQgGgRShwHNs0LcWsYkwobeb+/mE6fT4ejyuV8r17dz777NN8PpvLXRQK+UqltL+/G4a+4ziKraVU3xjjJ0+eOI4zmUwODg7u3r37m9/8BgDQbDaVOdN13Y2NDV03vvzybrVa13VzaWmFEGYYlq6bQRAtrawoiFSt0Xgy/7TV7j56/PSjjz8ZaTah3s7uwcHR4fXzZ/nCRatTL5YvN7e2HRePNENhaxYXFweDwdXV1fLy8vz8/MbG+vn5xcLTpcFQ84Oo1e5ube9KL/j01ueMy7NUplKtq6yw2iIrz6QL0MLTJUTw9fObvYP9vYP9Tq/7wUcfpjLpKIm3drYN0+31dXUVpdSXCkxhmK7jIst2Nd18b9p1AVJLfcXHOzk77Q8Hl8VCq9PePzzY2tleXl3hUuzs7SrizHuUn3q4qSCiqjvqGcUEdyEQnqQcb++ty5Bev5j2hs3+qE0F3D3YPEkdBJGknGqGnrvMa4a+tLKMKWm2W7nLnB+GhEohfQDx8upqGEeT2URdVz5ZmMsXLnf39xUAcKRrmYvzoTZaXV+jnHV67UarHkS+Gtbopra+uabW3u1uCyAXU7SwOK8Zo5sX17Nn0/6wl7vMTmbjja31KAmr9Uq9WXvxy+deIKdXEy755tba8xdXYcS3d5ey+cPT1Nbzr+L1jUXKwPXN1AFmoZSbXiVHJ/tf/eomX7hodxtewAG0KcWGoV1cZG6ez6RH1jeW6o3idBasrS0ULs/DgF/N4lq1YOh9gp2D/a2rWXx2eqBeTwQ7YcC1UTeXTT2/mYYBX19bZBR4kpydHrRbVc7gs6ukVi14klDi5rKpKBQ722ucwTBgvkfGY384aHfatST2gGuoNiqfS9drxU67JgUeDTuVcv7mZsKYDeGIMePiYv/ZsyCK6KtXv3/z5n+8r/mXv968efPm9be//ec/UiIHfV3X7MWnq3u7R3u7R5/d+vL2F/cKl5XbX9yrVpphMB4NTaXE5cwnWDLqOzaEAHvCRwC5pmUMR65hjuPxyspaKpVhTPz0px9ubGxBiLe3d8/O0s+e3ezvH7ZaHd8LKfEIlhAwjCRwuW1hSuRwYEgRbG3tVKv1wWD4gx/84PLy8vHjRxfZ1MLTxy6wdnY3s7mM53PbNixLt21LDVAcByh9ihDe8fHp/v4hhKjdbh4e7q+uLu/v76ZSp41GLZe7yGRSQeBZlqXmNVEUKX/I06dPDcMghHQ6nd3d3V6vd+fOnVKphDFWErt8Pj+ZTOv1JgCo0+ltbGypaynDsHw/rNZqx6cn59ns3sGBblhhNG53BpeFimUjy4ZnqXPTtobaYO7x/cti9ix1XG80bQeNNGM4HGKMHzx4MBgMHMdpt9t7e3s7OzudbveL23ccFwrp7+0f5i+L+cvij/7qb3TDqtYa1VpD3X9CRNTxp+NCLvz5hUWloG13O9u7O1s72/3hYO9g34VgZW3VtMBIs1xA1GkCZZ4K9dkOQpgZpm2Ytjp6UBdMpuUYpo0ImT272t3fa7Sa+cLlydmpAvQdn54oXRxhVD2dbNdxgIspcSGwHJswqkoME9y0LcUJhRhhipbXFsazcKh3dw82TWdEOTCdUamaZwKPp5PTVKrZbkVJ3Bv043GiIn9MCMN0gzB2XLi6vj6eTqr16sHRvmFpi8sL5WpleXUliEIm+O7+nm4ayWTc6rSjJM4Xcq1OMx5HtmsRhgFy1zZW43FUrpbS5ykXOpVaudGqHx4fzJ5NZ8+mRyeH7W5rMOrvHezG40h9+/RqojbflJOT06PJJCTUccCgXE3nLg8xNY6Od2dXSTIOUpmT3qDdaFXnHt+PEr9QyunmUAYMExCGvuvamUwqGQeMw/xlplTORgnv9xuVcl4NX0rFLATmxfnp5sbyi+ezauXS92gUCkrcKBSG3j/PnHiSOLY26Ld63Ybr6IN+a9BvJbFHsFMsXFjmcHdnPZM58n18cLARhjSKWBzzJBG+jzudCnD1auXSsbXAZ9qoaxoDNSRC0MLQFhyenu50u+V+v2zb7ZubcDKRr1/9/u3bV2/evPm3r6L+v0yJN998/fq//dPvFeITuGRv90ipnR4/evp0YSWdyj5dWHkvyXVspLgTgoeBP7Yt5DrIsVzHdJDjQtvhCAsme/3hwcFRuVz92c9+MTf32LbdXO7ScYBlOQcHRwBg03RGQ4uzwLYQcDlnkWlA1yFqbFSvN09OzrLZ7A9+8IPl5eVKpXx0dFgoFDRNW19fVyw9Xdccx1HTWQixguNBiKX0dd3c3z9stdoLC/P1epUxcnJylEqdEoJ2drYGg14chyoxrPoay7LCMMzlcqVSKZvNKmdDOp3+m7/5m8ePHyvWX6lUMk2zXK58/vltw7COjk4qlRoASIFspPCjJKk3Gwrora6lAKSG6bY7w15fMy2XMNof9o5PD4rlfKvT0HTDMN3RSB8Oh1JKRdg5OTlZX1/Xdb3RaKyvb+ztHwZhjAm7LJSGIz2bu/zTP/s/d/cOiqWKZbsKo+e4UC2VMWFhNC4Uy5VatVqv7R8eAARLlfJp6qxSq9abjdxlHkCq6OhBOEaYM+4r7yUXgZC+7QDKBGXCD6L3V+wQEdWMdHrdZrtVqpRTmXTuMr+9u9PpdXuDfubiXK3JlAYXIKgGN4hgNQ9WUeH3Em7CKJcsfX4y1PuZi7Nbn/8ic3F2mjpKZU4oR1ESMMEviwW1bjs5O3WAm8qkHeBKX1VGNp7MztLp3qB/fHp8/+G9y2Ku3W2epVPNdiuMIyb4WTolfa/T6x4cHRqWWa1XHWAjArlkALleIE/OjnuDbipzpmI1vUFXcXAU9rxSK0dJWK6Wbt/5otGqlypF9fvC48r90mo3+v1OsZRrdytRQiHWsrlTiKxnz6ZC0mI574fispj9/Pang1G30aoGkRQehdgNAx8Ap1aruMCq1or9QYsLdFlI9fp1NQMGrtHt1DmD1crl2urT4aDdblUn40CNe+NIMgrarWq7VS1cnhPscAbPTg963UbgM8ERRjYEpu/R88xJLnfWapUajYIqMeOxTBJxc5NQZlPiTMaBan8m4+D5zTTwmSeJ79HpOPQk1vW2EDYh2vW1z5j57Fn48uVv37z+5nvVmrdv3r55/fYf/us/I8gsE4TBOI6mgZ9gxKNw4smIMz+JZ2rbPRwYaqzj2Mg0gLK4IEgdy2WYYhdo/QF2XEaYC9BwqDkOuL5+HoYx55Ix4fvhcKj1+0PXhaZhK1WDNrIhEFKMbQtbposgg4AyxqvVOsZ4Op0mSZIkY9+LGPMGfW0w0DjzHBsCgIGLbRsgRNRKCEKsltCcy0ajhRCeTBIIXUIQ53Q6HTeb9XK5SClWRgelUlCwYVVQhsMh5zyOY6UuSpJEcf8cx+Gce57XbnfkftJAAAAgAElEQVSPjk7r9WapVFGQ8/eEcyYEl8KFAEAIEdUNCyI2HJm64Wq6bdlgqGmYIiYwYVAzRpRzw3R6vYHjOJZlMcZqtZoifnmep2mjTqfLhadmMQrI4Pmh7QCIyEgz1CRFBXzUQaMa5SBMu/2eMk8rfpVqLhQq3AXEMF0AqZChCwjjvpoNU+Z91xl5asasLsttBzAmAQK2azPBe4O+aVuIYICAaVumbRVKRXVIoVwuSv/kQqBANmoTpEbF750KLgSEUdM2K7Wy9OXNi5vp1RQRxCX3AokIUfzzeJwMtVEqk253O5iSIAopY4RKdVQFEFK6GMWg4ZKqVRci2LBM23WiJG53O6VKudvvmbaBCHSArZbfALkOsJvtRjKJx9NkejVRayl1rMDEuzTNeJoIjxOG+8OeSh6qo6rJbMwFp5ROp/FkGvoB9Xwaxd7N8yshRBAGk1lMOYoSH1MAsaMZA3UsLn0eBJ6UnDGCsDOehNNZlIy9ydSXHlKrJUaB79Ek9qaTkFFgGgPOoBSYMxj4TArsSSI4gsBUATw1xEliz/eoek9JgX2P+h6djD1CjCDAUrpCuFFEJhPJmDUec997t0RnFHxHvRFxJNW/JwxYEOAowuMxjWPsee7VVfDm9R/evHn5vWrNmzdvXr96+4//8DvlulVACUN3Ou2BNrLU/lsVF6XBVKeYykiHIKPEgy6mmIVeyBByDBPZDgIYEyaEZxgWIQwAFATRaKSbpo0QURY310WMegqojqBkNCLY48xXUAvOJSFM0zQVsdN12zSg61CMBIIcAg5chqCwTGyZ0LZd3TAty7Esx7JcKX3HAQBA07R0XRsO+4QgCF3XtR3Hwhi4rg2h67qu+pATQhhjtm0LIdRyXfU7yi2liH9q1+66ruJaeF6g/oSOAxAiACCMqeO6mqEbluEFgaIoQMR0wzEtqOm2abkOAMLjivM21Pq24+qGoxuWZZpK721/96vf749GI8u2IaKabhqm/d55oIqOKjTqDgsTpgy8qvQI6atWAlOinjbKskI5I5QizG0HqbU3ZR5lvpJnqs+wC5Blu2pCDNA7BAQXnuO6lFPKGWFU4Wk0Q9dNU3UxhFHbdQCCqrQJT7oQQAwVX0Z4Uj2sVMkjjDDBuZQAYUQowoQyoTb6ACJEKEBILbMUGl29iZRhCmKs5jWUCcq5F/iIYBWcIQwBBFS/bTn2UBspwrEiAaoDBUWuoZyoa2+V6yMMO8BWST8maBQHKkqjAjjqG/3Qo5wotM07oV0YSelLKRlDjEMucBh6lBBCWBCGtmtgCgiD8TigHEmfqf/BcEEm4wRClzESxR7CTpx4fkCFhIy5qsoEPptOQkpcBMxx4seR5AxyBtUKPAw4glbgM84go4BRgJCNsfO+Hqkqg6BNiZMkLAgQIUYUkSgiQYiCAAUB8n2AkBn47NlVksReEntfvbiaTSP1o32PxrGMIiqlEwQgCEAQoNkseP3y969fff09a83bt2++/ebr14KHwCW6Zg8Hpmkgx6aDvmnojmLQqJifAkoohQujPme+FBF0MYYEQ4wdt9dqI9vhlAvhcS4VLGY8nkZRolZFvh9K6UGIbNuFgAgeODZCkDMaDAeWaQBPxhBQ24JSBhBiQuh0OpPSd2woRBDHEyECzjzXQY6DbEuRdLgLIGPCcQClFGOixHKUYiGp41i2bdq2BSFwXXc2m/l+wBhXHc173aU6v1QuFyGEoherYLHCgwIAGGPj8SQMY0wYYwIApHJD6rbQsizTtizHRoQcHZ8en5xpurW1vd8fGLrhGKZTLJUWFufzhQsXWkNtYFq2C3B/MOr2epqu9wf9Xr/XaDYc13UBcFzHcYFaCSlBpR9EhHJNNzXdVKlldYellHJqoIswFdKTvofpO/6m2jorCqcfhpgIw3RdQCCiKphDuWQiBkgaBjZNSmk8HALb5o4jXFcC4Fk2sxziQm5YuD+0dQMB6NuOsB06HBmW4yJMAESUCxdAygWmTEjPtG2AAGFEeEKRXyhnACEhPeF5mPD3p2QOAJhQyjkXwgt8yinEaKRrCuBAGAXvEj2UMOoCQpmQXqC8l4hgRKDwuANMwmgyGUvfU9srVadUlFH6EiCXMEw54ZKp95SqHYSBeOL5IUumAaIu90gQexC7URKonLFqcNSVg4rzeYEkjAopoziaTJMw9oJIBJEQHvUDISRzgTmeRNNZLCSRHvUC7gc8SnxMAEIAAFcIxgXxfOYHLE6k9FAQsvE4wNiB0CIUQGhxjqQk0qOMQU8SzmAY8HHiY2RLgQVHBDuBzzwPjcdCShgEmBCLECsMaRDgwCdBgDl3PA/6HvE9IgSixJYSRhHxJA58lsumMulj36OG3pcCR6GQAl9fjx0wtJ1BHDPOnSQRlLmTafD69R9fvXrnUXj79u2/peL8K/Oa16++/eMfXjIqPRlT4tsWITgwDWoZGLhU0WqUxUnBQNUeihJPKRAI5o7l6iMdWPag03UNi1MBAOr1Bt1uX9OMRqPVanVs2yWEQQj7/b5lmQAA1eOMhqY2srSRbZkQAsaor9A5rWZX0/Rmo3V6eqKeMI5jV6uVXC6nugxCiG3bECLXwcoOruJw/X6Xc+q4FkSWYQ6z2fNOp8UYsyzr/PxiY2O7Xm9RKnTdULeX748VVIOjzAq5XC6Xy5mmmcvlyuWyekCNRqOd3b1Ot6+aC9UFmJbznYcAWq4tfW97Z+fP/o8/13TLtMCPf/JRr69DxG0Hfvzzn/3i05+btsYl0S0NYwoRG2mGZhhqbqoZ+lDX2t3O/uFBuVq+LBY3NrdVlzGezNTpk2W76q30Hj+qG5b60Fq2SyjXdEN5dav1Wrla8cMAYuQAt9FqDDVdN1yV4oOIAoggopSDkXbsgAs/aBJcxriUxL1x0se4FAZtxqpB0LbtDMT5IGxxUaOsKmSDi3oYOYxHlg0rtbrtgly+oJsW41JIT3i+F4QudDGFXDI/9NQeCiIMEXGBguZwVS69wNdNwwFOs904S58USnn1FAqisNPrUs7UdbUDXBcCACkXHhcSIIwZgRhJX9QaFcJgpVY9ODpUfnHbdVqddn84UE82dXWp2pkg8hGBimXjQieIWadfcdFIt7qNdqnVrRIOgkh0es3BqKdaGyV+UbVJ+XkpJ+PZWPpi9myqm0MXmUO92+pWZYC4hAg7zVa1020EoYhjjwvMBY4TH2EHQpcxGgQeoXA8CR1XLxTPPR/bzrDVroWRFJJg4tYb5f6gPZ3Ffij8gCexxyjgDI4TX3Uu6rU1nQRhiJvNy36/GoY4ikilct7vV6V0o4iEIWbMCXwqBeGMSME4Q0FAkoQFATWN4aO5u+eZk5vrSSZ9rNbkcSSjmK9vzVfrueks5AL4AWMcRbH38tUfXr36+s2bt9+r1nzz9Zt/+sffOTZybGxb2LYoxYFrCwjE+8Sweje9f1IBl3AWYMS1kaWNTNt0XNsFlq31B7ZmAAdyLm/d+vzk5GxxcfnJk4Xt7V01xL1//8H6+roQghCiZLUKuIsgBy6BgCBIMaK+H3z66a1qtfL06Xy5XHj0aE5KmcvlVlZWjo+PdnZ2CCGj0dB2bAgQZz5CxHFclcfTdY1z+tlnn+ztb21srJycHD1+PIcx0jQtl8svL6/u7x8BgHXdVFB027Zd1yWEcM593+ecn52dffzxx71e7/DwMJvNzs3NDYdDSun9+/fv3L2nIHKqoej1h7phDUe6YdqEMcM2IUb94XBtffPg8HgyfTb3aKHVHpgWhIhm8/kHc/e7/RYTuDfoOi7QdUfTLcOyRrqmFjembT18NPfTDz+o1Kpn6fTq2ubG5nYUj7nwGs32xua2qmuKZ65eHwpIqh5Z0gvu3X/4dGkRU5K5OF9ZW02fZ+Jxki9cLq0sH5+eGiaAiAsZAkgwYRAJLvRc7n+znA9+9au1yeQRAD+bTB75/p0ouv/8+ZLv3/W8L0ejHznuB3Fy//rmKWWfxclcEN7GeNtxhe04SyuLxXJhZ29bMzSAwGDU55LXm/VGq0Y57g26hmWEcYQIRphARCiTQoZqGu0HESL47v17rU6z2W4sry7uH+4mkzHE6PH8k2q9dv38Rq2xEMEQY8revaEgxgBB6UvbtT746Ke1RrlSqyytLG/tbE9m0/XNjXqzUSgVm+0WE9yFjhdItdtWGFDKCcQgSkJE7afLD3vD+tHpTr6YyRfPvZBZjv5g7m6pUpg9m6i0cRgHURJ+R7F5J+pVMsyTs8NM9vQsc+RAPV9Kj6c+ZbDZqmbOT8NIej7jAkuPRrHHBVYPqCDwGEdhJDa3Vo+Odwi1C8VMo1mpN8rTWVytFXv91kU2ZTv6ZBpRBtUzSrUeKiusOp3JOChcpj777EPHGUynHiHG0dFGPn9CiDEeizDEccziWPoeF5wGvggDkSRyOpVhQJPYGw7aR4c7X724ajbKrqM/u0oocbvd2t7Bam9QvXoWTaa+H6jmy//6m9+9fvXN9601r16+/d1vv6ZEug7RNdDvmbZJMAw8MVahG9fBSnepgsWOjRBknowp8TDio6HBqcAQA8u2dQOYFgL47Cz9ZP5puVwtlSp/8if/7uwsfX39vNcb/Pmf/8X8/PzZ2ZmUEkKMEMWIuw72vQRjPhxqtm0jBFOp0ydP5hrNytyju7t7mz//2UdhGB4dHWWzWYTQRx99pFy0nHPHdiGklulomq5mvZSSQiH/6NGDVProwcO7W1sbH3/8IYTAtu0gCDOZi1q1gRHTNA1CqO4STNM0TdN1XeWK0nV9cXFxZWVlcXExSZK9vb1arZYkSaVSWVhYHAy1m+dfabqp+gi1G1YhFESwZuiYENsBT+afchF89vmdRrNnmABhNp5OTlMnmYszRNzBqK/pxmhk9geaaVsjXTMsczAaGpaZu8w/evI4lUn7Ydjp9o+OT9V5dP6y+JOffqj23JbtvvvIIaLYoApnw4VXrlQ/++LzerMxe3alJqPJZKybxo/++q82Nrco82wHR/GUMgkRETIKY3BZ+FPK7/zm7/Z8/4HjfNLt/nWr9UNN+4DSLzX9w2r1PzruzwvF/+DCT+Lxk27vry3nF/3BD/OFT00LzZ5NP7n18c9+8aEfielVcpY+nnt8/yKX3thaXVyZL1eL5Wppc3vDAS6XglBmWg4mXHoRgMS2Xc8PDctc21jv9Dp//1/+rlDK15vVF7/85Xn2Yv7pwsnZabvb8cOAMEoY40JwEXDhQ0QcACBGhmXUGtX1zbV2t/HVr36ZzefK1cr0ara+uZHN57Z3d7L5HGGUcjXQcSEGpm1ADNSUx3bNTr+eL6YgMcu1/O27tzRzoIYs2fz50cmBWnKrBxSmyAE2l0zhb+JxhClqtOqZi7Ny7TJ9cTLQ2ken20HMw0jW6qXHTx4QCt49o3xGGSAEYAwhdKXkYeSFsazWiptby+nM4UX2hDKYSh+PJ+Hu3qaQJJtLlyuXaqyjmhpGgRrZxJEUHCFoS4EJsU5Otvf21qZTP0nEycnO6uqTycRLEuF5cDKRvkcEJ4wS3+NKmzke8yQWgc8m4+DkeG+c+M1GWdd6z2+mutY9Pdt79OT27t7KeOJ5PmYccoHixH/9+uu3b19/rzfUmzdvX718+0//+DsEGXCp61AIBIKeoWHgcFVi1AOKYCFFSLBQERspIl1zHBtRIgiilmEZg6FrWsQBCOBPb33+k5988Omnn62vb+7vH25sbJmmXa+37t27n8/nHz16FIah60JCuLrzdB3iuohQQik2jNEXtz/9d//+f3269JhQ9979zw4Od4IgSKVS+Xxefbt6+wAALMtxHaQbpmnaAADLskzTWFxc+PM//7O//pv/NNJ69+/f/fLLL3zfH41Go5H26NETIXzbBv9SKaXOoBQSVBm+EUKrq6srKysY4+Xl5Xa7TQiZzWbtTq9QLKt9EBdeFI8pE6rH0U1T9fmb29tb27vlSs1xycO5+WKpXqm264328upKKnPWH3Z0c2g5Rm8wGAx1ALFuGpqpG5apmwZhVC1rT85OAUJHx6e9/lBxGGZX11vbu0qloKRO6ue+T/GpBc3V9U3uMq/yL/nCJUAwHie1Rn13f+/e/QcjzcJEIMwJFQhTQr2ra5k5/9+ZuPt3f7+P8C3b/pmuf5CMnwxHP9aND4ajH3PxpQt/Mb/wPz27WZo9e9po/eVI/6lh/pjyPS9IvEA8mr//xZ1Pl9cWbKDPL861e3XL1Rrt8lDvnpwdVmrl5dWl9HlmbWPdBeoolKi8spC+5bhrG+v/6Uc/XFlbjsfR7v42QM706uoil1VL+p293enVjEshfRlGERcBZdJ2gGFZAMFytfzoydzf/OSv9g62vcDf3N5SSzHDMrP53GdffD4YDYUnIYambbjQcYDtQkc9grxA1pvVtY2ljz/5ye7BRm/YKtcu9w62/VAEkf/8q5ts/gJTpJ5O78uNH3rJJFaeqf6w9+jJw4eP7mWypw40ni4/yhVSQcx9nzOOjk/2XWAyjlRfowY36ijP9+V0GiNsx4k3GLayuZOj423b0S8LF5NpdJFN9Qft7Z31cuUyTvwgFIwCtSESHEmB40iqbVQcydksDEJaLGaSROh6p1y+aLfLtVp+PJaeB+KYceZKQcPAjyM/DDhjjueB6cR3Hf08c9JslCfjoFzKGXofI7teK86uwqHW0IzWdBYEIZ1dxVzgMJKvXv/x9ZuX/8O15r+7837z5uU3b//r//P/8vaeT5JVZ7rv/U/mw40499yIozMjaQDhmm668cKDcAIhD4gZCW+68U17W957n2WzstJuv/xa26cr04A4QkCXy8qyXf5+WIirued+mDlz41ZkZOzK3DvNjqo31n7f5/k9ZWARyyQY2ZR4GDpKGsXGFVUxVcWU4S2yPSwhxJaJCbYlHpgRgQCW3ktDUfV0xtBM1wv6+yPDw6Otre11dQ2Dg8MDA4OaZtTV1Z0/fz4WGxdC6LpF6Xf9Zkocx/E5ZwgCxkgYuh2dzYNDvRkl3tBUFYTu8N9+6uvrM5kMhFBVVcMwVEUDFkGYmCaQix1dVxkjHR2tbe1N6Uy8qqqCEBSLjQ8NDQ0NDdfU1PleCABGmEg/FKVUwkMppZLsV1tbW1lZOTExEYvFampq6urq+vr6hoaGamtrpTlALiW+dwakM6phAkVVpVDNdhzTggASRTWTKTWd0U2LWABHY+OEYUSstJowLE3VdBnzIlc0iqaawNIM/XJlxYVLF2PxWFt7xyuvvt7V3asbVi5fzOYK0fEJGSBnmEBaMTFhmm7K5hGhPJVW6hoaO7o6ddM4fuLT1954PTI0mEynxidire2tHV3dimqm0lpGMbhwC8Up1885ntnd+9RE4sVE8sVk6sVk6kXDeAWhN9PpP2j6H3t6n1DUl1X9X0fGnle0f0mkXmjreGRo+LnI4JOqdoYwx4L6mfOfqkbqg4+PNjTXVNddrqi+kFImLlWe64t0R2OjVTWV5y+eS6SS3BFyTCZrjbR3htm8BUFdQ300FrWg2dndns0HGVVJZdItba1dPd3JdEpaSZngjudx4QGILQshQuRaCRFYXVs5NDIg60uYy46NRy0Iunt7hkdH/taThohA2xWYIgualBPbFXItyARq72qKTgz39neOjA0ODg9EY2OKluns7ooMRcKcL0HF3186SV+4ROHkClkmaH+kJ5EeN4AyEh3wsywaG4onoj29Han0hOtxP7AxsSiDhAIusOvaAJie5+TzASZmd09bPDEKkdre0djR2aKoyYn4mAW0waG+js4WTKwgdPzA5gwGvvA9zhmkxJI5LXLCPRjp7upsUdVEJj2hZOJjo5FkMmro6VzWdV3kuJBR0xakkM96rggDm1JTCDMIeC7rygm6HH75HrdMhTOYzzthjlFuyEyIbM51XFYohtvb6zs7/9ncy93trb2V5Q1b+IJ7tsgiaFsGM3WeSVkIMoy4dF3KzJZ0StM1aWoJAj9PsLC56wiXYopMMx1PENPiTDiOb9uuHAxLBYqiaBASxhgAFmOUcyGn1FKFzJmHEdN1UwjBKBWCBYGDiQWgrhlpiYDgnGuaJhF8UvMCITANSzaaTRNIyYxlmZRiSpGwsQU009QcR5imgTGGEHlegBClVOi6YVmmZBUTQsIwlMHe34cxyGEWhFBizyFEEEJCGWUilVYQpnKwLU1JpglVXTeBKX1AFkC6YWEiDBMlksqly9WqZkKMLGgalhpPjSMCAUTpjKbpZkZVTWAlUkkpSBkbj8qkakXTkqmM54dSXGc73udffCm1vLLWSIOChJD+rTFsqJoOMUIEG5ZpQSDnzWEuqxkaQJhxT9UsLjw/yFImKHcpz+QLx/3gAz/4YGrqZHHy0ytXzkxNnZiePpVI/GZw8Ol4/Nde8N7nfz7rB+/l8h+HuY9yhU/84B3Gqy3AEYaKnmICK1pK0VKqnla0VDw5fvrsCQvq+WLWBIaiKZgS27U1wySUU2b/DUIqhO1KmJ4feohACxqYQkVT/dCX+kDbdeQkWw7XufBkADnjHCDIbe54NuUEYgtiyARPpJKRoUELglQm7XiudGDZri3FNV7gmsCQ5YZygilyfeEG3PU5EwhiK8z5EgifTKf80JcJCl7gfh/AQDmRnu9cIZsv5mxXUI6ES6iAtkeosDA1ucAIm9mc5/lC3rjAupFxXO55DoQWY8TzRBDahpkRNmLcUrW4sAlEhqqlPF8ImzCOsjkPE4sLLJczskfDKJBzKILNbOiYhqKpKd8TjELf5Z7LBccz00VKgC0gQoppphiFjs1tQR2beh6V11CTxbCQ9z2XTRZDKdLp7Wl3bJzNCtuDro89n+bybr7geb6Yms5f21z5/hrqf7XWbO9ub+2trW5IixOweCZtaQomyMfIlYVGUy0lYxg6lLkuMqkOI4EgVxUTmAgBDE1oaZpkSiCITQtKJySlPJ8vRiJD9fWNCBHbdjzPMwyDUmYYFsYMAkqJ7TpZW/iECNcJAcAASLwKpwwHgTM0FDlx4oQUv9i2Lem8CKF0OoUR0VQrkUgBgHXdEEIgBFU1o+sKZVDYxLa5YWgfffShaZqcC85t04TAwlLSIlF+MoYBIeT7vixnkiyRzWZlqIvkWriuy7mdUTQ5AJKrm+/TI3XTnEhMqLrW1tGRUTSIyODQWDqjR8eTnxw/BRGFGMXi4xk1GYuPpZUkwiSVVhVVN4Elp7zxZMIElgWBbhqIYExpcXJ6LBqrrqmToM9CcSqdUWWrSOZSIUylIVP2jP0gm89P5gp5CwKp1u3p661vbHA8lwlmux5lrpxDycw5wwQmUJmIOm48zGYIGSNkzPdTnpfkImaaA4rSLUTM8xOuP2G7MddPeH7KDzJhVoUoDZEASCpWkHAE5VTOkjVDiyfj3KaYQkyR7QpMCcRI1Q1MmLA9Qm3KbIkcFY4j9Ti2K/zQ7e7tvHDpkqrrUlmjaKonJbGMMs4R5rI5ZUEoHBtTjAjkNrVdJs9Ya3vbqTOnM6rieK5m6HJezm2OCOQ2M4Ehq4y0YiICATK4TRCx/NCVdSSbz1POhC1ZGUw6MCWSQq6GpNXbDz0maK6Qs13GBApyTnE6GBjqik4MOS77rhNMrGzO8wMbQF3YxA8czilCwLY559h2qONSYSPKTMYtP7DHokONTbWuxzGxHJd5vnA9Thm0BeYMCo44g5xBqdZj3/VxiGNTWxBbEIItz+Vh4LoOx9BIp6MApjHWZeglgibBVhBwzg3fZ+nUhJKJey5TlYRpZCaLYVtrgy0Q5xamqnAsQg3bQYVi6Lhseqawtb2+u7f9n13X7O3ur61uQEAtk1DiUeIBk+sq01WsaxBYRFMtWWgE9zhzHTuwha9rEAJmmVhXTQyJI1yGMDKtdCyuKdr4+IT0KI2ORglh4+MTZ8+ez2bzkptFCEkmk8lkmlIOASFYCO5LXV88lp6IpaLRuO9nAYCx8QnP8+Lx+KlTp2ZmZhRFkfo6XdcTiYRlmZYFKLFVVUeIMMZUVVNVJTLQr+uKBbSBSE8qlWQMX7hwgXOuKGosFseYWSaKxxOSASpH3XIV43menH9PTExACKPRaCKRIIQmEslEIqHreiqV0XSTMmGYUK4pTBNquuX54fDISHVtbVdP93sffHj6zLne/khdffPliprxWOr0mYuOE7R3dPT0ddsuVfVMZfXlVDqj6yCZyqQymUQqqeqaoqnjE7GmluZkOgUxGo1Ghe3qBmhuaZucmgnCnKLq0h6ZSKYl0lzTTVUzGBe6YcmlTSKVppwDBMfGo47n6qZ56sxpSY1xPE/VwEQ8YwFCmY0J000LYMSEl9EswyAEe4yFmTSgxEfQSadBLvcZZ6FmIOEEXlDUDGJaAkIHYd8wmWFgE2AubIhwKp3BhFoAarpBGQcQEUYgtixoIgI1wyCMMmFTJjAVlDoIc0XVhe0CBAmjmOKJxIRMlbtUcVl2vrzAl+saJrhwHcfzCLWlMyPIZjOqAhDUDFU4TDeV0egYppQwev7ihYlEXGZUIYI1QzeB6fo2ItCwdNmskWWFCcoEhthkHOumShgmjGqGzrhQNYNyJpU1sjwJR8ikXYm2kVMt3dQKk1lIzLQan/m8EE+N9Ec6XY/rRsZ2qOMyuUIRNhE2cT0hmRKUYsYRJpaqpcKsrWoTmp70A1vT02fPnQyznm5kHJc5LpMdn8AXGBmyuCCoUyIzoXxKLIxMXUtn0vHAtzU1ZeiZwLM5Q9nQo0SX4hrHpoHv+Z7teVxT49FoXyY93t7W1NhQnU7FRob7J2IjCOotzXWCIwukFW185rMwm3MGIp2EWmHWzea83b3N/+y6RuqGl8trpgFlci6CNsUusGyCXGBRzlxGHdmygYD+fSIdwYJRJ51UgAld4XBM+rq6eto7dc144YWXVM2ora3v74+0trb39va/887RfL5YVVXd39+Xy+UURamoqIQQy1USBMz3cg31zW2tnaaB3nrzHdMEDciszgcAACAASURBVA2NExPxpqbmwcHB119/vVAo1NTUSNo5AKCiogIAAADMpFXTBNlsdmBgoLOz3TDVo8feSiTHT53+pK6+6vLlC7HY2LtH38rlwtq62lhs3PM8zsXFixdVVbVtW06v5MxbynaSyURHZ9tEfPzSpQunz5waGRlqbWtpaKgdGxtpbGoCEMn/KNMC3HYwoaquh9lsZdXl2MSYH7jxxERFReXJU6cx4R9++GlPT0TVTM0wTpw8oRmZmvqKjJZoaWuqrK5CmKbSqYyaYoJGhvo7uzsam+vf++DY6bMnB4cjTS1NDY1NsXiiuaX12uZWT1//aDTq+n5aUTs6uxTVSGc0TLjrhcL2+voHu3v6GxpbTpw83dLW3N3b1dHV3tbRllZSFVWXDcvo7O7AFDNuj0UnhkeikpSMMEEYM8ERoZTahcKMEP7Fi1WaanHmMOpASKTUzvE8xmW8nICISvcmQBQibEGro6td0ZRUJoWIjJT0IkORgcE+4TDJ8QPIRARymxNGTGAxzrt7e0fGRiBGZ8+fsV3R2Fzf3tk6ODyQVhKd3e2GqTU2NeimNj0zaQGjraOVUKTqmgWI4wZhNt/V3T08OpJWUhcrzrkBr62v6Oxu7xvojScnqmurVV1pbG6QJiaIwcBg/990w1heQ2GKMMWO58ST48NjEdulldWXHE+MjA2NT4w1tzalldREYtz1bW5TJmT0PGSCIAJsl/cP9qp6KpmJ1TVWOT7r6G6KDHePjvePx4eaWmpyea+5pR4Ts1AMLKD29LYRCkxLgchwXEYp6O3rzCjxkdGBxqZqYaP+gY6J+EhzS11vX0dXdytloK29UdjY9ehYdGgiPuJ7jGCDM+C6hBAzCLjn0cDnqWRUUxPj40NNjdXx+OjIcF8mHRsZ7lMyE5aZKRbdMGRCAEotjEzXpdmsPTbWl0gM+T4pFr1YbLC5ucowkun02OBgJwQZx4HR8b7ilJ1WRjLqOGVmJNKVy3v5QrC1tba3v7W7u7O/v7e//++SDv9Pfqi93WvXtpaXVyDEcupk6IgSB1icYEe6MQX3lIyRSeu6BggWMmM3lVQNHVJia4oh1eYEgGNvv5WKjRdyhffe/9A0wfvvf5jJqMePnxgeHo1GY5mMWlVV6TiiuroKY9ze3tHR0eW5WYIFwZxz+913300kE7Ztnzx5EiH0wQcfJBKJt99+e3h4OBqNUkrPnTvneV5XVxcA4Ny5cy0tLQhhALCum67rVlRcSmfiTMDzF05ZQPn9C7/s6Gz99MRHsdho/0A3F6Sy6tJ4bPTU6U8xBn19fXV1dZ7nyasnaUSQmr36htrOrjYuiLBpReXFS5fORceHh4cH+vq6+/r7uvt6vMBTNDWVSeuWgQiSV/jnL54OQsEFqqurgtA6fvy4qmofffhpR1uP52eHRobqG2uFQ9597414aqyrp72qphJimMwkFC3p+Kyy5mJkuNcAykg08sHHR0+e/phy9OnJE5L5FGTDs+fP9Uf6L1Vcghg2tTSPxxLfA2h0AzY1t6fSmmWR0bHxjz/9sKGp1rDUd46+2dvfZVhqIhWrb6xxfXtgcNBx/eqaOt2wEKa6YSHMZA/FD3KOm/X8XHVNw1h0orO7p6W1VXZ83MBLK5nm1paqmurKqqpPPv309Nmzp86cHhweCnPe0Gh/Z0/rwFB3bX1FU0vtsQ/erm2owMyqrr0MkCFnZYgACxoAmbL0cJvW1FVCbNkuu3j5/OR0oaGp9s23X9cMRdXSmp6G0Kirq8rl/PHYaDbrVVZenJgYc10HQMkwJRVVFcJhqczEpcozYZ5V1p49debTVCY+NBIZHo2kMvHK6suFyVxkqJ8J2tHVEY2Nc1tohqGbBkBILv1c32tua3R8xh18seLs9GeFuoYqC2oXK866Pm9tbzQtjdvEC2wZJSqNVxbUq2ovelmCqNrQXEGFUdtwERKlovq0oo9ntJhto47OxrHoQGdXUzZn19Zdyigxx8UIa8KGmp5oa6/3A2aBTP9AB+NWbd0l00rV1F7UjSQXYCI+3NPbyrg1Fh2wHdTe0UCI7jiIUoNzixA9mxWui1V1oq2tznVhGNJ0erS5uXJgoG1y0h0d7QEw3dvbnM+LMCSM6ZwbrgsZ023b6u9vjUb7slkaibT6Puzvbx4e7ojHB4aG2mdmPE2NRqPd2RxqaroYi/W5Lmxrrf3yz9PZ0NneXt/f35Krm/39f9fq5n/W1+ysr19bXFwyTWCZmGKbEocSN5U0DJ1AQE0DGTrUVOt7/HAmrUuJDYIMWEQwhxEOTcgxfuNPryLD9L3gnXeOcm4nk+lTp8788Y+vSPt1T09fbW2tEPyVV14xTbOnp6+iojrw85pqQUB13Tpx4oTEcZ49e9ZxnEgk8v7777/22muWZeVy2cHBwe7ubkVR3nzzzUwm09TUdOLECYSwouiEMErp8eOfaHomCO3TZ44bZiaVjh0//tEbb7xGCCoU8gMDfdXVlZZlNDc3JhLxgYG+ixcvCJtjjCglGCOMkOPYvu9VVl4eHh4MAm9wcEBR0g0NdbFYtKOjbXh4cGR0ZDQ6VpwqUs6EIzAlJrBMYLm+V1F5IZ4Yq6mtOPbeO62tze3tnRcvVFy8UJmYyHherrK6enh0cDQ6+LsXf9XR3dLb39XR1Y4pS6YTKWUCU+vDT44pehIRc2CwJzoxfPbCSSbIR598ZFjmzGdXdNOorK4yLPPdY0eT6VRre9tAJMKEMAGwIDQBuHS5QjiObpiRoaFYPFrXUC0cduLUJ9wmYc5vbm2IJ8cVLf3Ka6+5bnDpcqWi6rLFI6NUMGEZRYeI+X6uprY+mU5HY+NVNVUS9O2HXnNrc2QoIhxRU1czNDJU31jf0dXR2Nw4faXY1Fo3ONIXT0XPXzrd0d06Oj744SfHHJ/V1FWZwPx7ka5sxxKGEYGV1RWT0wXCcFNLY76Y6+zuOHv+TGt7S76QLxZy7e2tkUi/DJYQgnV3d/b2dnMhLEBtJ1BU41LFpamZomakL1We8ULc2FJ1+uzJ/kgfYThfzLW2t0wkYhCDi5cv2K6IDA1EhiKUU0wxYYQJJgHM3OYVVRezed/1xcXL52yXAWTU1ledOPVxrhC0dbRY0Pw+g0E43PHsfDGXyqQuV56b/jxroXRN/YVc0YlODJw880FF9ZnitDf9WXY8Ntjb1+b5rLmlhgtQV385nhjhAjBuZXN2Kh1taq6enAo1PdHcUjM1HSZTYzW1F3t6W6dnsmFW9PS26kZyIj5cXXMhm3MaGisRVMOQE6ITots2dBzkuhgjraOjoVh0XRcOD3fF44MdHXWFgt3ZWQ9AqqbmnO8Tz0NCWNIGRYiazTJdjw8NdWpa7NixP7W3V2cyo2NjPfH4gGHECgVu6LF0eiiZipw+fSwej6jqeDw+LKk6uzvX9v6TtWZ3d29nZ69UKquqrqmWaWBgUUrcdMrUVKRrkGAbQa5kTE0FpoEtkzDq2iIg2AYW1TVgGQiYCFrQt526yurY8KihGb/+ze8URQMAVVXVjI5GhXA4txsamoaGhtra2n71q191d3c31DdFBkZcJzR0iCBXVaO2ttY0LQDg66+/ruu6EOLcuXMjIyOSMtPc3Dw8PHz5csUvf/nLrq6uhoaG/v5+jLGm6dls1vO8y5cvjo4O+779zrtvJJLjjssvXjzf09MdBH4YBrW11e3trUKwtrYWyzJaWhubmusZx5QhQoHv25RJ5ZVoamoYGOhT1czRo+9UV1eOjg5XVl6+dOkCY6SlpWU0OuZ4ruxWyqaAbhrMFgAZzS31qfTE6NiwomRME46NTUzE0pZJTRONjEUBskyg1jVUDY/2d/W0p5W0YVqKpkZjI4hYlyrOa0amsbnurXder6i6WFl9qba++lLFJcoZYVSSN13f6+rpNoHV0taqaBnZMsAUY4qraqoAso6f+OTdY2939XTW1NV09XT1R/qDbOB4TmV1ZSqTqqmr+dc/vZLOqBWV1QDi76kRXDhycMa47bje2fPnIkODJ0+fPHvhTE1dZWNzXZB1e/o6j5/4KDLUd+7C6YHBvrPnTze3Npy7cLowme0b6O7t7x4aGTh5+nhLW2NXT/tHn7yvaKmWtmapZ3F9hzAi6470WxOGL1VclBc4p86cJAx393Z193Y1tzZxwRgjjY31qVSyo6Pt7bffSiQmuro6RkeHKSWKahDqMG5frqiAGIyND39y4gPCrcaWmrqG2pa2ZoghIrC2voYJWltfc/S9dw1L74/0ppWE7TJEABPEBLqqZwhDri8qqi4alsptcurMp6qehthsbW9KZeJMkPrGOok9d30HESjzO/3Qc1zR1tHkZfl4fOij40f9LNetVEt7nQkzYd7O5p3qmkuGmUHYGB7pz+bc+oYq01KC0OYCOS61gNrUXMs4jCfGWtsa/vzlTCod6+hsZhzKWN7+gS7TUiqrLpw9dwJho7OrRTaDJXPv+97w1GQ2OjYoBGhoqKiqOpdMjnZ0NIyO9qXT0VRqrKurKZezfZ8yZkKoWFbatmEY8u/4NSgDYdo0E9ksY0yX5m/HAZwbjmPZthGPRwwjbhjxQsF1bDJZDLc2V//ztWZ3Z2dvYaGUTmeUjKFrUFMBJa5pUF3Dmgosk2TSRjqlKRkTAkawzdl3/mwIGGMeZy7FAhiIWHi4b7ClvlFTjFgsRbBIJVWJTDd0aJk4nVItE1DKGhoaB/oHG+pbEOSUOIaONBUgSKPRWE9Pn6rqqVTGsqBpWqYJHMfj3KaUJRIphIjvB21t7fX1jdXVtdKcCSGSHAZFUXp7exkj6XQSQBNjGIvFZNOXUqrrumWZXV1db731Vk9Pd2NTLUQGwiYXmFDgepzb2PU548iyzKamJtM04/EJTdPy+byqqqqqmqbZ1t5JKAcQIUwMEyBMbdcjlGNCCYEImxCZrus4jqtkdMskugYzaZMQJ6NqFgSGpQNkeIGt6opuGppupBVFom0l/jaZTvRH+sfGRxOpeCwe03STC9t2vHRGgQh3dHYdPfZeT29/30C/qisZNYUItKDph+7Y+OjY+KgFjWgsKkOZorEYRNj1A0xpOqMwYRumVVFZ09MbGYiMyNDLv2VdZoXtQUQQwQDBZDrJBI0nJ5Lpidb2pkuV5yhHlKNYfEwzMtHYiG5mVD1tAi2RigmHG5bR0NQQi49rhqqbmqJlJBpmNDoqoVnSCSkpE9Ji4XhuNDY+MBhhgiuaakEgFYwQI9dzZe9fXth2dnYODw91dnZyzsIwJFRARG3H6+3ra21vRQSOjA1iCgAy0kragkDO++PJRJANddPo7u3pj/R393Y4HpfiR8KgCTSADAtqwiFpJdnd2yUpE8LhshrmCtn+SN/YeDSbz4W5sDBZJIxK+TIiOJvPJVKx/sEuRE3NTAuXaGaaCkAFwMwKsrYFVMelFy6evlxxLjo+FB0fkoUGE5My4Lh0ZHRA01Oezwm1/EBEx4cg0rlA3++TzbmpdKyltX48NpxIRqXbW8LM5Xw6l3WzoYuRnkiMZDLjup5wXWzbkBBdCDAy0kuILpXEjJnyQc8jrotlPncQMNfFYcgZM20b5vNOPm8LARgzi0UvDFmh4IYhn5oKHAe5Dg0De/PaytbW2u7e1n+s1vzbOdTO1tbO0tKyrpuZjK6pAFgUAmaZLJO2dA0DiyFoM+pDIAh2IeDplAksjpGTTpm6hqBFTQ1iyLBJMvG0mdEJ4nKuxJlnmcTQEcG2qljAogBgACClXLJEKXFMA5sGgYAbOnQcT6KnGBcySkESGwzTUlVdEoXl4ZYFAYCmCXTdME0znU5LVR7GmDHmOK5hmKqqWRYwDEPTNACAaRqSxccYxRhZQGccAahzgaWQhzLoetwCGudcFhcIAedMBi0IIXRdN0wgAwwUVdcNSybAWQDZjmsBgzJkO0IIm1Iu5Y6WSaNjaU2DFsAWABY000rCsDTN0FLpjGkhTbd001RUTTdN3TAtCA3T0gwjnkwSygkViqpzbsuYBEkyN0ygm2Yqk0wrKam7l4ZA+d+CCAGQOm4IIM0ohsTTZBSDcbc4OYOJSGcMiLgFqG5AAJl0SFHmEsI1wzQsCxEMMaKCqLqim6oFdc3IYAqEI6lkwA9dypEFdZkwzG1HN8yMojqeRxhDmMjqJkk0tutAgphg0nQup06SL2FYphf4+WJBOtHlUpHbnGBMKZHC7kKhIA33nudxzqU7XAIoUuk0wN9NsmXXTNU1CwJphpWoY0ypBS2ALOFQRCzhUNk/AshAxHI8HmR9qfTDFElzpqw7ipYWjowXEpLvJVkZAAEmuO1ybhPMgHAoxCbhEBITYAMRiwnkelzYhDKIiEkZYBwCpDsuw9TSjQwmFuNQCme4wFJNQygwLZUyKEdXXGDKoB8Ix6VcYIxNRqGEk+eynkyVsgWRYFDOoOdSSkwp+XMc4jq0WAiyocMZQEhnFHgudV3q2NhzmedSxoDvMcfGjk0kGScbOoW8D4HmuXSyGISByOe9fN7LZZ3AF1dm8hsbpc3N1b397f393f/1WrO9vft9rZFXSaZBELRNg2oqkhUHAgEsTohr6EQSJ6DlQCAgELqKDBVSJLCBk9GkmTEpsjn3UkmNM0/JmIaOgEUR5BgJVTEtC8umDyWO7xU485UM5DTgzCOYe27ouSEExDKRbfuWiRBkEBBGbQCIaSIIiGFABClCTFW+U8nouo4xVhRVVTVNtzTVVDK6ktF03cxkVE0zZG4UhMh1PSEcywKGoVOKLcuA0MIEUYpNy6AUu64jhC13NgzTMEzDsACAnAtCKMIMYUaZo2omF67jBhLZy4VrO7ZhqJQSy7IQpLoGLZNZBkunYDKpp9KaphmKpiTTiUQqnlbSFkQZxUxndEU1M4qeSqu6ASSjU9VMiGgypWg6kHQrRTVUzUqmVAApgMQC2LAsTdcJYwDCdEbBlHhBQCi1ADItDBHXdKAbiFAbE5FWDIi4sH3DxBnFhIhZgFqAQsQNE1PmGiaGiCEsIKKqbmRUTVJgVF1FGMpwSMMyMEWUU9n4sKCJKRa2i7EgVBgGlCENhokYdxDmpoUwYYwLTJkFIKGMcSFNorbrSRIFgEg3TIAw4wIThglFmMhTjTEBABJChbAhRAhh9DcZkQUQwgwApGo6IhQgBDEBCBumBSDSTUtRNQsiABEm1HZd+Wk1Q9MMDWJouzb9rmtjyyJCOcMUS+eU/HaUU8IYIhQTyrjgtiNncLbrOa4v42IQgYZlAAQQkQN+IOuaaemEItvhhEDH4ZRhCE0hKCEQAEMICqGJELAdbgHDtrltM11XMAaMYRlhxjgBwHBdwTjBGHBOXEf4nuM6wrGZ9MxL37ZjM1sQz+WuwwRDvseLhdBzeeDb+ZxvC0KQ6TrMFoQzKBjyXc4ozGW9MLBtgTlDviezd70wcAgybUGyoevYNJd1i4UwGzquTT+7UtjdXdvZXf9P1Zqtra3Nze21tQ2ECAREXhlR4kJg6xq2DK5mkKYSQ6NqBlkGN3XGSKCpWFcphp6m4XTSgCa1qUcBT8cyWlKn2CHYxcgxDWLoWMlYqgJMg5gGURXT1BFG3DIJRoJRjxJPVzHFvuvkGLFt4TPiSKwEo660mLtOSIktHecECcvEnLmS4EUpRwjouiaEsCyIIDUNZBpINp4wopRyhL4LnOLclp0jQpiq6oRwRgWl3DAAIUwIl1FBqZCgPwixYUgTOJYgHtt2KbVNQOTohzJXUj7lAJgQyjmllBLCKLEtk5oGBabQFaZrRFEtVTUNywTIMixdN02IWCKpJtNaMqVlFFPVgKJayZQm+cSUuYpqKqqlqKamA1WzVM2SqGBJCKbMlnByhDkXrgxIMC3MhUeIY1rMshghLmUeIS6lnvxVUYCqQYwdxnyEHc4DSj1MXMMgnAeEeAByC1CEBaE2QFjGUekmwJQhwqRqkTIBEdUMyzChBQgmNqG2BSihtmlhVQNc+AgLw4CmBaQlXVooJGaQMuH5IaFcxulBRKTbgxAuu9SeF8ilq2QtOo7nOB6EGADEuC1VRQhTAJFpQhlxhQmX1o0wm5fx4RARQgXCFBMuHFfYrgWRouqyUSWRQ64bAIRMYEGMCWMySITbtrzuY1xIxrvkBEkPmuP6hHBJQ8SUWBAYlilzJiBGJgSUUUIQo8S2uS2469qMEc9zGCOCM85pGPqcU4QgAKZt8yDwADANQ+Oc2ra83Mdyw3EEQtCyDEqQLRhnFAJTbtuC+Z4rOJXrHcFx4Du+J2TynGNTzxWUAM/lBFvycUahYzPfE7ms53s2o6hYyLoOD0M3DNzJYi6X9fO5IAhc33VD3/M923WY57KpyeyXX87s7Kz+f1Brrl3bWl1dN01oGghDoSqWriJNRabBLMM2dYGAZ+rCMoSpCyWNgelA06E44DRnmQJaNkWupREKONQQh8IVOc5CSnxOA10jlskNnWoqxsgl2DY0CAG3DAosrmsEAccybAQ8ghzLJJZJJMgGQS7J544dcubJlZHv5Rl1LRNDwDASpoExZhCCVCoJIbQsiCBTMqZlUgRtBG2CueAuRoxSYRrQsjBCzHVDzhxDR5S4tggYdTGyBQ858xn1OPMw4pw7lAjLwkK4nLsIMUoEQtTz84Q6XPgQcWEHthNqOjRMbLshwiQIfCFsITwEuVwbAssxVA6BLfOzLYhlholpQcPCFqAQCVWDmo5Mi6gaiCcUTYe6gQHklLkAslRax8S2ADUtYgEKIAOQAcgp812vCJFjAeE4BUJ9jF0IbYw9CB3T5KbJKQ2EyAmRs+08pQGlgWlySnzbznveJGOh6xYx9gyDQWC77hQhIYSe4xSDYNqyuGESylwLUEW1AOSM+1yEAHJNRxZglkU1DSFscxFw4VPmul5e2KFhEoRthAWhDiaCUNt2fEJtGbmJCSdUcOEy7lDmcOFS7jhu4Hqh52ezuaLjhozaEFJChOMEnLsAEAgpwdxxfD/IEioAJIRyiCgmglCHMtcPCpgIw4SOGwBIKLNdL7QdnzKbMocLn1KXUMcCjDKPUs92soS6lHnCdrktHNf1fJ9yjghhgiNCuC2CMMuFCxGl3HHckHGHC89xQ2H7CFMmbEIZIgQgjAmlXBDGCeO243DOKMW2LTzP5YxKFpzj2J7nIAQ4o7LWIAgQghACSjFj1La557mcM9d1gsDPZoN8Lus6thBccBb4nu85lGDPdVzHtgXzXMexhevwbOi6Dvc9WyqGPVfkc0E+6zs2lRdcjqCcIgxNzxU2J57LPde2OQ983xEiF4bZMAx8v1goFHI53/V8N5gqTmaDwHV44NtffD792WeFra3y3t7G/0qtkeVmb29ve3t7e3tndXWNczE5OT1ZvOJ7Od/Lce5x5oZBLvBz+fyULdwgyBUKU4XCVCE/mcsWJ4vTk8Vp389lw3w+Vwy9bN4PPWEXw+z01EwY5sMw9/nnX+ZyhUJ+0rY93wunpmbCMFssFnK5XDabm5ycyeeLV658IYQXBvlcrmDbThCEhUIxl8tPT8988cWfP//8i8nJqamp6amp6UKhWCxOTk5OFouTjusKYbuun8/nilNZz+eEAIxBEHiUkiAIAj/0/SAIwlwu6/v+1NTUF1984XmuZVmFQn5mZiafL+ZyhcnidDabn5qc+fLLr6YmZ6YmZ6anZwqF/ORkMQzDIPCnp6fz+XyxWLhyZaZQyH/55f8oFIt+EArbDsLwz1/+j+mZKzNXPpucnnYc4QdOcTJfLOaLxclsLl8oTAruYSQ8NwyzuXwxny/khMP80HV9h3LqB4HjeIQyQqnjep7ve75PKHU9LwizfhC6ns+FbTsuocwPwmwubzuu43p+EIbZguMGjDtBmMvlJoOw4Ae5MCzk85PZXEGG7U5OzUxOzYTZvB9kC8Wp4uS04/qeH7pekMsV84XJmSufh9l8Ll8sFKfyhSnXCyVZxvezYZj3g2wQho7rSjJONpfP5YthNs+4ncsXc7ki50429x3qNggDP/Bdz3U91/M9z/cLxcLkVDGby/qhH2SDMBfm8rniZDGXz+XyuVwhF4RBNhcG2SCbz07NTBWnipPTk9l81nFsz3MnJwvZbBBmAyGY77uu5wSBV5zKBznJGOe25+QK+SAbuL6XLxTyxYIf+rb7XehdcaqYLeQKk4XJ6ckgDIXjhrl8vjhZmJwKwmwuX/CDMFcoTk4Xi1PZyen85HQ+Xwyz+aAwmc0W/Hwx/OyLK4ViMZsLi1PF4lQxCAPP98JcWCgWhMOLU/mpmWKY83OFMF/M5otZ+Uiu4PkhzxfcXN7JFdyp6XByKsjlnXzBnZrOFop+vuDlC57cnpwKp6azU9PZwmQwNZ298nlxcir87PPi5FQon8oVvOJkUCz6V67krszkgoB99lnhiy+KMzPZz67kZ2ayn32WnZ7xJqfc4qRz5bPwu9uVIF8QU9P+zEz4xReF6enA83AQsC++KBSLbhCwmenclSvFLz6fvjJT/PMXM1/++crUZParv3xxZaaYy3n5nPfF55NffD715y8mP/ssf+Wz7OSku7Nd3t+/9rfG8H+k1nyvNZYbX3311euvv/7xxx8fP378ww8/+uSTT958861jx9599+hrb7/7yvFPj7179LX33n/z/Q/feu+DN9/74M23333l3aOvHj322tH3Xv/gw7c+/fS906c+PHn82ImPj9ZVna+uPn/i9AcXL506d+HTM2c/vlRx+sTJD86c/fjM2Y9Pnf6wqvrcpyfeO3vuk48+eeeDj97+9MT77x595cKlk5crTp87f7yi6uzFy6fOnjt+6sxHFy+dPH/xxPkLn54998m585+eOffJ6TMfXbx08tMT77//wZvvvPvKhx+9feLk+6fOvn/qzHsfffLWiVPHaurOnTn34aWKE5cqTlyuPHXm7MeXK85cvHTq4uVT1TUXLlecqaw6W1l1rqbuYn1DRUXl2cqqc5VVZ89d+LS65nxV9bnmlurq2gv1G7LRAQAAIABJREFUjRe7euqbWirq6s83Nl9uaavq6Kpr76xtbq1sbKpsbqlubK5qaqmuq7/c3FrT2FTZ0FjR0Fh5ueJUfePFrp6GmrrzdQ2X6xsq6+orLlecr62raO9obOuob26p7utva22rq62/2NBU2dhU2dff1t5Z39HZ2NZe39RSXd9Y0dhU2dRc1dJW29xa09BU2dZe19HZ0Nxa09Xd1N3bMjTcPTzS09nV2NvX1tff3j/Q0dff1tnV2NxSPRYdiE0M9Q90RAY7e/vbenpbunuaBwY7I4OdQ8PdI6O9I6O9wyO9vX2tQ8PdkaGu0bG+eGJkZLR3cKgrkRpR1InhkZ7Rsb6xaH9ff9tApGN4pKdvoL2nt2V8YnA8Njg61jcRH45NDE3Eh8bGB8Zjkchg50CkYyzaG09GRsY6x8a744mBaKw3kRqMJwfiyUgiOTQ23huN9Q2PdA6NdMbiAxllNJ0ZmUhEkunhaKwvnogk08PDo12x+EAqPTw82hWN9Q6Pdo2Nd4+Nd8eTAwODLaPj3WOxntFo18Bgy9BIx9Bod/9gR/9gR/9Q58BQ1/BY30i0PzLcNTDUOR4fiMb7RqLd/UNt/UNt0Xh/ZLhjONo9Ot47NNr5/XZkpGNwtHNwpHNorGs8MTCRjIyM90RGOoaj3RPJyERqcGyiLzLS3hdpGR3vjY73jo51R2N9kcG2gcG2oZHOvoGW0WhPZKgtMtSaTA9GYz2j0a5orGdsvGd4rHNkrDMy1DI40hiNd/QO1PQP1o1EW7r7qrv6qnojtUNjrX2Rhshwy9h450Sid2SsfWCwaTTaMZHoHR5tS6QHhkfb+iONE8m+WLxnItk3PNYeGWoZHG7p7qmKDNYPjzT19lePRVsTqZ7RsdaR0eaBSF1XX8XAcO3QWMPQaH1kpG5wtH5orGF4rGFsomVotHlwpGVotGUk2tbRXdXeVdk/2NjTVzsw2DQ63jU43B5L9MfifcOjHSNjncn0oKqPKfpYPNmbSHZnlIhpjSaSffFk33isO5Ec2Nyc39ld+3fyhuVu/9vfl5j9/f3t7e29vb1isfjDH/7wH/7hH370ox/+4Ac/uPHGG//Lf/k/fvzjH9564Cc33fzPP7nxR//1//zff/Df/+t11//j9Tf88JZbr7/t4I03/OSH113/TzfdfN0NN/zw+uv+8Ybr/+m6H/6363/0g9tuvv6WW67/0Y//2513HTp46OZbD/zk0OFbrrv+H2/4yY9uO3jjkTtuO3zkwD9f949333P44Ud/euddB2898JNbD/zkrrtvv+vuQ0fuOHD/A3ffe9+Rw0cOyD1vPXDDjTf9+Lrr/+knN/74ppuvu/GmHx8+cuutB2646ebrbrr5nw/cduPth2+66eYfXXfDD47cecvhO24+cPD6Ww788513H7j98E0Hbrv+1gM3HLr9loOHbjp46OaDB2+65dbrDx85cOSOAzfdfN2B2248fOTWgwdvOnzkwG0Hbzxw209uvOnH9z9w1z33Hj585OafPnDknnsPHrnj5kOHbzxw23WHbv/JkTtuvuPOW4/ccevDj9z3zM8ff/KpR+9/4K477zp08NBNB277yR13Hjxw8PrbD9943/2HDx668dYD199403W33HrDbQdvPnT7rXfdffsdd9528NDN9953xz33HrnjztvuuvvQ7YdvueuuQ4duv+Xe+448+NA9d919++EjB+6869Cjj93/4EP33nX37ffed+Suuw8dPnLrPfceefiR++SJuufewzfe9M+3Hrjh4KGb7rzzoHydI3cceOLJhx997P577j384EP3PPrY/Q8+dM99P73j/gfuvvOug4duv/nQ7TfffvjWO+687ZYDNxw+ckCe7Uce/enhIwduP3zrw4/c99jjD9xx520PP/LThx+576GH733iyYfvf+Duu++5/d77jjz9zOO/+e0vHnzonvsfuPuhh++7466Dh26/+eChmw8fOXD4yG133XPgoUfufOSxu++8++aHH73rqacfeOiRO++7/+BDj9zxsyfuv/entz/6+H2PPX7fAw/d+dMHjjz+xP2PPnbvI4/e+8RTDz759EO/+OUTv3j+ifsfuOPJpx967vmfPfHkA48+du/9Dx5+7PF7H/vZvU8+/cBPH7j9oUfufObZh5/9xSMvvPTcSy//8qmfP/b4Ew89+cxjTzz96GNPPPTozx584ulHH3/y4Qcfue+pnz/8s6cffPKZhx99/L7Hnvjpc7984vEnH/jZUw8+/fNHnnnu0Wef/9lvX3judy/+4pe/efoXv3ri6WcffeLpB3/+i8ee//WTz/3yiV/86skXX/7ly3/87fO/fuqXv3n62ed/9vSzj/7q10//4V9+/cJLzz/3/M8e/9lPn33usV//9pmnnn74d79/9ncv/PyXv37idy/8/JlnH37m2Yefe/6xZ559+OlnHnzqmQef/9Wjv/rtYy+89PQLf3jm9y899cJLTz//q0eeff7B377w5Mt//MXvX/r5S3947sU/PPvCS8+++Idnn//VY889/8hLLz/3+xef+dOrv5Ebr7z22zfffunY+6+8/e7Lf3z1Ny+9/OxLf3jm1dd+/cabv3vr7RfePfryJ8ffePOt37/+5u9ef+O3L/7hqX/507N/fPUXf/jjM79/6Ynfv/TEv77y3B9f/cXR919+++jLb7z1wquv/+6Nt17806u/efmPz7/8r8//6dVfv/bG7985+q9/fOW3b7798rH3X/3TK799/c2XPjn+9rH3X33rnX95460X3j360tvvvHTsvX959bXfvP32H1555bcnTx5bXv5md3dzd+8/Xmu+P2Bra2tjY2NtbW15efnq1avlcnlpaWllZaVcXl5eXl5ZKa+slMvlUrlcWllZWlkpr6wsLa8sra2trK6Wy8ulcrm0XC4tL5XKS4vlpVJ5Yb40N1tanC+VFpaWFpeXS8vLSyur5XJ5UR61slJeXVteWSmvr6+ub6yur6+Wl0vfPb66vLKytLy8tLy8VC4vzsxMfv31X1ZXy+Vyafm7ty4vLS2ura2sr6+ur69ubKxubKyura2UywsLC98uLy+WlxfK5YWl8ny5PF8uzy8vLy6vLK2ulldWy98dXl4sl0vl5dLCwtzCwmypNF9eLsm3W1paLJcXS6WFcnmxXF4ol+cXFq+WSnNLS/OLi1cXFq4uLF5dXJxbKi+Ul0vLy6VyubRYmp+fn11cnF9YkPffzi9+s1iaXSzNLS0tlJYWl5ZKpdLiwsL84uJCqTRfKi2USgtzc1cXFubK5dLi4nyptDA/PyvfdGFxrlSal59kqbxYKi0sLS0sLMzNzV1dLM0vLs7Nzn5z9eo38/NXv7369cLCnHxqdu7b+fnZUmm+VJqfm/tWnvalpcVSaeG711+YnZu7Ojv77dzc1cXF+W+++eovX325sDA7O/ft7Oy3s7Pfzs/Pyvtvvvnr7Ow3c/Py7ebn/rbD4uJcqbTw9ddf/fWvf/n226+//uarb7756q9//Yt8zbn5r2fnvlosfTs7+9X8/Nel0tX5ha9n576am//rwsK333zzl/mFb0ulucXFq/ML3y4sXl1YvLpYml1YvFoqzc7Pf7O4OLuwcLVUml1aml9amp9f+HZ27utS6erc/F9Lpaul0rcLi98slWflfbk8P784N7cwu1Can52/urA4N7cwO78wt1CaXyzNl5bmF0pXF0qzi0tzpfJ8qTw/X7q6UJotLc0tLS/8348vzS0tLSwuzc2XrpaW5heX5kpL8+XlhaXlhYXS1cWl2fLKwtLy/PJqqby8sLJSkn8M5fLC8sri6urS0tL8wuLV0tLs8sr8/OLXS+XZpfLsYunbpfLsyspCuTy7vDy3UPq6vDy7sjpfXp5dXZ1fWZsvr8yurS2srS2srM6trs0vLV9dWZ0rL19dWZ1bKn9bXr66VP5WHrKyOre6tjC38JfFpa/X1hdW1+ZXV+fX1hdWVubWNxbX1xdXV+c3NkobG0trawsbG6X1jdLq2sLK6tzK6tz6+uLa+sLK6vzyyuza2sLq2uLGxsrGxvLGxvLq6tLaenl9vbyxsby+Xl7fWFpbL21slFdWF1ZWF9bWS2tr391WV+fW1q4uLf11ZeXq2vr82ur88vLc0tLs9vbq7s6/N0dhd3d3Z2fn39Savb29zc3Nra2ta9eubW9vb21t7ezsyO3Nzc3l5eWdnd39/f2dnV35+vJe/ipvOzu7+3v7+7v7e9v7+9t7a+WVzdWN/b39ra3t7z/S3t7+7s7e9vaOhJXKV9ja2v67T7b33W67+9/7SDEin3/+xd+/6c7O3u7u3vcf5u9+9ra2Nnd3vwsb3t3b2dy8trW1Kb+jfM2dnf+XU/T9l5Jf8/vP9v3z/4/d978r2N8duLX1byz2e3s7+/s7+3v/5lJ2dWV9aWllc3Pr77/+9vaOfKPt7Z3Nza3Nza2trZ2trW2527Vrm5ub2/LZ7e2dnZ29nZ29ra2dvz/2/4efne3dnZ3dzc2t1dU1+cH+/tm9vf3t7Z2d7V3pxNv7Ln11Z2dnc3d3c39/f39/d29/Z39/f3t7a+/fnJO97++3t7f29vZ2d3f29nb39nb/Zurb29/fuXZtbXd3a3NzfXdva39/d29/e3NzfWt7c2tnZ39/f2t7Z3Nre3Nre2V1bWt7Z2Nzc3t3b3dvd39/f29/b2Nz49rWte3d7b39PfnI/v7+zt6O/Ju9tnVte2d7e3d7c+vaxubG5vam/HVjc2NlbWVze3P92vry6vL65sbGtfWVleWlpdLOzvb+/t729tbOzvbOzvbq6kppaXFzc311rby5tb65ub69fW1re2NnZ3N9Y3VjY21pqbS5ubG1tbmzvbW7u7Ozs721de27s7p77drW6upaaX9/a2VlcW29fG1zdW9/69rm6tbO+tb2+ubW6tb22tr6/0Xaez41lmX5ov/Djff93Xjv3ngxEXf69Y2YiRe3u6t76k51ue6uyq7KyqzMJJPMxHvvvZcEkjACAUISSAgECG8FCO+9kZAEQnhJCCeEjjf7fdigobKye7pndhCKwzn77L22W2ft9Vtr7VuCRKD/EUVhgIHzimVoiiRwmiIYmqIpgiIJnMAwDGEYiiAwhqYYhqIo4u7ulmFoiqYYhiEIgiQpiqLhdH20DFgAGIJAKRoHAGphaJohGQajaQ/DoATuZmgMAAawJMNQFIkzDP038hqoEf6IfQ3DMCRJ3t3dYRjm8XgQBMEwDEVRl8uFIBhB0ARB4jiJYQRJ0iRJ4zjh8aAYhpMkjWE4TTEkTqF3GHKLuK9uaYymKRrHCcgaKIpGEBTHCZifou75hceD4jiJ4wRFMRhGkCTl8SAoisFrmmYJgiRJimVZHCdYlkVRnCAokqRxnCQIEkGwhwVJkSSFYTiOkxRF0zRNEOTdncdb40MtNE0zOE48ZGMIgkJRjKIY2CKSpD0eFGbAcYIgSAzDMQwnSYokKRwnSJJCEARFcThyFEVBUimKRlGcphmaokmSgJyaYViCoCiScd0g11duDMURBINFYRiOYQRBkCiKIQiO48TdHYIgKIKgKIrjOIlhuMeDouh9NpKkMYzAMIIg7imBY0EQFIYRKIojCIZhOGwRQVBwU4xhOGwaHDWCoCFfg1XAwimKvmcZNAOji+A4SVGMx4NAaPLmxnV7e4eiGCQJxwlv8wmCJAgKjhGO4wSB0zRFUSSGYRiG4ThO05S3vXAc4TSAN+GLLtctvIAcliQpgqBIkoQdgaIogiCQE2MY5vHckSRJkDRB0ncexHV7575DPAiG4QSKEThJoTgOeRCC4ShOeBAUwwkExQiSxHACJ0mcIAmSQuE1SaE44UEwjCARFHXduu88yJ0HQXHCfedxexAUwzEMv7vzuFy3cC55PAiG4SiKIQjmcrkQxIMgCIqikFqPx+PxeO7u3Dh+n5MgYEMIHCPc7js4fLApd55bBHEjiPvuzoWidziOeBA3inkIAkNRD4YjUBinaIKiCZLEaIqmSYahWRwjCIwgcYoiKAzFMQTHcRLHcYIgHsjDSZKC04kiWRQhMZTAcRLx4ChC4BiFYzRNA4ZhIRNEUQTDMJqmAAAkSWAYhmEegvAwNO6+vbp1XdEURVMUSZAUQVMk9TceDvUXeQ1N0wRBePNB6YamaZIkITuEi58k75crQVA4TjAMC9ctQZA0STMUw5IsYABD0DRFAwClCYYkyYdiYV/TNA0FhHtuAuUUjweBX06Koh7RxtA0TZIUTQOWBThOPGoOYFmAoiiCYCTJeIUdhrmXkiDlUDpgWZamWShMEQRJ0wzM5hVhvBdQTCEIkqLu+QvDMCRJMQxLkvcyCEXRBEHBVrAsC3kfZFhwzLyJoQFNsTTFEvj9fW/rIDEY9vC5o1mKYijqXnaDbJRhAElSkPtQFE1RkBIGx0mCoMCD0o2iGJYFkB5vgq3+4A6KYt4BBQ9iHcOwNA27iIH0wKGBRD6W42D/wGkAy4EcGccJKDOTJEkQBPx6YRgGRTnYUtj/kGyWBVCOg9dwWcIaoYxJEARF0bBMmqYpioJTlCAInCBxgiQpGsMJhgU0w+IERdMsCwBNsxhO4ARJ0Qz5SArDcJKiWZJiSIqmaAYnKIKkSYomSJphAUUzMD/DshTN0PAjQTMESTMMgPP8YSoyj+VxmoaTnGFZlmFYkiThLsHb7fDL55353qEHANA0SVEEAIAgMJqmCAKnaRL+EQROUQSUoUiSgDdJnKBJmiRIiqQoimZohiQoAidJjKRphqLgNPiJ4EnTrHf6AQBYhgUA0DTwfpLhuGMYBofsMQcgCISmMIpEKZIgMILACQIlMAT3CuZ/Y/qQ11AUBXdM/f39Wq12cnISw7Cfv0bT9NXV9ebm5v34odjq6iqCII/znB2fDPT2w2t4eBO8np+fPz09AwAwDM2yrMeDjI6O/rwKgiAhY9rc3FheXn78aH/fiuO42+0eGtKq1erBwcH+/n6PxwMe9l80zWAYptWOYhh+dHSyuLj0mHK9Xg+vvVsebw8sLCwcHR2xLLi7u5ucnNRoNHNz8/9uJ7Ise3V13dfX73A4ftJLDDE5NW7Z3zMYDOvrGw+5AQDg6upqfHwCAHBzc7O6ugYppyhqf3+/paVlf9/6mCoAgN1uv7y89P57fHR8eHjoPTGDpumbmxuLZW97exsAsLa2dnl5aTabYaTBhYWFk5MTi2XPZDLZbGdDQ0N7e3tOpxPHcTj7Ly8vZ2dn3G738vKy2+1+3ASj0XhwcAAAMJmMcNRomjk9PZ2amtLr9QiCPvQqAwB4PEF/nh5vk8H91pu9uLhyOi9gS09OziwW6+MMZvPuAw9i9Xq90+n8aMnww2KxWm9crp/eBzhBURTjur3TDo8uLq1sbm0z7E82w95r+mHl/JUF9NFd9srK2uiojmGY+fn58/Pzvb097wSDCUHuZmenAQAI6llZgVORQdC74ZGh5ZXF6ZlJFlAOx9naGpzkDAAf7IsZksSMJj2OIz+9zxIE9lO8maUoCkXRhYUFmqYPDw9XVlagscjZ2ZnZbIaZFhcXr64u4XlE4GHJgAfpA/IaiqJg8Kbj4wOSQACgH/bC931EkzRD/01Qtzd9RK5hWRbH8WfPnjU0NGRnZwsE/LW1NYvFolKp2tvbllcWN7fWGYaxWMwdHRrDzvbgUP/+/m5La7Pb7bq7u52aGt/bNd5cX4lKhQFv3xq2NozGnfoGeUFhnl6/bbGYk5MTwyNCr68vGYb2IHdKZcPLlz9aLOb19ZWBgd7q6kq9YWt2dophSIahbfazH1884/N5m5vrJyeHJtNOU5NKJq9DEPft7Y1CWf/LX/6iqUkZHBKYlZVhd9ju7tz9/QM3Ny6Kop4+/SEkJHRra1sikRoMBrPZ3NGhaVQpRkeHb93Xk5NjZ2fHCwtzo6PDFxfni4tzJpMhOTlhZFQLAODzeXw+T6sdlMnq9HqDwbCzu7s3PDx8cHBYUVF5eHik1+stlv3x8bG5+RkAQGmZIDomcn9/d3x89PT0aHhk0GTWUxQeHOI3pO2X10vz8/NOTo5nZmZPTk7X1lZ390yxsdE9vV31DbIff3y2uDRPECgAICw8JDIybGpqvKpKtL29sbQ8bzTq+YLirq52q3XPZDLOzU1XVVV0dbcvLS9cX18uLs5RFOG+czU2Niwuzv3i//0fs7PTfEFxc3NjWlqyTjcqEpX5+b0dGuofHOzjcouSkxOysjOGh4daW5sXF+egQmRpaf73v//fDsdZUJD/nsW8ubnmcJxZrXu7e+a6upqCwrzu7s7yitKUlKTzcwcAYEg7EBsblZycKJXWulw3a2vLLteVwbB1deXc3t46OTl2Op3Hx0d2u21ra9Ng0J+cHJtMJpvNPjMz53K5jEaT3W6HjD4nJzc9PR0A4PF4UlLSCgqK9HrDwsLi3NzC3p5lfn7p6OhodHTk+PhoeHjYZDKazaa1tbX6ernJZFxcXJiZnV5bW52dn+ns7hgaHji/cKxvrB6dHFgP9mfn552XlyRFUwxzhyC//vUnnd09Sckpozrd4eHhjtFo3t0d1ekc584tvX5v3+o4d47qdOLqGr1hZ3FpeWV1bWpm5vTs7ODwaFuvPzg8nJycOnc6a2pqLZZ9AMDZmW1pafnw8MjPz7+3t5dl2e+//35+fk4qlZaWlp6enm5tbTocju3tzf19U1Z2SlOzYn5hys/v9eraAklhKOr2fftS065u0zQRJFIlLk9MjHU4bIfHFgS93d3b2d5es+ybTCb96tpiZ1fb7NzkrftKr18/PrEeHOyurs67XBc0hdttx2uri7azw+mpMYNhgySxUZ02KMjPg9yazIbklIRmtaq1tWllZXFiUnd0fGizn0rqquvqauLiY5aXFwyGrdvbm9XV5a2tzb29XZvNxjD3sn94eHh3d3e9vG5iQntwYDk+OlA11u9bzPv7FofdzjIMQ/99usKPyDXwNygoyGKxHBwcfPLJb7lcbkJCQmhoqEBQIizlv3vnCwDQDg9GRoanpSV/8cVnCmX9n7/70+GR5eLSnpGZ8ubNi5ISDr+4KCTQX1ZbFRsT0dvXlZ2bUSUuj46JlMpqnj3/nsPNBwC0tjXl5mYlJSWMjAwGh/hnZKZGRoVptf3/+tm/mHcNR0dWYWmxn79vXn5mekZyXn5WZFRodEzE8x+fnp4d0zTl8dx+8cVnZ2fHVWLR06ffJyTGJScnffLJJ7OzswAAlUrl6+sbHBzc29urVCrfv3+XmprE4xUmJMbWSsS5uZmZmWlff/3FmzevGhSy0lJ+XHx0enrKzMwEyzI+r39cXVsCAGxsrD558iQ+Pl4oFD59+rSqqioiIkImk3366acCgeDP3307pO0HAJSUcAuLcqvEFTU1lW98X733893YXAUAREeHv3nj8+zZ9+npqWlpqV988YVcLv/2ybeSuuq8/Jzi4iJRZdnLl8/DI0JWVhcBAE1NimfPf5iaHvd969PX1/Xy5bPSMn5goF9ObqZCIY+ICC0tE4SGBpWUcDMz07q6OopLuJeX5wsLc0VF+QjiTkiM9fd/l5GZyuEW1NRWwWFNTU36/umff3j2tKlJ2axu/OKL3+/tmRcXZ0WVZXDYt7bX/+f//EVcfMz7975VVRUvXz7LL8iRy+syM1M7OlqTkuIzMlM7uzT/+tmnXF4hAMCws/X8xx++ffKn+YWZ6prKt29fC0tLsnMyOrvai4u5XG5RRkaaWFyZn5+bkBCXkZFWVydpaJCnpCS/evWqqqoqJiZma2sLAHB2dpacnPztt9+enJx0dHTExcWmp6eVl5fHxcXl5+eVlJQIBPyGBsVvfvNrsbgyLy9XoajPykpva2sJDg4sKeGlpaVERkeEhQdHxURIZZJiPqdeIauuqSzk5GdmZXz59Ve1dRJwrx7Gv/jqy/0D6+iY7suvv0pMTkpISgwODcnOzSnkFIlrqqNioisqRZFRkS9evtCN6bKysyKiIlPSUrnFvISkxKDgoKyc7Cd//rNEInnx4sX+/r7D4RAKhTKZrKKiwsfHB8qzL178GBwc9OrVy9JSQXl5aUhIUFtbS2Cgf3dPe5umKTIqdGZmPC09MTomzGjaAgCkZySFhQdDRlBYmCcQFlfXVJaVCxTKeqm0pkEhk9SJc/Oy8guypdIaDrego6NVXl9XIuAmJ8WEhL7r6GwCAIyO9iUnRzc1yQKDfGtry1VN9eqWxiJOngdxAcDW1lZl56SHhQe1tKqWlufS0hMrREKNprm8nJ+VnWo269PSk2pqKwMC/fh8flhYaG5uNgAA7oDj4qLPzo4WF2diY0Nra8srRcLoqNCN9eWKcmG9XMqy9E91/H8br3mcIK/BceK7756q1a1icU10dGxMTNw33zwJDQ1PT88IDAz66qs/IAgyOTEVFRXN5wsCA4P5fMF33327ZzGZdw0vXz3/7Pf/8srnxxI+x9fXp7S05A9//KKwKC88IiQ3L/Obb/+Yk5uRk5sZFh4CAODzixMTE8PCwgoKCn7720/CwsIiIyOqqqr+23/7v4eG+k1mfWRUaGRUaEhowIuXP3z75I/wjKf379/t7VkAADc3N//4j78wGHbKy0Xl5eUvXrx6+/ZdQ0PD8fGxy+USCAT7+/tffvllSkpKUVHRl19+GRUVJZPJAgMD8/PzS0pKOBzO69evBQJ+VlZmenr6N9988/z5c51OBwDIycnJz88/OjoqKysLCQlZWlrKz8+Pi4vjcDhpaWkcDic3N3d1ddXHx+fm5hoAUFRUVFhYmJmZodPp/vjHP2ZnZwEAWBb4+wX09vbLZfJXr3xycvJmZ+d4vJJf//o3UVFRSUmJ5eXlPB43KSmRzy/RaDQul6utrbWoqCguLi4qKrKmuvqrr74KCgrKzs4uLCxQq9XJySn+/gHFxSW1tXVv3rwtKCjU6cZwnJienikqKjw6OmxqUo2Pj3/yyW8aGuqjoqK8eCoNAAAgAElEQVRsNtvh4VFYWFhbW2tTU1NycvLJyUlcXFxERPj29nZxMQ/uX6ampn7/+9/v71tSU1NDQkLKyspWVlbKykp//PHHqqrK1JSUvLy8oaGh9PT0jIwMAMDy8vLbt2+DggJVKlVKSvLc3Nzo6Kifn5+f33ulUtnS0hIQEBAfHx8TE1NeXq5UKuPj49fW1gIDA6Hb/fPnz/v6+gAAra2tQqEwMDAwNjaWw+GUlpZGRUUplcqCggKxWJyTk5ORkSEWi5OTk1UqVXJycmtrK8yZkpJSV1c3ODhYVlb28uVLPz+/ubnZoqKi6OhojUbD5XJKS0szMjIqKyvPz89RFMUw7Fe/+tXMzExdXd3nn3+enp56dHSYkBA/Pq7LyEgrLRU8efJNTk7WwEBfZmb61NREXV1tQUFeY6PiN7/5VXh4qMlkrKkRp6Wlcjic8PDwi4uLo6OjyMhInU5XVFQUEBAA9+8+Pj6Dg4NSqTQoKIjP5+/t7Y2O6t68eVNQkC+TSbOyMmdmpouLeYWFBVNTkzTNxMbGTE5ObG1tRkVF5efnCwSChoaG9PT0wMBAPr/EbDbJ5dLIyPCEhLjBwf7k5ESBoKSvr6dBIcvPzyouya8Q8QEA/QOd/v6vhaVcUaWgUSWPjAzr6GgXCgVXV5cAgKamptTUlODgIIGAPzGuEwqKd3dNNdVVNdWVooqymenJkKCA1JSkjPSMnu6+wsKipaVFp9OBEx6axt6+89nYXGpurq+s5AtLOXn5mRmZybNzk3l5OcXFHIZh/rO8BmpVEQRra2tvbdVotSNnZ3aZrF6pVKlUzQpFo1Qql8sVFxdXh4fHIyNjo6Nj3d09c3MLLS3NF5fnl5fO6uqqpmZVd3enqLJcqWzo6GhraJB1drZ3dLY3NiqUyoaW1uaxsdGBgT4AGKvVKhQKe3t729s7ysvLe3t7W1tbW1tbhcLSlZVllmW6uztLSwVDQwN1dbVNzaqODs3urqmjo93hcFIU7XbflZVVnJ9fTE5Oj4zoRkZ0vb19ZWVll5eXt7e3zc3Nd3d3NpttZmamvr6+vr6+u7t7cHCws7PTbDYrFIrV1dXW1taenp7Ozs7Gxsbm5mapVGo2m1kWXF9fS6XSpqammZmZmpqanp6esbGxxsbGycnJ3t7e8fFxkUg0MTEhl8uhGqW7u3tubk6n09XV1U1NTWs0GhwnaJpRqZoNhp35+cXe3gGVqlkikba3dwoEwrq6OqVSOTw8XFNTo1Qqu7q61tbWCIIQi8WVlZUGg6Gtra22trakpKShoaG5uVkikXR0dLa1tXd397W3dzY3q/v6BurqZHx+KUGQNzc3AoFgcnKys7MLADAxMeF0OmUyWU1NzcTEhEgkmpmZmZmZkcvlPT09IpFoampqcHCoo6MjLy8PRdHNzc2cnByn0ymXy7VaLYfDWV5ebmhoKCsrUygU3d3dtbW1XV3dtTW1SqWSYZilpSWJpG59fV0ikSiVSplMptPpamtrtVptbW1tf3//2NhYdHRMVVWVQqE8Pj4uKChobm5WqVTl5eXz8/M1NTXr6+sAgL6+vpubm83NTYlE0tnZmZqaKpVKdTqdXC7XaDQtLS0KhWJgYEAmk3V3d4vF4v7+/ra2Nq1WW1paKpVKl5eXhUJhSUmJXF4/PDzc2tKq1Wo1Go1Wq52fn29padHpdEKhcG1tDcOwrKwspVLZ29t7cXEhFPJnZ6eDggLLyoRra6sqlbK0VFBVJVpaWmhtVff0dA0PD2m1g8vLi0plg1wu7evrmZ6ebGlR9/f3y+VyqI4ZGBhQKpXLy8symez29pZhGLlcDnVkfX19TU1NfX19Op1OKpWqVKr+/oGWllatVtvT09vX12cymXAcr6ys6ujoaG9vHxgYUCiUfX198/PzfL5gaWlJJKro7+/t7Gzv7u5sblbB8GBbWxs9PV2rq0vT01ODQ4PT01Msy46MDMvlspGRYa12aHx8bGRktK2trbu7x+VyMQxzfn6+v7+v1+vPz89drhtNW8vqytLszNTI8NCwdnB5eVEmlfT19rRr2g8PjxsalIuLC2azEUXdBIk0KOoGBrsXFqdOz/bVLQ3qFuXAYPfc/JRarerp6SIIjP4P7KEep/ujFP49BfNHM5AkTtPk31YvPC6P+iuaOIZhSPIjukaWvUe1vDqtD5SOMEE9/88xub8FpcNx/K88/eCUPxzHSZL8uZqZJKmfIwKPVfc/HyovyPLXyXuMBAEASJJkWbC7u3tycuIlAP6i6L3ulqIoqOP3bpOtVuvt7e3BwQHUED92UvFiheBBfU4Q96eOedGWx4gBhmEQUoDEwAvvL3zRW473F77i9Y+B2LaXWkiDt6s/sGtnGOYBdKM+eOUxvgMAsFgsbrcbPnrcLgCYxkaFV1P70LE0y9IURTzc8fbyTzx44DDBAr134JzxNgeiZo/trT7oWC+1f2m4GebfVgdzb6/0k5uABThGfMRW6VGHPJxL+fgZyzAUuDdf+nmlDE6gGIZQNAYABQAJAPvwSwNA0wxsJk1R+N91iAL4KK/x2p5ApkPT9Pn5BcRZGYaFxilu9x28g6IY7HcURQkCxzAURRGKIkmSIEni9tZF0xSGoSzLPBhZkBCtZBiGpu8NK0gSYnU0imIkST5YYZAMQ+M4Ds26GAaC7iSGodCOBhrOeDwIRIURBIX2IJAeHMehZdD19TU0FEJRFM4SLyILsb3r62uYE76C47hXGw9fhNAyhNsBgMAzgWG4F4KFCwz+oij6gM5CCxeSZe8BdYZh4ejAWsDDegP/BldTXhNKuJwgJRiGQZ09QVDQsuMBcKWhGcWDNSD9MBBew0UGGvh42+6d4vdnZjzibjiOP6aKpum7uzsISkJi4OuQJACAF9KG4QFgBti98BHMA5vzEBrpvpegpRB8BRaO47iXHsgZvZV6WT/8997K6GEEmYcE8VqCILx9+NgaHmaAtjkwJBws8h5FJnH4pSQIjKIIksQBYCgKHktCAcDSNEEQOCwc0gAHGhYIjxMgSQK2kmUZuAQwDCFJnCQJgsCh+R9B4PARRZEMQ8O6cBxjGArHMZomcRwybgJFPRRFQHpomgSAIUmcZWmSJEiSokiGphkEQVEEoykW2g0QOMkyDCwcABZaHVAUCesiCQzHPBSFkQTKMoTnzuW5c1EkRhIoSeIkSVIUAeF2HEdxAqUojGEJAEiCcNM0wrIEQXpwwkOSOEURNE15OeB/hNd4GY3Ldbu4uIzjBI7jDMOur2+dntrgwMlk9UNDwwsLiwCAnp7e/PxC8CBZeDweiqK8yPfMzEx8fDw0Vby9vQUPXzkvsg5zwlkFAKiqqtZqhymKQhAUWsd5Jxm8oGka2tSQJIlheH5+4cTE1NmZ7fj4RK/fOTo6Bg/fTAzD4Dzr6elJTEwMDw+vrKxMT0/31ggbK5FI4uPj1Wr14uIiy7K3t7fFxcVOp9Pj8cC1kZeXV1RUVFcn83YR5LZeQyEvyutdgSKRyGsK0N3dx+PxwQMkDI1HTk5Od3Z2dnd3j46OvN80p9MJGQp4+Gy6XK6IiIiNjY3a2tqxsTGYraiIw+WWtLS0AQC8dkmPh29ycrKgoGBwcPDxsDocjr29vUdN+MnnCLIPi8VSW1tbW1ur1+ubmpqg7lan03kphFTZ7fbo6GiFQtHc3Owd6KurK2+ZH7WQAADc3Nx4M+t0OpVKBe7NkfDr62s4WE6nMzs7G5awt7en0WjAI0mhsrJyampqbW2trKzssSwwODjY0tLi7YH9/f2CgoKP0gDZ+uDgoFrd/NMnHxd1H2Sc+4QgnuzsbJvN9vOcOI55PG6aJlHUA+5Fb/ZjwtFjI937C4oioTz1YCQNRkeHZ2amAACHh1a7/Qy+S5L4g1Bz3/ahoT7tcP/x8T5JIg9lQpGWpmny7u6WoojHTevuat/bNXj/vb5ymE3bAACWwR/a6+UdDIYhADA7xu06qRjDXAODXUfHFgAAADTDUAxDsSwFdxh/e/oJr4GGajTNHB0dFxRwmprUb9++l8sVIpF4c3OLZUFPT98XX3xVUyOpqZHMzy8GBga/fOmjVKqys3P7+vp5vOLh4ZHs7Oyent6KClFsbNy//utn4+MTWu1wdnZOb29fRkZmQECgzWZzuVwREZGBgUHdXT3Z2XlNKvXWlv4Pf/hGICjjcorr65Usy87Nzb965SMSVU5PTyclJUskdWlp6Txe8erqWlRUjFKpyszMLi0tHx0de/XqdUmJYGRkVK1u5XKLFQplUFBQZWUlwzA2m21gYOD9+/dOp/OLL76Ijo6enJzMycmB05HD4fzqV78SiURtbW0CgUAgEGRnZ7e0tHA4nOPjYwDAixcvIiMjUlMzDAZjVlZudbWkqamlo71rZESXmJDS3d2blZU9PDzM4XDEYrFcLtfpdJGRkeHh4VDB3NSkjoqK4fOFRUXc6elZpVLV0tL28uVrmUyuVjf7+/t3dHS0tLS0trZyudyhoaGSkpKioiL42aRpWiwW//a3vy0qKjo9PRUIBI2NjTk5uRkZWXJ5/dzcvEhU2dHRNTQ0PDY2MTY2bjKZGIYJDAyMi4s7ODhQKBSpqanr6+tCoTAlJWV4eFgmkxUVFVmt1uHh4dLS0r6+vsbGRofDAfl4fHx8V1fX9vZ2QkJCampqVFTUxsaGWq0+OTmpqamZn783Mrq8vPzkk082NzfT0tKqq6sHBgampqZCQ0MnJyfr6+uXlpYYhlleXhaLxVKptL29fX9/v7m5uampKSMjo62tTSQS1dXVdXR0ZGRkTExM2O32w8PDd+/e7e7uajQanU4HB0ij0YyPj3/++efNzc3w+7S4uPjpp59WV1f39fU9ffqUy+WOjo4uLi5qtVqxWFxUVDQ4OKjRaAQCQX19vY+PD+RK1dXVs7OzLS0tXh5hMpl8fX2zsjLm5mZbWpqHh4fy83NNpp3h4SGxuLKvr0etbpqfnx0c7Ofzi4+PD1mWXVtbKSsTnp2d0DTt4+MzOzvb1dU1NjbW29s7NDS0srLS3t4ukdSKRGUAAAxHBgf7TCbD/MKMVFY7PTNhNu+MjAzNL8y2tDQdHFgUCvnw8GBXV/vQUP/i0vzQUD/L0ldXzmZ1o1Y7MDU1vr6+WllZ4e//fmJirKOj3Ww2zc5OK5UNBIGdnh4PDvavri2VV/DaOxStGnl7R8PC4tiIrksqr5ieHTIYVyR1VZeX53sWU0Fh7ubmWl9/945RP6ob7h/oyc3NzMpIsVp3pXU13V2a1ZV5rbbPYjE2KuVjY9qZ2YmFxdmjY2tDg3xychxKaqurK7FxkQyD9fa19/V3tmmaJqd0kFXgOPqBqep/gNeQAIDLy6uEhOSYmLjU1LSQkDB//8DZ2Xmn87KoiMvjlcjl9WFhEXFxCa2tmuTkVLW69fPPv8zLK/DzC+jt7cvIyHr16nV8fGJvb99/+S//R2urZm1tPSoqJjAwmMcr+f77Z11d3ZeXV+/f+0skdeFhUdXiuu+/e15RXiWuklSLJdlZ+b6v/XCMHB+fjIyMjo6O+e///f+prq7h84URkdEBAYF/+MOfEhKS2ts7CguLkpNTBQJhXFx8cbFAKCxrbdX4+we+e/cuNTXV398fIpGLi4uRkZEAgMjISJlM9k//9E/BwcECgQAAIBQKnz171t/f/9133wUHB1dXV/P5fIlE4ufnZzQaAQCvX7/+x3/8RUd7V15u4R++/oZfUhrgH1JRXhURHpORnt2u6crNzc/Ozg4KChKLxTwe7/z8PD09ncPh8Pl8AIBG05GWlpGWllFcXBIaGv7mzdv29s6MjEy4/hMSEuRyeW5uro+PD4/HS0xMfPr0aUpKCoIgcBQYhvnss88WFxf7+/s//fR/y+Xy8nIRny8UiapiY+Pb2zuiomKCg0Nfv/aNjo41GAwMw+j1+q+//hoyr/j4+PT09CdPnhQUFBQXF79+/TotLa2mpiYrKysvL6+goCAwMBDKmyRJ+vv7m81mgiD8/f1LSkpSUlLEYnF0dHRZWVldXV14eDgUPW5vb7/44guXy9Xe3h4SEiIQCOLi4l68eLGyshIWFhYdHQ0AaG5uTkhI8Pf3F4lEX3755cuXL9PT0yEwlJSUBNW6v/rVr4qLi1EUXV5e/vHHH6uqqnx9fZVKpUAgGB8f9/Hxyc/PT0pKCggIODs7W1xchBBYcXExh8PJzMwUi8X/8i//wuFwEhISRCJRZWVlb2/vixcv/P39R0ZGPvvss4qKCpPJFBERER4enpOT8+233w4NDd3c3BQUFJSUlLx54xMfH8vnF+fkZL175yuVSvz934eHh7a1tchkdYGB/kVFBa9fv1Io6gEAExNjz58/a2xUAgCSk5PhcKvV6vLy8sjIyNzcvLy8vOrqqsqqsrn56fmFqcys1BI+p7SsRKmUxcZFiipLE5NiVU0NUdFhosrS2LjIwqLcuPioKnFFbl4Gh5vPMHizWqkd7l9bX4pPiBZXV+TmZZWVC2pqqkJDg8vLy+Ry6fb2Jk1T29ubSUkJGk1LZHRQS5u0oChlcKitqrqYL8zNzU+KivHLL0zNy890Xjj0hvXsnHQON48v4DarlROTo8fHh7U1lUIBp6SkMDsrtVIkaG1tLCrMGRsbalErsrJSOdw8Li8/KNgvMTFucnIcMgS9Xp+fnw0AMbcwISzjcXn5XF7B5ua6Xr/19yhn/wKvgWbjdrsjKSk1NjaByy0OC4t4985fpxtHEDQhIfnp02dSqTw1NT05OTU0NMLfPzA1Nf2TT36Xl1cYGBgcEBD87p3/d9/9EB4eNTU181//z/8rISE5Jyfv+fOXz5+/KC2tCA4O7esbQBDkm2+eSKVyHlcQGhL19Psfk5My3r0NTEnOePbDy7e+Abeuu5np+ffv/ZUKVXBwaGWluK5OlpqSnpycGh4WWVjInZiYiomJCw+PLCuryMrKSUpK4XKLQ0PDnz9/8fLly6qqqvDw8NPTUwBAd3d3cHDw9fV1dHS0SqX685//nJaWtrS0BAAoKioKDQ0FAEil0pycnLm5ucLCwra2tjdv3gwMDEBeU1/fIOCXZ2cVBAeFj46OFxbwXr18m5Ge06hsrhTVvHr1OjExMTQ0dGVlxd/ff3p6Ojs7WyAQCIVCAEBDgzI8PCI/v6iuTpaWlhEREVVUxE1Pz8zIyORyuUlJSUqlMjQ0NCAgoKysLCUlJSoqqqenZ3Jy8vLykmVZj8fz3XffbWxsLCwsvH3rOz4+npGRFRUVW1ZWERsbX1jImZyc5nKL3771y88vRFH09vZWrVYXFBSUlpZyOBwOh1NXV5ecnDw2NlZQUBAWFlZdXa1QKKDQt7a29uLFC4jaAABqa2uLiorq6+sFAkFtbW1eXl5ZWVl6erpIJOLxeBUVFbu7uxcXFxiG/frXv25qauJwOLCjgoODX79+rVarP/3003fv3rEsq9Fo+Hx+WlpaU1PTN998IxAIxsbGiouLQ0JCVCrV4OAgj8f75ptvYmJiLi4urFarr6+vSCTi8/mzs7MJCQm1tbVv3759+fJlTk5OdHT0zs7Ozs5OQkJCSEgIj8dLT0/Pysqqr68XCku5XO7bt28FAkFBQQGXyw0LCwsODm5oaPjyyy/j4+MlEom/v7+fn59QKIyMjGxra3O770pKSmJj4wID/Xk8zvz8nFwu43I5CkV9Tk5WWZkQHsvz/fd/Tk5OzMnJqqgoAwDk5+c+efJNeXkpACAqKkogEGRmZmq12qioqLCwsMrKqtzcXKm0tqy8ZHV1Wa/f4Au4oWGB+QVZospSUWVpcUnhe783xSWFkVGhCYkxxcWFvX0deflZCwuz4ury/MJsABhNuzojM8Vo2i6vECSnxAuEPL6ANzDQl5ubLRKVx8fH9vR0MQx9eGgtKipQKOtj46JXVufy8jOUjdIqcWlefkadtCorO6WyqrS+oe7uznV6elghEiqUMnVr48rqPIebNz4xXCeprKwsyc5OEolKZLKq6urSgoJ0TXtjWlpsfUNtnVScmpYgrqngC7jb25sGvZ5hgNN5kZgY16ZRTs+Mtrap5PW1VeKy3V3j0dEB3En9p3gN1BW6XLebm1t7e/tW64HRaNreNjidFwAAq/Vgamr6/Nx5eHhss9mnpqat1gOLZX9paXl9fXPfcnB5cb21qV9dXd/c3L5wXm1u6A+sRybT3va2YWN9y7p/YNCb3W7P8fHJb37zu+WlNZKkt7cMZtP+8ZFtfm7x3HGxsa43m/YokurrHfR94+e5Q+7ukOmpucODk4ODowPrse3sfGlpxem82N+37uwYT0/Pjo9PVlfX7XaH0WheXl5ZW1s7OTkxmUx3d3cMwzgcDr1ej+P4zs7O0dGR0+mcmpo6PDxkGGZ/f99oNEId8OTk5OHhodVqtVgsOzs7UIu0vr5+fX1zfGRz2C+np+bMJovJuHt0eGI7O99Y15+dOjbWNwwGw+bmJkEQq6urZrP5+Pj45OTk6OiIYZjj49Pd3T2LZf/4+FSv3zEazVdX12bz7uLiktVq3d3dPTs70+v1Fovl5OTk/Px8dnbWYDBYrVa3282yrNvtnp+fdzgcLMvOzMxYLPt7e/traxtHRyenp7aZmTmPB/F4EARB7+7uoBYMGp7f3Nw8ffq0tbX17u5ubW3NbrcbjcaVlZXT09P+/v7nz5/HxcWNj4/v7u7Ozs5KpVIAAEmSKysrk5OTOI4fHBwYDAaj0bi9ve1yuTY2Nq6urux2+/X1NUmS8Azi4+Njj8czOjq6sbGxsbGxvb09OTm5uLhIkiR8fWdn5+Dg4OjoaHx8fG9vz2q1Tk9P7+/v22w2s9lssViMRqPdbgcAwPGamZk5PDw0GAzQsn5ubm57e1uv19/e3rIsu7W1NTs7a7VaDw8PLRbL+vo6giC7u7sLCwtms9lsNq+trcFKjcadra3N/f39lZWVra2t7e1to9EIGSUAwGazTU5O2u1nRqPBbDY6HLbDw4O1tZWAAL+UlKShoYHt7a2NjbWdHf3urml318Qw1P7+3vz8rNVqwTDUaDReXV2trKwcHR2ZTCZY4+Hh4dX1xY5pCwDAMMTW9tqt+/LwcD8uPlJeX2s9sCyvzBlN24adjd09g/XAjON3C4vTdsfxvtV0enZIkKjbfbW0PHd9fW53nKyuLl5eObb1Gw6H7ezs5PzcDimhadLlunY4bLOzM+/evb2+vrLZbA6H3Wrd39nZsdttDrv95OR4Z2cTJzwEiZyeHl5dn5t3DRjmXlld2LMY7Y6js9P9wwOTzWY9Oto9Pt51OI6cTltObmpTk/zm5nLHuOm6vVxdWzw/tzmd59CA+PT0aHZu7Nx5enFpPzre37fugvsIB3/fYd7goz4KXoDzg/RYD/oBh4K3P1rB46B/4AEs93g8UJULfqrdfFyX03nxgXvRfyD9HFCExH+AjP68vd47f93H5y8lL7TsrfEDjPavFOtVn0PiH3uf/ryWx5DT40aZzeafQrz3CfKUk5OTBzT0PnkzP4ZvwE97BjLlv97wj4K4f2lSPrYVeNyonxZIflRWZxj67/quIsjd3Z37p+ZnXjrZw0OrybTzQUUQ2fVqeR8CQXhnu7coBlJCUThBYAAAhiEBYI+PD+32058RwtL0X7SoeLAM+OjA3Rd+fX0BPdQ+mliWwXAU5oQUPtKq0ACQAHxgaMJeXdvPnY/pZFiWoGiMomB8iX9LXrwSw3DoFfw3+nnD9HF/qMdFoyi6tLTk3djDp3a7HX6UvNlomj44OICeex+sZG/bHoMaAIDJycnd3V2bzbawsADLhwR481xeXq6vr93e3s7NzUHjC4LAvcyCZVmbzWaxWOBpQQ6Hg6Zpu90+MTGxu7trNBq3trZIkrRarVtbW2azmWGYzc1Nt9sNF/Pu7u7U1NTS0hI0+gQAnJycXF1deQs3m81HR0cURVmt1oWFhfn5ebiAoZUU1FnCnBsbGxYL1NIDi8ViMpkeDw9UvkJc1mtCAu/DL/bExITJZDIajfAb7uUC3l/ImCB6Dfvn9PQUTjgURUmSPD4+Zhjm+vr65OSEIAiDwaDX6+12+9HREYqidrsdRdHDw8Otra0PeJyXT0HA+LERDY7jer0ewoiPjTXAT01FvPD5Iw9+EnIls9nstceBrYAAH8MwZ2dnEOS+vLy8urqCkNz19bXXu9JrnMKyLMvSGIZQFAlDi7Es7XDYHgAaAABzenrsdt/QNAVB66urC7fbRZL48fGh0+mAqDZFEQhyB3kEy9IQ1nE6HRbLLkXhTue/fdXs9jMcRx9gI5ZhKJomLZZdgsAYhkKQu50dPcwPgR64sCEoQxA4jL8LkWyHw05RBIwi5vG4wb2/MU0QmNVqgTGVjo+Pr66ubm5cDocDmkrBrsZx9PLSCaH383M7rI5lGRzHvM3Hccwb64eiCIfD5g0PhGHI+bkdmmoAwLAsQzMESaI0g9vsxwSB3Lqvjo733e6ro+N9u/3EeXFmNG5ZD3ZJEmEY8s5zA8OYAcDabDaX6xbc73sY8iF9YGj276aP+EMxDON0OjUazdnZmcfjubq6io6OnpiYOD8/hxN6c3NTq9Xu7+9brVaTyUTTNIwWDvcme3t7Lpfr5OQEsh6TyXR5eXl6egoD4sD9BawxMDBQLpfbbLaQkBBo43t6emqz2bRaLYSNW1pawsLCLi8vX758ub+/b7FYrq6uTk9PrVYr3K0YDIbBwcGAgIDs7Ozp6WkAgEajgQqU4ODgiIgIm82WnZ1dWloaEhKComhWVhbkJgCA0tLS169fl5WVJSYm2u12k8mk1WqPj4+Pjo5OT08JgvDz82toaAAAjIyMvHv37v3790NDQwRBBAUFra2tgUc2XSEhIWq1Gm405ubmQkJCbm9vb29vLRbLzc0NZAE3NzcWi4UgCIvFYrVa4UJSqVRxcXEikSgtLc3Hx2d3dxcuRS/Th966drt9eHjY5XKxLHt+fn5zc0KCL6QAABZ8SURBVANfvL6+hoYz0HL/9PRUJpPJZDIOh8PlcgUCQUJCAo7j6enpKpUqODhYKpVarVbIoex2OwzzZ7fbHQ7H0dGR2+32eDy3t7cIguzv7+t0utevX0MnSWgvY7PZbm5uXC6Xy+XCMMxisdhsNmhpAi2GKIqy2WyQh/J4vIKCgouLi5ubGziyLpcLZr68vCwsLOzt7fV4PCsrKz09PSkpKSzLpqSklJaWXl5eOhwO2LTr6+vT01No8QEAGB0djomJcrlu1tdXNzbWLi4u9Pqt9fXVnJys7u5O7we8vl6mVDZsbW0UFRVIJDUkicN1S5L4xcX54eEBZFgAgJ6erujoSAS5y8rKODy0HhxYEcSzvr46NTWh12/hOHZ+boMSyrt3vnb7GcsyCQlxPB5nZmZqcXEBxkL0eNw63cjlpfPy0nl7ewOjFwIADg+tISFBFxfn5eWlMzNTe3vmhYW5/f29q6uru7vbpKSEzc11AEBmVnpHe1tfX3dZmZBlGcf5mdt9Y7OdWq2W4mKuwaAfHOzPyEg7PT2GDayurhIIeaM67eSU7uTk4Pzc5nZfT07ptvXr2/p1BLm1O062t9cMhs3FxVmSwo6O912uy3OnzeNxAZYmSKSgMGdpaba1ram7p71RVT841JuSmtA/0FUlLo9PiKYZgqLxvv6u1dVFP3/fw6P9zk7N+voqjIfpdrtwHHG5rikKp2jyP8Vr4NdpdXXV19dXIBBAk/mIiIg3b95AaEYikTx//jw/P18ul/v5+UHTFYgFwJtpaWlFRUUJCQk//PBDdXX1119/nZubKxaLY2NjJycnKyoqoqKiYFEVFRX5+fnj4+N5eXkBAQESiUQsFqelpQUGBvb09AAAhoaGvv76a7FY/O23305PTwcEBDQ2NpaUlAQGBmZmZsLQ6zMzM9nZ2bW1tdDfcnh4+NWrV76+vlAhyuPxNBrN7e1tWFhYTU1NW1sbeDDZhMgRACAqKuqHH37gcDgRERGbm5s8Hi8pKWliYsLHx0etVj9M33qFQgEAmJmZ+dOf/lRYWAjvQ16Tnp6uVqsVCkVJSQlEtSDA/Pr166qqqry8vNbW1ubmZmiD7+/v/+rVK7PZzLLsN998A1nk4eFhVFTUz/eM7e3tgYGBMTEx7969g989iUSSmJgIUWSTyQTtVhoaGj7//PPy8nKJRBIUFASFRLPZ/P3338vl8h9++GFzc/P169dyuRwKWTqdLiQkpKqqyt/fPzc3Vy6XV1RU1NfX83i86urq8fHx5ORkmUz27NkzHo9nMBhYlu3q6qqtra2vrxeJRC0tLWVlZdnZ2dnZ2e3t7S0tLUlJSRkZGVlZWWVlZdC46bvvvpPL5Z2dnWVlZSKRKCIiYn9/H8fxxsbG4eHh1NTU2NjY9vb2ysrKycnJzMzMqampkJCQtLS04uLi3NzcqKgooVCYnp4eHh7+YN0LZmam/vSnP/B4nIYGOYdTGB8fGxsbnZiYUFoqePHiuUJRf35+7vF4tNpBkaji5OTof/2v/6+0VAAAuL11hYYGz8xMVVdX+fm9M5l2oKw9MqJNSUkCANTWVsvl0levXqhUSqWyISUlSSQqLy8vi4mJqq+XdXRo3rx5fX5uB4DNyckKDPRfXJwPCHi/traSlZXR2KgIDw+VyepCQ4NraqqLigogjsOyTHZ2pkxW19qqnpqaqKysCAz0n5qa4PE4PT1d6empi4vzAID8/KyAgLcJibHVNaI2TVNScpy6RZmXn9XW1qJSKYuKCoqKCjMz02Jjo41GAwBgbHzE9+2rubnpnNy00dF+gZDToJBkZCZ1dKrrpFV10qrhkT4ON7eru6WhoXZufqK9o7mjs7mgMOvk9BCKdbUS8dTUeEFhbkVFKZ/PQ1A3n89Dsbvl5UWlsh4AsK3fqK+X3t5e8wW8Ej5nSNvb1a3p6m7r6W1vUEjVLcrFpRmGwRn2P8droNBrNpuTk5OFQmFSUlJMTMznn3/+i1/8AsI6PB6Pz+e3t7dDREAikXz11Vetra3b29sxMTGpqanx8fFPnjzhcrm+vr6xsbFpaWnJycl7e3ufffbZ6OioSCR68uRJd3c3XOTJycnV1dVpaWmlpaUQnnzy5AkEdAAAnZ2dYWFhq6urv/vd7zQazffff5+bmyuRSFJTU9va2mJiYnx8fLq7u+GRDyMjIwCApqamt2/fQkVgY2PjP/zDP8CFV1FR8ctf/tL7mQUAQBQWuhr7+PhsbW0lJSW1t7dHRkYODQ0VFxfHxcU1NjbCnuFyuRKJBEVRiHp++umnBoMBbr5ubm58fX3hiqqqqoIrUCwWx8TEwOUnEAgiIyPz8vIkEklCQkJaWlpcXNzMzAwA4P379w0NDS6XS6/X//jjjyaTaW1t7fz83Ol0QigqPDxcLpd3d3dnZGRAwZDL5X711VcQ+kVRFO6qNBrN1tbWl19+GR4eHhwcbDQaPR7PwsLCy5cvjUZjaGjo9PT05ubmt99+u7CwAPlsVFTU4uLi+/fvFQpFW1tbZmZmY2NjeHj4P//zPyuVyrq6OqlUGhoayufzIcONiYkxGo1qtTo0NLS6ujoiImJ9fX18fNzX17eysjIgIGB9fb24uPjHH3+EkmN4eHhVVZVMJqurq4MiFcuye3t7UVFRFxcXmZmZbW1t5eXlSUlJY2NjMTExcrm8ubk5MjJSLpdnZ2fLZLKZmZnc3Fwej1dbW+3lNVVVovLy0sLC/NjY6OJi7sTEWGJivExWJxQKYmKiFYr6ra2NqakJoVBgNBpEovKoqAiP5w4AIBZXhoeHKpUNHE4hACyCeAAAq6vLiYnxLperrq62vl6WmprM43GKi7nJyYkKRf3792/X19eKi7la7WBCQtzZ2YnH4zabTfn5udHRkSkpSevrqyEhQdnZmTk5WSkpSf39vUajMTc3Wy6XQkXl6uryL3/5C4tlV6sdzMrKSEpKWF9fTUpK5HI5xcXctfUVAACXl19TK1IopTm5GXxB0e6eobevIzEpNiEhTqVSisWi4mLu0NBAZmaGTjfCMMz5uWNI2xMdE1Jckj87N5aSGsvhZheX5C+vzJTw8zu7muMSwiur+COjfZnZKVViwebW4sHBzns/n+7udrjKxeLK9fXVy8uL+PjY4eGhpaWF5mYVAECjad3a2gAATE1NqNVN19eX4+O69g71kz//obqmYni4v1YiGhzsiY2LODjYBQCa8/2dvMabvEb3FxcXDQ0NWq22vLwcOgfyeLzu7m5omapWq+fm5hobGzs6Ojo7OzUaTV5eHvSLg9BpQUGBSqVqaGiQSqUSiaS+vh6inqenp1KptLy8HELO0C0Nmpl1d3cLhcKysjKpVNrQ0ACFlJWVlaamJpfLVVVVpVarhUJhXV1df38/dFerq6urrKzU6XQSiUSlUkGPuMnJSSi8sCx7cXEBAV0AwNnZWVdXFwBgeXnZaDQyDKPT6fh8PrSRbWtrm5ub6+npaWxs5PP54+PjnZ2doaGhS0tLcFMKKbTZbA9Gek01NTU1NTUAgKWlpezsbKfT2d7ePjg4ODs7q1QqOzs7BQJBe3u7QqEYHBxsbW3t7e0tKSnZ2tqqrq4uLy+HOh2j0Zifn19dXd3f35+fn19TUyMUCqemphQKBRSjpqen4+LipqenGxoaoNqlpKQkISFBoVDU1NQsLi5eXV3RNK1SqZxOp8VimZ6enp+fLysrq6+vHxkZ4fF419fXdXV1CoVCqVQ2NTXZ7XaWZQUCga+vb1tbW0FBgcFgaGhoUKlUZ2dnCwsLSqVyZWVlfn6+qqqqpKRErVZDvi8Wi9PT0/V6fVRUVElJCZfLnZ6edjqdarX67OwsNjZWo9E0NzcnJiZC6ay0tHRsbEwikSgUio6OjqamJgAAQRAFBQUymUwikXR3d8vl8srKyoGBAYlE0t7enpSUVFRU1NHRMTU1FRER0dvbK5PJWltbBIKSrq4OlmVOT4+FQv7Y2Ghvb3d6eqpS2WC1WgoK8qRSSWOjksO5FzbHxkYVivq9PTN0XMRxjKZpnW5EKpWMjGhVKuX5uc1k2gEAXF9fCoX8ysqKubmZlZWlmhpxU1Nja6taKpUMDvZXV1cJBCWjo8O5udnp6alQDVRaKmhpaZ6cHK+pEUulkoKCvIYGuUqllMulHE7h9PRkZ2f71NQEw9AMQ9/d3TY3qyiKWFlZam9va2lp1mhaBYKSurpaiaTGYtkFgFW3KEd1g0vLs81qhaq5oaVN1dRcn5KaUFCQ19fXMzjYX1YmHB/X1dfLlpYWWJbt6mof1Q1oh3taWpUjo/284rymZrlMLh7VDbS0Kubmx6trytUtis6ulmZ1w5C2h8vL040NaNqbxsdHAQA0TbW2tpjNxuvrK612CMexmZnp3V0zAGBgoN/hsLEse3l50dPTZTDoOzs7SBIbGOw27Gy0tqmGtL0exNXX3+nx3ABAsuA/bcsH1YQ/zwrVhMxfiGb81zmcTCaDFivezB/ojz94nX2IRvqXCvwoKOOFfqDTjVfx6VVq0jQNZQHq34JvfqSKxy5C0MUG3n/sOgh1T9DAFzxy9fw5YV5nPIgZeanyKlO9Xhpe14qzszOvTsdLIVTNPO4c6JIDqfWWxjAMgiBepxBILcuy0LkJXotEoqysrMnJSfgU9skHPUkQBGy+17kJKv5hZgRBvDp1+MjtdrtcLqje9tIGXcwoioL+K7BkiOjTD3E8oXMGQRAXFxfwRQDA1dUVjDkLAHt15TQYtlmWYVna5bpmGArHUfhH06Tb7fJ43CjqQZA7iiJwHIPnatA06XQ6EOSOZdmTk6O8vByHwwb1shiGeDxukiQYhkJRz+Wl87FX1IOVGkNRxM3NFYwN7vG4oTPW7e3NxcU5AADGD4cOUySJwWw0TXpzUhQB8SnoguD1t8IwBDo6kSROkijNEDRN4LiHonCKxl2uK5LCcAKBbkckiWMY+pg2DEcurxwMS1AUShAISaEAUAxLYPgdwxIY7qYolGEImsZYQDAsjuFumsHuPDcA3EcTh2OKIAicTl6nNgzD4bRkGMZkMsHIjfCMAIYlPZ5bDPfQNMGyFEVhFI2Dv+0IOm/6ybmXAADvIQref+H0ghk+AJK8a+bxeoYT6LGXo7cyOGu96C9UIn4AQnv9pLxM7aNcjCAIBEG8bngPzpz3pz5A3AT6H7P3h5TfO/vBBtIPoVVh8G2oV/dOfS/98Pga6Mnt9cZ8rIf3xtOF+lGYGXaX1+8RMj6vMzS8A8mANcImQJYBu4V5iK3rdSaEhEFK2IfjLmB6XOxHC2QfhUCD/A5FUW+sT1imt2mw0sc+jfBfh8MBg7Z5h8zrAAnHy+s2CTvZ4/F4ewlS7k1e/gjLhxdeqAu2lHnwwyQIgmEo6JoE1zaGIXDtPUTkxR4cl1jo6AhRJxxHMQzBcRRGCL+5uYJAEnzqfR3HUZLEEeSOIKDrI0rTJMvS8CwglmWg2zfDUCSJQ29JmBOyEi9vgiQhyJ2XL8C6IN+B/xIEhuMo5JXQFo4g4IDedzKchjA2Lk2TsKVej1BIHrymKAKergSBMIoiGIYkSIxlGYLECAIjCIyiCXj+BMNQ8JvrHVyapmEUbS9/gQMHlyScLQ+M6d5flKZp6MlJ0zScwn/XBuqe1zwWVeiHpNVqoctfV1fXysqK1WrNysoaHR31gsQTExMSiQS+XllZOTo6WllZ6fF4Ojo6oDLioyIDy7JnZ2dqtRpBEIZhTk5OoAXt/9/etb2k04Thf6X/orsu+w+iiIgg66Kyq4K8iAgxKko7EQSdiCLIi5QiOxh0Y0UnrCw6C5YpSWGpta6681087fuNu/Zpv49fB9mHiHXnPDvzzDsz77wTCoUODw8xdRIEwWq13t3dud3uqakpLBO0tLRsbm46HA673R6NRlOpVDQaJWYBfdAZYvRPvEH1UZ/EcE1cQzQPp0gkgnPS+Cp0PJriBJVQENqj4f/T56SA+KmgPKJ1pMXTEHySEwmbivcQYUTZ+Dy6NLEbCSZ8DJQQ5YHECoqH51YK8vz8HAqFEJaKhmfiNbA/MQgiB7+gJmkAAJtQ/VA3EEWRfFJhRfG9b6PT4gEMgvtPSExIJsVEIk08QRCSKWSb4e9R0VlqYgF4xkFuCEoyz8dgaRwSEzwgIJKGn1gsAorBxSlIF3HG42+CEBPFd8+iKCQSIqzBi2IimUy+vgryCAKz+SigKEtAAs6d4yASiZzUZlCNNJRSY6OWIwgCKp96BBEcRiCKLSlfppJIiK+vb7g3BRd1YIyA0YJPEQ1TrA0THTDGRkZG+vr6nE5nYWGhx+NZX18vKCjY2NgYGxubnZ29uroaGBgoLy9HkOrq6rW1tcbGRpvN1tHRcXFxgfdY9nM6ndg3cbvdjDGv11tVVQUTU+Fw2OVyVVZW+ny+9vb2oaEhBKyoqFhaWjKZTEaj0Wg0np6ednZ2QkvdZDKBkmhspPwrnplKk1AhK/GaLArQAM4vnPOTmnQFRYmipZj5pPn3fCWrk2DpYiafN3LlI5c4KIrAv1Snm7F+FBlQVyagFjk/ynPGQjFZY1DiLNEo6kqRB3UB5eE3Jf8pCot7piSKjzFGd07Re3UR5BwhBkSbIh2WdNWnNC1HxCm78l8krSx81cEOkaLR8pKj7O09G3xtqOtK3ZhhPV7iZiQZq5SC0EdRf3f6THIQ9gdQ2+V7n/lbrdaZmZmmpqbW1taOjo6Xl5f5+fmenp65ubmmpqZoNDoxMaHX65eXlxcXF5ubm71e797eXlFREXRSkDOz2VxbW2s2m2tqatra2rDHHAwGDQaD3+/v6uryeDzX19eTk5NLS0vFxcUGgwHZaGhoODs7s9vtpaWlw8PDkiSNj4+73W6j0VhSUoItc1E2gPIn5dagQcPXIgPXYCFwcHDQYrGsrq7CyC62n2BOdXp6+ubmpru7u7q6GspgOp1ue3s7Ho/rdLrr6+tIJLK/v88YGxsbq6+vdzgcdXV1Q0NDsDJ7dXUFo60HBwehUGhkZGR7e/vo6Eiv15tMpt3d3WAwqNfrd3Z2wuFwb2/v7e3t8fHx6OgoY8xms1kslpOTE5/PRwL8l1eaBg0aPg0l19Bq7uXl5dnZmSRJKysrNzc3e3t7Tqfz7e1tbm7u/v7e7/efnp7ifhlJkra2tgKBQDKZDIfDjLGnpyfo7Pf395eVlSUSibKystHRUUwLHx8fDw4OsOiTTCYvLi6g8MIYi8fjCwsL5+fnx8fHUMP3er2SJD08PIRCoVgs5nK5YrGY1+v1+3HDVOqjfTENGjT8KGSwAaqeGxNI6uF3kWkWw0+8QQEejwcW4ba2tqDhqphq8vHQA++Hd1Lk6pcSzW/Ms4as4Je9NGSEkmsU+HetjOvYRBO8Kx8Ki9jqDfKsyLjolRFMRT0/HJRnUvzRkE9AdwiHw7zakQYen+Ma3imVDnUofhM3IVsazppcjviBw0gupcPd8hrX5CWwPqC4pFgDITvXKKSJXJyYTDekrZPjxCFHouGXhL+336qFvo+AnGtck69QK0loUCAL13wxcuSahHz3CPturiEhKyvXqHVSNHwWP3ypS+Oa/8bP4pocIX3tHEqtYUUQBAGms8RMJuZ4UPC/1BbzuInTAJOSDzT8vcLyMdNz7inm8Vf4//iVXPMtkDilT0IkEgkEAliZ+q52lt/DKepcEITLy0u6t+trCsvP0/O1er8S/wC6YWjFlMehGwAAAABJRU5ErkJggg==" width="640" /> </div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify;">
<br /></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify;">
<span style="mso-fareast-language: IN; mso-no-proof: yes;"><br /></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify;">
Anatomi ubun-ubun pada bayi</div>
<div class="MsoListParagraphCxSpMiddle" style="mso-list: l1 level1 lfo2; text-align: justify; text-indent: -18.0pt;">
<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">2.<span style="font: 7.0pt "Times New Roman";"> </span></span></span><img alt="" height="263" src="data:image/png;base64,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" width="400" /></div>
<br />
<br />
<div class="MsoListParagraphCxSpMiddle" style="mso-list: l1 level1 lfo2; text-align: justify; text-indent: -18.0pt;">
<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">3.<span style="font: 7.0pt "Times New Roman";"> </span></span></span><span class="MsoHyperlink">Ukuran fontanel normal</span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify;">
Fontanel
anterior berbentuk berlian dan berukuran 4-5cm (sekitar 2inci) pada titik
terlebarnya (dari tulang ke tulang).</div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify;">
Fontanel
posterior berbentuk segitiga, biasanya berukuran 0,5-1 cm (kurang dari œ inci)
pada bagian terliasnya.</div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify;">
Fontanel normal
teraba datar, keras dan berbatas tegas terhadap sisi-sisi tulang tengkorak.
Sering terlihat pulsasi pada fontanel anterior. Batuk, menangis, atau berbaring
dapat menyebabkan fontanel mengembung sementara. Fontael tegang dan gembung
juga melebar menandakan adanya peningkatan intra kranial. Fontanel yang sangat
cekung dan tenggelam menandakan dehidrasi.</div>
<div class="MsoListParagraphCxSpLast" style="text-align: justify;">
Sensasi menekan
bola pingpong pada batas tulang parietal dan oksipital sepanjang sutura
lamboidea bisa jadi merupakan tanda hidrosefalus atau sifilis bawaan, tetapi
normal pada neonatus dengan presentasi bokong. Keadaan ini dikenal sebagai
kraniotabes fisiologis.</div>
<div class="MsoListParagraphCxSpLast" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1; text-align: justify;">
<b><span style="color: #333333; font-family: "Arial","sans-serif"; font-size: 10.5pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: IN; mso-font-kerning: 18.0pt;">Buku Ajar Keperawatan Pediatrik Vol 1 Wong</span></b></div>
<div class="MsoListParagraph" style="text-align: justify;">
<span style="background: white; color: #333333; font-family: "Arial","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: IN;"> </span><span style="background: white; color: #333333; font-family: "Arial","sans-serif"; font-size: 8.5pt; line-height: 115%; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: IN;">Oleh Donna L. Wong, dkk</span></div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-90615203540633269972014-05-09T20:39:00.000-07:002014-05-09T20:52:09.172-07:00curcol soal belajar..hahahha... XD<span style="font-family: Arial, Helvetica, sans-serif;">Morning... :D (10 Mei 2014)</span><br />
<span style="font-family: Arial, Helvetica, sans-serif;"><br /></span>
<span style="font-family: Arial, Helvetica, sans-serif;">hallo hallo, selamat pagi...hehehhe</span><br />
<span style="font-family: Arial, Helvetica, sans-serif;">entah kenapa hari ini saya ingin menulis sesuatu yang sebenarnya tidak penting, cuma sekedar curcol, etc... mungkin karena sudah lama tidak nulis di blog ini...</span><br />
<span style="font-family: Arial, Helvetica, sans-serif;">pingin menulis sesuatu yang berisi sih, mau bagi-bagi pelajaran lagi, tapi ya berhubung harus dari sumber yang sahih dan menggunakan bahasa Indonesia yang benar, jadinya belum terealisasikan rencana yang itu..hahahhah</span><br />
<span style="font-family: Arial, Helvetica, sans-serif;">mungkin cuma sekedar mau share saja, hari ini saya merasa cerah,, mungkin karena hari ini libur, biasa lah, hari sabtu memang di jadwal ditulis belajar mandiri, tapi sumpah, rasanya penat weh..hahahhaha</span><br />
<span style="font-family: Arial, Helvetica, sans-serif;">tak terasa liburan bentar lagi, dan jiwa saya sudah melayang-layang di rumah,,, dan sebenarnya lagi, ini bukan lah sesuatu yang penting di bahas di blog ini.. tapi entah kenapa saya benar-benar lagi ini ingin menulis...</span><br />
<span style="font-family: Arial, Helvetica, sans-serif;">baiklah, daripada tulis tak ada isi, mending bahas tentang semangat belajar yang sudah turun sekali,hehehheh...</span><br />
<span style="font-family: Arial, Helvetica, sans-serif;">jadi ini lah ceritanya, sekarang kan sudah semester 4, tapi makin ke sini bukannya tambah rajin belajar, jadinya malah makin malas belajar, bisa dibilang agak jenuh, *belum sangat jenuh" ^^,, padahal ini masih panjang loh perjalanannya... ingat sekali, waktu semester 2 benar-benar rajin belajar,, pulang kuliah belajar, sore-sore belajar, benar-benar rajin weh... dan serius, hasilnya tidak mengecewakan, serius,, senang sekali weh nilainya tambah bagus.. ya itu perjuangan.. tapi sekarang semangat juangnya benar-benar turun... KTI belum ada progress, SOCA aja persiapannya 1% dari 100%..padahal akhir semester sudah dekat...</span><br />
<span style="font-family: Arial, Helvetica, sans-serif;">sekarang ini benar-benar berharap mukjizat Tuhan rasanya..tapi ya tetap usaha donk, belajar..hahahhaha, meskipun tiap belajar rasanya tiap hal yang dibaca malah mental lagi keluar, hahahhaahha...</span><br />
<span style="font-family: Arial, Helvetica, sans-serif;">ya semoga saja hasil semester ini baik... hari ini lagi on fire mau belajar...semoga di sisa waktu ini bisa lebih serius belajar..</span><br />
<span style="font-family: Arial, Helvetica, sans-serif;"><br /></span>
<span style="font-family: Arial, Helvetica, sans-serif;">o ia, mungkin salah satu cara ini bisa bantu waktu belajar weh</span><br />
<br />
<ul>
<li><span style="font-family: Arial, Helvetica, sans-serif;">jangan lupa berdoa menurut keyakinan masing2 sebelum belajar (berhubung saya katolik jadi doanya minta penerangan Roh Kudus biar lebih semangat n fokus belajar ^^)</span></li>
<li><span style="font-family: Arial, Helvetica, sans-serif;">jangan lupa matikan hp n gadget lain.. *hp itu perusak fokus belajar,,hahahahha</span></li>
<li><span style="font-family: Arial, Helvetica, sans-serif;">siapakan juga segelas susu atau apapun biar nggak usah pergi2 kalau lagi haus..hahahahha...</span></li>
<li><span style="font-family: Arial, Helvetica, sans-serif;">belajar itu jangan dalam keadaan bad mood oi, nanti bukannya belajar, malah marah2 sendiri sama buku..</span></li>
<li><span style="font-family: Arial, Helvetica, sans-serif;">pasang target lah, tapi nggak usah tinggi2 banget, minimal satu bab selesai lah...</span></li>
<li><span style="font-family: Arial, Helvetica, sans-serif;">o iya, paling penting, study hard sih study, hard, tapi jangan too hard juga,, makin dipaksa bukannya makin pintar malah mental semua pelajarannya... buat jeda lah, belajar 1,5-2jam istirahat dulu, terus lanjut lagi^^</span></li>
<li><span style="font-family: Arial, Helvetica, sans-serif;">semoga bisa bantu proses belajar mu... :)</span></li>
</ul>
<br />
<span style="font-family: Arial, Helvetica, sans-serif;"><br />semangat oi,, semangat...... /(^O^)\</span><br />
<span style="font-family: Arial, Helvetica, sans-serif;"><br /></span>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjqXFJpGNeOY9TW9c2b1tWvBQxq6L8cLIUBWocA4I4YVTSLvhiXR-8w7M_HiYiClbtSQInwQUZZAuyBU40Uzry0j4KFOaV0VgJgqQCtwOzwMRkYBABTVma8Kh8HAkdCPw5XI-64KK6zBzs/s1600/study_hard_by_DomoBraden.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjqXFJpGNeOY9TW9c2b1tWvBQxq6L8cLIUBWocA4I4YVTSLvhiXR-8w7M_HiYiClbtSQInwQUZZAuyBU40Uzry0j4KFOaV0VgJgqQCtwOzwMRkYBABTVma8Kh8HAkdCPw5XI-64KK6zBzs/s1600/study_hard_by_DomoBraden.jpg" height="303" width="320" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjfLnbhpq6P1UL_BZkVkeTZh6agmDEapZhcTCresje1lmyscPADNisx4CjsF2jJzuvWE5NHyC_NA1DqITVDfAFYeqwzHMmdX_lzvuTCxToOYaFaRiErA-UQnF-0rjplcwr0eBDpohgpaEY/s1600/study+hard.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjfLnbhpq6P1UL_BZkVkeTZh6agmDEapZhcTCresje1lmyscPADNisx4CjsF2jJzuvWE5NHyC_NA1DqITVDfAFYeqwzHMmdX_lzvuTCxToOYaFaRiErA-UQnF-0rjplcwr0eBDpohgpaEY/s1600/study+hard.jpg" height="212" width="320" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhSjINxQZQZcOdPZGbtOKH4se_jWxP2sVzwcY5sgJ-emle2uuov8jeGkH4x-stinIulPvUIk4yIXHtY44aTNZMHfV1XiRx3fGAawsEN4UmjSOo5akvpE2C3zF4t3BEjIRii4f5393f4ykU/s1600/study.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhSjINxQZQZcOdPZGbtOKH4se_jWxP2sVzwcY5sgJ-emle2uuov8jeGkH4x-stinIulPvUIk4yIXHtY44aTNZMHfV1XiRx3fGAawsEN4UmjSOo5akvpE2C3zF4t3BEjIRii4f5393f4ykU/s1600/study.jpg" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhh3URo62tk0sVg42Rpg2T_NhP72USt3HyRJREtmxWGAM0jh24p32MrGOxpQBYcLDb7GWjAiX2MQU3n0K2WFtcRHUebu3dFFDTPFoLL0GI_GW0uFcsMfvOOpLdAPViNY1hSx1SqhGxZ22Y/s1600/keep-calm-study-hard-pray-hard-and-do-the-best-2.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhh3URo62tk0sVg42Rpg2T_NhP72USt3HyRJREtmxWGAM0jh24p32MrGOxpQBYcLDb7GWjAiX2MQU3n0K2WFtcRHUebu3dFFDTPFoLL0GI_GW0uFcsMfvOOpLdAPViNY1hSx1SqhGxZ22Y/s1600/keep-calm-study-hard-pray-hard-and-do-the-best-2.png" height="320" width="274" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<span style="font-family: Arial, Helvetica, sans-serif;"><br /></span>luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com1tag:blogger.com,1999:blog-7294540944450239332.post-80209660999578147672014-01-15T05:05:00.001-08:002014-01-15T05:05:17.412-08:00You Are Loved - Short Film<iframe allowfullscreen="" frameborder="0" height="270" src="//www.youtube.com/embed/QLdc_OQCdjw" width="480"></iframe>luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-79647312807005553892014-01-15T02:52:00.003-08:002014-01-15T02:52:32.647-08:00Sampel dan Teknik Pengambilan Sampel<div class="MsoNormalCxSpFirst" style="line-height: 150%; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;"><br /></span></div>
<div class="MsoNormalCxSpFirst" style="line-height: 150%; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;">Dalam suatu penelitian, setelah
menentukan hipotesis, peneliti akan menentukan subyek yang harus diteliti. Subyek
yang diteliti biasanya merupakan suatu populasi. Populasi adalah keseluruhan
atau himpunan obyek dengan ciri yang sama. Populasi yang diteliti biasanya
dalam jumlah yang besar, sehingga data yang diambil biasanya bukanlah
kesuluruhan dari populasi melainkan hanya sebagian dari populasi yang disebut
sampel. Misalnya sesendok sayur dianalogikan sebagai sampel untuk dicoba,
sedangkan sepanci sayur yang sama dianalogikan sebagai populasi. Penelitian
dengan menggunakan sampel biasa digunakan untuk menghemat waktu, dana, dan
biaya penelitian.</span></div>
<div class="MsoNormalCxSpFirst" style="line-height: 150%; text-align: justify;">
<span style="font-size: 12pt; line-height: 150%; text-indent: 36pt;">Sampel yang
diambil haruslah sedapat mungkin mewakili populasi yang ingin diteliti / representatif.
Untuk mendapatkan sampel yang representatif maka dibutuhkan teknik atau
cara-cara tertentu agar data yang didapat sesuai dengan tujuan penelitian.
Pengambilan sampel untuk penelitian disebut sampling. Teknik sampling yang
tidak baik dapat mempengaruhi validitas data, terutama validitas eksternal data
karena akan menentukan seberapa besar data tersebut dapat digeneralisasi dan menyebabkan
terjadinya kesalahan dalam kesimpulan hasil penelitian.</span></div>
<div class="MsoNormalCxSpLast" style="line-height: 150%; text-align: justify; text-indent: 36.0pt;">
<span style="font-size: 12.0pt; line-height: 150%;"><br /></span></div>
<div class="MsoListParagraphCxSpFirst" style="line-height: 150%; margin-left: 21.3pt; mso-add-space: auto; mso-list: l4 level1 lfo1; text-align: justify; text-indent: -21.3pt;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">a.<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%;">Jenis-jenis
Sampel<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 0cm; mso-add-space: auto; text-align: justify; text-indent: 21.3pt;">
<span style="font-size: 12.0pt; line-height: 150%;">Pada umumnya hanya ada dua jenis sampel, yaitu
sampel-sampel probabilitas <i>(probability
samples/random sample)</i> dan sampel-sampel nonprobabilitas <i>(non probability samples/non random
samples). Probability</i> berarti berhubungan dengan kemungkinan populasi yang
di ambil menjadi sampel sedangkan <i>random</i>
berhubungan dengan bagaimana sampel akan diambil nantinya. Pada sampel-sampel
probabilitas, setiap individu memiliki kesempatan yang sama untuk menjadi
sampel karena dilakukan secara acak. Sedangkan pada sampel-sampel
nonprobabilitas, kesempatan yang didapat individu untuk menjadi sampel tidak
sama karena tidak dilakukan acak.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 0cm; mso-add-space: auto; text-align: justify;">
<br /></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: 21.3pt; text-align: justify; text-indent: -21.3pt;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">b.<span style="font-size: 7pt;">
</span></span><!--[endif]--><span style="font-size: 12.0pt;">Cara Pengambilan
Sampel<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 150%; text-align: justify; text-indent: 21.3pt;">
<span style="font-size: 12.0pt; line-height: 150%;">Untuk mendapatkan
masing-masing jenis sampel dibutuhkan teknik <i>sampling </i>yang berbeda. <o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 150%; text-align: justify; text-indent: 21.3pt;">
<span style="font-size: 12.0pt; line-height: 150%;"><br /></span></div>
<div class="MsoListParagraphCxSpFirst" style="line-height: 150%; margin-left: 21.3pt; mso-add-space: auto; mso-list: l0 level1 lfo2; text-align: justify; text-indent: -17.85pt;">
<!--[if !supportLists]--><i><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">1.<span style="font-size: 7pt; font-style: normal; line-height: normal;">
</span></span></i><!--[endif]--><i><span style="font-size: 12.0pt; line-height: 150%;">Random Sampling<o:p></o:p></span></i></div>
<div class="MsoListParagraph" style="line-height: 150%; margin-left: 21.25pt; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;">Pengambilan
sampel dengan menggunakan teknik random sampling dilakukan secara acak. Teknik
ini menggunakan asumsi pemakaian metode statistik inferensial atau induksi
sehingga hanya bisa digunakan jika anggota populasi bersifat homogen atau
diasumsikan homogen. Teknik ini dapat dibedakan menjadi:<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 39.25pt; mso-add-space: auto; mso-list: l5 level1 lfo3; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">a.<span style="font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%;">Pengambilan sampel secara acak
sederhana <i>(Simple Random Sampling)</i><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 39.1pt; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;">Hakikat metode ini adalah setiap anggota individu populasi
homogen memiliki kesempatan yang sama untuk menjadi sampel. Sehingga apabila
besarnya sampel berbeda maka besarnya kesempatan individu juga berbeda. Teknik
ini dapat dilakukan dengan dua cara, yaitu mengundi anggota populasi (lottery
technique) dan dengan menggunakan tabel bilangan atau angka random (random
number) yang dapat dilihat di buku statistik. Keuntungan teknik in adalah harga
rata-rata sampel merupakan estimator rata-rata populasi yang tidak bias dan
pelaksanaannya mudah. Kelemahannya, sampel dapat menyebar pada jarak yang jauh
atau juga sebaliknya akan mengumpul pada area tertentu.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 39.1pt; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;"><br /></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 39.1pt; mso-add-space: auto; mso-list: l5 level1 lfo3; text-align: justify; text-indent: -17.85pt;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">b.<span style="font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%;">Pengambilan sampel secara acak
Sistematis <i>(Systematic Random Sampling)</i><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 39.1pt; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;">Teknik ini merupakan modifikasi dari <i>Simple Random Sampling</i> dan digunakan untuk populasi yang dianggap
homogen dan telah tersedia daftar dan nomor urut setiap unit populasi.
Pengambilan sampel pertama menggunakan <i>simple
random sampling</i>, sedangkan pengambilan sampel kedua dan seterusnya ditentukan
secara sistematis dengan meloncat data (interval sampel). Misalnya akan diambil
30 unit sampel dari 120 unit, maka interval sampel adalah 120/3 = 4. Jika
sampel pertama jatuh pada nomor urut 11, maka sampel selanjutnya adalah nomor
urut 15,19,23, dst. Keuntungan dan kelemahannya sama dengan sample random
sampling.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 39.1pt; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;"><br /></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 39.1pt; mso-add-space: auto; mso-list: l5 level1 lfo3; text-align: justify; text-indent: -17.85pt;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">c.<span style="font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%;">Pengambilan sampel secara acak
Stratifikasi <i>(Stratified Random Sampling)</i><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 39.1pt; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;">Metode ini digunakan jika unit data memiliki karateristik
yang heterogen, maka perlu dicari lapisan/strata karakteristik umum dari tiap
anggota populasi. Jika jumlah unit tiap strata sama maka digunakan metode
simple stratified random sampling. Jika jumlah unit tiap strata berbeda maka
digunakan metode proposional stratified random sampling. Misalnya populasi
penelitian adalah siswa SD kelas 5 di SD X. Berdasarkan pendataan dari sekolah
sebanyak 250 siswa. Berdasarkan perhitungan statistik, sampel yang dianggap
representatif adalah 60 orang siswa. Cara pengambilan sampel berdasarkan strata
tingkat penghasilan orang tua, yakni: penghasilan rendah, menengah dan tinggi.
Maka sampel akan diambil masing-masing strata 20. Keuntungan metode ini adalah
presisi dari sampel bisa meningkat dan pelaksanaannya relatif mudah.
Kelemahannya adalah sampel dapat menyebar dengan jarak yang jauh dan dibutuhkan
daftar unit sekaligus stratanya.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 39.1pt; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;"><br /></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 39.25pt; mso-add-space: auto; mso-list: l5 level1 lfo3; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">d.<span style="font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%;">Pengambilan sampel secara Kelompok
atau Gugus (<i>Cluster Sampling</i>)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 39.25pt; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;">Pada teknik ini digunakan populasi yang heterogen. Pada
populasi terdiri dari beberapa cluster/area yang didalamnya mengandung unit
populasi yang heterogen. Peneliti tidak mendaftar semua angota atau unit yang
ada dalam populasi, tetapi cukup mendaftar banyaknya gugus dalam populasi,
kemudian mengambil sampel dari gugus-gugus tersebut. Misalnya peneliti akan
meneliti di Kecamatan X yang terdiri dari 12 kelurahan, maka peneliti hanya
mengambil sampel dari 3 kelurahan di kecamatan itu secara acak. Keuntungan
metode ini adalah penyebaran populasi dapat dihindari, tidak diperlukan daftar
dari seluruh unit populasi tetapi cukup daftar unit populasi dalam cluster yang
terpilih. Kelemahannya adalah sulit diperoleh cluster yang heterogenitasnnya
benar-benar sama, sehingga sampel yang diperoleh merupakan estimator kasar
untuk populasi.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 39.25pt; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;"><br /></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 39.25pt; mso-add-space: auto; mso-list: l5 level1 lfo3; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">e.<span style="font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%;">Pengambilan sampel secara Gugus
Bertahap (<i>Multistage Sampling</i>)<o:p></o:p></span></div>
<div class="MsoListParagraph" style="line-height: 150%; margin-left: 39.1pt; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;">Metode ini
merupakan kombinasi berbagai metode sebelumnya, dengan urutan yang bervariasi.
Pengambilan sampel dilakukan dilakukan berdasarkan tingkat wilayah secara
bertahap sehingga lebih mungkin dilaksanakan jika populasi terdiri dari
berbagai macam tingkatan wilayah. Wilayah tersebut dibagi menjadi subwilayah yang
lebih kecil, subwilayah tersebut dibagi lagi menjadi lebih kecil, begitu
seterusnya hingga subwilayah terkecil sehingga peneliti dapat memilih sampel
dari subwilayah tersebut. Misalnya sebuah kabupaten dipilih beberapa kecamatan
sebagai sampel. Dari sampel kecamatan dipilih beberapa kelurahan sebagai
sampel, kemudian dari sampel tersebut dipilih lagi beberapa RW sebagai sampel.
Dari sampel RW tersebut dipilih lagi yang lebih kecil yaitu RT sebagai sampel,
maka sampelnya adalah sebagian atau semua warga di RT tersebut.<o:p></o:p></span></div>
<div class="MsoListParagraph" style="line-height: 150%; margin-left: 39.1pt; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;"><br /></span></div>
<div class="MsoListParagraph" style="line-height: 150%; margin-left: 39.1pt; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;"><br /></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 21.3pt; mso-add-space: auto; mso-list: l0 level1 lfo2; text-align: justify; text-indent: -14.2pt;">
<!--[if !supportLists]--><i><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">2.<span style="font-size: 7pt; font-style: normal; line-height: normal;">
</span></span></i><!--[endif]--><i><span style="font-size: 12.0pt; line-height: 150%;">Non Random Sampling<o:p></o:p></span></i></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 21.25pt; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%;">Pengambilan sampel dengan menggunakan teknik non random
sampling dilakukan tidak secara acak dan tidak didasarkan atas kemungkinan yang
dapat dihitung. Jika menggunakan teknik ini maka penggunaan statistik
inferensial atau induksi bisa jadi tidak valid. Teknik ini dapat dibedakan
menjadi:</span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 21.25pt; mso-add-space: auto; text-align: justify;">
<i style="line-height: 150%; text-indent: -18pt;"><span style="line-height: 150%;"><span style="font-size: 7pt; font-style: normal; line-height: normal;"><br /></span></span></i></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 21.25pt; mso-add-space: auto; text-align: justify;">
<i style="line-height: 150%; text-indent: -18pt;"><span style="line-height: 150%;"><span style="font-size: 7pt; font-style: normal; line-height: normal;"> </span><span style="font-style: normal; line-height: normal;">a. </span></span></i><i style="line-height: 150%; text-indent: -18pt;"><span style="font-size: 12.0pt; line-height: 150%;">Purposive Sampling</span></i></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 21.25pt; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12pt; line-height: 150%;">Pada metode ini, peneliti mengambil
sampel dengan pertimbangan tertentu, berdasarkan ciri atau sifat-sifat populasi
yang sudah diketahui sebelumnya, maka peneliti perlu mengidentifikasi dulu
semua karakteristik populasi. Teknik ini sangat cocok digunakan untuk desain
penelitian study kasus (</span><i style="font-size: 12pt; line-height: 150%;">case study</i><span style="font-size: 12pt; line-height: 150%;">),
di mana banyak aspek dari kasus tunggal yang dapat diamati. Misalnya penelitian
bertujuan untuk mengetahui pengaruh merokok di kalangan siswa SMA dengan
prestasi belajar di sekolah, maka sampel terbatas pada siswa SMA yang merokok
saja.</span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 21.25pt; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12pt; line-height: 150%;"><br /></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 21.25pt; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12pt; line-height: 150%;">b. </span><i style="line-height: 150%; text-indent: -18pt;"><span style="font-size: 12.0pt; line-height: 150%;">Quota Sampling</span></i></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 21.25pt; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12pt; line-height: 150%;">Teknik ini dilakukan dengan cara
menetapkan sejumlah anggota sampel secara </span><i style="font-size: 12pt; line-height: 150%;">quotum</i><span style="font-size: 12pt; line-height: 150%;">
atau jatah. Dasar untuk mengambil unit sampel tergantung pada berapa besar
jumlah sampel yang telah ditentukan. Anggota populasi mana yang menjadi sampel
tidak terlalu dipersoalkan asalkan sudah memenuhi quota yang diinginkan.</span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 21.25pt; mso-add-space: auto; text-align: justify;">
<i style="line-height: 150%; text-indent: -18pt;"><span style="font-size: 12.0pt; line-height: 150%;"><br /></span></i></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 21.25pt; mso-add-space: auto; text-align: justify;">
<i style="line-height: 150%; text-indent: -18pt;"><span style="font-size: 12.0pt; line-height: 150%;">c. Accidental Sampling</span></i></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 21.25pt; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12pt; line-height: 150%;">Pada metode ini pengambilan sampel
dilakukan dengan mengambil kasus atau responden yang kebetulan ada di tempat
yang telah disesuaikan dengan konteks penelitian. Perbedaannya dengan </span><i style="font-size: 12pt; line-height: 150%;">purposive sampling</i><span style="font-size: 12pt; line-height: 150%;"> adalah pada metode
ini sampel yang diambil berasal dari responden yang memang kebetulan berada di suatu
tempat pada keadaan tertentu, tanpa sebelumnya diketahui oleh peneliti. Sedangkan
pada </span><i style="font-size: 12pt; line-height: 150%;">purposive</i><span style="font-size: 12pt; line-height: 150%;"> peneliti memilih
sendiri kasus atau respondennya.</span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 21.3pt; mso-add-space: auto; text-align: justify;">
<br /></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-left: 21.3pt; mso-add-space: auto; mso-list: l4 level1 lfo1; text-align: justify; text-indent: -21.3pt;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">c.<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%;">Menghitung
Jumlah Sampel<o:p></o:p></span></div>
<div class="MsoListParagraph" style="line-height: 150%; margin-left: 0cm; text-align: justify; text-indent: 21.3pt;">
<span style="font-size: 12.0pt; line-height: 150%;">Pada
dasarnya jumlah atau besar sample (<i>sample
size</i>) digunakan untuk menentukan jumlah sampel replikasi yang akan
dilakukan oleh peneliti. Untuk menetapkan besar sampel tergantung pada dua hal,
yaitu adanya sumber-sumber yang dapat digunakan sebagai batas maksimal dari besarnya
sampel dan kebutuhan dan rencana analisis yang menentukan batas minimal dari
besarnya sampel. <o:p></o:p></span></div>
<div class="MsoListParagraph" style="line-height: 150%; margin-left: 0cm; text-align: justify; text-indent: 21.3pt;">
<span style="font-size: 12.0pt; line-height: 150%;"><br /></span></div>
<div class="MsoListParagraphCxSpLast" style="line-height: 150%; margin-left: 18.0pt; mso-add-space: auto; mso-list: l2 level1 lfo5; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="line-height: 150%;"><span style="font-size: small;">1.</span><span style="font-size: 7pt; line-height: normal;"> </span><span style="line-height: normal;">Jumlah Sampel untuk Estimasi Proporsi</span></span></div>
<div class="MsoNormalCxSpFirst" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: "Times New Roman";">Ada 3 hal yang terlebih dahulu perlu
diketahui sebelum menghitung jumlah sampel, yakni, a. Perkiraan proporsi untuk
sifat tertentu yang terjadi dalam populasi. Apabila tidak diketahui proporsi
atau sifat tertentu tersebut, maka P (proporsi = 0,50 atau 50%) b. Presisi adalah
derajat ketepatan yang diinginkan, berarti penyimpangan terhadap populasi,
biasnya 0,05 (5%) atau 0,10 (10%) dan c. Derajat kepercayaan</span></div>
<div class="MsoNormalCxSpFirst" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; text-align: justify;">
n = besar sampel</div>
<div class="MsoNormalCxSpFirst" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; text-align: justify;">
Z <sub>1-a/2</sub> = nilai Z pada derajat
kemaknaan (biasanya 95% = 1,96)</div>
<div class="MsoNormalCxSpFirst" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; text-align: justify;">
<span style="text-indent: -36pt;">P </span><span style="text-indent: -36pt;"> </span><span style="text-indent: -36pt;">=
proporsi suatu kasus tertentu terhadap populasi, bila tidak diketahui proporsinya,
ditetapkan 50% (0,50)</span></div>
<div class="MsoNormalCxSpFirst" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; text-align: justify;">
<span style="text-indent: -36pt;">d</span><span style="text-indent: -36pt;"> </span><span style="text-indent: -36pt;">= derajat
penyimpangan terhadap populasi yang diinginkan: 10% (0,10), 5%(0,05) atau 1%
(0,01)</span><o:p style="text-align: center;"> </o:p><span style="font-size: 12pt;"> </span></div>
<div class="MsoNormal" style="line-height: 18.0pt; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; text-align: justify;">
Contoh:<o:p></o:p></div>
<div class="MsoNormal" style="line-height: 18.0pt; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; text-align: justify;">
<span style="font-size: 12pt;">Tujuan: mengetahui
prevalensi gizi buruk gizi buruk pada Balita di Kecamatan Sawangan<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 18.0pt; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; text-align: justify;">
<span style="font-size: 12pt;">Diketahui : a)
Perkiraan proporsi (p=0,15), b) Presisi (d=0,05), c) Derajat kepercayaan 95%
(Z1-X/2 = 1,96)<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 18.0pt; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; text-align: justify;">
</div>
<!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif";
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;mso-ansi-language:IN;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:175.85pt;
height:38.25pt'>
<v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--><div class="MsoNormal" style="line-height: 18.0pt; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; text-align: justify;">
<br /></div>
<div class="MsoListParagraph" style="line-height: 18.0pt; margin-bottom: 6.0pt; margin-left: 18.0pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; mso-list: l2 level1 lfo5; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-size: 12pt;">2.<span style="font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><span style="font-size: 12pt;">Jumlah Sampel untuk
Estimasi Rata-rata<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 18.0pt; margin-bottom: 6.0pt; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; text-align: justify;">
<span style="font-size: 12pt;">Untuk menghitung besar
sampel, peneliti perlu mengetahui: perkiraan varians (kuadrat dari Standar
Deviasi), presisi, dan derajat kepercaan</span><span style="font-size: 12pt; line-height: 18pt; text-indent: 36pt;"> </span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 18.0pt; margin-bottom: 6.0pt; mso-add-space: auto; text-align: justify; text-indent: 21.3pt;">
<span style="font-size: 12pt;">Contoh<o:p></o:p></span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 18.0pt; margin-bottom: 6.0pt; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12pt;">Sebuah
penelitian bertujuan untuk mengetahui rata-rata berat badan anak Balita di
Kecamatan Cimanggis, dengan ketentuan: BB rata-rata anak balita 12,5 kg, standar
Deviasi 6 kg (Q), derajat Kepercayaan 95% (1,9), dan simpangan maksimum dari
rata-rata 1 kg (d=1)<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 18.0pt; margin-bottom: 6.0pt; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; text-align: justify; text-indent: 35.45pt;">
<br /></div>
<div class="MsoListParagraphCxSpFirst" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 18.0pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; mso-list: l2 level1 lfo5; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-size: 12pt; line-height: 150%;">3.<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12pt; line-height: 150%;">Kriteria Inklusi dan Eksklusi<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12pt; line-height: 150%;">Dibutuhkan kriteria inklusi dan ekslusi
agar karakteristik sampel tidak menyimpang. Kriteria inklusi adalah kriteria
yang perlu dipenuhi oleh setiap anggota populasi yang dapat diambil sebagi
sampel. Sedangkan kriteria ekslusi adalah ciri-ciri anggota populasi yang tidak
dapat digunakan sebagai sampel.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12pt; line-height: 150%;"><br /></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12pt; line-height: 150%;"><br /></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 21.3pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12pt; line-height: 150%;"><br /></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin: 0cm; mso-add-space: auto; text-align: justify;">
<span style="font-size: 12pt; line-height: 150%;">Daftar Pustaka<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin: 0cm; mso-add-space: auto; text-align: justify;">
<br /></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; mso-list: l1 level1 lfo6; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-size: 12pt; line-height: 150%;">1.<span style="font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><span style="font-size: 12pt; line-height: 150%;">Notoatmodjo,
Soekidjo. 2010. Metodologi penelitian kesehatan. Jakarta: Rinerka Cipta.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; mso-list: l1 level1 lfo6; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-size: 12pt; line-height: 150%;">2.<span style="font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><span style="font-size: 12pt; line-height: 150%;">Santoso,
Gempur. 2005. Fundamental: Metode penelitian kuantitatif dan kualitatif.
Jakarta: Prestasi Pustaka Publisher.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; mso-list: l1 level1 lfo6; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-size: 12pt; line-height: 150%;">3.<span style="font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><span style="font-size: 12pt; line-height: 150%;">Pratiknya,
Ahmad W. 2000. Dasar-dasar metodologi penelitian & kesehatan. Jakarta: PT
Raja Grafindo Persada.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 18.0pt; margin-bottom: 6.0pt; text-align: justify;">
<br /></div>
<br />
<div class="MsoListParagraph" style="line-height: 150%; margin-left: 0cm; mso-add-space: auto; text-align: justify;">
<br /></div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com3tag:blogger.com,1999:blog-7294540944450239332.post-38905394197559926512013-11-20T08:38:00.003-08:002013-11-20T08:38:21.785-08:00Belajar Bersyukur dan Tetap Semangat<div class="MsoNormal" style="text-align: justify;">
<span style="line-height: 115%;">Sebenarnya
ini bukan salah satu bagian tulisan saya yang isinya mau bagi-bagi ilmu
kuliah,hehehehehe, tapi ya begitulah, tulisan ini sebenarnya hanya untuk
sharing pengalaman, bagaimana kita bisa bersyukur di tengah kesusahan kita, dan
bagaimana kita butuh seman</span>gat agar tetap bisa bertahan <span style="font-family: Wingdings; line-height: 115%;">J</span><span style="line-height: 115%;"><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="line-height: 115%;">Jadi,
setelah sekian lama tidak mengikuti tugas kunjungan Rumah Sakit sebagai legioner,
entah kenapa hari ini saya tergerak karena diajak teman. Akhirnya ikut lagi
kunjungan RS dan tentu saja lahannya masih sama, RS Atma Jaya, Jakarta. (alasan
selama ini tidak ikut sebenarnya malas X|,hehehhehe, jangan ditiru ya...)<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="line-height: 115%;">Ada
3 orang pasien yang kami kunjungi, 1 orang ibu di bagian VIP, dan 2 bapak-bapak
di kelas biasa. Ternyata si ibu Nunik (nama pasien di bagian VIP), sudah 8x
masuk RS karena penyakit yang sama, radang usus. Tapi entah kenapa di RS Atma
Jaya ini, beliau merasa tenang sekali. Menurut beliau untuk sakit nya kali ini,
dia sudah pasrah, bukan berarti dia tidak melakukan apa-apa, tapi mungkin untuk
kesembuhannya sendiri dia sudah menyerahkannya kepada Tuhan. Ketika dikunjungi
ibu Nunik hanya sendirian. Beliau sendiri bilang kalau memang dia tidak mau ditunggui
oleh anak-anaknya, toh dia masih bisa melakukan semuanya sendiri. Tidak mau
merepotkan anak-anaknya. Dan ketika diajak berdoa,beliau jga ikut berdoa dengan
khusuk. Setelah bedoa pun beliau masih sempat mengucapkan terima kasih. </span><span style="font-family: Wingdings; line-height: 115%;">J</span><span style="line-height: 115%;"><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="line-height: 115%;">Pasien
ke 2 dan ke 3, bapak Tambun dan bapak Elli ini berada dalam ruangan yang sama.
Ruangan ini di isi 6 bed, jadi lumayan berisi. Suasana di dalam sendiri tidak
terlalu kaku. Pasien yang pertama kali kami kunjungi adalah bapak Tambun.
Orangnya kelihatan bersahabat, dan banyak senyum. Ternyata memang benar bapak
Tambun ini orangnya <i>friendly</i>
banget.hahahahha. Beliau ini ternyata dulunya ketua legio. Kesan diterima ini
yang saya suka. Waktu berdoa pun beliau sempat bilang, âdoa aja, nggak apa2,
jngan takut, yang penting kan tulusâ ,hehhehehe, soalnya awalnya saya agak malu
waktu disuruh pimpin doa, jadinya digantikan temannya saya. Selesai dari situ
kami langsung diarahkan ke bapak Elli, pasien di sebelahnya sama pak Tambun
tadi. Berhubungun bednya dekat-dekatan jadi ya begitulah. Memang ruangan ini isinya bapak-bapak semua,
jadi ya rame juga.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="line-height: 115%;">Bapak
Elli, pasien ke 3 ini, sudah lumayan berumur, dan menderita penyakit gagal
ginjal dan harus dicuci darah, makanya harus menggunakan tabung oksigen.
Awalnya sih waktu ngobrol agak kaku, tapi ternyata bapak Elli ini orangnya
sendiri juga tidak termasuk bapak-bapak yang kaku. Lumayan banyak cerita.
Setelah bertanya asal kami bertigadari mana, langsung didoakan gitu supaya
lulus cepat biar bisa jadi dr yang baik. Diamini juga sama bapak Tambun n bapak
di sebelahnya. Sepertinya bapak Elli ini sempat putus asa, soalnya bapak-bapak
dalam ruangan itu kayak selalu menyemangati bapak Elli ini. Beliau sendiri
kelihatannya senang, dan memang mengaku jadi lebih semangat. Ketika berdoa pun
dia mengamini setiap syukur yang saya ucapkan, termasuk syukur akan teman-teman
yang baik, yang selalu menyemangati dia. Juga tidak lupa, beliau sendiri
memiliki kesan bagus tentang pelayanan RS. Katanya, beliau senang karena
diperhatikan oleh suster2nya. Senang dan bersyukur deh bisa dirawat di sana
kata pak Elli. Selain itu teman-teman disekitarnya juga sangat mendukung.
Menarik, ketika kami berdoa, ruangan yang semula cukup ribut, mendadak jadi
tenang. Rupanya kami diberi kesempatan untuk mendoakan Pak Elli, meskipun
sebenarnya Cuma pak Elli dan pak Tambun, pasien Katolik yang ada di ruangan
itu. Terima kasih untuk bapak-bapak tadi </span><span style="font-family: Wingdings; line-height: 115%;">J</span><span style="line-height: 115%;"><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Wingdings; line-height: 115%;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="line-height: 115%;">Apa
yang berkesan dari kunjungan kali ini? Tentu saja pelajarannya:<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpFirst" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="line-height: 115%;">1.<span style="line-height: normal;"> </span></span><!--[endif]--><span style="line-height: 115%;">Benar benar saya sadar
bahwa kuasa Tuhan itu ada dan bekerja melalui orang-orang sekitar kita. Banyak kebaikan
yang kita alami sebenarnya jika saja kita mau sedikit saja memberi waktu untuk
diri kita merefleksikan apa saja yang kita punya dan dapat setiap hari, tanpa
memikirkan apa yang tetambil atau sakit yang kita alami.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="line-height: 115%;">2.<span style="line-height: normal;"> </span></span><!--[endif]--><span style="line-height: 115%;">Doa itu obat yang sangat
mujarab ketika hati sedang gundah. Coba saja, jalin komunikasi dengan Tuhan
lewat doa yang tulus dan khusuk </span><span style="font-family: Wingdings; line-height: 115%;">J</span><span style="line-height: 115%;"><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="line-height: 115%;">3.<span style="line-height: normal;"> </span></span><!--[endif]--><span style="line-height: 115%;">Jangan pernah putus asa,
dan tetap semangat. Dan tentu saja, jangan lupa menyemangati orang lain juga.
Senyuman kita, kata-kata penyemangat dari kita, semua itu bisa memberi orang
lain kebahagiaan, niscaya bisa membantu orang lain yang mungkin sedang putus asa agar tetap bertahan.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="line-height: 115%;">4.<span style="line-height: normal;"> </span></span><!--[endif]--><span style="line-height: 115%;">Syukurilah apa yang ada. Karena
sebenarnya dengan kita bisa bersyukur saja, itu sudah bisa mengurangi sedikit
sakit yang kita rasakan, jadi lebih ikhlas bukan?? Stress berkurang.. </span><span style="font-family: Wingdings; line-height: 115%;">J</span><span style="font-size: 13.5pt; line-height: 115%;"><o:p></o:p></span></div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-84844270430405689762013-11-13T10:34:00.003-08:002013-11-13T10:34:52.554-08:00Limonin dari Lemon untuk HIV<div class="MsoNormal" style="background: white; line-height: 13.5pt; margin-bottom: 4.5pt; margin-left: 0cm; margin-right: 0cm; margin-top: 4.5pt; mso-outline-level: 1;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/14648393?dopt=Abstract" title="Planta medica."><span style="background-position: initial initial; background-repeat: initial initial; color: #660066; font-family: Arial, sans-serif; font-size: 8.5pt;">Planta Med.</span></a><span class="apple-converted-space"><span style="background-position: initial initial; background-repeat: initial initial; font-family: Arial, sans-serif; font-size: 8.5pt;"> </span></span><span style="background-position: initial initial; background-repeat: initial initial; font-family: Arial, sans-serif; font-size: 8.5pt;">2003
Oct;69(10):910-3.</span><b><span style="font-family: Arial, sans-serif; font-size: 15pt;"><o:p></o:p></span></b></div>
<div class="MsoNormal" style="background: white; margin-bottom: 4.5pt; margin-left: 0cm; margin-right: 0cm; margin-top: 4.5pt; mso-line-height-alt: 13.5pt; mso-outline-level: 1;">
<b><span style="font-family: Arial, sans-serif; font-size: 15pt;">Effect of limonin and nomilin on HIV-1 replication on infected human
mononuclear cells.<o:p></o:p></span></b></div>
<div class="MsoNormal" style="background: white;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Battinelli%20L%5BAuthor%5D&cauthor=true&cauthor_uid=14648393"><span style="color: #660066; font-family: "Arial","sans-serif";">Battinelli L</span></a><span style="font-family: Arial, sans-serif;">,<span class="apple-converted-space"> </span></span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Mengoni%20F%5BAuthor%5D&cauthor=true&cauthor_uid=14648393"><span style="color: #660066; font-family: "Arial","sans-serif";">Mengoni F</span></a><span style="font-family: Arial, sans-serif;">,<span class="apple-converted-space"> </span></span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Lichtner%20M%5BAuthor%5D&cauthor=true&cauthor_uid=14648393"><span style="color: #660066; font-family: "Arial","sans-serif";">Lichtner M</span></a><span style="font-family: Arial, sans-serif;">,<span class="apple-converted-space"> </span></span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Mazzanti%20G%5BAuthor%5D&cauthor=true&cauthor_uid=14648393"><span style="color: #660066; font-family: "Arial","sans-serif";">Mazzanti G</span></a><span style="font-family: Arial, sans-serif;">,<span class="apple-converted-space"> </span></span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Saija%20A%5BAuthor%5D&cauthor=true&cauthor_uid=14648393"><span style="color: #660066; font-family: "Arial","sans-serif";">Saija A</span></a><span style="font-family: Arial, sans-serif;">,<span class="apple-converted-space"> </span></span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Mastroianni%20CM%5BAuthor%5D&cauthor=true&cauthor_uid=14648393"><span style="color: #660066; font-family: "Arial","sans-serif";">Mastroianni CM</span></a><span style="font-family: Arial, sans-serif;">,<span class="apple-converted-space"> </span></span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Vullo%20V%5BAuthor%5D&cauthor=true&cauthor_uid=14648393"><span style="color: #660066; font-family: "Arial","sans-serif";">Vullo V</span></a><span style="font-family: Arial, sans-serif;">.<o:p></o:p></span></div>
<h3 style="background: white; margin-bottom: 7.7pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.4pt;">
<span style="color: #724128; font-family: "Arial","sans-serif";">Source<o:p></o:p></span></h3>
<div style="background: white; line-height: 13.1pt; margin-bottom: 6.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 6.0pt;">
<span style="font-family: Arial, sans-serif; font-size: 10pt;">Department of Pharmacology of
Natural Substances and General Physiology, University "La Sapienza",
Rome, Italy. licia.battinelli@uniroma1.it<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<i>Citrus Lemon </i>atau
jeruk sitrun atau Lemon mengandung banyak manfaat. Salah satunya dapat digunakan dalam
pengobatan alternatif AIDS. Dari sifatnya yang asam saja sudah bisa mengganggu
virus itu sendiri. Kandungan <i>Limonin </i>dan
<i>Nomilin </i>yang terdapat di kulitnya
dapat digunakan untuk menghambat replikasi HIV-1 bahkan yang sudah menginfeksi
makrofag.<o:p></o:p></div>
<br />
<div class="MsoNormal">
Dosis yang digunakan dites dalam sediaan sel mononuklear
darah tepi yang diinfeksi dengan HIV-1
setelah diinkubasi dengan <span style="line-height: 115%;">limonin and nomilin (EC (50) values: 60.0
microM and 52.2 microM, rata-rata). Ternyata kedua bahan ini dapat menghambat
produksi p-24 yang berfungsi sebagai antigen HIV. Secara umum mekanisme nya
menghambat aktivitas protease pada HIV-1. Akan menunjukan hasil yang lebih baik
jika dosis yang diberikan ditambah pada hari 14 dan memuncak pada hari ke 18.
Dosis bisa dimulai dari 20microM, 40 microM hingga 80 microM.<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="line-height: 115%;"><br /></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiRpg_8zKgxLwymESclK40BERvFr50udMpYLUkwpEOx-lNtSIFhsTay_TWHap8xgUilk_X5fJCNV0ijLQw9LcKPtw_p2jZfAkP9FBx_ReQF4Gl2yghKmZmBFVdC40oe0OzoBOlUWEtrGVw/s1600/Lemon.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="226" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiRpg_8zKgxLwymESclK40BERvFr50udMpYLUkwpEOx-lNtSIFhsTay_TWHap8xgUilk_X5fJCNV0ijLQw9LcKPtw_p2jZfAkP9FBx_ReQF4Gl2yghKmZmBFVdC40oe0OzoBOlUWEtrGVw/s320/Lemon.jpg" width="320" /></a></div>
<div class="MsoNormal">
<span style="line-height: 115%;"><br /></span></div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-71614067097596039832013-11-08T15:56:00.000-08:002013-11-08T15:56:03.153-08:00Anggrek Raksasayang tepikirkan dalam benak saya waktu disebeut anggrek raksasa ya pasti bunga anggrek yang besarnya 10kali lipat bunga anggrek normal,, tapi tak disangka, waktu lihat, anggreknya lagi tidak berbunga :(<div>
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgXc3uAx9yUfgAab4ZvehNzTLDwO7S-L-PMwTqd7nz1F6PiMiH9O8_GWjWZqNC6ySwA3tzJ2EnEgailzOu1Pj8CdpWwU2VkuvKY5ePsqfdMBhmql3JTdtnPo0ID-cgplHdF_zT3MY6NTv8/s1600/IMG_5153.JPG" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="150" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgXc3uAx9yUfgAab4ZvehNzTLDwO7S-L-PMwTqd7nz1F6PiMiH9O8_GWjWZqNC6ySwA3tzJ2EnEgailzOu1Pj8CdpWwU2VkuvKY5ePsqfdMBhmql3JTdtnPo0ID-cgplHdF_zT3MY6NTv8/s200/IMG_5153.JPG" width="200" /></a><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiWgTCSpobIfL0al6yXtEpvu2WtYQcRQoWvgdvSMB5pHHys_Du-h-UBzTiX6Dnc8prd6hx_GLmeumJBIl3jaTpMqLfmVAXhcsht0KApJpf3LISrRoARfuVzVjACaIAR83MhwpNh3DbHkbA/s1600/IMG_5140.JPG" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="150" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiWgTCSpobIfL0al6yXtEpvu2WtYQcRQoWvgdvSMB5pHHys_Du-h-UBzTiX6Dnc8prd6hx_GLmeumJBIl3jaTpMqLfmVAXhcsht0KApJpf3LISrRoARfuVzVjACaIAR83MhwpNh3DbHkbA/s200/IMG_5140.JPG" width="200" /></a> </div>
<div class="separator" style="clear: both; text-align: left;">
anggrek, normalnya lah sekecil ini. nah, pas jalan-jalan ke Kebun Raya Bogor kemarin, saya menemukan anggrek raksasa yang rupanya seperti ini:</div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjX8sekd9qfBkJKSbTXwq6ctQmd6rxwQ8PKjoxLIIzbMmXuas4FRx9ZxoRKi17nlBdjyK0HZDZFMOO2zKyXBNAEgG_36Z3qES1DseWYdXOlPLX9BLyrLWBD-cu7NwwNIECUzkzdTA3A8r8/s1600/IMG_5181.JPG" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjX8sekd9qfBkJKSbTXwq6ctQmd6rxwQ8PKjoxLIIzbMmXuas4FRx9ZxoRKi17nlBdjyK0HZDZFMOO2zKyXBNAEgG_36Z3qES1DseWYdXOlPLX9BLyrLWBD-cu7NwwNIECUzkzdTA3A8r8/s320/IMG_5181.JPG" width="240" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiXdluBfitytLH-c9BupfckoO78klnjY3JA49ZGOZaX8cH-tq5_OEUXeCq3DHvLnzO3qwNQ3hReUB5bfGq9f4X3EUqJHoXMt-O8OPZzVSqOrB5Os6agmnNZTrql1zFzY_IdN6rsMVCcuQA/s1600/IMG_5182.JPG" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="240" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiXdluBfitytLH-c9BupfckoO78klnjY3JA49ZGOZaX8cH-tq5_OEUXeCq3DHvLnzO3qwNQ3hReUB5bfGq9f4X3EUqJHoXMt-O8OPZzVSqOrB5Os6agmnNZTrql1zFzY_IdN6rsMVCcuQA/s320/IMG_5182.JPG" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi-fv1SZqIBB-nK2MdxCWy19lBT3pCn_ObTCF_5YEfsmOcsnP9IG8chvb37RIvGHnBn_oIjFfdAZ8SSlxQUV7K2MFMmVcu_qKWfYlhtlcn3kPmJGcTDbM3WDhQiLJw_Gy0tByQSV3fQlKE/s1600/IMG_5180.JPG" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="240" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi-fv1SZqIBB-nK2MdxCWy19lBT3pCn_ObTCF_5YEfsmOcsnP9IG8chvb37RIvGHnBn_oIjFfdAZ8SSlxQUV7K2MFMmVcu_qKWfYlhtlcn3kPmJGcTDbM3WDhQiLJw_Gy0tByQSV3fQlKE/s320/IMG_5180.JPG" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
di luar dugaan ternyata saya tidak melihat ada bunga di sini.hahahhahah..</div>
<div class="separator" style="clear: both; text-align: left;">
tapi ya begitulah, setelah membaca papan infonya, saya tidak terlalu kecewa akhirnya.</div>
<div class="separator" style="clear: both; text-align: left;">
menarik dan unik.hahahhahahah</div>
<br />
<br />
<div>
<br /></div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com2tag:blogger.com,1999:blog-7294540944450239332.post-11922625507711817912013-10-20T08:39:00.001-07:002013-10-20T08:39:52.304-07:00Da Lopez brother, skinnyindonesia24SkinnyIndonesia24-da lopez brother<br />
<br />
who r they??<br />
hahahhaha, mereka adalah andovi da lopez dan jovial da lopez,,, idola baru saya :)<br />
tak banyak yang bisa saya bahas, tapi menurut saya, mereka ini benar-benar smart boys, jenius, etc.hahhahaha<br />
pertama kali nonton videonya yang judulnya modus, sumpah, ngakak parah, hahahha, kreatif..<br />
englishnya keren, dan ternyata ya begitulah, si adik (dovi) dulu sempat tinggal di India 2 tahun, si kakak (jovi) malah tinggal di denmark 7 tahun, jadi ya begitulah keren...hahhaahah<br />
dan sejujurnya saya sangat menyukai mereka. terutama si adik ini, dovi, yang kuliah di FHUI angkatan 2012, ehm, kakaknya kuliahnya Teknik Nuklir di UI juga, -_-' (topiknya berat untuk saya). dari videonya orangnya lucu, dan sangat terbuka, penasaran saya mereka ini aslinya seperti apa. n menurut saya, orang yang keren itu ya kayak mereka ini.hahahhah<br />
o ia, yang buat saya tertarik itu juga ya nama da lopez di belakangnya. susah sekali loh dapat info tentang mereka, dan akhirnya setelah nonton video mereka, baru deh ketahuan, ayahnya asal NTT ibunya asal Manado. Pantas lah ada da lopez nya. setau saya mah itu kan nama orang flores, khusunya bagian agak ke timur, hehehheheheh<br />
baiklah, sekian dulu,<br />
berita selanjutnya tentang mereka akan menyusul (^o^)vluphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-43614356430174434492013-10-12T11:11:00.001-07:002013-10-12T11:14:49.870-07:00Congratulation Timnas INDONESIA U-19, vs Korsel (3-2) ^__^<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgcsVTRH6ag4JldkAmIvwBiHWO9E2nT2H5kiCJDn1Frar4YxDmzRG6crMWdB6hsrGQDaLctQLBHDbWXag2nd5PP74nPB_8DZc0UJZbVk9piU4lwWnTI_Uog97lYqYEm8hBqB-O27MVbhMs/s1600/IMG-20131012-01915.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="240" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgcsVTRH6ag4JldkAmIvwBiHWO9E2nT2H5kiCJDn1Frar4YxDmzRG6crMWdB6hsrGQDaLctQLBHDbWXag2nd5PP74nPB_8DZc0UJZbVk9piU4lwWnTI_Uog97lYqYEm8hBqB-O27MVbhMs/s320/IMG-20131012-01915.jpg" width="320" /></a> </div>
<div class="separator" style="clear: both; text-align: center;">
yabes dan official timnas :)</div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEho5Nr0Nt3zlS23wn7Qw3hGIzvjBbpuk9y0-PXWMzEWWJcTq6pQXjGVrC8aKxfYv2opDwT1J7t1G23QkVs_RyOWltbMxizXGEnleadLmeNeh56SbEX-EJsSTXtHDb6aldAqFkYL0FyQsiM/s1600/IMG-20131012-01916.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="240" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEho5Nr0Nt3zlS23wn7Qw3hGIzvjBbpuk9y0-PXWMzEWWJcTq6pQXjGVrC8aKxfYv2opDwT1J7t1G23QkVs_RyOWltbMxizXGEnleadLmeNeh56SbEX-EJsSTXtHDb6aldAqFkYL0FyQsiM/s320/IMG-20131012-01916.jpg" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
ekspresi syukur mereka :)</div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjZ5-lqVn1MXK6SeU8JLBRomRfAPiaYhyAovLE1-u8iEegoFEWMfz-mqUcN8MXZODQXbtx0fGXJXnw-iBymM7oXADo9SChsBegWbMI0Mc2e2CpHEJt1jRzdxG2JOFXTO_2Jo-odjaISV6M/s1600/IMG-20131012-01917.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="240" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjZ5-lqVn1MXK6SeU8JLBRomRfAPiaYhyAovLE1-u8iEegoFEWMfz-mqUcN8MXZODQXbtx0fGXJXnw-iBymM7oXADo9SChsBegWbMI0Mc2e2CpHEJt1jRzdxG2JOFXTO_2Jo-odjaISV6M/s320/IMG-20131012-01917.jpg" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
hayo,, yg ngaku suporter setia timnas u-19 pasti tau siapa pemain bernomor punggung 6 ini :)</div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
HORE,,,, Bravo Timnas u-19,, Selamat buat kalian, :)</div>
<div class="separator" style="clear: both; text-align: left;">
yups,, kurang lebih sama lah isi hati sebagian besar penduduk Indonesia yang merayakan kemanangan Garuda Jaya vs Korea Selatan (12 Oktober 2013)</div>
<div class="separator" style="clear: both; text-align: left;">
bagaimana tidak? baru beberapa menit pertandingan, hujan deras sudah mengguyur lapangan GBK.</div>
<div class="separator" style="clear: both; text-align: left;">
dan alhasil dalam waktu kurang lebih 20 menit, lapangan benar-benar becek dan terpaksa pertandingan dihentikan pada menit ke 42. Harusnya sih memang dihentikan sejak awal. Keadaan lapangan yang sangat becek mempengaruhi kualitas permainan tim kedua belah pihak. yang paling berpengaruh adalah bola-bola datar yang kebanyakan tak sampai di kaki tujuan, baru di tengah jalan sudah ditarik sama lumpur.hahhahahaha</div>
<div class="separator" style="clear: both; text-align: left;">
tapi ya begitulah, apa mau dikata, akhirnya panitia berhasil mengurangi sedikit tingkat kebecekan.</div>
<div class="separator" style="clear: both; text-align: left;">
tiba-tiba terpikirkan, kenapa GBK tidak pakai penutup lapangan saja? dan jawabannya, sudah pasti, "tidak ada dana" -__-"</div>
<div class="separator" style="clear: both; text-align: left;">
padahal kalau dilihat, kualitas permainan Garuda Jaya benar-benar oke tadi malam. dan sesuai yang dijanjikan pelatih, tekanan terus diberikan. yang saya lihat sih anak-anak Garuda Jaya aktif menyerang, sayang tidak didukung kondisi lapangan. Tapi ya sudahlah, berhenti mengeluh, lihatlah, kita menang, dan masuk babak selanjutnya. :)</div>
<div class="separator" style="clear: both; text-align: left;">
benar-benar perjuangan buat anak-anak timnas u-19 melawan Korea Selatan yg 12 kali menang AFF. berdiri di samping pemain korea, pemain kita kelihatan unyu-unyu banget..hahahahhaha, beruntunglah kita punya coach sekeren Indra Sjahfri. dengan motivasinya, kegeniusannya, kita bisa lolos :)</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
Dan siapakah bintang malam ini? EVAN DIMAS, kapten kita. :)</div>
<div class="separator" style="clear: both; text-align: left;">
sekarang saya tahu kenapa dia begitu dieluk-elukan. yaps, Evan Dimas mencetak hatrick malam tadi. 1 gol di babak pertama dan 2 gol di babak ke dua. Jalannya pertandingan n cantiknya gol-gol evan bisa dilihat sendiri di youtube.heheheheh</div>
<div class="separator" style="clear: both; text-align: left;">
tentu saja, kemenangan kita bukan cuma karena kemampuan Evan sendiri, peran penting pemain lain pun ikut memberi tekanan bagi tim lawan dan tentu saja dalam proses terjadinya gol =)</div>
<div class="separator" style="clear: both; text-align: left;">
Permainan berlangsung cukup panas, ehmmn, maksudnya, sempat terjadi emosi-emosian antar pemain, dari ekspresi, gerak tubuh, benar-benar kelihatan. Maklum saja, namanya darah muda, masih panas-panasnya, masih labil-labilnya.hahahhahahah,,, meskipun banyak kartu kuning (lumayan lah, lebih dari 2 itu banyak :D), tapi kita beruntung tak mendapat kartu merah. Sempat terjadi adu mulut, bahkan senggol-senggolan, untungnya tak berbuntut panjang. nah pemain yang saya lihat emosinya masih naik turun ya yg no 8. entah kenapa saya agak takut dia mendapat kartu merah. Puji Tuhan, ternyata tidak, malah akhirnya setelah saya pikir-pikir lagi, emosionalnya dia ternyata turut berperan dalam mengaduk-aduk mental lawan *bahasa kerennya, wkwkwkk*.</div>
<div class="separator" style="clear: both; text-align: left;">
Sedangkan pemain korea yang banyak disorot adalah si pemain no 11 yg masuk dalam 3 daftar pemain yang harus diwaspadai timnas kita. ya dari ngomel-ngomelnya dia, jatuhnya dia, dan yg paling menarik adalah rambutnya dia. dan tentu saja, dari segi postur mereka sepertinya berhasil tumbuh optimal..hahahahah. ya bgtulah, ada salah satu berita yg mebahas tentang hujan yang membuat bedak salah satu pemain korea luntur.. hadeeeehhh, apaan sih, pentingkah itu?? yang mau dilihat kan permainnannya. ya, tapi harus saya akui, kiper korea memang ganteng sekali =), dan pantas saja mereka menang 12 kali, dari segi permainan, mereka memang bagus. tapi entah kenapa, di matanya saya tetap indonesia lebih bagus ya. *subjektif sekali,hahahhaha*</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
Nama-nama pemain yang sering disorot ya seperti Maldini dan Ilham Udin ternyata memang pemain yang berkualitas, begitupun dengan pemain yang lainnya *sayanya aja yang pelupa*. Ilham udin beberapa kali mendapat kesempatan untuk membobol gawang lawan, tapi ya begitulah, belum berhasil *artinya nantinya akan berhasil =)*. Dan di manakah Yabes? dia akhirnya masuk di menit ke 88, bermain cukup baik. meskipun tak mencetak gol, tapi ternyata kehadirannya pun ditunggu oleh banyak orang, termasuk oleh bapak satpam kompleks kosan saya. katanya: "mana itu pemain no 31, dimasukkin aja, mainnya bagus tuh", dalam hati saya bangganya minta ampu.hahhahaha... (<i>flashback: pulang gereja udah setengah delapan lewat, berhubung tv kosan rusak, saya harus numpang nonton di kosan teman yg juga rumah makan, tempat biasa bapak-bapak juga pesan minuman n kadang nonton bola</i>). O ia, dan tidak lupa kita ucapkan terima kasih kepada bapak penjaga gawang, Rafi Murdianto, yang beberapa kali menyelamatkan gawang kita, keren loh mas bro... :)</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
dan terenngrengreng,,, skor bertahan 3-2 hingga tiupan pluit panjang terdengar di GBK. dengan demikian pertandingan selesai. berpelukan dan loncat-loncat adalah gerakan refleks pertama dan kedua dari para pemain timnas, pelatih, dan official timnas u-19. Yups, sayapun ikut terharu, ekspresi mereka, benar-benar bahagia, terharu, bangga, pokoknya sesuatu lah. dan tak lupa, bersujud. ini lah pesan dari pak pelatih dan tentu saja tertanam otomatis dalam hati mereka, pesan dari orang tua mereka: jangan lupa bersyukur pada Tuhan.. inilah ekspresi mereka, jangan lupa bersyukur pada Tuhanmu *perlu dicatat:<u> anggota tim ini berasal dari timur ke barat dengan banyak perbedaan tapi jadi satu dalam timnas u-19 :)</u>*</div>
<div class="separator" style="clear: both; text-align: left;">
dan begitulah, iklan pun lewat, sama seperti beberapa menit sebelum pertandingan LIVE ini ini berakhir, ada iklan komersil yg lewat. what the,, -__-". *heran saya, kenapa rcti yang harus menayangan pertandingan ini*</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
akhirnya. CONGRATULATION GARUDA JAYA (timnas Indonesia U-19) \(^o^)/</div>
<div class="separator" style="clear: both; text-align: left;">
sisa waktu ini, latihan yang rutin ya, jangan sombong n terbawa euforia kemenangan vs korsel ini. pertandingan sesungguhnya kalian adalah di Myanmar 2014 nanti. Pertahankan prestasi kalian. Ingat janji kalian, ingat motivasi kalian. Ingat bangsa n negara kita tercinta INDONESIA :)</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<br />luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com2tag:blogger.com,1999:blog-7294540944450239332.post-10020681963544782132013-10-11T07:31:00.003-07:002013-10-11T07:31:44.352-07:00<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;"><span style="color: blue; font-size: large;"><i><b>KARSINOMA NASOFARING</b></i></span><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Merupakan salah satu jenis kanker terbanyak di
Indonesia. Terdiri atas 3 jenis berdasarkan penggolongan WHO.<o:p></o:p></span></div>
<table border="0" cellpadding="0" class="MsoNormalTable" style="text-align: justify;">
<tbody>
<tr>
<td colspan="2" style="padding: .75pt .75pt .75pt .75pt;"><div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;">
<span style="font-family: Arial, Helvetica, sans-serif;"><b>WHO criteria</b><o:p></o:p></span></div>
</td>
</tr>
<tr>
<td style="padding: .75pt .75pt .75pt .75pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="font-family: Arial, Helvetica, sans-serif;">Type 1<o:p></o:p></span></div>
</td>
<td style="padding: .75pt .75pt .75pt .75pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="font-family: Arial, Helvetica, sans-serif;">Differentiated squamous cell carcinoma<o:p></o:p></span></div>
</td>
</tr>
<tr>
<td style="padding: .75pt .75pt .75pt .75pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="font-family: Arial, Helvetica, sans-serif;">Type 2<o:p></o:p></span></div>
</td>
<td style="padding: .75pt .75pt .75pt .75pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="font-family: Arial, Helvetica, sans-serif;">Nonkeratinizing carcinoma<o:p></o:p></span></div>
</td>
</tr>
<tr>
<td style="padding: .75pt .75pt .75pt .75pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="font-family: Arial, Helvetica, sans-serif;">Type 3<o:p></o:p></span></div>
</td>
<td style="padding: .75pt .75pt .75pt .75pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="font-family: Arial, Helvetica, sans-serif;">Undifferentiated carcinoma<o:p></o:p></span></div>
</td>
</tr>
</tbody></table>
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;"><b>ETIOLOGI</b><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpFirst" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">a.
<!--[endif]-->Herediter<!--[if supportFields]><span style='font-size:10.0pt;
mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span> ADDIN
ZOTERO_ITEM CSL_CITATION
{"citationID":"1og7cccs0r","properties":{"formattedCitation":"(1)","plainCitation":"(1)"},"citationItems":[{"id":13,"uris":["http://zotero.org/users/local/WTj1y5bM/items/FWZUFPVV"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/FWZUFPVV"],"itemData":{"id":13,"type":"book","title":"Robbins
& Cotran Pathologic Basis of
Disease,","publisher":"Elsevier Health Sciences","number-of-pages":"6007","source":"Google
Books","abstract":"One of the best-selling medical
textbooks of all time, Robbins and Cotran Pathologic Basis of Disease is the
one book that nearly all medical students purchase, and is also widely used by
physicians worldwide. A \"who's who\" of pathology experts delivers
the most dependable, current, and complete coverage of today's essential
pathology knowledge. At the same time, masterful editing and a practical
organization make mastering every concept remarkably easy. Online access via
Student Consult includes self-assessment and review questions, interactive case
studies, downloadable images, videos, and a virtual microscope that lets you
view slides at different magnifications. The result remains the ideal source
for an optimal understanding of pathology.Offers the most authoritative and
comprehensive, yet readable coverage available in any pathology textbook,
making it ideal for USMLE or specialty board preparation as well as for course
work.Includes access to the complete contents online via Student Consult, along
with self-assessment and review questions, over 100 interactive clinical case
studies, downloadable images, videos, and a virtual microscope that lets users
view slides at different magnifications.Delivers a state-of-the-art
understanding of the pathologic basis of disease through completely updated
coverage, including the latest cellular and molecular biology.Demonstrates
every concept visually with over 1,600 full-color photomicrographs and
conceptual diagrams - many revised for even better quality.Facilitates learning
with an outstanding full-color, highly user-friendly
design.","ISBN":"1437720153","language":"en","author":[{"family":"Kumar","given":"Vinay"},{"family":"Abbas","given":"Abul
K."},{"family":"Fausto","given":"Nelson"},{"family":"Aster","given":"Jon
C."}],"issued":{"date-parts":[["2009",6,10]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(1)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]-->, gen HLA-A2,B-17,Bw26<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span> ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"1ve25dmanc","properties":{"formattedCitation":"(2)","plainCitation":"(2)"},"citationItems":[{"id":113,"uris":["http://zotero.org/users/local/WTj1y5bM/items/8Z92J57P"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/8Z92J57P"],"itemData":{"id":113,"type":"article-journal","title":"Review
of nasopharyngeal carcinoma","container-title":"Ear, Nose
& Throat Journal","page":"168-70, 172-3,
184","volume":"85","issue":"3","source":"ProQuest","abstract":"We
review the literature on nasopharyngeal carcinoma that has been published
within the past 5 years. Nasopharyngeal carcinoma is a highly morbid disease,
and survival is poor. Its management remains extremely difficult, not just for
otolaryngologists but for radiation oncologists and medical oncologists, as
well. A clear understanding of its etiology is still lacking, but
nasopharyngeal carcinoma is widely suspected to be the result of both a genetic
susceptibility and exposure to environmental factors or Epstein-Barr virus
infection. With no clear cause, treatment is controversial. For example, an
optimal radiation regimen has not been determined, reports in the literature
regarding the role of chemotherapy for advanced disease are conflicting, and
treatment of local recurrences is unsettled. Still, advances in immunologic
research and chemotherapy offer hope for better control of the disease. We hope
that our assessment of the recent literature will provide otolaryngologists
with a more clear understanding of the etiology and management of
nasopharyngeal carcinoma.","ISSN":"01455613","language":"English","author":[{"family":"Jeyakumar","given":"Anita"},{"family":"Brickman","given":"Todd
M."},{"family":"Jeyakumar","given":"Alwin"},{"family":"Doerr","given":"Timothy"}],"issued":{"date-parts":[["2006",3]]},"accessed":{"date-parts":[["2013",10,8]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(2)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Orang yang keluarganya
pernah mengidap penyakit ini uga lebih rentan.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">b.
<!--[endif]-->Virus (EBV)<!--[if supportFields]><span style='font-size:10.0pt;
mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span> ADDIN
ZOTERO_ITEM CSL_CITATION
{"citationID":"820rollik","properties":{"formattedCitation":"(1)","plainCitation":"(1)"},"citationItems":[{"id":13,"uris":["http://zotero.org/users/local/WTj1y5bM/items/FWZUFPVV"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/FWZUFPVV"],"itemData":{"id":13,"type":"book","title":"Robbins
& Cotran Pathologic Basis of
Disease,","publisher":"Elsevier Health
Sciences","number-of-pages":"6007","source":"Google
Books","abstract":"One of the best-selling medical
textbooks of all time, Robbins and Cotran Pathologic Basis of Disease is the
one book that nearly all medical students purchase, and is also widely used by
physicians worldwide. A \"who's who\" of pathology experts delivers
the most dependable, current, and complete coverage of today's essential
pathology knowledge. At the same time, masterful editing and a practical
organization make mastering every concept remarkably easy. Online access via
Student Consult includes self-assessment and review questions, interactive case
studies, downloadable images, videos, and a virtual microscope that lets you
view slides at different magnifications. The result remains the ideal source
for an optimal understanding of pathology.Offers the most authoritative and
comprehensive, yet readable coverage available in any pathology textbook,
making it ideal for USMLE or specialty board preparation as well as for course
work.Includes access to the complete contents online via Student Consult, along
with self-assessment and review questions, over 100 interactive clinical case
studies, downloadable images, videos, and a virtual microscope that lets users
view slides at different magnifications.Delivers a state-of-the-art
understanding of the pathologic basis of disease through completely updated
coverage, including the latest cellular and molecular biology.Demonstrates
every concept visually with over 1,600 full-color photomicrographs and
conceptual diagrams - many revised for even better quality.Facilitates learning
with an outstanding full-color, highly user-friendly
design.","ISBN":"1437720153","language":"en","author":[{"family":"Kumar","given":"Vinay"},{"family":"Abbas","given":"Abul
K."},{"family":"Fausto","given":"Nelson"},{"family":"Aster","given":"Jon
C."}],"issued":{"date-parts":[["2009",6,10]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(1)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]-->, HPV-18 <!--[if supportFields]><span style='font-size:10.0pt;
mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"2olmceru89","properties":{"formattedCitation":"(3)","plainCitation":"(3)"},"citationItems":[{"id":107,"uris":["http://zotero.org/users/local/WTj1y5bM/items/WUKHXMZB"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/WUKHXMZB"],"itemData":{"id":107,"type":"article-journal","title":"Oral
Sex Is a Risk Factor for Human Papillomavirus-Associated Nasopharyngeal
Carcinoma in Husbands of Women with Cervical
Cancer","container-title":"Gynecologic and Obstetric
Investigation","page":"73-5","volume":"70","issue":"2","source":"ProQuest","abstract":"Sexually
transmitted human papillomavirus (HPV) is etiologically related to cervical
carcinoma and a distinct subset of cancers of the nasopharyngeal tract. We
report 2 patients with HPV-associated cervical cancer and synchronous diagnoses
of HPV-related head and neck cancer of their husbands. These patients had
active oral sex for more than 20 years. The first patient was a 64-year-old
woman who had an abnormal Papanicolaou smear and was found to have squamous
cell carcinoma of the cervix on cervical punched biopsy. Her husband was
diagnosed with laryngeal squamous cell carcinoma 1 year previously, and was
treated with total laryngectomy and adjuvant radiation. HPV-16 DNA was detected
in both their tumor specimens using polymerase chain reaction. The other
patient was a 50-year-old female with cervical carcinoma treated surgically and
with concurrent chemo-radiotherapy. HPV-31 DNA was detected in her tumor
specimen. Three years later, her husband presented with nasopharyngeal
carcinoma, although not a tobacco or alcohol user. HPV-18 DNA was detected in
his tumor specimen.These findings strongly suggest that HPV may play a major
role in the carcinogenesis of urogenital and nasopharyngeal tumors and the
transmission potential of orogenital sex.\nCopyright © 2010 S. Karger AG, Basel
[PUBLICATION
ABSTRACT]","DOI":"http://dx.doi.org/10.1159/000291199","ISSN":"03787346","language":"English","author":[{"family":"Huang","given":"Lee-wen"},{"family":"Seow","given":"Kok-min"}],"issued":{"date-parts":[["2010",8]]},"accessed":{"date-parts":[["2013",10,8]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(3)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">c.
<!--[endif]-->Lingkungan<!--[if supportFields]><span style='font-size:10.0pt;
mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span> ADDIN
ZOTERO_ITEM CSL_CITATION
{"citationID":"15i2kj6tru","properties":{"formattedCitation":"(4)","plainCitation":"(4)"},"citationItems":[{"id":90,"uris":["http://zotero.org/users/local/WTj1y5bM/items/AM4332KU"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/AM4332KU"],"itemData":{"id":90,"type":"book","title":"WHO
Classifications of
Tumoure"}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(4)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: 54pt; text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Zat karsinogen<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: 54pt; text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Radiasi<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-bottom: 0.0001pt; text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Faktor
ini terutama faktor eksogen dapat menyebabkan terbentuknya sel tumor lewat
mutasi gen nya seperti Gen yang biasa terganggu adalah (onkogen: bcl2, ras, myt. Tsg: p53, rb,,
SPLUNC1, UBAP1, BRD7, Nor1, NGX6, and LTF <!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt;mso-bidi-font-family:Minion-Regular'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"20krn8n6cn","properties":{"formattedCitation":"(5)","plainCitation":"(5)"},"citationItems":[{"id":59,"uris":["http://zotero.org/users/local/WTj1y5bM/items/EZM799IK"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/EZM799IK"],"itemData":{"id":59,"type":"article-journal","title":"Early
Detection of Nasopharyngeal
Carcinoma","container-title":"International Journal of
Otolaryngology","volume":"2011","source":"www.hindawi.com","abstract":"Nasopharyngeal
carcinoma (NPC) is a unique disease with a clinical presentation, epidemiology,
and histopathology differing from other squamous cell carcinomas of the head
and neck. NPC is an Epstein-Barr virus-associated malignancy with a marked
racial and geographic distribution. Specifically, it is highly prevalent in
southern China, Southeast Asia, and the Middle East. To date, most NPC patients
have been diagnosed in the advanced stage, but the treatment results for
advanced NPC are not satisfactory. This paper provides a brief overview
regarding NPC, with the focus on the early detection of initial and recurrent
NPC
lesions.","URL":"http://www.hindawi.com/journals/ijol/2011/638058/abs/","DOI":"10.1155/2011/638058","ISSN":"1687-9201","language":"en","author":[{"family":"Tabuchi","given":"Keiji"},{"family":"Nakayama","given":"Masahiro"},{"family":"Nishimura","given":"Bungo"},{"family":"Hayashi","given":"Kentaro"},{"family":"Hara","given":"Akira"}],"issued":{"date-parts":[["2011",6,8]]},"accessed":{"date-parts":[["2013",10,8]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(5)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt;mso-bidi-font-family:Minion-Regular'><span
style='mso-element:field-end'></span></span><![endif]--> kehilangan kromosom heterozigot <!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM
CSL_CITATION
{"citationID":"2ernh7jjfd","properties":{"formattedCitation":"(6)","plainCitation":"(6)"},"citationItems":[{"id":116,"uris":["http://zotero.org/users/local/WTj1y5bM/items/V84BM53J"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/V84BM53J"],"itemData":{"id":116,"type":"article-journal","title":"The
tumor supressor function of STGC3 and its reduced expression in nasopharyngeal
carcinoma","container-title":"Cellular & Molecular
Biology
Letters","page":"339-52","volume":"13","issue":"3","source":"ProQuest","abstract":"STGC3
is a novel candidate tumor suppressor gene that was found to be associated with
nasopharyngeal carcinoma (NPC) via the cDNA cloning and RACE processes. The
biological function of the STGC3 protein and its expression level in
nasopharyngeal carcinoma remain unknown. This study aimed to evaluate the STGC3
protein expression level in NPC and to investigate the inhibitory function of
STGC3 as a candidate tumor suppressor gene. We assessed the expression of the
STGC3 protein in NPC biopsies and normal control specimens via Western blot and
immunohistochemical analysis. The expression of STGC3 as induced by doxycycline
(Dox) via a tetracycline (Tet)-regulated system in human nasopharyngeal
carcinoma cell line CNE2 was also established, and the effect of STGC3
restoration on the biological behavior of CNE2 was observed. A reduced level of
STGC3 expression (0.978 ± 0.213 versus 0.324 ± 0.185, P < 0.05) was detected
in NPC versus normal nasopharyngeal tissue by Western blot assay.
Immunohistochemical assays for STGC3 detected positive staining in the nuclei
and cytoplasm of epithelial cells, and the positive expression rate in NPC, 8
of 21 (38%), was lower than that in normal nasopharynx samples, 16 of 22 (72%).
After STGC3 expression was restored, the growth capacity and clone formation
potential of CNE2 cells in soft agar were significantly suppressed, and the
cell percentage in G0/G1 phase increased, while the percentage of cells
entering the S and G2 phases decreased. This indicates that an abnormality in
STGC3 expression is associated with nasopharyngeal carcinogenesis and that it
may play an important role in controlling cell growth and regulating the cell
cycle.","DOI":"http://dx.doi.org/10.2478/s11658-008-0006-9","ISSN":"1425-8153","language":"English","author":[{"family":"He","given":"Xiu-sheng"},{"family":"Deng","given":"Min"},{"family":"Yang","given":"Shuai"},{"family":"Xiao","given":"Zhi-qiang"},{"family":"Luo","given":"Qiao"},{"family":"He","given":"Zhi-min"},{"family":"Hu","given":"Bo"},{"family":"Chen","given":"Zhu-chu"}],"issued":{"date-parts":[["2008",9]]},"accessed":{"date-parts":[["2013",10,8]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(6)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]-->, pengulangan kromosom 3p21 <!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM
CSL_CITATION
{"citationID":"57uru1hvc","properties":{"formattedCitation":"(2)","plainCitation":"(2)"},"citationItems":[{"id":113,"uris":["http://zotero.org/users/local/WTj1y5bM/items/8Z92J57P"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/8Z92J57P"],"itemData":{"id":113,"type":"article-journal","title":"Review
of nasopharyngeal carcinoma","container-title":"Ear, Nose
& Throat Journal","page":"168-70, 172-3,
184","volume":"85","issue":"3","source":"ProQuest","abstract":"We
review the literature on nasopharyngeal carcinoma that has been published
within the past 5 years. Nasopharyngeal carcinoma is a highly morbid disease,
and survival is poor. Its management remains extremely difficult, not just for
otolaryngologists but for radiation oncologists and medical oncologists, as
well. A clear understanding of its etiology is still lacking, but
nasopharyngeal carcinoma is widely suspected to be the result of both a genetic
susceptibility and exposure to environmental factors or Epstein-Barr virus
infection. With no clear cause, treatment is controversial. For example, an
optimal radiation regimen has not been determined, reports in the literature
regarding the role of chemotherapy for advanced disease are conflicting, and
treatment of local recurrences is unsettled. Still, advances in immunologic
research and chemotherapy offer hope for better control of the disease. We hope
that our assessment of the recent literature will provide otolaryngologists
with a more clear understanding of the etiology and management of
nasopharyngeal
carcinoma.","ISSN":"01455613","language":"English","author":[{"family":"Jeyakumar","given":"Anita"},{"family":"Brickman","given":"Todd
M."},{"family":"Jeyakumar","given":"Alwin"},{"family":"Doerr","given":"Timothy"}],"issued":{"date-parts":[["2006",3]]},"accessed":{"date-parts":[["2013",10,8]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(2)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--><!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span> ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"2oo134mu2q","properties":{"formattedCitation":"(7)","plainCitation":"(7)"},"citationItems":[{"id":122,"uris":["http://zotero.org/users/local/WTj1y5bM/items/62MJXZ6M"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/62MJXZ6M"],"itemData":{"id":122,"type":"article-journal","title":"Effect
of family history of cancers and environmental factors on risk of
nasopharyngeal carcinoma in Guangdong,
China","container-title":"Cancer
Epidemiology","page":"419-24","volume":"34","issue":"4","source":"ProQuest","DOI":"http://dx.doi.org/10.1016/j.canep.2010.04.011","language":"English","author":[{"family":"Ren","given":"Ze-Fang"},{"family":"Liu","given":"Wen-Sheng"},{"family":"Qin","given":"Hai-De"},{"family":"Xu","given":"Ya-Fei"},{"family":"Yu","given":"Dan-Dan"},{"family":"Feng","given":"Qi-Sheng"},{"family":"Chen","given":"Li-Zhen"},{"family":"Shu","given":"Xiao-Ou"},{"family":"Zeng","given":"Yi-Xin"},{"family":"Jia","given":"Wei-Hua"}],"issued":{"date-parts":[["2010"]]},"accessed":{"date-parts":[["2013",10,8]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(7)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]-->.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;"><b>FAKTOR RESIKO</b><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpFirst" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">a.
<!--[endif]-->Alkohol dan rokok<!--[if supportFields]><span style='font-size:
10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"16r6vfm6tr","properties":{"formattedCitation":"(8)","plainCitation":"(8)"},"citationItems":[{"id":143,"uris":["http://zotero.org/users/local/WTj1y5bM/items/MDGIHBJJ"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/MDGIHBJJ"],"itemData":{"id":143,"type":"article-journal","title":"Human
Papillomavirus and Head and Neck Cancer","container-title":"Oncology","page":"927,
933","volume":"24","issue":"10","source":"ProQuest","abstract":"Approximately
25% of all HNSCCs worldwide contain HPV DNA. [4,5] The prevalence is highest
among patients with oropharyngeal squamous cell carcinoma. HPV 16 and HPV 18,
two high-risk HPVs that are also observed in cervical cancer, together account
for almost all HPV types in HNSCC, with HPV 16 being the most common type.
[4,5] Patients with HPV-related HNSCC are characterized by moderate smoking and
alcohol use, certain sexual behaviors, and younger age (5-10 years) compared
with patients who have HPV-unrelated HNSCC. [6] Regarding specific molecular
characteristics, nearly all HPV-related HNSCCs express the oncoproteins E6 and
E7, lack p5 3 mutations, and express pl6. Compared with HPV-negative tumors,
oropharyngeal squamous cell carcinomas caused by HPV are associated with a
better survival regardless of treatment strategy. [5,7,8] The specific cause of
the higher rates of response to chemotherapy and radiation therapy among
patients with HPV-positive tumors is not known, but the different molecular
profiles likely play a role. Expression of the E6 and E7 oncoproteins may make
HPV-positive HNSCCs more immunogenic than HPV-negative HNSCCs; anti-E6 and
anti-E7 antibodies are found in the majority of HPV-positive cases. [9]
Interestingly, data recently reported by Ang et al. suggest that tobacco
smoking negatively affects the prognosis of both HPV-positive and HPV-negative
HNSCCs.[8]","ISSN":"08909091","language":"English","author":[{"family":"Diergaarde","given":"Brenda"},{"family":"Grandis","given":"Jennifer
R."}],"issued":{"date-parts":[["2010",9]]},"accessed":{"date-parts":[["2013",10,8]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(8)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">b.
<!--[endif]-->Pria lebih banyak 2-3 kali daripada yang perempuan <!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM
CSL_CITATION
{"citationID":"1nmbtg8l9l","properties":{"formattedCitation":"(4)","plainCitation":"(4)"},"citationItems":[{"id":90,"uris":["http://zotero.org/users/local/WTj1y5bM/items/AM4332KU"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/AM4332KU"],"itemData":{"id":90,"type":"book","title":"WHO
Classifications of
Tumoure"}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(4)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">c.
<!--[endif]-->Ras kaukasian jarang, sedangkan pada ras mongolian lebih banyak,.
Diketahui nbhwa indonesia merupakan daerah endemic tetapi dengan mortalitas yg
lebih rendah dari china, taiwan dan malaysia. <!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM
CSL_CITATION
{"citationID":"1eqvbkhu7h","properties":{"formattedCitation":"(9)","plainCitation":"(9)"},"citationItems":[{"id":161,"uris":["http://zotero.org/users/local/WTj1y5bM/items/SWZIMCM8"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/SWZIMCM8"],"itemData":{"id":161,"type":"article-journal","title":"Polymorphism
analysis of Epstein-Barr virus isolates of nasopharyngeal carcinoma biopsies
from Tunisian patients","container-title":"Virus
Genes","page":"137-45","volume":"34","issue":"2","source":"ProQuest","abstract":"Many
studies suggest that the focal distribution of nasopharyngeal carcinoma (NPC) may
be influenced not only by host genetics, diet and environments but also by
interplay with Epstein-Barr virus (EBV) genetics. Specific EBV gene variants
(the A and C types, the BamHI f configuration, a C terminal 30 bp deletion and
a N terminal loss of an XhoI site in the BNLF1 gene) have been explored in high
incidence areas in southern Asian NPC patients. In contrast, in Tunisia where
NPC represents the most frequent type of Head and Neck cancer the distribution
of these polymorphisms remains poorly investigated. In order to characterize
the epidemiology of EBV variants in Tunisian NPC patients, we have investigated
the A or B type of the EBV nuclear antigen (EBNA)2 gene, the C or D type of the
BamHI W1/I1 region, the F/f variants of the BamHI F region and the presence or
the absence of the XhoI site, 30 bp deletion and Taq1 site in the BNLF1 gene in
47 NPC biopsies, 12 being younger than 30 and 35 older than 30. Our results
show a unique genetic profile of the tumor EBV strains regarding the A and D types,
the prototype F and retention of the XhoI restriction site in the N terminal
region of BNLF1 gene. With regard to the C terminal region of this gene, four
genetic profiles were detected: (1) the occurrence of the 30 bp deletion in
association with the Taq1 site in 39 cases (83%), (2) the presence of the Taq1
site by itself in 5 cases, (3) the occurrence of the 30 bp deletion by itself
in 2 cases and (4) the occurrence of a new deletion of 81 bp covering the 30 bp
deletion in association with the Taq1 site in one case. With the exception of
the 81 bp deletion, which has not been previously described in the literature,
the summarized results have shown the same genetic profile in Tunisian NPC
tumor isolates as tumor isolates from other North African and Mediterranean
countries. Hence, the observed EBV polymorphisms are not fully specific of to
the Tunisian NPCs. Nevertheless, the notion of a divergence between North
African and Asian tumor EBV isolates is reinforced by this
study.","DOI":"http://dx.doi.org/10.1007/s11262-006-0051-2","ISSN":"09208569","language":"English","author":[{"family":"Ayadi","given":"Wajdi"},{"family":"Feki","given":"Lamia"},{"family":"Khabir","given":"Abdelmajid"},{"family":"Boudawara","given":"Tahia"},{"family":"Ghorbel","given":"Abdelmonem"},{"family":"Charfeddine","given":"Ilhem"},{"family":"Daoud","given":"Jamel"},{"family":"Frikha","given":"Mounir"},{"family":"Hammami","given":"Adnane"},{"family":"Karray-Hakim","given":"HĂ©la"}],"issued":{"date-parts":[["2007",4]]},"accessed":{"date-parts":[["2013",10,8]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(9)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--> angka mortalitas tahun 2004 yaitu sebesar 127/100.000 jiwa <!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM
CSL_CITATION {"citationID":"2kvfvl8tlt","properties":{"formattedCitation":"(10)","plainCitation":"(10)"},"citationItems":[{"id":155,"uris":["http://zotero.org/users/local/WTj1y5bM/items/GQMMS7NH"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/GQMMS7NH"],"itemData":{"id":155,"type":"report","title":"V10.
Cancer, all sites; personal history of malignant
neoplasm","publisher":"Timely Data Resources,
Inc.","publisher-place":"Capitola, United
States","page":"0","source":"ProQuest","event-place":"Capitola,
United States","URL":"http://search.proquest.com/docview/1267795637/140FECEDF41601E4F6F/6?accountid=48149","language":"English","issued":{"date-parts":[["2013"]],"season":"First
Quarter"},"accessed":{"date-parts":[["2013",10,8]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(10)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">d.
<!--[endif]-->Perempuan yg pernah melakukan koitus di usia 16-18 tahun menunjukkan
adanya ebv di secret genitalnya<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span> ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"1tqbo721dv","properties":{"formattedCitation":"(11)","plainCitation":"(11)"},"citationItems":[{"id":189,"uris":["http://zotero.org/users/local/WTj1y5bM/items/6TFFW8N3"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/6TFFW8N3"],"itemData":{"id":189,"type":"article-journal","title":"Sexual
history and Epstein-Barr virus infection","container-title":"The
Journal of infectious
diseases","page":"731-736","volume":"186","issue":"6","source":"NCBI
PubMed","abstract":"To determine the role of sexual contact
in transmission of Epstein-Barr virus (EBV) and occurrence of infectious
mononucleosis (IM), a cross-sectional study was undertaken of EBV serologic
testing and histories of IM and sexual behavior among 1006 new students at
Edinburgh University. Prevalence of EBV seropositivity was significantly
greater among women (79.2%) than among men (67.4%; P<.001) and among those
who had ever been sexually active (82.7%) than among those who had not (63.7%;
P<.001). Having a greater number of sex partners was a highly significant
risk factor for EBV seropositivity. Two thirds of IM cases, but only a tenth of
asymptomatic primary EBV infections, were statistically attributable to sexual
intercourse. The findings suggest that EBV transmission occurs during sexual
intercourse or closely associated behaviors. Transmission in this way appears
to account for most cases of IM but for only a minority of cases of
asymptomatic EBV infection, which mainly occur at younger
ages.","DOI":"10.1086/342596","ISSN":"0022-1899","note":"PMID:
12198605","journalAbbreviation":"J. Infect.
Dis.","language":"eng","author":[{"family":"Crawford","given":"Dorothy
H"},{"family":"Swerdlow","given":"Anthony
J"},{"family":"Higgins","given":"Craig"},{"family":"McAulay","given":"Karen"},{"family":"Harrison","given":"Nadine"},{"family":"Williams","given":"Hilary"},{"family":"Britton","given":"Kathryn"},{"family":"Macsween","given":"Karen
F"}],"issued":{"date-parts":[["2002",9,15]]},"PMID":"12198605"}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(11)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--><!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"244urtqjf4","properties":{"formattedCitation":"(12)","plainCitation":"(12)"},"citationItems":[{"id":92,"uris":["http://zotero.org/users/local/WTj1y5bM/items/D4W6A5IW"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/D4W6A5IW"],"itemData":{"id":92,"type":"article-journal","title":"Evidence
of shared Epstein-Barr viral isolates between sexual partners, and low level
EBV in genital secretions","container-title":"Journal of
medical virology","page":"1204-1209","volume":"78","issue":"9","source":"NCBI
PubMed","abstract":"Epstein-Barr virus is present in the
saliva of most persistently infected individuals and is generally thought to be
spread by close oral contact. However, there are now several reports of EBV in
genital secretions, suggesting the possibility of sexual transmission between
adults. The present study was undertaken to investigate the risk of sexual
transmission of EBV. PCR analysis was used to examined the degree to which a
group (n = 11) of patients with infectious mononucleosis (IM) shared the same
viral isolates as their sexual partners, and compare this to the extent of
isolate sharing among a different group (n = 18) of IM patients and their
non-sexual contacts. There was significantly more sharing of EBV isolates among
the IM/sexual-contact pairs than among the IM/non-sexual-contact pairs (P =
0.0012). Female cervical (n = 84), male urethral (n = 55), and semen (n = 30)
samples from asymptomatic, unselected volunteers were analyzed for the presence
of EBV DNA, revealing 7%, 5%, and 3% to be EBV positive, respectively.
Fractionation of cervical and urethral samples into cellular and supernatant
fluid components showed EBV to be mainly cell-associated. Quantitation of EBV
in these samples gave levels of below 10 EBV genomes per microg of DNA. Overall
the findings support the possibility that EBV could on occasions be transmitted
sexually, however, the low levels detected in genital secretions compared to
saliva suggest that this is not a major transmission route. The finding of
small quantities of cell-associated virus suggests a latent infection; thus EBV
is probably in the B lymphocyte rather than in the epithelial cell component of
the
secretions.","DOI":"10.1002/jmv.20682","ISSN":"0146-6615","note":"PMID:
16847960","journalAbbreviation":"J. Med.
Virol.","language":"eng","author":[{"family":"Thomas","given":"Ranjit"},{"family":"Macsween","given":"Karen
F"},{"family":"McAulay","given":"Karen"},{"family":"Clutterbuck","given":"Daniel"},{"family":"Anderson","given":"Richard"},{"family":"Reid","given":"Stuart"},{"family":"Higgins","given":"Craig
D"},{"family":"Swerdlow","given":"Anthony
J"},{"family":"Harrison","given":"Nadine"},{"family":"Williams","given":"Hilary"},{"family":"Crawford","given":"Dorothy
H"}],"issued":{"date-parts":[["2006",9]]},"PMID":"16847960"}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(12)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--><!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span> ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"196rlou70r","properties":{"formattedCitation":"(12)","plainCitation":"(12)"},"citationItems":[{"id":92,"uris":["http://zotero.org/users/local/WTj1y5bM/items/D4W6A5IW"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/D4W6A5IW"],"itemData":{"id":92,"type":"article-journal","title":"Evidence
of shared Epstein-Barr viral isolates between sexual partners, and low level
EBV in genital secretions","container-title":"Journal of
medical
virology","page":"1204-1209","volume":"78","issue":"9","source":"NCBI
PubMed","abstract":"Epstein-Barr virus is present in the
saliva of most persistently infected individuals and is generally thought to be
spread by close oral contact. However, there are now several reports of EBV in
genital secretions, suggesting the possibility of sexual transmission between
adults. The present study was undertaken to investigate the risk of sexual
transmission of EBV. PCR analysis was used to examined the degree to which a
group (n = 11) of patients with infectious mononucleosis (IM) shared the same
viral isolates as their sexual partners, and compare this to the extent of isolate
sharing among a different group (n = 18) of IM patients and their non-sexual
contacts. There was significantly more sharing of EBV isolates among the
IM/sexual-contact pairs than among the IM/non-sexual-contact pairs (P =
0.0012). Female cervical (n = 84), male urethral (n = 55), and semen (n = 30)
samples from asymptomatic, unselected volunteers were analyzed for the presence
of EBV DNA, revealing 7%, 5%, and 3% to be EBV positive, respectively.
Fractionation of cervical and urethral samples into cellular and supernatant
fluid components showed EBV to be mainly cell-associated. Quantitation of EBV
in these samples gave levels of below 10 EBV genomes per microg of DNA. Overall
the findings support the possibility that EBV could on occasions be transmitted
sexually, however, the low levels detected in genital secretions compared to
saliva suggest that this is not a major transmission route. The finding of
small quantities of cell-associated virus suggests a latent infection; thus EBV
is probably in the B lymphocyte rather than in the epithelial cell component of
the
secretions.","DOI":"10.1002/jmv.20682","ISSN":"0146-6615","note":"PMID:
16847960","journalAbbreviation":"J. Med.
Virol.","language":"eng","author":[{"family":"Thomas","given":"Ranjit"},{"family":"Macsween","given":"Karen
F"},{"family":"McAulay","given":"Karen"},{"family":"Clutterbuck","given":"Daniel"},{"family":"Anderson","given":"Richard"},{"family":"Reid","given":"Stuart"},{"family":"Higgins","given":"Craig
D"},{"family":"Swerdlow","given":"Anthony
J"},{"family":"Harrison","given":"Nadine"},{"family":"Williams","given":"Hilary"},{"family":"Crawford","given":"Dorothy
H"}],"issued":{"date-parts":[["2006",9]]},"PMID":"16847960"}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(12)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]-->.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">e.
<!--[endif]-->Masyarakat yang sering memakan ikan asin (mengandung nitrosamin)
sebagai karsinogen<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">f.
<!--[endif]-->Tukang masak (lebih sering terpapar asap <!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM
CSL_CITATION
{"citationID":"rj456si9u","properties":{"formattedCitation":"(13)","plainCitation":"(13)"},"citationItems":[{"id":142,"uris":["http://zotero.org/users/local/WTj1y5bM/items/W5VPPPZ5"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/W5VPPPZ5"],"itemData":{"id":142,"type":"book","title":"Diagnosis
dan Tata Laksana SEPULUH JENIS KANKER TERBANYAK DI
INDONESIA","publisher":"EGC","publisher-place":"Jakarta","event-place":"Jakarta","ISBN":"979-448-147-5","author":[{"family":"Tambunan","given":"Gani
W."}],"issued":{"date-parts":[["1995"]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(13)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">g.
<!--[endif]-->Tempat kerja, orang yang sering terpapar formaldehida lebih rentan <!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM
CSL_CITATION
{"citationID":"2pnopn3peb","properties":{"formattedCitation":"(10)","plainCitation":"(10)"},"citationItems":[{"id":"gCFNVglz/EfseCPOX","uris":["http://zotero.org/users/local/WTj1y5bM/items/GQMMS7NH"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/GQMMS7NH"],"itemData":{"id":"gCFNVglz/EfseCPOX","type":"report","title":"V10.
Cancer, all sites; personal history of malignant neoplasm","publisher":"Timely
Data Resources, Inc.","publisher-place":"Capitola, United
States","page":"0","source":"ProQuest","event-place":"Capitola,
United
States","URL":"http://search.proquest.com/docview/1267795637/140FECEDF41601E4F6F/6?accountid=48149","language":"English","issued":{"year":2013,"season":"First
Quarter"},"accessed":{"year":2013,"month":10,"day":8},"page-first":"0"}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(10)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--><!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span> ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"f9q4ag3h9","properties":{"formattedCitation":"(14)","plainCitation":"(14)"},"citationItems":[{"id":242,"uris":["http://zotero.org/users/local/WTj1y5bM/items/I29BPIAF"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/I29BPIAF"],"itemData":{"id":242,"type":"article-journal","title":"Carcinogenic
potential of formaldehyde in occupational settings: a critical assessment and
possible impact on occupational exposure
levels","container-title":"International Archives of
Occupational and Environmental
Health","page":"695-710","volume":"81","issue":"6","source":"ProQuest","abstract":"To
review epidemiological studies which led to a change in the classification of
formaldehyde by the International Agency for Research on Cancer (IARC) in 2004
as well as studies published thereafter, with the objective to examine whether
occupational exposure levels for formaldehyde should be adapted.\nCohort and
case-control studies investigating the association between occupational
exposure to formaldehyde and nasopharyngeal cancer (NPC) and reporting
estimates of formaldehyde exposure as well as the most recent meta-analyses,
published after 1994, were reviewed.\nEvidence of an association between
occupational formaldehyde exposure and NPC appears debatable. Results of the
cohort studied by Hauptmann et al. (Am J Epidemiol 159(12):1117-1130, 2004)
were key findings in the IARC evaluation. In this study, mortality from NPC was
elevated compared with that of the US general population. However, internal
comparison analysis using alternative categorization revealed that none of the
relative risk for NPC was statistically significantly increased in any category
of exposure (Marsh and Youk in Regul Toxicol Pharmacol 42(3):275-283, 2005) and
re-analyses of the data highlighted the inappropriateness of the exposure
assessment used by Hauptmann et al. (Am J Epidemiol 159(12):1117-1130, 2004)
and Marsh et al. (Regul Toxicol Pharmacol 47(1):59-67, 2007). Two other cohorts
(Coggon et al. in J Natl Cancer Inst 95(21):1608-1615, 2003; Pinkerton et al.
in Occup Environ Med 61(3)193-200, 2004) reported no increase in NPC. Two
case-control studies brought some evidence of an increased risk of NPC but the
assessment of exposure levels was uncertain.\nHuman studies fail to raise a
convincing conclusion concerning the carcinogenicity of formaldehyde and are
not helpful to delineate a possible dose-response relationship. Experimental
data indicate that in rats, the carcinogenic activity of formaldehyde is
associated with cytotoxic/proliferative mechanisms. Therefore protecting from
these effects associated with formaldehyde exposure should be sufficient to
protect from its potential carcinogenic effects, if any in humans.\nCurrent
occupational exposure levels to formaldehyde, set to protect against local
irritation, should not be adapted. [PUBLICATION ABSTRACT]","DOI":"http://dx.doi.org/10.1007/s00420-007-0241-9","ISSN":"0340-0131","shortTitle":"Carcinogenic
potential of formaldehyde in occupational
settings","language":"English","author":[{"family":"Duhayon","given":"S."},{"family":"Hoet","given":"P."},{"family":"Van
Maele-Fabry","given":"G."},{"family":"Lison","given":"D."}],"issued":{"date-parts":[["2008",5]]},"accessed":{"date-parts":[["2013",10,9]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(14)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--><o:p></o:p></span><br />
<span style="font-family: Arial, Helvetica, sans-serif;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;"><b>GEJALA DAN MANIFESTASI KLINIS</b><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Manifestasi klinis CNP biasanya dihubungkan dengan
letak anatomiknya terhadap hidung, tuba eustachii dan dasar tengkorak dan adanya jaringan submukosa
luas pembuluhh limfe.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpFirst" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Epistasis (pendarahan dari hidung)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Hidung tersumbat<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Pilek yg sudah lebih dari 1 bulan. Terutama pada orang usia diatas
40tahun.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Lendir berdarah di tenggorokan belakang<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Suara berdengung di telinga (tinusitis)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Kehilangan pendengaran<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Tidak berfungsinya saraf otak (n V, VI, X)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Sakit kepala (biasanya dimulai dengan unilateral baru bilateral)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span> ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"1q8gra6d47","properties":{"formattedCitation":"(13)","plainCitation":"(13)"},"citationItems":[{"id":142,"uris":["http://zotero.org/users/local/WTj1y5bM/items/W5VPPPZ5"],"uri":["http://zotero.org/users/local/WTj1y5bM/items/W5VPPPZ5"],"itemData":{"id":142,"type":"book","title":"Diagnosis
dan Tata Laksana SEPULUH JENIS KANKER TERBANYAK DI
INDONESIA","publisher":"EGC","publisher-place":"Jakarta","event-place":"Jakarta","ISBN":"979-448-147-5","author":[{"family":"Tambunan","given":"Gani
W."}],"issued":{"date-parts":[["1995"]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]-->(13)<!--[if supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Gangguan neurologik kelumpuhan gangguan fungsi penglihatan(terganggunya
kiasama optikum)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Pembengkakan leher (biasanya karena pembengkakan kelenjar limfe<o:p></o:p></span><br />
<span style="font-family: Arial, Helvetica, sans-serif;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;"><b>PATOFISIOLOGI</b><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Virus EBV yang masuk akan menyebabkan terjadi nya sel-sel abnormal lewat mutasi gen
nya.<o:p></o:p></span></div>
<div class="MsoNormal" style="background-color: white; background-position: initial initial; background-repeat: initial initial; margin-bottom: 0.0001pt; text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;"><span style="border: 1pt none windowtext; padding: 0cm;">Langkah awal infeksi litik EBV ditandai
dengan aktivitas protein ZEBRA yang disandi oleh gen BZLF1 yang terdapat pada
sel epitel dan limfosit B. Beberapa produk yang berbeda-beda dari gen yang
mempuyai korelasi dengan tahapan siklus replikasi litik dapat diidentifikasi
dan dikategorikan menjadi: Early Membrane Antigen (EMA), Early Intra- Celulair
Atigen (EA), Viral capcid Antigen (VCA),Late Membrane Antigen (LMA). Pada
infeksi latent terjadi ekspresi dari beberapa protein antara lain: Epstein Barr
Nucleus Antigen 2 & 5 (EBNA 2 & 5) yang dapat diteksi 2-5 jam setelah
infeksi, Latent Membrane Protein 1 & 2 (LMP 1&2) yang dapat diteksi 5-7
jam setelah infeksi.</span><o:p></o:p></span></div>
<div class="MsoNormal" style="background-color: white; background-position: initial initial; background-repeat: initial initial; margin-bottom: 0.0001pt; text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;"><span style="border: 1pt none windowtext; padding: 0cm;"><br />
Infeksi laten yang bersifat diam dan tidak memproduksi partikel-partikel virus
yang baru, dikaitkan salah satunya dengan KNF. Bentuk laten infeksi EBV pada
KNF termasuk tipe II dengan karakteristik terekspresinya protein LMP disamping
protein EBER dan EBNA1.</span><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Virus EBV akan menyerang sel epitel nasofaring,
menghasilkan LMP (laten membran protein) yg mencegah sel diapoptosis. Gen LMP ditemukan hampir disebagian besar
penderita CNP<o:p></o:p></span><br />
<span style="font-family: Arial, Helvetica, sans-serif;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;"><b>PEMERIKSAAN FISIK DAN PENUNJANG</b><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Pemeriksaan fisik<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpFirst" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Inspeksi<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Palpasi<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Pemeriksaan Penunjang<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpFirst" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Endoskopy, rinoskopi (tetapi
akan susah dilihat, soalnya sudah membengkak)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->MRI<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->CT scan<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Biopsi aspirasi (pemeriksaan serologic)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Biopsi nasofaring (periksaan histologi)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="text-align: justify; text-indent: -18pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">-
<!--[endif]-->Tes antigen EBV<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;"><b>STADIUM</b></span></div>
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Table. TNM classification</span><br />
<span style="font-family: Arial, Helvetica, sans-serif;"><br /></span></div>
<table border="1" cellpadding="0" cellspacing="0" class="MsoTableLightShadingAccent5" style="border-collapse: collapse; border: none; margin-left: 6.75pt; margin-right: 6.75pt; text-align: left; width: 356px;">
<tbody>
<tr style="height: 17.35pt; mso-yfti-firstrow: yes; mso-yfti-irow: -1;">
<td colspan="2" style="border-bottom: solid #4BACC6 1.0pt; border-left: none; border-right: none; border-top: solid #4BACC6 1.0pt; height: 17.35pt; mso-border-bottom-themecolor: accent5; mso-border-top-themecolor: accent5; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Primary tumor (T)<o:p></o:p></span></span></b></div>
</td>
</tr>
<tr style="height: 18.55pt; mso-yfti-irow: 0;">
<td style="background: #D2EAF1; border: none; height: 18.55pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">TX<o:p></o:p></span></span></b></div>
</td>
<td style="background: #D2EAF1; border: none; height: 18.55pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Primary
tumor cannot be assessed<o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 17.35pt; mso-yfti-irow: 1;">
<td style="border: none; height: 17.35pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">T0<o:p></o:p></span></span></b></div>
</td>
<td style="border: none; height: 17.35pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">No
evidence of primary tumor<o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 17.35pt; mso-yfti-irow: 2;">
<td style="background: #D2EAF1; border: none; height: 17.35pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Tis<o:p></o:p></span></span></b></div>
</td>
<td style="background: #D2EAF1; border: none; height: 17.35pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Carcinoma
in situ<o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 35.9pt; mso-yfti-irow: 3;">
<td style="border: none; height: 35.9pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">T1<o:p></o:p></span></span></b></div>
</td>
<td style="border: none; height: 35.9pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Tumor
confined to the nasopharynx, or tumor extends to oropharynx and/or nasal
cavity without parapharyngeal extension (eg, without posterolateral
infiltration of tumor) <o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 17.35pt; mso-yfti-irow: 4;">
<td style="background: #D2EAF1; border: none; height: 17.35pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">T2<o:p></o:p></span></span></b></div>
</td>
<td style="background: #D2EAF1; border: none; height: 17.35pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Tumor with
parapharyngeal extension (posterolateral infiltration of tumor)<o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 17.35pt; mso-yfti-irow: 5;">
<td style="border: none; height: 17.35pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">T3<o:p></o:p></span></span></b></div>
</td>
<td style="border: none; height: 17.35pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Tumor
involves bony structures of skull base and/or paranasal sinuses<o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 35.9pt; mso-yfti-irow: 6;">
<td style="background: #D2EAF1; border: none; height: 35.9pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">T4<o:p></o:p></span></span></b></div>
</td>
<td style="background: #D2EAF1; border: none; height: 35.9pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Tumor with
intracranial extension and/or involvement of cranial nerves, hypopharynx, or
orbit, or with extension to the infratemporal fossa/masticator space <o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 17.35pt; mso-yfti-irow: 7;">
<td colspan="2" style="border: none; height: 17.35pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Regional lymph nodes (N)<o:p></o:p></span></span></b></div>
</td>
</tr>
<tr style="height: 17.35pt; mso-yfti-irow: 8;">
<td style="background: #D2EAF1; border: none; height: 17.35pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">NX<o:p></o:p></span></span></b></div>
</td>
<td style="background: #D2EAF1; border: none; height: 17.35pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Regional
nodes cannot be assessed<o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 17.35pt; mso-yfti-irow: 9;">
<td style="border: none; height: 17.35pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">N0<o:p></o:p></span></span></b></div>
</td>
<td style="border: none; height: 17.35pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">No
regional lymph node metastasis<o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 53.2pt; mso-yfti-irow: 10;">
<td style="background: #D2EAF1; border: none; height: 53.2pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">N1<o:p></o:p></span></span></b></div>
</td>
<td style="background: #D2EAF1; border: none; height: 53.2pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Unilateral
metastasis in cervical lymph nodes =6cm in greatest dimension, above the
supraclavicular fossa, and/or unilateral or bilateral retropharyngeal lymph
nodes =6 cm in greatest dimension (midline nodes are considered ipsilateral
nodes) <o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 34.65pt; mso-yfti-irow: 11;">
<td style="border: none; height: 34.65pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">N2<o:p></o:p></span></span></b></div>
</td>
<td style="border: none; height: 34.65pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Bilateral
metastasis in cervical lymph nodes =6cm in greatest dimension, above the
supraclavicular fossa (midline nodes are considered ipsilateral nodes) <o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 35.9pt; mso-yfti-irow: 12;">
<td style="background: #D2EAF1; border: none; height: 35.9pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">N3<o:p></o:p></span></span></b></div>
</td>
<td style="background: #D2EAF1; border: none; height: 35.9pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Metastasis
in a lymph node >6cm and/or to the supraclavicular fossa (midline nodes
are considered ipsilateral nodes)<o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 17.35pt; mso-yfti-irow: 13;">
<td style="border: none; height: 17.35pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">N3a<o:p></o:p></span></span></b></div>
</td>
<td style="border: none; height: 17.35pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">>6cm in
dimension<o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 17.35pt; mso-yfti-irow: 14;">
<td style="background: #D2EAF1; border: none; height: 17.35pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">N3b<o:p></o:p></span></span></b></div>
</td>
<td style="background: #D2EAF1; border: none; height: 17.35pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Extension
to the supraclavicular fossa<o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 18.55pt; mso-yfti-irow: 15;">
<td colspan="2" style="border: none; height: 18.55pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Distant metastasis (M)<o:p></o:p></span></span></b></div>
</td>
</tr>
<tr style="height: 17.35pt; mso-yfti-irow: 16;">
<td style="background: #D2EAF1; border: none; height: 17.35pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></b></div>
</td>
<td style="background: #D2EAF1; border: none; height: 17.35pt; mso-background-themecolor: accent5; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">No distant
metastasis<o:p></o:p></span></span></div>
</td>
</tr>
<tr style="height: 17.35pt; mso-yfti-irow: 17; mso-yfti-lastrow: yes;">
<td style="border-bottom: solid #4BACC6 1.0pt; border: none; height: 17.35pt; mso-border-bottom-themecolor: accent5; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">M1<o:p></o:p></span></span></b></div>
</td>
<td style="border-bottom: solid #4BACC6 1.0pt; border: none; height: 17.35pt; mso-border-bottom-themecolor: accent5; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #31849b;"><span style="font-family: Arial, Helvetica, sans-serif;">Distant
metastasis<o:p></o:p></span></span></div>
</td>
</tr>
</tbody></table>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Table. Histologic grade<a href="http://www.blogger.com/blogger.g?blogID=7294540944450239332"> </a><o:p></o:p></span></div>
<table border="1" cellpadding="0" cellspacing="0" class="MsoTableLightShadingAccent4" style="border-collapse: collapse; border: none; margin-left: 48pt; text-align: justify;">
<tbody>
<tr>
<td colspan="2" style="border-bottom: solid #8064A2 1.0pt; border-left: none; border-right: none; border-top: solid #8064A2 1.0pt; mso-border-bottom-themecolor: accent4; mso-border-top-themecolor: accent4; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;">
<b><span style="color: #5f497a;"><span style="font-family: Arial, Helvetica, sans-serif;">Histologic
grade (G)<o:p></o:p></span></span></b></div>
</td>
</tr>
<tr>
<td style="background: #DFD8E8; border: none; mso-background-themecolor: accent4; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #5f497a;"><span style="font-family: Arial, Helvetica, sans-serif;">GX<o:p></o:p></span></span></b></div>
</td>
<td style="background: #DFD8E8; border: none; mso-background-themecolor: accent4; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #5f497a;"><span style="font-family: Arial, Helvetica, sans-serif;">Grade cannot be assessed<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #5f497a;"><span style="font-family: Arial, Helvetica, sans-serif;">G1<o:p></o:p></span></span></b></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #5f497a;"><span style="font-family: Arial, Helvetica, sans-serif;">Well
differentiated<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="background: #DFD8E8; border: none; mso-background-themecolor: accent4; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #5f497a;"><span style="font-family: Arial, Helvetica, sans-serif;">G2<o:p></o:p></span></span></b></div>
</td>
<td style="background: #DFD8E8; border: none; mso-background-themecolor: accent4; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #5f497a;"><span style="font-family: Arial, Helvetica, sans-serif;">Moderately differentiated<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #5f497a;"><span style="font-family: Arial, Helvetica, sans-serif;">G3<o:p></o:p></span></span></b></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #5f497a;"><span style="font-family: Arial, Helvetica, sans-serif;">Poorly
differentiated<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="background: #DFD8E8; border-bottom: solid #8064A2 1.0pt; border: none; mso-background-themecolor: accent4; mso-background-themetint: 63; mso-border-bottom-themecolor: accent4; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #5f497a;"><span style="font-family: Arial, Helvetica, sans-serif;">G4<o:p></o:p></span></span></b></div>
</td>
<td style="background: #DFD8E8; border-bottom: solid #8064A2 1.0pt; border: none; mso-background-themecolor: accent4; mso-background-themetint: 63; mso-border-bottom-themecolor: accent4; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #5f497a;"><span style="font-family: Arial, Helvetica, sans-serif;">Undifferentiated<o:p></o:p></span></span></div>
</td>
</tr>
</tbody></table>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Table. Anatomic stage/prognostic groups<a href="http://www.blogger.com/blogger.g?blogID=7294540944450239332"> </a><o:p></o:p></span></div>
<table border="1" cellpadding="0" cellspacing="0" class="MsoTableLightShadingAccent3" style="border-collapse: collapse; border: none; margin-left: 48pt; text-align: justify;">
<tbody>
<tr>
<td style="border-bottom: solid #9BBB59 1.0pt; border-left: none; border-right: none; border-top: solid #9BBB59 1.0pt; mso-border-bottom-themecolor: accent3; mso-border-top-themecolor: accent3; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;">
<b><span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">Stage<o:p></o:p></span></span></b></div>
</td>
<td style="border-bottom: solid #9BBB59 1.0pt; border-left: none; border-right: none; border-top: solid #9BBB59 1.0pt; mso-border-bottom-themecolor: accent3; mso-border-top-themecolor: accent3; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;">
<b><span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T<o:p></o:p></span></span></b></div>
</td>
<td style="border-bottom: solid #9BBB59 1.0pt; border-left: none; border-right: none; border-top: solid #9BBB59 1.0pt; mso-border-bottom-themecolor: accent3; mso-border-top-themecolor: accent3; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;">
<b><span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N<o:p></o:p></span></span></b></div>
</td>
<td style="border-bottom: solid #9BBB59 1.0pt; border-left: none; border-right: none; border-top: solid #9BBB59 1.0pt; mso-border-bottom-themecolor: accent3; mso-border-top-themecolor: accent3; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;">
<b><span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M<o:p></o:p></span></span></b></div>
</td>
</tr>
<tr>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">0<o:p></o:p></span></span></b></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">Tis<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N0<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">I<o:p></o:p></span></span></b></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T1<o:p></o:p></span></span></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N0<o:p></o:p></span></span></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td rowspan="3" style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">II<o:p></o:p></span></span></b></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T1<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N1<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T2<o:p></o:p></span></span></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N0<o:p></o:p></span></span></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T2<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N1<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td rowspan="5" style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">III<o:p></o:p></span></span></b></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T1<o:p></o:p></span></span></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N2<o:p></o:p></span></span></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T2<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N2<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T3<o:p></o:p></span></span></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N0<o:p></o:p></span></span></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T3<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N1<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T3<o:p></o:p></span></span></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N2<o:p></o:p></span></span></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td rowspan="3" style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">IVA<o:p></o:p></span></span></b></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T4<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N0<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T4<o:p></o:p></span></span></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N1<o:p></o:p></span></span></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T4<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N2<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">IVB<o:p></o:p></span></span></b></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T Any<o:p></o:p></span></span></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N3<o:p></o:p></span></span></div>
</td>
<td style="border: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M0<o:p></o:p></span></span></div>
</td>
</tr>
<tr>
<td style="background: #E6EED5; border-bottom: solid #9BBB59 1.0pt; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; mso-border-bottom-themecolor: accent3; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<b><span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">IVC<o:p></o:p></span></span></b></div>
</td>
<td style="background: #E6EED5; border-bottom: solid #9BBB59 1.0pt; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; mso-border-bottom-themecolor: accent3; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">T Any<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border-bottom: solid #9BBB59 1.0pt; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; mso-border-bottom-themecolor: accent3; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">N Any<o:p></o:p></span></span></div>
</td>
<td style="background: #E6EED5; border-bottom: solid #9BBB59 1.0pt; border: none; mso-background-themecolor: accent3; mso-background-themetint: 63; mso-border-bottom-themecolor: accent3; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<span style="color: #76923c;"><span style="font-family: Arial, Helvetica, sans-serif;">M1<o:p></o:p></span></span></div>
</td>
</tr>
</tbody></table>
<br /><div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;"><b>TERAPI</b></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;"><a href="http://www.blogger.com/blogger.g?blogID=7294540944450239332" name="top"></a><b>Stages 0 and I<o:p></o:p></b></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">The usual treatment for these early stage cancers is <a href="http://www.cancer.org/ssLINK/nasopharyngeal-cancer-treating-radiation-therapy" target="_top">radiation therapy</a> aimed at the
nasopharyngeal tumor. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Although the cancer has not yet spread to lymph nodes
in these stages, the nearby lymph nodes in the neck are usually treated with
radiation therapy as well. This is considered preventive (prophylactic)
radiation. Some patients may have cancer cells in these lymph nodes that canât
be detected. Although there are too few cancer cells in the lymph nodes to
cause them to be enlarged, these cells could continue to grow and spread if not
destroyed by radiation therapy.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<b><span style="font-family: Arial, Helvetica, sans-serif;">Stages II, III, IVA and IVB <o:p></o:p></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">These cancers have spread outside of the nasopharynx
and often to lymph nodes in the neck or above the collarbone. Patients with
these stages of NPC usually receive chemoradiation (<a href="http://www.cancer.org/ssLINK/nasopharyngeal-cancer-treating-chemotherapy" target="_top">chemotherapy</a> given along with <a href="http://www.cancer.org/ssLINK/nasopharyngeal-cancer-treating-radiation-therapy" target="_top">radiation therapy</a> to the
nasopharynx and neck lymph nodes). The chemotherapy (chemo) drug most often
used is cisplatin, but sometimes another drug is used as well. This is usually
followed by more chemo, most often with cisplatin plus 5-FU. Most studies have
found that chemoradiation helps patients live longer than just radiation
therapy alone. But adding chemo leads to more side effects, which can affect quality
of life. Itâs important to understand what the side effects are likely to be
before starting this treatment. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">If cancer is still in the lymph nodes after this
treatment, <a href="http://www.cancer.org/ssLINK/nasopharyngeal-cancer-treating-surgery" target="_top">surgery</a> (neck dissection) may be done to
remove the lymph nodes.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<b><span style="font-family: Arial, Helvetica, sans-serif;">Stage IVC<o:p></o:p></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">These cancers have spread to distant parts of the body
and can be hard to treat. The usual treatment is <a href="http://www.cancer.org/ssLINK/nasopharyngeal-cancer-treating-chemotherapy" target="_top">chemo</a>, often with cisplatin and one other
drug. If there is no sign of the cancer after chemotherapy, <a href="http://www.cancer.org/ssLINK/nasopharyngeal-cancer-treating-radiation-therapy" target="_top">radiation therapy</a> to the
nasopharynx and the lymph nodes in the neck or chemoradiation is given to try
to kill any remaining cancer cells. Another option in some cases is to give
chemoradiation as the first treatment.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">If there are still signs of cancer after the initial
chemotherapy, another chemotherapy regimen using different drugs may be tried.
Chemotherapy plus the targeted drug cetuximab (Erbitux) may be another option.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Because these cancers can be hard to treat
effectively, taking part in a <a href="http://www.cancer.org/ssLINK/nasopharyngeal-cancer-treating-clinical-trials" target="_top">clinical trial</a> of newer treatments may be a good
option. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<b><span style="font-family: Arial, Helvetica, sans-serif;">Recurrent nasopharyngeal cancer <o:p></o:p></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Cancer is called<i> recurrent</i> when it come backs
after treatment. Recurrence can be local (in or near the same place it started)
or distant (spread to organs such as the lungs or bone). If your cancer returns
after treatment, the choices available to you depend on the location and extent
of the cancer, which treatments were used the first time around, and your
overall health. It is important to understand the goal of any further treatment
â whether it is to try to cure the cancer, to slow its growth, or to help
relieve symptoms â as well as the likelihood of benefits and risks. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Some tumors that recur in the nasopharynx can be
removed by <a href="http://www.cancer.org/ssLINK/nasopharyngeal-cancer-treating-surgery" target="_top">surgery</a> using an approach through the nose
(called <i>endoscopic skull base surgery</i>). This is a specialized surgery
that should only be done by a surgeon with a great deal of experience in this
procedure, so itâs not available at all medical centers.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Recurrent NPC in regional (neck area) lymph nodes can
sometimes be treated by additional <a href="http://www.cancer.org/ssLINK/nasopharyngeal-cancer-treating-radiation-therapy" target="_top">radiation therapy</a>. But if
doctors believe that more radiation would cause serious side effects or if the
initial response to radiation was incomplete, surgery (neck dissection) may be
used instead. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Cancer that recurs in distant sites is usually treated
with <a href="http://www.cancer.org/ssLINK/nasopharyngeal-cancer-treating-chemotherapy" target="_top">chemotherapy</a>. If chemotherapy has been given
already, different chemo drugs may be tried. The targeted drug cetuximab may be
given along with chemo, generally on a <a href="http://www.cancer.org/ssLINK/nasopharyngeal-cancer-treating-clinical-trials" target="_top">clinical trial</a>.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">New drug treatments being tested in clinical trials
and new surgical procedures may help some patients with recurrent NPC, as well
as improve knowledge that can help others with NPC in the future. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">If the cancer canât be cured, further treatments may
be aimed at slowing its growth or relieving symptoms caused by the distant
spread of the cancer. For example, if the cancer has spread to the spine,
radiation therapy may be given to the area to relieve pain and reduce the
chances of further complications. Even if a cure is not possible, it is
important to remember that there are many <a href="http://www.cancer.org/ssLINK/palliative-care" target="_top">options to
relieve symptoms</a> of advanced cancer. (<a href="http://www.cancer.org/cancer/nasopharyngealcancer/detailedguide/nasopharyngeal-cancer-treating-by-stage">http://www.cancer.org/cancer/nasopharyngealcancer/detailedguide/nasopharyngeal-cancer-treating-by-stage</a>)<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Arial, Helvetica, sans-serif;">Bisa juga lewat imunoterapi<o:p></o:p></span><br />
<span style="font-family: Arial, Helvetica, sans-serif;"><br /></span>
<span style="font-family: Arial, Helvetica, sans-serif;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<div style="text-align: left;">
<span style="font-family: Arial, Helvetica, sans-serif;">DAFPUS <o:p></o:p></span></div>
</div>
<div class="MsoBibliography" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<!--[if supportFields]><span
style='font-size:9.0pt;line-height:115%;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:IN'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_BIBL {"custom":[]}
CSL_BIBLIOGRAPHY <span style='mso-element:field-separator'></span></span><![endif]--><span style="line-height: 115%;"><span style="font-family: Arial, Helvetica, sans-serif;">1. Kumar
V, Abbas AK, Fausto N, Aster JC. Robbins & Cotran Pathologic Basis of
Disease,. Elsevier Health Sciences; 2009. <o:p></o:p></span></span></div>
</div>
<div class="MsoBibliography" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<span style="line-height: 115%;"><span style="font-family: Arial, Helvetica, sans-serif;">2. Jeyakumar A,
Brickman TM, Jeyakumar A, Doerr T. Review of nasopharyngeal carcinoma. Ear Nose
Throat J. 2006 Mar;85(3):168â70, 172â3, 184. <o:p></o:p></span></span></div>
</div>
<div class="MsoBibliography" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<span style="line-height: 115%;"><span style="font-family: Arial, Helvetica, sans-serif;">3. Huang L, Seow K.
Oral Sex Is a Risk Factor for Human Papillomavirus-Associated Nasopharyngeal
Carcinoma in Husbands of Women with Cervical Cancer. Gynecol Obstet Invest.
2010 Aug;70(2):73â5. <o:p></o:p></span></span></div>
</div>
<div class="MsoBibliography" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<span style="line-height: 115%;"><span style="font-family: Arial, Helvetica, sans-serif;">4. WHO
Classifications of Tumoure. <o:p></o:p></span></span></div>
</div>
<div class="MsoBibliography" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<span style="line-height: 115%;"><span style="font-family: Arial, Helvetica, sans-serif;">5. Tabuchi K,
Nakayama M, Nishimura B, Hayashi K, Hara A. Early Detection of Nasopharyngeal
Carcinoma. Int J Otolaryngol [Internet]. 2011 Jun 8 [cited 2013 Oct 8];2011.
Available from: http://www.hindawi.com/journals/ijol/2011/638058/abs/<o:p></o:p></span></span></div>
</div>
<div class="MsoBibliography" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<span style="line-height: 115%;"><span style="font-family: Arial, Helvetica, sans-serif;">6. He X, Deng M, Yang
S, Xiao Z, Luo Q, He Z, et al. The tumor supressor function of STGC3 and its
reduced expression in nasopharyngeal carcinoma. Cell Mol Biol Lett. 2008
Sep;13(3):339â52. <o:p></o:p></span></span></div>
</div>
<div class="MsoBibliography" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<span style="line-height: 115%;"><span style="font-family: Arial, Helvetica, sans-serif;">7. Ren Z-F, Liu W-S,
Qin H-D, Xu Y-F, Yu D-D, Feng Q-S, et al. Effect of family history of cancers
and environmental factors on risk of nasopharyngeal carcinoma in Guangdong,
China. Cancer Epidemiol. 2010;34(4):419â24. <o:p></o:p></span></span></div>
</div>
<div class="MsoBibliography" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<span style="line-height: 115%;"><span style="font-family: Arial, Helvetica, sans-serif;">8. Diergaarde B,
Grandis JR. Human Papillomavirus and Head and Neck Cancer. Oncology. 2010
Sep;24(10):927, 933. <o:p></o:p></span></span></div>
</div>
<div class="MsoBibliography" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<span style="line-height: 115%;"><span style="font-family: Arial, Helvetica, sans-serif;">9. Ayadi W, Feki L,
Khabir A, Boudawara T, Ghorbel A, Charfeddine I, et al. Polymorphism analysis
of Epstein-Barr virus isolates of nasopharyngeal carcinoma biopsies from
Tunisian patients. Virus Genes. 2007 Apr;34(2):137â45. <o:p></o:p></span></span></div>
</div>
<div class="MsoBibliography" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<span style="line-height: 115%;"><span style="font-family: Arial, Helvetica, sans-serif;">10. V10. Cancer, all
sites; personal history of malignant neoplasm [Internet]. Capitola, United
States: Timely Data Resources, Inc.; 2013 First Quarter p. 0. Available from:
http://search.proquest.com/docview/1267795637/140FECEDF41601E4F6F/6?accountid=48149<o:p></o:p></span></span></div>
</div>
<div class="MsoBibliography" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<span style="line-height: 115%;"><span style="font-family: Arial, Helvetica, sans-serif;">11. Crawford DH,
Swerdlow AJ, Higgins C, McAulay K, Harrison N, Williams H, et al. Sexual
history and Epstein-Barr virus infection. J Infect Dis. 2002 Sep
15;186(6):731â6. <o:p></o:p></span></span></div>
</div>
<div class="MsoBibliography" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<span style="line-height: 115%;"><span style="font-family: Arial, Helvetica, sans-serif;">12. Thomas R, Macsween
KF, McAulay K, Clutterbuck D, Anderson R, Reid S, et al. Evidence of shared
Epstein-Barr viral isolates between sexual partners, and low level EBV in
genital secretions. J Med Virol. 2006 Sep;78(9):1204â9. <o:p></o:p></span></span></div>
</div>
<div class="MsoBibliography" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<span style="line-height: 115%;"><span style="font-family: Arial, Helvetica, sans-serif;">13. Tambunan GW.
Diagnosis dan Tata Laksana SEPULUH JENIS KANKER TERBANYAK DI INDONESIA. Jakarta:
EGC; 1995. <o:p></o:p></span></span></div>
</div>
<div class="MsoBibliography" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<span style="line-height: 115%;"><span style="font-family: Arial, Helvetica, sans-serif;">14. Duhayon S, Hoet P,
Van Maele-Fabry G, Lison D. Carcinogenic potential of formaldehyde in
occupational settings: a critical assessment and possible impact on
occupational exposure levels. Int Arch Occup Environ Health. 2008 May;81(6):695â710.
<o:p></o:p></span></span></div>
</div>
<div class="MsoNormal" style="margin-bottom: 2pt; text-align: justify;">
<div style="text-align: left;">
<br /></div>
</div>
<div class="MsoNormal" style="text-align: justify;">
<div style="text-align: left;">
<br /></div>
</div>
<br />
<div class="MsoNormal" style="text-align: justify;">
<div style="text-align: left;">
<a href="http://www.cancer.org/acs/groups/cid/documents/webcontent/003124-pdf.pdf"><span style="font-family: Arial, Helvetica, sans-serif;">http://www.cancer.org/acs/groups/cid/documents/webcontent/003124-pdf.pdf</span></a><span style="font-size: 10.0pt; mso-bidi-font-size: 11.0pt;"><o:p></o:p></span></div>
</div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-9861059168281076412013-10-10T10:10:00.000-07:002013-10-10T10:10:20.128-07:00Si "Kartu Truf" Timnas U-19, Yabes Roni Malaifani<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgS9sL-IoHuamWgzY87_y-dYcnhhVQkUGc-SRt56xETmG6v22xwXa7VbdNZid4xO_GfPJuzOvNyJ_shdnsBF2zcyOMnELgotBfdCN7c2dPdCLh829PjdmzCzu6cq7Jztgfbu76BoFzgcAo/s1600/084131_50617_yabes_alor_dlm.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="209" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgS9sL-IoHuamWgzY87_y-dYcnhhVQkUGc-SRt56xETmG6v22xwXa7VbdNZid4xO_GfPJuzOvNyJ_shdnsBF2zcyOMnELgotBfdCN7c2dPdCLh829PjdmzCzu6cq7Jztgfbu76BoFzgcAo/s320/084131_50617_yabes_alor_dlm.jpg" width="320" /></a> </div>
<div class="separator" style="clear: both; text-align: center;">
Inilah alasan saya menyesal setengah mati karena ketiduran pas Timnas U-19 vs Filipina</div>
<div class="separator" style="clear: both; text-align: center;">
(10 Oktober 2013)</div>
<div style="text-align: justify;">
<span style="text-align: center;"><br /></span></div>
<div style="text-align: justify;">
<span style="text-align: center;">Yabes Roni Malaifani, awalnya sangat susah mencari info tentang pemain timnas u-19 yang satu ini. bayangkan saja, info yang ada cuma dia adalah pemain asal Alor, itu pun adanya di wikipedia -__-</span></div>
<div style="text-align: justify;">
<span style="text-align: center;">padahal saya kepingin sekali lihat pemain timnas u-19 satu-satunya yang berasal dari NTT ini. Penasaran sekali akan rupa pemain yang bisa menggerakkan hati coach Indra, dan jreng jreng jreng, benar-benar muka NTT kata saya,hehehehhe</span></div>
<div style="text-align: justify;">
<span style="text-align: center;">K</span><span style="text-align: center;">arena satu-satunya yang bisa masuk skuad timnas u-19 tak heran dia jadi kebanggaan kami semua warga NTT.:-</span><span style="text-align: center;">) </span><span style="text-align: center;">semuanya bangga, lihat saja, di recent update bbm semua teman-teman sedaerah memberikan dukungan penuh buat pemain yg satu ini. *semakin menyesal karena tak nonton ;( *</span></div>
<div style="text-align: justify;">
<span style="text-align: center;">Yups, benar-benar bangga, yabes dipanggil masuk timnas saja sudah bangga sekali, apalagi kalau bisa cetak gol dipertandingan perdana. dan ya begitulah, karena ketiduran, ditambah faktor tv pengganti super mungil dari ibu kos yang tak ada 1 pun chanell lokal maka lengkaplah penderitaan saya setiap kali timnas u-19 main.</span></div>
<div style="text-align: justify;">
<span style="text-align: center;">yang lebih menjengkelkan adalah live streaming rcti.com pun tak bisa dibuka. untungnya ada salah satu live streaming yg bisa saya dapatkan dengan susah payah, n satu-satunya yg bisa saya dapatkan. Live streaming yang lain keok :@... </span><span style="text-align: center;">berhenti bicara tentang kemalangan saya, mari bicarakan pemain ini.</span></div>
<div style="text-align: justify;">
<span style="text-align: center;"><br /></span></div>
<div style="text-align: justify;">
<span style="text-align: center;">Yabes, pemain asal NTT, asal Alor, kelahiran Moramam, 2 Februari 1995, bernomor punggung 31, mencuri perhatian pencinta sepakbola nasional lewat golnya di babak kedua timnas u-19 vs filipina beberapa jam yang lalu. Inilah gol pertamanya di pertandingan perdananya juga bersama timnas u-19. Disebut sebagai 'kartu truf'' oleh pelatih Indra tak membuat pemain ini jadi besar kepala. dia sendiri mengakui masih memiliki kekurangan dalam umpan dan kontrol bola dan masih perlu banyak berlatih. *hahahhaha, good boy*</span></div>
<div style="text-align: justify;">
<span style="text-align: center;">Gol nya di pertandingan tadi tentu menjadi trending topic buat warga NTT. Maklum saja, kami semua bangga sekali ada pemain timnas u-19 yang berasal dari NTT. Bahkan ada nonton bersama keluarga alor di kefamenanu. *yang tidak tahu di mana kefamenanu, coba buka atlas ya^^ *</span></div>
<div style="text-align: justify;">
<span style="text-align: center;">Masuk di babak ke dua sebagai pemain pengganti, Yabes tidak ingin menyia-nyiakan pencarian pelatih Indra Sjafrie. dan trengtereng \(^o^)/, dia berhasil menyumbangkan gol di menit ke 82 lewat umpan dari Paulo Sitanggang.</span></div>
<div style="text-align: justify;">
<span style="text-align: center;">Meskipun cuma kebagian 9 menit terakhir pertandingan, tapi saya sempat melihat si yabes ini main. Gayanya benar-benar khas NTT, cepat, berani, n skill individual nya good.. tendangannya juga keras.</span><span style="text-align: center;">yups, masih perlu kontrol n kordinasi dengan sesama pemain tentu saja :). karena main tim, jadi main nya over-overan juga ya,hehehehehhe. </span><span style="text-align: center;">dari kacamata orang awam seperti saya sih lihatnya begitu, mari kita ihat apa kata para profesional tentang si yabes ini. harapannya sih dapat komentar positif, jadi bisa main lagi di pertandingan selanjutnya vs korsel 12 oktober ini. ^___^</span></div>
<div style="text-align: justify;">
<span style="text-align: center;"><br /></span></div>
<div style="text-align: justify;">
<span style="text-align: center;">Good job yabes, tingkatkan terus kemampuanmu, jangan sombong, ingat berdoa n kompak ya dengan rekan2 setim mu. Semoga saja penampilanmu terus meningkat, harumkan nama bangsamu n tanah airmu, jangan lupakan NTTmu, n bawa selalu Alor dalam hatimu :)</span></div>
<div style="text-align: justify;">
<span style="text-align: center;"><br /></span></div>
<span style="text-align: center;"><br /></span>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjJtIicJQGfmLLZLK8bI5aFKv_073PxwEc6ElULxYe-5SvZ2p1ecyF7kosqd3J7CXXHzvCMJ7y4tOZYZ9_J5f7wodUXnnR_wPJkONJ_fN67Ljihl-XffMZUlOTcEwxArNOInoSt9N6mWgQ/s1600/yabes.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="265" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjJtIicJQGfmLLZLK8bI5aFKv_073PxwEc6ElULxYe-5SvZ2p1ecyF7kosqd3J7CXXHzvCMJ7y4tOZYZ9_J5f7wodUXnnR_wPJkONJ_fN67Ljihl-XffMZUlOTcEwxArNOInoSt9N6mWgQ/s400/yabes.jpg" width="400" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
cuma ini gambar yang bisa saya dapat, kurang jelas, tapi nikmati saja lah..hehehehheh</div>
<br />
<br />
sumber:<br />
<a href="http://sportsatu.com/2013/10/08/yabes-ingin-bayar-kepercayaan-indra-sjafri/">http://sportsatu.com/2013/10/08/yabes-ingin-bayar-kepercayaan-indra-sjafri/</a><br />
<a href="http://regional.kompas.com/read/2013/10/10/2300256/Yabes.Roni.Squad.U-19.Bikin.Bangga.Warga.NTT?utm_source=WP&utm_medium=box&utm_campaign=Kknwp">http://regional.kompas.com/read/2013/10/10/2300256/Yabes.Roni.Squad.U-19.Bikin.Bangga.Warga.NTT?utm_source=WP&utm_medium=box&utm_campaign=Kknwp</a><br />
<a href="http://www.tribunnews.com/superball/2013/10/10/indonesia-kandaskan-filipina-2-0">http://www.tribunnews.com/superball/2013/10/10/indonesia-kandaskan-filipina-2-0</a><br />
<br />luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-67428700043688842132013-09-24T16:43:00.002-07:002013-09-24T16:43:21.329-07:00Hipersensivitas<div>
<span style="font-family: Arial, Helvetica, sans-serif;">Hipersensivitas</span></div>
<span style="font-family: Arial, Helvetica, sans-serif;"><br /></span><div class="MsoListParagraphCxSpFirst" style="margin-left: 18.0pt; mso-add-space: auto; mso-list: l3 level1 lfo1; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">1.
<!--[endif]-->Reaksi 4 tipe (gejala, efek, penyebab, cara penanganan,
pencegahan)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: 18.0pt; mso-add-space: auto; mso-list: l3 level1 lfo1; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">2.
<!--[endif]-->Mediator dalam reaksi hipersensivitas<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: 18.0pt; mso-add-space: auto; mso-list: l3 level1 lfo1; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">3.
<!--[endif]-->Shock anafilaktik (mekanisme)<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-family: Arial, Helvetica, sans-serif;">Jawab:<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpFirst" style="margin-left: 18.0pt; mso-add-space: auto; mso-list: l1 level1 lfo2; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">1.
<!--[endif]-->Ada 4 tipe menurut gell n coombs <o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #215868;"><span style="font-family: Arial, Helvetica, sans-serif;">Tipe 1 / reaksi cepat
/ reaksi anafilaksis<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #215868;"><span style="font-family: Arial, Helvetica, sans-serif;">Adalah hipersensivitas
yang segera timbul ketika alergen masuk ke tubuh. Reaksi alergi hanya akan
timbul pada paparan ke 2. Alergen akan
ditangkap oleh fagosit, dipresentasikan ke sel Th2, sel ini kemudian melepas
sitokin IL-4 yg merangsang pembentukan sel memori dan sel B membentuk IgE. igE
akan diikat oleh sel yg memiliki reseptor igE, Fce-R, seperti sel mast, basofil
dan eosinofil.(fase sanitasi) Bila tubuh terpajan ulang dengan alergen yg sama,
alergen akan diikat igE (ikatan silang) yg menimbulkan degranulasi sel mast
(fase aktivasi), granul-granul yg keluar itu antara lain adalah histamin dan
menimbulkan gejala hipersensivitas.(fase efektor)<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #215868;"><span style="font-family: Arial, Helvetica, sans-serif;">Gejala: anafilaksis
(penigkatan kepekan), urtikaria, angioderm, mengi, hipotensi, nausea, vomit,
sakit abdomen, diare<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #215868;"><span style="font-family: Arial, Helvetica, sans-serif;">Penyebab: alergi obat,
serbuk sari bunga, gigitan serangga. Biasanya alergen yang ditemukan adalah
protein molekular dengan berat 10000-40000 dalton, dan larut dalam air. Bsa seperti
enzim, protein carrier, (1), penisilin, enzim, antiserum, ekstrak alergen (2)<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #215868;"><span style="font-family: Arial, Helvetica, sans-serif;">Cara penanganan:
diberi epinefrin untuk mnghambat shock anafilaktik, dan kortikosteroid g tidak
berefek pada ah1 (5)<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #215868;"><span style="font-family: Arial, Helvetica, sans-serif;">Pencegahan:
memperhatikan alergi, memberitahu tahu dokter tentang alergi, dan tidak meminum
obat sembarangan.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<br /></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #984806;"><span style="font-family: Arial, Helvetica, sans-serif;">Tipe 2/reaksi
sitotoksik<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #984806;"><span style="font-family: Arial, Helvetica, sans-serif;">Terjadi karena
dibentuk antibodi igG dan igG terhadap antigen yang merupakan bagian
selpenjamu. Reseptor FcÉŁ-R. Ikatan ini akan mengaktifkan kompleen yang
mengakibatkan lisis. Lisis juga dapat terjadi melalui sanitai sel NK sebagai
efektor ADCC.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;"><span style="color: #984806;">a.
</span><!--[endif]--><span style="color: #984806;">Reaksi transfusi<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #984806;"><span style="font-family: Arial, Helvetica, sans-serif;">Gejala: demam, menggigil,
nausea, bekuan darah, hemoglobinuria.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #984806;"><span style="font-family: Arial, Helvetica, sans-serif;">Penyebab: reaksi
transfusi, anti B berikatan dengan sel darah B, menimbulkan kerusakan darah
direk oleh hemolisis. Reaksi cepat biasanya biasanya dipacu igM. Dalam beberapa
jam Hb banyak ditemukan dalam darah,hemoglobinuria. Pada reaksi lambat
dipengaruhi igG.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #984806;"><span style="font-family: Arial, Helvetica, sans-serif;">Penyakit hemolitik
bayi baru lahir karena rehesus tak cocok,. Anemia hemolitik: abiotika seperti
penisilin , sefalosporin dan streptomisin dapat diabsorbsi membentuk kompleks
tertentu. Kompleks ini mengikat obat pada SDM,= dgn komplemen menyebabkan
lisis.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #984806;"><span style="font-family: Arial, Helvetica, sans-serif;">Cara penanganan: <o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #984806;"><span style="font-family: Arial, Helvetica, sans-serif;">Pencegahan:
pemeriksaan sel darah<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<br /></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: grey;"><span style="font-family: Arial, Helvetica, sans-serif;">Tipe 3/ kompleks imun<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: grey;"><span style="font-family: Arial, Helvetica, sans-serif;">Mirip tipe 2, terjadi
karena endapan antigen+antibodi dalam jaringan atau pembuluh darah. Kompleks
ini kemudian akan cepat dimusnahkan kalau besar, kalau terlalu kecil,bisa lebih
lama berada dlama sirkulasi. Maka makrofag akan datang dan menghancurkan jaringan
di sekitar situ.setelah mendapat sinyal dari komplemen yg juga mengeluaran
mediator.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: grey;"><span style="font-family: Arial, Helvetica, sans-serif;">Antigennya bisa dari
malaria, spora, atau autoimun. C3a n c5a dapat meningkatkan permeabilitas
vaskular: edem.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: grey;"><span style="font-family: Arial, Helvetica, sans-serif;">Peny arthus:
menyebabbkan vaskulitis karean neutrofil memakan kompleks imun bersamaan dengan
trombosit, melepaskan berabagai senyawa, akhirnya pendarahan disertai nrkrosis.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: grey;"><span style="font-family: Arial, Helvetica, sans-serif;">Serum sickness:
neutrofil mengeluarkan granula; kerusakan jaringan (demam, lemah, vaskulitis
sistemik, edema, eritrema.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<br /></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #4f6228;"><span style="font-family: Arial, Helvetica, sans-serif;">Tipe 4<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="background-color: white; background-position: initial initial; background-repeat: initial initial; color: #4f6228;"><span style="font-family: Arial, Helvetica, sans-serif;">Reaksi
ini yang juga dikenal sebgaai hipersensitivitas seluler, terjadi 24 hingga 72
jam sesudah kontak dengan allergen. Hipersensitivitas tipe IV diantarai oleh
makrofag dari sel-sel T yang sudah tersensitisasi.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="background-color: white; background-position: initial initial; background-repeat: initial initial; color: #4f6228;"><span style="font-family: Arial, Helvetica, sans-serif;">Terbagi
atas 2 tipe dasar<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="background-color: white; background-position: initial initial; background-repeat: initial initial; color: #4f6228;"><span style="font-family: Arial, Helvetica, sans-serif;">1.delayed
type hypersensitivy (DTH)<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="background-color: white; background-position: initial initial; background-repeat: initial initial; color: #4f6228;"><span style="font-family: Arial, Helvetica, sans-serif;">Sel
CD4 Th1 mengaktifkan makrofag sebagai efektor. Cd4Th1 melepas interferon gamma
yg mengaktifkan makrofag menginduksi inflamasi. Kerusakan jaringan karena
produk makrofag, seperti enzim.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="background-color: white; background-position: initial initial; background-repeat: initial initial; color: #4f6228;"><span style="font-family: Arial, Helvetica, sans-serif;">2.. T
cell media cytolisis . Cd8. Langsung membunuh sel. Virus hepatitis menyebbkan respon ini sehingga membunuh
hepatosit.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="font-family: Arial, Helvetica, sans-serif;"><span style="background-color: white; background-position: initial initial; background-repeat: initial initial; color: #5f497a;">Ada 4
jenis reaksi hipersensitivits tipe IV, yaitu :</span><span style="color: #5f497a;"><br />
<span style="background: white;">a.Reaksi Jones Mote</span><br />
<span style="background: white;">Reaksi JM ditandai oleh adanya infiltrasi
basofil di bawah epidermis. Reaksi biasanya terjadi sesudah 24 jam tetapi hanya
berupa eritem tanpa indurasi, yang merupakan ciri dari CMI (Baratawidjaya,
2002)</span><br />
<span style="background: white;">b.Hipersensitivitas Kontak dan Dermatitis Kontak</span><br />
<span style="background: white;">Dermatitis kontak timbul pada kulit tempat
kontak dengan alergen. Sel langerhans sebagai APC memegang peranan pada reaksi
ini</span><br />
<span style="background: white;">c.Reaksi Tuberkulin</span><br />
<span style="background: white;">Terjadi 20 jam setelah terpajan dengan antigen.
Reaksi terdiri atas infiltrasi sel mononuklear. Setelah 48 jam timbul
infiltrasi limfosit dalam jumlah besar di sekitar pembuluh darah yang merusak
hubungan serat-serat kolagen kulit</span><br />
<span style="background: white;">d.ReaksiGranuloma</span><br />
<span style="background: white;">Reaksi granuloma merupakan reaksi
hipersensitivitas yang paling penting karena menimbulkan banyak efek patologis.
Hal tersebut terjadi karena adanya antigen yang persisten di dalam makrofag
yang biasanya berupa mikroorganisme yang tidak dapat dihancurkan atau kompleks
imun yang menetap misalnya pada alveolitis alergik. Reaksi granuloma terjadi
sebagai usaha badan untuk membatasi antigen yang persisten, sedang reaksi
tuberkulin merupakan respon imun seluler oleh antigen mikroorganisme yang sama
misalnya M. tuberculosis dan M. Leprae<o:p></o:p></span></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<br /></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;"><span style="color: #632423;">2.
</span><!--[endif]--><span style="color: #632423;">Tipe 1: histamin (10-15menit), PG
& LT (6-8 jm), sitokin<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #632423;"><span style="font-family: Arial, Helvetica, sans-serif;">Tipe 2: <o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="color: #632423;"><span style="font-family: Arial, Helvetica, sans-serif;">Tipe 3: <span style="background: white;">anafilatoksin, opsonin, kemotaksin, adherens imun dan
kinin<span class="apple-converted-space"> </span></span><o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="font-family: Arial, Helvetica, sans-serif;">Tipe 4: <span class="apple-converted-space"><span style="background: white;"> </span></span><span style="background: white;">sitokin (berupa IFN-Îł, TNF-ÎČ, IL-2,IL-3) dan kemokin (berupa
IL-8, MCAF, MIF)<span class="apple-converted-space"> </span></span><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="font-family: Arial, Helvetica, sans-serif;"><span style="background: white;"><span class="apple-converted-space"><br /></span></span></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoListParagraph" style="margin: 0cm 0cm 0.0001pt 17.85pt; text-indent: -17.85pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;"><span style="background-color: lightgrey; background-position: initial initial; background-repeat: initial initial;">3. </span><!--[endif]-->Anaphylaxis berasal dari bahasa yunani, Ana = jauh
dari ; phylaxis = perlindungan, anaphylaxis berarti menghilangkan perlindungan.</span></div>
<div class="MsoListParagraph" style="margin: 0cm 0cm 0.0001pt 17.85pt; text-indent: -17.85pt;">
<span style="font-family: Arial, Helvetica, sans-serif;">Menurut Dorland (kamus kedokteran) anafilaksis adalah rekasi alergi umum dengan
efek pada bebeapa sistem organ terutama kardiovaskuler, respirasi, dan
gastrointestinal, yang merupakan rekasi imunologis yang didahului dengan
terpaparnya elergen yang sebelumnya sudah tersensitisasi.<span style="background: lightgrey; mso-highlight: lightgrey;"><o:p></o:p></span></span></div>
<div class="MsoListParagraph" style="margin: 0cm 0cm 0.0001pt 17.85pt; text-indent: -17.85pt;">
<span style="font-family: Arial, Helvetica, sans-serif;"><br /></span></div>
<div class="MsoNormal" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="font-family: Arial, Helvetica, sans-serif;"><b><span style="background-color: white; background-position: initial initial; background-repeat: initial initial;">Penyebab Reaksi
Alergi Berat</span></b><br />
<span style="background: white;">Reaksi anafilaktik terjadi ketika sistem imun
tubuh bereaksi berlebihan terhadap antigen, yang ditandai dengan adanya
âserbuanâ substansi asing. Sel-sel darah putih memproduksi substansi yang
disebut antibodi sebagai reaksi terhadap antigen. Antibodi bersirkulasi dalam
pembuluh darah dan melekatkan diri pada sel-sel tertentu dalam tubuh. Dalam
reaksi alergi, antibodi disebut sebagai immunoglobulin E (IgE). Ketika antibodi
berkontak dengan antigen, mereka memberikan sinyal terhadap sel-sel lainnya
untuk memproduksi senyawa kimiawi tertentu yang disebut âmediatorâ. Histamin
adalah contoh mediator. Efek mediator ini pada organ dan jaringan tubuh
menyebabkan gejala reaksi.</span><br />
<br />
<span style="background: white;">Pemicu reaksi anafilaksis melibatkan berbagai
substansi. Hanya sedikit jejak pemicu yang diperlukan untuk menyebabkan reaksi berat.
Pemicu reaksi alergi, termasuk anafilaksis meliputi:</span><br />
<span style="background: white;">1. Peresepan atau obat-obat over-the-counter</span><br />
<span style="background: white;">2. Racun dari sengatan serangga seperti lebah,
semut api, tawon.</span><br />
<span style="background: white;">3. Makanan, terutama makanan yang berprotein
tinggi â paling sering ikan, kerang, kacang, buah-buahan, gandum, susu, telur,
produk-produk kedelai.</span><br />
<span style="background: white;">4. Bahan tambahan makanan, seperti sulfit.</span><br />
<span style="background: white;">5. Transfusi darah atau produk darah yang lain.</span><br />
<span style="background: white;">6. Substansi lain seperti latex (karet alami)</span><br />
<span style="background: white;">7. Material pewarna dan kontras termasuk yang
digunakan pada prosedur dan tes radiologi.</span><br />
<!--[if !supportLineBreakNewLine]--><br />
<!--[endif]--><o:p></o:p></span></div>
<div class="MsoNormal" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="font-family: Arial, Helvetica, sans-serif;"><span style="background-color: white; background-position: initial initial; background-repeat: initial initial;">Kadang-kadang,
pemicu reaksi alergi sangat jelas, seperti sengatan lebah atau obat-obat baru
dalam peresepan. Kadang-kadang, pemicu malah tidak diketahui. Orang-orang
dengan asma, eczema dan hay fever lebih sering terkena reaksi anafilaksis
daripada mereka yang tidak memiliki kondisi ini.</span><br />
<br />
<b><span style="background: white;">Gejala Reaksi Alergi Berat</span></b><br />
<span style="background: white;">Gejala anafilaksis dapat bervariasi. Pada
beberapa orang, reaksi bermula sangat pelan, tetapi sebagian besar gejala
muncul secara cepat dan tiba-tiba. Gejala yang paling berat dan paling
membahayakan jiwa adalah kesulitan bernapas dan kehilangan kesadaran. Kesulitan
bernapas disebabkan adanya pembengkakan dan atau spasme saluran nafas (yang
dapat melibatkan pembengkakan lidah atau saluran nafas). Pada beberapa kasus
yang jarang, nafas dapat berhenti sama sekali.</span><br />
<span style="background: white;">âą Kehilangan kesadaran karena tekanan darah
rendah yang berbahaya, yang disebut dengan âsyokâ.</span><br />
<span style="background: white;">âą Pada kasus yang lebih serius, jantung dapat
berhenti memompa sama sekali.</span><br />
<span style="background: white;">âą Kejadian ini dapat memicu kematian karena
reaksi anafilaksis.</span><br />
<!--[if !supportLineBreakNewLine]--><br />
<!--[endif]--><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpFirst" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<br /></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<br /></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<br /></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<br /></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<span style="font-family: Arial, Helvetica, sans-serif;"> Daftar Pustaka</span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<br /></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">1.
<!--[endif]-->Immunology.6âth
edition, roitt, brostoff, male. Toronto: musby, 2001<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">2.
<!--[endif]-->Imunologi dasar
UI, edisi 9<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">3.
<!--[endif]-->Ilmu penyakit
dalam UI, edisi 5,<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">4.
<!--[endif]--><a href="http://www.medicinesia.com/kedokteran-dasar/imunologi/hipersensitifitas-tipe-i/"><span style="color: windowtext;">http://www.medicinesia.com/kedokteran-dasar/imunologi/hipersensitifitas-tipe-i/</span></a><o:p></o:p></span></div>
<br />
<div class="MsoListParagraphCxSpLast" style="margin: 0cm 0cm 0.0001pt 7.1pt; text-indent: 28.9pt;">
<!--[if !supportLists]--><span style="font-family: Arial, Helvetica, sans-serif;">5.
<!--[endif]--></span><span style="font-family: Arial, Helvetica, sans-serif;">Farmakologi ui,
edisi 5</span><span style="font-size: x-small;"><o:p></o:p></span></div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-81203835838595387342013-09-24T16:37:00.001-07:002013-09-24T16:37:38.011-07:00terapi HIV dengan mengggunakan HIV entry inhibitor<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-layout-grid-align: none; text-align: center; text-autospace: none;">
<span style="font-family: "Times New Roman","serif"; font-size: 16.0pt; line-height: 150%; mso-bidi-font-size: 12.0pt;">Paper: Imunodefisiensi dan HIV<o:p></o:p></span></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-layout-grid-align: none; text-align: center; text-autospace: none;">
<br /></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-layout-grid-align: none; text-align: center; text-autospace: none;">
<span style="color: #292526; font-family: "Times New Roman","serif"; font-size: 16.0pt; line-height: 150%; mso-bidi-font-size: 12.0pt;">â<b>HIV entry inhibitors: mechanisms of action and<o:p></o:p></b></span></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-layout-grid-align: none; text-align: center; text-autospace: none;">
<b><span style="color: #292526; font-family: "Times New Roman","serif"; font-size: 16.0pt; line-height: 150%; mso-bidi-font-size: 12.0pt;">resistance pathwaysâ<o:p></o:p></span></b></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; tab-stops: 75.0pt; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiROueAkor1881hyphenhyphenKfc587v3n5L4GIHonhBd5mxB08mHdyioPw66vqXWwibyWC0JLOwtRINJBjA5hyyQnEbaBOwf7x_KH3UtBNSKYg04JvB7pHeJw1w-rmhmmu5XnhWUxvsglhf4OBrNaE/s1600/Atmajaya_logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiROueAkor1881hyphenhyphenKfc587v3n5L4GIHonhBd5mxB08mHdyioPw66vqXWwibyWC0JLOwtRINJBjA5hyyQnEbaBOwf7x_KH3UtBNSKYg04JvB7pHeJw1w-rmhmmu5XnhWUxvsglhf4OBrNaE/s1600/Atmajaya_logo.jpg" height="320" width="186" /></a></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<br /></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<!--[if gte vml 1]><v:shapetype id="_x0000_t75"
coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
filled="f" stroked="f">
<v:stroke joinstyle="miter"/>
<v:formulas>
<v:f eqn="if lineDrawn pixelLineWidth 0"/>
<v:f eqn="sum @0 1 0"/>
<v:f eqn="sum 0 0 @1"/>
<v:f eqn="prod @2 1 2"/>
<v:f eqn="prod @3 21600 pixelWidth"/>
<v:f eqn="prod @3 21600 pixelHeight"/>
<v:f eqn="sum @0 0 1"/>
<v:f eqn="prod @6 1 2"/>
<v:f eqn="prod @7 21600 pixelWidth"/>
<v:f eqn="sum @8 21600 0"/>
<v:f eqn="prod @7 21600 pixelHeight"/>
<v:f eqn="sum @10 21600 0"/>
</v:formulas>
<v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
<o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_9" o:spid="_x0000_s1026" type="#_x0000_t75"
style='position:absolute;left:0;text-align:left;margin-left:152.35pt;
margin-top:15.85pt;width:151.5pt;height:260.15pt;z-index:251659264;
visibility:visible;mso-wrap-style:square;mso-width-percent:0;
mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
mso-position-vertical:absolute;mso-position-vertical-relative:text;
mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
mso-height-relative:page'>
<v:imagedata src="file:///C:\Users\DONNAS~1\AppData\Local\Temp\msohtmlclip1\01\clip_image001.jpg"
o:title=""/>
<w:wrap type="square"/>
</v:shape><![endif]--><!--[if !vml]--><img align="left" hspace="12" src="file:///C:/Users/DONNAS~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" v:shapes="Picture_x0020_9" /><!--[endif]--><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;"><o:p></o:p></span></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<br /></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<br /></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<br /></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Oleh:<o:p></o:p></span></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<br /></div>
<h2 align="center" style="line-height: 150%; margin-top: 0cm; text-align: center;">
<span style="color: windowtext; font-family: "Times New Roman","serif"; font-size: 12.0pt; font-weight: normal; line-height: 150%; mso-bidi-font-weight: bold;">Pricilia Donna
Esperansa Sea (2012-060-106)<o:p></o:p></span></h2>
<h2 align="center" style="line-height: 150%; margin-top: 0cm; text-align: center;">
<span style="color: windowtext; font-family: "Times New Roman","serif"; font-size: 12.0pt; font-weight: normal; line-height: 150%; mso-bidi-font-weight: bold; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: IN;">Tiffany Fransiska (2012-060-
237)<o:p></o:p></span></h2>
<h2 align="center" style="line-height: 150%; margin-top: 0cm; text-align: center;">
<span style="color: windowtext; font-family: "Times New Roman","serif"; font-size: 12.0pt; font-weight: normal; line-height: 150%; mso-bidi-font-weight: bold; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: IN;">Juliana Rajagukguk
(2012-060-264)<o:p></o:p></span></h2>
<h2 align="center" style="line-height: 150%; margin-top: 0cm; text-align: center;">
<span style="color: windowtext; font-family: "Times New Roman","serif"; font-size: 12.0pt; font-weight: normal; line-height: 150%; mso-bidi-font-weight: bold; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: IN;">Maria Yasintha Valentine Nuwa
(2012-060-268)</span><span style="color: windowtext; font-family: 'Times New Roman', serif; font-size: 12pt; font-weight: normal; line-height: 150%;"> </span></h2>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<br /></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 14.0pt; line-height: 150%; mso-bidi-font-size: 12.0pt;">Fakultas Kedokteran UNIKA Atma Jaya Jakarta<o:p></o:p></span></b></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 14.0pt; line-height: 150%; mso-bidi-font-size: 12.0pt;">2013/2014<br clear="all" style="mso-special-character: line-break; page-break-before: always;" />
<o:p></o:p></span></b></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 14.0pt; line-height: 150%; mso-bidi-font-size: 12.0pt;"><br /></span></b></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 14.0pt; line-height: 150%; mso-bidi-font-size: 12.0pt;"><br /></span></b></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 14.0pt; line-height: 150%; mso-bidi-font-size: 12.0pt;"><br /></span></b></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 14.0pt; line-height: 150%; mso-bidi-font-size: 12.0pt;">Pendahuluan<o:p></o:p></span></b></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<br /></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Fungsi utama sistem
imun adalah sebagai pertahanan terhadap infeksi berbagai mikroba. Integritas
sistem imun merupakan hal yang esensial bagi bagi pertahanan tersebut, namun
apabila terjadi defek pada salah satu komponen sistem imun tersebut maka akan
menyebabkan sistem imun tidak bisa berfungsi secara adekuat yang dikenal
sebagai penyakit imunodefisiensi. Keadaan ini menyebabkan peningkatan kerentanan
tubuh terhadap berbagai penyakit
infeksi. Penyakit defisiensi imun tersering mengenai limfosit, komplemen dan
fagosit. Secara umum, keadaan ini dapat terjadi secara primer yang disebabkan
karena kelainan genetik yang diturunkan (congenital) dan secara sekunder atau
didapat, dengan insidensi defisiensi imun primer lebih jarang daripada
sekunder.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Immunodefisiensi primer
atau congenital sering kali menimbulkan kelainan pada <i>innate immunity</i> yang akan mempengaruhi pembentukan sel
limfosit. Abnormalitas pada pembentukan
limfosit yang mungkin disebabkan mutasi gen dapat menyebabkan kesalahan pada
pengkodean gen. Gangguan pembentukan dan fungsi limfosit B dapat menyebakan
defisiensi pembentukan antibodi yang ditandai dengan penurunan immunoglobulin
di serum, respon terhadap vaksin yang buruk, dan pada beberapa kasus menurunkan
jumlah sel limfosit B di jaringan limfoid dan plasma. Sedangkan gangguan
pematangan sel limfosit T ditandai dengan penurunan produksi antibodi dan sel T
di darah tepi. Biasanya gejala baru
muncul pada setelah usia 3-4 bulan, karena masih ada efek proteksi dari
antibodi maternal.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Immunodefisiensi
sekunder merupakan kelainan respon imun yang tidak diturunkan secara genetik namun
didapat. Imunodefisiensi sekunder dapat disebabkan oleh karena terapi
pengobatan yang menyebabkan penurunan fungsi limfosit. Selain itu juga dapat
disebabkan berbagai faktor biologi, komplikasi penyakit, malnutrisi, pengobatan
imunosupresan, neoplasma dan infeksi
yang nampak jelas pada penderita AIDS yang disebabkan infeksi HIV.</span><span lang="EN-US" style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%; mso-ansi-language: EN-US;"><o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">HIV (<i>Human
Immunodeficiency Virus</i>) adalah virus RNA bentuk sferis termasuk retrovirus
yang menyerang sistem kekebalan tubuh manusia, penyebab AIDS (<i>Acquired Imunodeficiency Syndrom)</i>. Virus
ini terdiri dari 2 grup, yaitu HIV-1 (punya gen vpu tapi tidak punya vpx) dan
HIV-2 (punya vpx tapi tidak punya vpu). Di antara kedua grup tersebut, yang
paling banyak menimbulkan kelainan dan lebih ganas di dunia adalah grup HIV-1.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Infeksi HIV terjadi
melalui 3 jalur transmisi utama, yaitu mukosa genital, peredaran darah, dan ibu
ke janin. HIV menyerang sel yang memiliki marker CD4 dan menurunkan jumlah
selnya, sehingga mempengaruhi kekebalan tubuh dengan mrngurangi sel imun.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;"><br /></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;"><br /></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;"><br /></span></div>
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 14.0pt; line-height: 150%; mso-bidi-font-size: 12.0pt;">Pembahasan<o:p></o:p></span></b></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify; text-indent: 42.55pt;">
<br /></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Target utama infeksi
HIV adalah sel yang mempunyai reseptor CD4, yaitu limfosit CD4+ dan
makrofag/monosit. Pada mulanya sistem imun dapat mengendalikan infeksi HIV,
namun dengan perjalanan dari waktu ke waktu HIV akan menimbulkan penurunan
jumlah sel limfosit CD 4 sehingga menyebabkan terganggunya homeostasis dan
fungsi sel-sel lainnya dalam sistem imun tersebut. Namun marker CD4 saja tidak cukup karena beberapa
sel lain seperti megakariosit, mukosa rektal, sel serviks, mikroglia limfosit
CD8 dan epitel ginjal juga dapat terinfeksi HIV. Selain itu reseptor kemokin
(CXCR4 dan CCR5) ternyata ikut berperan dalam mempengaruhi masuknya HIV ke
dalam sel. HIV dapat menimbulkan patologi penyakit melalui beberapa mekanisme,
antara lain terjadinya defisiensi imun yang menimbulkan infeksi oportunistik (IO), terjadinya autoimun,
reaksi hipersensitivitas, dan kecenderungan terjadinya malignansi atau
keganasan pada stadium lanjut.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Pada respon antibodi,
HIV justru meningkatkan pembentukan IgA dan IgG dan mempengaruhi fungsi
neutrofil. Tetapi respon antibodi terhadap HIV sangat lemah, hanya sebagian
kecil antibodi yang dapat menetralisasi HIV karena itu HIV dapat melewati
respon antibodi sehingga dapat tetap hidup dan menginfeksi sel lain. HIV juga
dapat tetap bertahan dalam tubuh karena mempunyai kemampuan untuk bertahan
dalam limfosit CD4 dan bereplikasi. Dengan pemberian obat antiretroviral dapat
menekan replikasi HIV sehingga jumlah limfosit CD4 stabil bahkan meningkat
sehingga bisa mengurangi infeksi oportunistik. Namun demikian gejala IO dapat
kembali terjadi karena sebagai akibat gejala inflamasi. Meskipun begitu,
beberapa terapi bisa diberikan kepada pasien HIV untuk menekan reaksi HIV yaitu
dengan memanfaatkan langkah-langkah utama dalam proses infeksi HIV pada
sel,yaitu (1) bertemunya gp120 virus dan limfosit CD4, (2) pengikatan gp120 dengan reseptor kemokin CXCR4 dan CCR5,
dan (3) fusi membran virus dan membran sel target.</span><b><span style="font-family: "Times New Roman","serif"; font-size: 14.0pt; line-height: 150%; mso-bidi-font-size: 12.0pt;"><o:p></o:p></span></b></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Struktur
virus HIV-1 terdiri atas 2 untaian RNA
identik yang merupakan genom virus yang berhubungan dengan p17 dan p24 berupa
inti polipeptida. Semua komponen tersebut diselubungi envelop membran
fosfolipid yang berasal dari sel pejamu. Protein gp120 dan gp41 yang disandi
virus ditemukan dalam envelop. Antigen gp120 adalah glikoprotein permukaan
HIV-1 yang mengikat reseptor CD4 pada sel T
dan makrofag. Protein gp120 virus terdiri dari domain dalam dan luar
yang terhubung oleh sebuah jembatan. Virus menginfeksi sel dengan menggunakan
glikoprotein envelop yang disebut gp120 (120kD glikoprotein) yang terutama
mengikat CD4 dan dari sel manusia.<o:p></o:p></span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Setelah
virus berikatan dengan reseptor sel, membran sel virus bersatu dengan membran
sel pejamu dan virus masuk sitoplasma. Setelah HIV masuk kedalam sel dan terbentuk
dsDNA, integrasi DNA viral kedalam genom sel pejamu dan membentuk provirus.
Provirus tetap laten sampai kejadian dalam sel terinfeksi mencetuskan
aktifasinya, yang mengakibatkan terbentuk dan penglepasan partikel virus. Walau
CD4 berikatan dengan envelop glikoprotein HIV-1, diperlukan reseptor kedua
supaya dapat masuk dan terjadi infeksi. Galur tropik sel T-HIV-1 menggunakan
koreseptor CXCR4, sedangkan galur tropik makrofag menggunakan CCR5. Kedua
reseptor ini merupakan reseptor kemokin dan ligan normalnya dapat menghambat
infeksi HIV ke dalam sel.<o:p></o:p></span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<br /></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Inhibitor
HIV : Mekanisme Dan Resistensinya</span></b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;"><o:p></o:p></span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Inhibitor
ikatan CD4-gp 120 dan mekanismenya<o:p></o:p></span></b></div>
<div class="MsoNormalCxSpLast" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Terdapat banyak
molekul yang mampu menghambat ikatan CD4-gp 120. Molekul-molekul tersebut
memiliki struktur dan mekanisme yang berbeda. Diantaranya :<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpFirst" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 14.2pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; mso-list: l2 level1 lfo1; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Symbol; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;">·<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">PRO-542
(CD4-IgG2</span></b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">) adalah suatu rekombinan antibodi berbentuk
tetravalen dan larut dalam plasma. Molekul ini dapat menggabungkan empat
salinan dari ikatan domain CD4 dan meniru reseptor CD4. Merupakan salah satu
dari inhibitor ikatan CD4-gp120. Selain itu studi lain menemukan bahwa gabungan
PRO-542 dengan enfuvirtide menunjukkan hasil yang positif dalam menghambat
replikasi HIV. <o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 14.2pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; mso-list: l2 level1 lfo1; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Symbol; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;">·<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">TNX-355</span></b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">
adalah antibodi monoklonal non-imunosupresif yang diarahkan langsung kepada
reseptor CD4. Molekul ini bersaing dengan gp120 pada HIV untuk mengikat CD4.
Awalnya diketahui bahwa sisi pengikatan antibodi pada reseptor CD4 berbeda
debgan sisi yang terlibat dengan HIV gp120. Dengan demikian, TNX-355 dapat
mencegah perubahan konformasi sebelum HIV berhasil masuk ke sel. Percobaan awal
pada pasien yang terinfeksi HIV menunjukkan bahwa dosis TNX-355 yang sedikit
mengurangi RNA HIV-1 dalam plasma dan
meningkatan jumlah CD4 + sel T.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 14.2pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; mso-list: l2 level1 lfo1; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Symbol; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;">·<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">CADA</span></b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">
adalah inhibitor spesifik dari ikatan CD4-gp120 yang tidak berinteraksi
langsung dengan reseptor CD4 atau dengan gp120. Aktivitas antivirus CADA
diasumsikan untuk mengatur ekspresi reseptor CD4 setelah translasi.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 14.2pt; margin-right: 0cm; margin-top: 0cm; mso-add-space: auto; mso-list: l2 level1 lfo1; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Symbol; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;">·<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">BMS-806</span></b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">
memiliki afinitas yang tinggi untuk
mengikat HIV gp120, sehingga menghalangi perubahan konformasi pada gp120
setelah CD4 terikat. Pengikatan BMS-806 pada HIV gp120 termasuk spesifik,
reversibel dan koreseptor independen. Namun molekul ini tidak aktif terhadap
HIV-2 dan simian immunodeficiency virus (SIV). <o:p></o:p></span></div>
<div class="MsoNormalCxSpFirst" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 36.0pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Molekul-molekul
diatas tidak menunjukkan sitotoksisitas yang signifikan, bahkan tidak memiliki
toksisitas pada hewan. Namun memiliki bioavailabilitas yang baik.<o:p></o:p></span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<br /></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Interaksi
gp120 dengan koreseptor kemokin<o:p></o:p></span></b></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 36.0pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Selain
mengikat ke reseptor sel CD4, HIV perlu mengikat koreseptor kemokin untuk masuk
ke dalam sel. Koreseptor utama yang terlibat dalam masuknya HIV kedalam sel
adalah CCR5 dan CXCR4. Pembentukkan kompleks CD4-gp120 memunculkan perubahan
konformasi pada envelop virus sehingga dapat berinteraksi dengan CCR5 atau
CXCR4.<o:p></o:p></span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 36.0pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">CCR5
dan CXCR4 memiliki tujuh famili reseptor pasangan protein G transmembran. CCR5
dan CXCR4 memiliki struktur heliks yang terdiri dari empat domain transmembran,
tiga loop ekstraseluler, dan satu domain N-terminal. Kompleks CD4-gp120
mengikat koreseptor melalui daerah V3 meskipun daerah V1/V2 dan C4 mungkin bisa
juga terlibat dalam interaksi. Sekuens asam amino V3 menentukkan terhadap
pengikatan dengan CCR5 dan/atau CXCR4. Dengan demikian, isolasi virus dapat
diklasifikasikan menjadi jenis R5, X4, dan R5/X4, tergantung pada ikatan mereka
dengan koreseptornya.<o:p></o:p></span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<br /></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Antagonis
CCR5 dan mekanismenya<o:p></o:p></span></b></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; mso-layout-grid-align: none; text-align: justify; text-autospace: none; text-indent: 36.0pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Antagonis CCR5 dan
CXCR4 dibagi menjadi tiga kelompok tergantung pada ukurannya yakni molekul
besar (PRO-140), medium (Met-RANTES dan AOP-RANTES ) yang dimodifikasi menjadi
ligan natural yang membuat CCR5 tidak dapat dimasuki. Dan yang terakhir
beberapa molekul inhibitor kecil untuk <span style="color: #292526;">CCR5
(TAK-779, SCH-C, SCH-D, UK-427857 and GW-873140) atau untuk CXCR4 (AMD3100 and
KRH-<o:p></o:p></span></span></div>
<div class="MsoNormalCxSpLast" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<span style="color: #292526; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">1636)
telah dikembangkan.</span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;"> Kebanyakan antagonis CCR5 adalah
molekul kecil yang menghambat interaksi CCR5-gp120.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpFirst" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; mso-list: l1 level1 lfo2; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Wingdings; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings;">§<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">TAK-779</span></b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">
adalah molekul non-peptida pertama yang memblok replikasi R5 secara in vitro
dengan mengganggu interaksi dengan koreseptor CCR5. TAK-779 memiliki
bioavaibilitas yang kecil dan pengembangan klinis nya dihentikan karena reaksi
lokal saat pemberian yang membuat sulit dalam manajemen. Penelitian lebih
lanjut berdasarkan TAK-779 menyebabkan identifikasi TAK-220. Senyawa ini sangat
efektif terhadap blok replikasi R5 dan tahap ujiklinis fase II saat ini sedang
berlangsung.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; mso-list: l1 level1 lfo2; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Wingdings; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings;">§<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">TAK-652</span></b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">
merupakan antagonis baru dari Takeda Chemical Industries. TAK-652 menunjukkan
bioavailabilitas yang baik dan memiliki potensi yang tinggi terhadap HIV.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; mso-list: l1 level1 lfo2; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Wingdings; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings;">§<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">PRO-140</span></b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">
adalah antibodi monoklonal yang menghambat pengikatan gp120 HIV.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; mso-list: l1 level1 lfo2; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Wingdings; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings;">§<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Maravirok</span></b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">
merupakan antagonis CCR5 yang dikembangkan oleh Pfizer. Hasil awal uji coba
fase II sangat menjanjikan. Hampir semua pasien mengalami penurunan plasma
viremia dan tetap ditekan selama setidaknya 10 hari pasca pengobatan.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; mso-list: l1 level1 lfo2; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Wingdings; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings;">§<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Dan
yang terakhir, <b>Aplaviroc</b> menunjukkan
hasil yang signifikan baik secara in vitro maupun in vivo aktivitas antivirus.
Namun telah diumumkan tentang penghentian pengembangan klinis karena
menimbulkan hepatotoksisitas yang serius. <o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<br /></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Antagonis
CXCR4 dan mekanismenya<o:p></o:p></span></b></div>
<div class="MsoListParagraphCxSpFirst" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; mso-list: l0 level1 lfo3; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Wingdings; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings;">§<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">AMD3100</span></b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">
antivirus yang berpotensi menunjukkan penghambatannya terhadap X4 telah
dikonfirmasi dalam berbagai studi baik secara in vitro maupun in vivo.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; mso-list: l0 level1 lfo3; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Wingdings; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings;">§<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">KRH-1636</span></b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">
merupakan salah satu antagonisCXCR4 lagi
yang serupa dengan AMD3100. Studi yang telah dilakukan terhadap tikus menunjukkan
bahwa obat ini dapat diserap dengan baik dengan demikian diharapkan dapat
memiliki bioavalaibilitas yang baik.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; mso-list: l0 level1 lfo3; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Wingdings; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings;">§<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;"> </span></span><!--[endif]--><b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">KRH-2731</span></b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">
adalah antagonis CXCR4 baru yang mengikat ke loop ekstraseluler kedua dan
ketiga (ECL2 dan ECL3). Penelitian yang secara invitro telah menegaskan bahwa
KRH-2731 memiliki aktivitas antivirus yang berpotensi terhadap penghambatan X4
dan R5X4, yang bisa 10 kali lipat lebih tinggi dari AMD070 yang merupakan salah
satu senyawa AMD3100.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<br /></div>
<div class="MsoNormalCxSpFirst" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Resistensi
terhadap antagonis CCR5 dan CXCR4<o:p></o:p></span></b></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 36.0pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Secara
teoritis ada 2 jalur utama resistensi terhadap antagonis CCR5 dan CXCR4, yaitu
pergeseran dalam penggunaan koreseptor dan perubahan daerah genom-envelop pada
HIV yang memungkinkan interaksi antara gp120 dan koreseptor meskipun ada
inhibitor. Sejauh ini, kebanyakan resisten antagonis CCR5 menggunakan
koreseptor CCR5 daripada beralih ke CXCR4. Selain itu terjadi bermacam-macam
mutasi pada daerah yang berbeda pada HIV gp120 (V3, C2, V2, C4). Kebanyakan
mutasi resisten ini khusus untuk setiap senyawa yang berbeda yang diharapkan
dapat mencegah resistensi silang. Dalam kasus apapun, resistensi CCR5 antagonis
tidak menunjukkan resistansi silang dengan ARV, RT dan inhibitor protease. Atau
resisten silang terhadap molekul penghambat lain, seperti ikatan inhibitor
CD4-gp120 dan enfuvirtide.<o:p></o:p></span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Resistensi
terhadap CXCR4 antagonis kurang dijelakan dibandingkan resistensi terhadap CCR5
antagonis. Mutasi pada domain V3 HIV gp120 tampaknya menjelaskan hilangnya
kerentanan terhadap banyak dari senyawa ini. Namun, mutasi pada gp120 HIV
wilayah lainnya (V1, V2 dan V4) juga telah dikaitkan dengan resistensi terhadap
CXCR4 antagonis, termasuk delesi lima asam amino dalam domain V4[kodon 364-368
(FNSTW)].<o:p></o:p></span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Meskipun
hasil awal belum mengidentifikasi pergeseran dalam penggunaan koreseptor
sebagai jalur utama untuk menghindari resistensi CCR5 antagonis, hal ini
penting sebagai pengontrol terutama pada pasien dengan campuran R5 dan X4
virus. Pergeseran penggunaan koreseptor CCR5 dari arah CXCR4 menggunakan CCR5
antagonis bisa memiliki konsekuensi yang bahaya dalam perkembangan penyakit
HIV, karena virus X4 yang diisolasi cenderung lebih ganas dari virus R5. Di
sisi lain, sebaliknya bisa juga dengan penggunaan CXCR4 antagonis, dalam hal
pergeseran terhadap virus R5.<o:p></o:p></span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<br /></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Peleburan
inhibitor dan mekanismenya<o:p></o:p></span></b></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Setelah
interaksi antara kompleks gp120-CD4 dan reseptor kemokin CCR5 atau CXCR4,
perubahan konformasi tambahan berlangsung di envelop virus yang menyebabkan
pergeseran dari non-fusogenik ke keadaan fusogenik dari HIV gp41, yang akhirnya
mendorong proses fusi . N-terminal domain gp41 dimasukkan melalui peptida fusi
(FP) ke dalam membran sel. Kemudian, gp41 mengalami reorganisasi struktural
yang memprovokasi interaksi antara daerah heptad HR1 dan HR2, membentuk
termostabil, struktur bundel enam helix, yang sangat penting bagi virus dan
fusi membran sel. Perubahan energi bebas berhubungan dengan pembentukan bundel
enam helix memberikan tenaga yang diperlukan untuk pembentukan pori fusi, dan
kapsid virus memasuki sel target melalui proses ini.<o:p></o:p></span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Enfuvirtide
adalah peptida sintetik dari 36 asam amino yang meniru sebuah fragmen HR2 dari
gp41. Yang mengikat HR1 pada wilayah pembentukan struktur bundel enam helix,
yang sangat penting untuk proses fusi. Pada uji klinis, keamanan enfuvirtide
ditunjukkan dari manfaat virologi dan
imunologi pada penambahan enfuvirtide bersama dengan ARV pada pasien TB.
Enfuvirtide disetujui untuk pengobatan infeksi HIV pada tahun 2003.<o:p></o:p></span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<br /></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Resistensi
terhadap fusi inhibitor<o:p></o:p></span></b></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 36.0pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Hasil
selanjutnya diperoleh dalam studi klinis menunjukkan bahwa resistensi pada
pasien yang menerima enfuvirtide juga karena perubahan luas dari kodon 36-45
dalam HR1. Enfuvirtide harus dipertimbangkan sebagai obat dengan hambatan
genetik rendah untuk perlawanan.<o:p></o:p></span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Berbagai
kerentanan terhadap enfuvirtide pada virus yang terisolasi telah terbukti pada
pasien enfuvirtide-naif, serta individu menjalani terapi enfuvirtide. Faktor
penentu heterogenitas ini tidak jelas, tetapi polimorfisme di wilayah HR2 dari
gp41 serta perubahan HR2 dipilih selama pengobatan enfuvirtide bisa menjelaskan
fenomena ini. Beberapa perubahan HR2 telah diakui pada pasien di bawah terapi
enfuvirtide. Oleh karena itu, sulit untuk menyimpulkan bahwa perubahan HR2
dapat mempengaruhi kepekaan enfuvirtide. Namun, ada juga yang mengidentifikasi
perubahan spesifik dalam HR2 selama terapi enfuvirtide (yaitu mutasi S138A),
yang merupakan kompensasi mutation. <o:p></o:p></span></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Selain
faktor virus, penentu host (yaitu tingkat ekspresi koreseptor pada sel target)
juga dapat mempengaruhi kerentanan terhadap enfuvirtide. Dengan cara ini,
tingginya tingkat CCR5 pada permukaan sel mungkin mengakibatkan fusi HIV lebih
cepat, mengurangi waktu di mana HIV gp41 dapat ditargetkan oleh enfuvirtide.
Oleh karena itu, individu yang membawa Î32-CCR5, yang mengungkapkan rendahnya
tingkat CCR5, tampaknya merespon lebih baik terhadap enfuvirtide.<o:p></o:p></span></div>
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-ansi-language: IN; mso-bidi-language: AR-SA; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;"><br clear="all" style="mso-special-character: line-break; page-break-before: always;" />
</span>
<br />
<div class="MsoNormal">
<br /></div>
<div align="center" class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: center;">
<b><span style="font-family: "Times New Roman","serif"; font-size: 14.0pt; line-height: 150%; mso-bidi-font-size: 12.0pt;">Penutup<o:p></o:p></span></b></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-indent: 1.0cm;">
<br /></div>
<div class="MsoNormalCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 35.45pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Salah
satu penyebab penyakit imunodefisiensi pada manusia adalah karena infeksi HIV (<i>Human Imunodeficiency Virus)</i>. HIV
bekerja pada sel target yang mempunyai marker CD4, seperti limfosit T dan
makrofag. Namun CD4 saja tidak cukup karena HIV tetap dapat menginfeksi sel-sel
lain, bahkan sel yang mengandung CD4 negatif. Koreseptor kemokin CCR5 dan CXCR4
juga memegang peranan penting dalam infeksi HIV pada sel target. Respon
defisiensi imun yang terjadi tidak hanya bersifat selular tetapi juga bersifat
humoral, karena sel T helper ikut mengaktivasi limfosit B. Dapat menimbulkan
infeksi oportunistik (IO), terjadinya
autoimun, reaksi hipersensitivitas, dan kecenderungan terjadinya malignansi
atau keganasan pada stadium lanjut.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify; text-indent: 42.55pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">HIV merupakan virus yang
unik dan sangat berbahaya karena menular, dapat bertahan hidup dalam limfosit
CD4, memiliki respon terhadap antibodi yang lemah. Hanya sebagian kecil
antibodi yang dapat menetralisasi HIV karena itu HIV dapat melewati respon
antibodi sehingga dapat tetap hidup dan menginfeksi sel lain serta mengakibatkan
kematian. Vaksinnya sendiri belum ditemukan. Salah satu terapi HIV yang dapat
dibuat adalah dengan menghinhibisi reaksi penyatuan virus dan sel target.<o:p></o:p></span></div>
<div class="MsoNormalCxSpLast" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; mso-add-space: auto; text-align: justify; text-indent: 36.0pt;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Memasukkan
inhibitor merupakan pilihan terapi yang
menjanjikan untuk pasien yang terinfeksi HIV. Enfuvirtide adalah inhibitor fusi
pertama yang disetujui dalam penggunaan klinis, tetapi banyak senyawa lain yang
saat ini masih dalam tahap pengembangan. Pengetahuan mengenai mekanisme dari
masing-masing molekul ini sangat penting untuk memahami dan memprediksi jalur
resistensi yang sesuai. Banyak perubahan yang terjadi pada domain gp120 telah dikaitkan dengan resistensi inhibitor. Selain itu, masih harus di
konformasi apakah pergeseran penggunakan koreseptor mungkin jalur alternatif
bagi HIV untuk menghindari tekanan obat pada pasien yang telah terekspos
antagonis CCR5 atau CXCR4.<o:p></o:p></span></div>
<div class="Default" style="line-height: 150%; text-indent: 42.55pt;">
<br /></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-indent: 1.0cm;">
<br /></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-indent: 1.0cm;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 150%;">Daftar Pustaka</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-indent: 1.0cm;">
<span style="font-family: Times New Roman, serif;">IPD UI, jilid 1</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-indent: 1.0cm;">
<span style="font-family: Times New Roman, serif;">Imunologi Dasar UI, edisi 8</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-indent: 1.0cm;">
<span style="font-family: Times New Roman, serif;">Abass, Immunology,</span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-indent: 1cm;">
<span style="font-family: Times New Roman, serif;"><span style="line-height: 24px;">J. Antimicrob. Chemother.-2006-Briz-619-27.pdf</span></span></div>
<br />
<div align="center" class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: center;">
<br /></div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-4680734245417671052013-06-29T05:48:00.002-07:002013-06-29T05:48:29.309-07:00Histologi dan Peredaran Darah Ginjal :)<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; vertical-align: baseline;">
<b><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">Struktur ginjal (histogi)<o:p></o:p></span></b></div>
<div class="MsoListParagraphCxSpFirst" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; mso-add-space: auto; mso-list: l1 level1 lfo2; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-family: Symbol; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;">·<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">Setiap
ginjal terbungkus oleh selaput tipis yang disebut <b>kapsula renalis</b> yang terdiri dari jaringan jaringan ikat kolagen
padat tidak beraturan. Kadang ada fibroblast dan pembuluh darah. <o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; mso-add-space: auto; mso-list: l1 level1 lfo2; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-family: Symbol; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;">·<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">Lapisan
luar terdiri dari lapisan korteks (subtansia kortekalis), dan lapisan sebelah
dalam bagian medulla (subtansia medularis) berbentuk kerucut yang disebut renal
piramid.<br />
Korteks:<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; margin-left: 1.0in; margin-right: 0in; margin-top: 0in; mso-add-space: auto; mso-list: l0 level2 lfo1; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri;">-<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">tubulus
proksimal ( <b><span style="color: #c00000;">epitel
selapis kubis warna merah</span></b> dengan brush border)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; margin-left: 1.0in; margin-right: 0in; margin-top: 0in; mso-add-space: auto; mso-list: l0 level2 lfo1; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri;">-<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">tubulus
distal (<b><span style="color: #002060;">epitel
selapis kubis pucat</span></b> tanpa brush border)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; margin-left: 1.0in; margin-right: 0in; margin-top: 0in; mso-add-space: auto; mso-list: l0 level2 lfo1; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri;">-<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">macula
densa, masih berhubungan dengan sel juktaglomerulus<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; margin-left: 1.0in; margin-right: 0in; margin-top: 0in; mso-add-space: auto; mso-list: l0 level2 lfo1; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri;">-<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">tubulus
koligentes<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; margin-left: 1.0in; margin-right: 0in; margin-top: 0in; mso-add-space: auto; mso-list: l0 level2 lfo1; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri;">-<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">pars
rekta tubulus proksimal<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; margin-left: 1.0in; margin-right: 0in; margin-top: 0in; mso-add-space: auto; mso-list: l0 level2 lfo1; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri;">-<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">segmen
tebal asendes ansa henle<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; margin-left: 1.0in; margin-right: 0in; margin-top: 0in; mso-add-space: auto; mso-list: l0 level2 lfo1; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri;">-<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">pembulu
darah<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; margin-left: 1.0in; margin-right: 0in; margin-top: 0in; mso-add-space: auto; mso-list: l0 level2 lfo1; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri;">-<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">ada
kapsula bowman (<b><span style="color: #0070c0;">ingat
polus tuberalis: yang bersinggungan dengan tubulus proksimal</span></b> dan <b><span style="color: red;">polus vaskularis:
tempat masuk keluar arteriol aferen dan eferen</span></b>)<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; margin-left: .5in; margin-right: 0in; margin-top: 0in; text-align: justify; vertical-align: baseline;">
<span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">Medula:<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpFirst" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; margin-left: 1.0in; margin-right: 0in; margin-top: 0in; mso-add-space: auto; mso-list: l0 level2 lfo1; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri;">-<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">segmen
tebal desendes ansa henle (<b><span style="color: #c00000;">sel mirip tubulus proksimal</span></b>)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; margin-left: 1.0in; margin-right: 0in; margin-top: 0in; mso-add-space: auto; mso-list: l0 level2 lfo1; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri;">-<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">segmen
tipis ansa henle (apitel selapis gepeng)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; margin-left: 1.0in; margin-right: 0in; margin-top: 0in; mso-add-space: auto; mso-list: l0 level2 lfo1; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri;">-<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">segmen
tebal asendes ansa henle (<b><span style="color: #002060;">sel mirip tubulus distal</span></b>)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; margin-left: 1.0in; margin-right: 0in; margin-top: 0in; mso-add-space: auto; mso-list: l0 level2 lfo1; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri;">-<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">vasa
rekta<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; margin-left: 1.0in; margin-right: 0in; margin-top: 0in; mso-add-space: auto; mso-list: l0 level2 lfo1; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 150%; mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri;">-<span style="font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">apeks
papilla renal (ada area kribosa (yg berlubang-lubang), ada duktus papilla
Bellini menyalurkan urin ke ureter)<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; mso-add-space: auto; mso-list: l1 level1 lfo2; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-family: Symbol; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;">·<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">Puncak
kerucut tadi menghadap kaliks yang terdiri dari lubang-lubang kecil disebut
papilla renalis. Masing-masing piramid dilapisi oleh kolumna renalis, jumlah
renalis 15-16 buah.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; vertical-align: baseline;">
<a href="http://ilper.wordpress.com/2012/04/19/sistem-perkemihan-urinaria/urin2/"><span style="color: windowtext; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman"; mso-no-proof: yes; text-decoration: none; text-underline: none;"><v:shapetype coordsize="21600,21600" filled="f" id="_x0000_t75" o:preferrelative="t" o:spt="75" path="m@4@5l@4@11@9@11@9@5xe" stroked="f">
<v:stroke joinstyle="miter">
<v:formulas>
<v:f eqn="if lineDrawn pixelLineWidth 0">
<v:f eqn="sum @0 1 0">
<v:f eqn="sum 0 0 @1">
<v:f eqn="prod @2 1 2">
<v:f eqn="prod @3 21600 pixelWidth">
<v:f eqn="prod @3 21600 pixelHeight">
<v:f eqn="sum @0 0 1">
<v:f eqn="prod @6 1 2">
<v:f eqn="prod @7 21600 pixelWidth">
<v:f eqn="sum @8 21600 0">
<v:f eqn="prod @7 21600 pixelHeight">
<v:f eqn="sum @10 21600 0">
</v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:formulas>
<v:path gradientshapeok="t" o:connecttype="rect" o:extrusionok="f">
<o:lock aspectratio="t" v:ext="edit">
</o:lock></v:path></v:stroke></v:shapetype><v:shape alt="http://ilper.files.wordpress.com/2012/04/urin2.jpg?w=300&h=249" href="http://ilper.wordpress.com/2012/04/19/sistem-perkemihan-urinaria/urin2/" id="Picture_x0020_3" o:button="t" o:spid="_x0000_i1025" style="height: 255pt; mso-wrap-style: square; visibility: visible; width: 307.5pt;" type="#_x0000_t75">
<v:fill o:detectmouseclick="t">
<v:imagedata o:title="urin2" src="file:///C:\Users\GILVYON\AppData\Local\Temp\msohtmlclip1\01\clip_image001.jpg">
</v:imagedata></v:fill></v:shape></span></a><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";"><o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; vertical-align: baseline;">
<br /></div>
<div class="MsoListParagraph" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; mso-add-space: auto; mso-list: l2 level1 lfo3; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-family: Symbol; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;">·<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">Garis-garis
yang terlihat di piramid disebut tubulus nefron yang merupakan bagian terkecil
dari ginjal yang terdiri dari glomerulus, tubulus proksimal (tubulus kontorti
satu), ansa henle, tubulus distal (tubulus kontorti dua) dan tubulus urinarius
(papilla vateri).<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; vertical-align: baseline;">
<br /></div>
<br />
<div class="MsoListParagraph" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; mso-add-space: auto; mso-list: l2 level1 lfo3; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<!--[if !supportLists]--><span style="font-family: Symbol; font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;">·<span style="font-family: 'Times New Roman'; font-size: 7pt; line-height: normal;">
</span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">Pada
setiap ginjal diperkirakan ada 1.000.000 nefron, selama 24 jam dapat menyaring
darah 170 liter. Arteri renalis membawa darah murni dari aorta ke ginjal,
lubang-lubang yang terdapat pada piramid renal masing-masing membentuk simpul
dari kapiler satu badan malfigi yang disebut glomerulus. Pembuluh aferen yang
bercabang membentuk kapiler menjadi vena renalis yang membawa darah dari ginjal
ke vena kava inferior.<o:p></o:p></span></div>
<div class="MsoListParagraph" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; mso-add-space: auto; mso-list: l2 level1 lfo3; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
<span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";"><br /></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; vertical-align: baseline;">
<b><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">Peredaran darah ginjal</span></b><span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";"><o:p></o:p></span></div>
<div class="MsoListParagraph" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; mso-add-space: auto; mso-list: l2 level1 lfo3; text-align: justify; text-indent: -.25in; vertical-align: baseline;">
</div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; vertical-align: baseline;">
<span style="font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: Arial; mso-fareast-font-family: "Times New Roman";">ginjal mendapat darah dari <b><span style="color: red;">aorta abdominalis</span></b> yang mempunyai percabangan arteri
<b><span style="color: red;">arteri renalis</span></b>.
Arteri ini berpasangan kiri dan kanan. Arteri renalis bercabang menjadi <b><span style="color: red;">arteria segmental,</span>
</b>terus ke <b><span style="color: red;">arteri
interlobus</span></b> nanti cabang lagi jadi <b><span style="color: red;">arteri arkuata</span></b>. Arteri ini terhubung
ke <b><span style="color: red;">arteri
interloburalis</span></b> yang berada di tepi ginjal bercabang menjadi kapiler
membentuk gumpalan-gumpalan yang disebut glomerulus. Glomerulus ini dikelilingi
oleh alat yang disebut kapsula bowman. Di dalam kapsula bowman lewat <b><span style="color: red;">afferent arteriol</span></b>
lalu ke <b><span style="color: red;">kapiler
glomerulus</span></b><span style="color: red;"> lalu ke <b>efferent arteriol</b></span> setelah disaring. Dari sini darah ke <b><span style="color: #7030a0;">kapiler
peritubular</span></b> yang berjalan di sekitar tubulus, nanti lewat <b><span style="color: #002060;">vena
interlobularis</span></b> ke <b><span style="color: #002060;">vena arcuata</span></b> lalu ke <b><span style="color: #002060;">vena interlobus</span></b> kemudian menjadi
<b><span style="color: #002060;">vena renalis</span></b>
masuk ke <b><span style="color: #002060;">vena
kava inferior</span></b>.<o:p></o:p></span></div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com1tag:blogger.com,1999:blog-7294540944450239332.post-72017346698460322412013-05-12T08:23:00.002-07:002013-05-12T08:23:52.902-07:00<br />
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span style="font-size: 16.0pt; line-height: 115%; mso-bidi-font-size: 11.0pt;">SANTA PRISCILLA </span></b><i><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-size: 11.0pt;">(16
Januari)</span></i><b><span style="font-size: 16.0pt; line-height: 115%; mso-bidi-font-size: 11.0pt;"><o:p></o:p></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<br /></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgWhO1qR0UHcZb0ZXBkADrHxeIKukCD4rB5u7YmqpdTUjGa5C3faxPGyQZPbtynLOep12gPKcsYoINqTlmzLfUCV-mjaJTZCozCYYd63FdfLtRoNBcXil1nvO_lXEUcZVV_8IeI16Xm70Q/s1600/santa-priscilla-nestor-patialiakaks.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgWhO1qR0UHcZb0ZXBkADrHxeIKukCD4rB5u7YmqpdTUjGa5C3faxPGyQZPbtynLOep12gPKcsYoINqTlmzLfUCV-mjaJTZCozCYYd63FdfLtRoNBcXil1nvO_lXEUcZVV_8IeI16Xm70Q/s320/santa-priscilla-nestor-patialiakaks.jpg" width="175" /></a><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhZM9cE54nYYvD57VdNNnQVGKD34ZpaXuH3okhZbA9kFxGjBZOQM0zz4kr3Lampi04S-pWRJggmajbaa7iuV39Xy4H5JZpeAOfHZjOLBZuCRQPgmxc8rDW_YasHaKB9KfodtmMrWsGThJI/s1600/5471.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhZM9cE54nYYvD57VdNNnQVGKD34ZpaXuH3okhZbA9kFxGjBZOQM0zz4kr3Lampi04S-pWRJggmajbaa7iuV39Xy4H5JZpeAOfHZjOLBZuCRQPgmxc8rDW_YasHaKB9KfodtmMrWsGThJI/s320/5471.jpg" width="196" /></a></div>
<div align="center" class="MsoNormal" style="text-align: center;">
</div>
<div align="center" class="MsoNormal" style="text-align: center;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
Santa Priscilla adalah seorang
gadis Romawi, yang dikenal juga dengan nama Santa Prisca. Ia adalah salah satu
pendiri katakombe tertua di Roma, yakni Katakombe Santa Priscilla, di jalan Salaria,
Roma.</div>
<br />
<div class="MsoNormal" style="text-align: justify;">
Santa Priscilla adalah istri dari Mainus
Acilius Glabrio, yang meninggal dunia karena teguh mempertahankan imannya pada
masa penganiayaan terhadap kaisar Domitianus (81-96). Menurut<span style="background-color: white; background-position: initial initial; background-repeat: initial initial;"> cerita, Santo Petrus pernah menggunakan
rumah Priscila di jalan Salaria sebagai markasnya. Dibawah rumah itu, digali
katakombe - katakombe. Santo Pundens dianggap sebagai putera dari Priscila.
Priscila meninggal pada tahun 98.<span class="apple-converted-space"> <o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjkB2Q162SGgcsN03fR3cXijNFs_w4N98y7xTk4nFuXN0F_YDfItZYfh0deT1HN5sGqRkR7OTFNIwSWa_Y3cE0TkO2Nad8qAthqX88dzmsKuPGBX6oAU4KxfA8q9ezqfPQBmmtk9rjbxao/s1600/180px-madonna_catacomb.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjkB2Q162SGgcsN03fR3cXijNFs_w4N98y7xTk4nFuXN0F_YDfItZYfh0deT1HN5sGqRkR7OTFNIwSWa_Y3cE0TkO2Nad8qAthqX88dzmsKuPGBX6oAU4KxfA8q9ezqfPQBmmtk9rjbxao/s1600/180px-madonna_catacomb.jpg" /></a><span style="background: white; color: #2e2613; mso-bidi-font-weight: bold;">Di Gereja Katakombe St. Priscilla
di Roma</span><span class="apple-converted-space"><span style="background: white; color: #2e2613;"> di</span><span style="background-color: white; background-position: initial initial; background-repeat: initial initial;"> </span></span><span style="background: white; color: #2e2613;">tampilkan sebuah lukisanfresco abad ke-2 yang menggambarkan<span class="apple-converted-space"> </span><i>Nativity of Christ</i><span class="apple-converted-space"> </span>atau Kelahiran Tuhan kita Yesus
Kristus. Lukisan ini menjadi salah satu asal-usul perayaan Natal. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<h3 style="background: white; margin-bottom: .0001pt; margin: 0in; text-align: justify;">
<span style="background-position: initial initial; background-repeat: initial initial; color: #2e2613; font-family: Calibri, sans-serif; font-size: 11pt; font-weight: normal;">Priscilla dan Aquila adalah
pasangan Yahudi yang diusir meninggalkan Roma oleh kaisar Claudius. Mereka
bekerja sebagai pembuat tenda. Mereka lalu pergi ke Korintus dan bertemu Santo
Paulus. Di sana mereka lalu bertobat dan menjadi pengikut Yesus. Keduanya
kemudian mengikuti St. Paulus sampai di Efesus kemudian menetap tiga tahun di
sana sebelum kembali ke Roma. Keduanya dipercaya meninggal sebagai martir di
Roma. Kisah keduanya dapat ditemukan di Kitab Suci. Salah satunya dalam </span><span style="color: #5c1101; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: normal; mso-ascii-theme-font: minor-latin; mso-bidi-font-weight: bold; mso-hansi-theme-font: minor-latin;">Acts 18:18,</span><span style="background-position: initial initial; background-repeat: initial initial; color: #2e2613; font-family: Calibri, sans-serif; font-size: 11pt; font-weight: normal;"> </span><sup><span style="background-position: initial initial; background-repeat: initial initial; font-family: Calibri, sans-serif; font-size: 11pt; font-weight: normal;">18 </span></sup><span style="background-position: initial initial; background-repeat: initial initial; font-family: Calibri, sans-serif; font-size: 11pt; font-weight: normal;">After this, Paul stayed many days
longer and then took leave of<span class="apple-converted-space"> </span>the
brothers</span><sup><span style="background-position: initial initial; background-repeat: initial initial; font-family: Calibri, sans-serif; font-size: 11pt; font-weight: normal;">[</span></sup><a href="http://www.biblegateway.com/passage/?search=Acts%2018:18;&version=ESV;#fen-ESV-27562a" title="See footnote a"><sup><span style="background-position: initial initial; background-repeat: initial initial; color: #b37162; font-family: Calibri, sans-serif; font-size: 11pt; font-weight: normal;">a</span></sup></a><sup><span style="background-position: initial initial; background-repeat: initial initial; font-family: Calibri, sans-serif; font-size: 11pt; font-weight: normal;">]</span></sup><span class="apple-converted-space"><span style="background-position: initial initial; background-repeat: initial initial; font-family: Calibri, sans-serif; font-size: 11pt; font-weight: normal;"> </span></span><span style="background-position: initial initial; background-repeat: initial initial; font-family: Calibri, sans-serif; font-size: 11pt; font-weight: normal;">and set sail for Syria, and with
him<span class="apple-converted-space"> </span>Priscilla and Aquila. At<span class="apple-converted-space"> </span>Cenchreae<span class="apple-converted-space"> </span>he had cut his hair, for he was under
a vow.<o:p></o:p></span></h3>
<h3 style="background: white; margin-bottom: .0001pt; margin: 0in; text-align: justify;">
<span style="background-position: initial initial; background-repeat: initial initial; font-family: Calibri, sans-serif; font-size: 11pt; font-weight: normal;"><o:p> </o:p></span></h3>
<h3 style="background: white; margin-bottom: .0001pt; margin: 0in; text-align: justify;">
<span style="background-position: initial initial; background-repeat: initial initial; font-family: Calibri, sans-serif; font-size: 11pt; font-weight: normal;">Mereka disebutkan tujuh kali
dalam empat buku yang berbeda dari Perjanjian Baru. Mereka selalu disebut
sebagai pasangan dan tidak pernah secara individual. Dari tujuh referensi, nama
lima kali Priscilla disebutkan pertama, menyiratkan bahwa dia adalah anggota
terkemuka dari pasangan-luar biasa dalam suatu masyarakat laki-laki dominan.
Dalam Alkitab, pria biasanya disebutkan pertama;. Misalnya , Adam dan Hawa,
Sampson dan Delilah, Ananias dan Safira, membuat lima penampilan nama Priscilla
pertama pengecualian cukup terkenal.<o:p></o:p></span></h3>
<h3 style="background: white; margin-bottom: .0001pt; margin: 0in; text-align: justify;">
<span style="background-position: initial initial; background-repeat: initial initial; font-family: Calibri, sans-serif; font-size: 11pt; font-weight: normal;"><o:p> </o:p></span></h3>
<div class="MsoNormal" style="text-align: justify;">
<span style="background-color: white; background-position: initial initial; background-repeat: initial initial;">Mutualitas mereka dalam pelayanan dan kepemimpinan mereka
dapat menginspirasi pasangan Kristen hari ini untuk bekerja sama sebagai guru
dan pengkhotbah Injil. Priscilla adalah contoh klasik dari seorang guru wanita
dalam sejarah gereja mula-mula.. Dia adalah seorang misionaris terkenal,
pendeta, dan rekan kerja Paulus. Dia dianggap oleh beberapa orang sebagai
penulis anonim dari Surat kepada orang Ibrani. (</span><span style="background: white; color: #333333;">Hoppin, Ruth.<span class="apple-converted-space"> </span><i>Priscilla's
Letter: Finding the Author of the Epistle to the Hebrews.</i><span class="apple-converted-space"> </span>Lost Coast Press, 2000.<span class="apple-converted-space"> </span>ISBN 1-882897-50-1)<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="background: white; color: #333333;">Santa Priscilla adalah seorang guru yang hebat. Dia juga
adalah istri yang setia dan bisa menjadi partner yang baik bagi St. Aquila.
Bersama St. Aquila mereka menjadi sahabat baik santo Paulus, sehingga santo
Paulus menyebut mereka sebagai. </span><span style="background-color: white; background-position: initial initial; background-repeat: initial initial;">"my helpers in Christ, who have for my life
laid down their own necks" (Romans 16:3-4).</span><span style="background: white; color: #333333;"><o:p></o:p></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhHZngJWQcfdRBuh_OxjoKSY5FQxQSaALJifqXwkBlD72T1ViysG99W2H50TdcEp3HMAEZPJ0_Rd1dbEpebICEMwKotgrZ7voBM9C7AfTOJR_hWrSEd4mnIIWn5QP2Vh8Hes53my5lxpyc/s1600/tumblr_mi6a7bYKIY1qmvtcro1_500.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhHZngJWQcfdRBuh_OxjoKSY5FQxQSaALJifqXwkBlD72T1ViysG99W2H50TdcEp3HMAEZPJ0_Rd1dbEpebICEMwKotgrZ7voBM9C7AfTOJR_hWrSEd4mnIIWn5QP2Vh8Hes53my5lxpyc/s320/tumblr_mi6a7bYKIY1qmvtcro1_500.jpg" width="228" /></a><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiFVHjPcJtrwyf6zRmMZv3zh-J_Nu6WTEPkCRI56SRfNW_gHE6hQO1ZSPuDORgbl_IyLYwfysQEEHlhshphgqZaoObnM-8lc6VElwdsTWujVCExueAQQpk24Rqe3G3PD6BhutAFb7RbQcA/s1600/sts-p-and-a.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="228" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiFVHjPcJtrwyf6zRmMZv3zh-J_Nu6WTEPkCRI56SRfNW_gHE6hQO1ZSPuDORgbl_IyLYwfysQEEHlhshphgqZaoObnM-8lc6VElwdsTWujVCExueAQQpk24Rqe3G3PD6BhutAFb7RbQcA/s320/sts-p-and-a.jpg" width="320" /></a></div>
<h3 style="background: white; margin-bottom: .0001pt; margin: 0in; text-align: justify;">
<span style="background-position: initial initial; background-repeat: initial initial; font-family: Calibri, sans-serif; font-size: 11pt; font-weight: normal;"> <div class="" style="clear: both; text-align: center;">
</div>
</span></h3>
<h3 style="background: white; margin-bottom: .0001pt; margin: 0in; text-align: justify;">
<span style="background-position: initial initial; background-repeat: initial initial; font-family: Calibri, sans-serif; font-size: 11pt; font-weight: normal;"><o:p> </o:p></span></h3>
<div class="MsoNormal" style="text-align: justify;">
<span style="background: white; color: #2e2613;">Daftar Pustaka:<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<a href="http://santosantagereja.blogspot.com/2012/07/st-aquila.html"><span style="font-size: 10.0pt; mso-bidi-font-size: 11.0pt;">http://santosantagereja.blogspot.com/2012/07/st-aquila.html</span></a><span style="font-size: 10.0pt; mso-bidi-font-size: 11.0pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<a href="http://santosantagereja.blogspot.com/2012/01/st-priscilla.html"><span style="font-size: 10.0pt; mso-bidi-font-size: 11.0pt;">http://santosantagereja.blogspot.com/2012/01/st-priscilla.html</span></a><span style="font-size: 10.0pt; mso-bidi-font-size: 11.0pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<a href="http://www.catholicnewsagency.com/saint.php?n=531"><span style="font-size: 10.0pt; mso-bidi-font-size: 11.0pt;">http://www.catholicnewsagency.com/saint.php?n=531</span></a><span style="font-size: 10.0pt; mso-bidi-font-size: 11.0pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<a href="http://en.wikipedia.org/wiki/Priscilla_and_Aquila#Priscilla"><span style="font-size: 10.0pt; mso-bidi-font-size: 11.0pt;">http://en.wikipedia.org/wiki/Priscilla_and_Aquila#Priscilla</span></a><span style="font-size: 10.0pt; mso-bidi-font-size: 11.0pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<a href="http://www.indonesianpapist.com/2011/12/asal-usul-perayaan-natal.html"><span style="font-size: 10.0pt; mso-bidi-font-size: 11.0pt;">http://www.indonesianpapist.com/2011/12/asal-usul-perayaan-natal.html</span></a><span style="font-size: 10.0pt; mso-bidi-font-size: 11.0pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<a href="http://www.catholic.org/saints/saint.php?saint_id=769"><span style="font-size: 10.0pt; mso-bidi-font-size: 11.0pt;">http://www.catholic.org/saints/saint.php?saint_id=769</span></a><span style="font-size: 10.0pt; mso-bidi-font-size: 11.0pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<br /></div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-90975889238728438692013-04-28T22:20:00.001-07:002014-03-04T04:19:30.903-08:00vitamin D bagi kesehatan lansia<br />
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span lang="MS" style="font-size: 16.0pt; line-height: 115%; mso-bidi-font-size: 11.0pt;">Makalah Biokimia<o:p></o:p></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span lang="MS" style="font-size: 16.0pt; line-height: 115%; mso-bidi-font-size: 11.0pt;">Vitamin dan Sistem Saraf</span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<br /></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<br /></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgu6SW5wzoIyYwYt6egmjLphFvI5bFHSMaJxJD3nLot1c3z5IMHPGa0Z_DorlcwO5cwnWRzteYh7bs7-pRgVRHugExXk9VPISoYV2LXgxzSyZ0zMXL-TZB_CRWhr5qR4rumogIU37ODE-s/s1600/Atmajaya_logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgu6SW5wzoIyYwYt6egmjLphFvI5bFHSMaJxJD3nLot1c3z5IMHPGa0Z_DorlcwO5cwnWRzteYh7bs7-pRgVRHugExXk9VPISoYV2LXgxzSyZ0zMXL-TZB_CRWhr5qR4rumogIU37ODE-s/s320/Atmajaya_logo.jpg" height="320" width="186" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div align="center" class="MsoNormal">
<span lang="MS" style="font-size: 14pt; line-height: 21px;">Pricilia Donna Esperansa Sea (2012-060-106)<o:p></o:p></span></div>
<div align="center" class="MsoNormal">
<span lang="MS" style="font-size: 14pt; line-height: 21px;">Johannes Paulus Fernandes (2012-060-203)</span></div>
<br />
<div align="center" class="MsoNormal" style="text-align: center;">
<br /></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<br /></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span lang="MS" style="font-size: 14.0pt; line-height: 115%; mso-bidi-font-size: 11.0pt;">FKUAJ 2012<o:p></o:p></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span lang="MS" style="font-size: 14.0pt; line-height: 115%; mso-bidi-font-size: 11.0pt;"><br /></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span lang="MS" style="font-size: 14.0pt; line-height: 115%; mso-bidi-font-size: 11.0pt;"><br /></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span lang="MS" style="font-size: 14.0pt; line-height: 115%; mso-bidi-font-size: 11.0pt;"><br /></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span lang="MS" style="font-size: 14.0pt; line-height: 115%; mso-bidi-font-size: 11.0pt;"><br /></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span lang="MS" style="font-size: 14.0pt; line-height: 115%; mso-bidi-font-size: 11.0pt;"><br /></span></b></div>
<div align="center" class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;">
<b><span lang="MS" style="font-size: 12.0pt; mso-bidi-font-size: 11.0pt;">Vitamin D bagi
Kesehatan Mental Lansia<o:p></o:p></span></b></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 45pt;">
<b><span lang="MS" style="font-size: 12.0pt; mso-bidi-font-size: 11.0pt;">âSome
New Food for Thought: The Role of Vitamin D in the Mental Health of Older
Adultsâ<o:p></o:p></span></b></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 45pt;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 45pt;">
<br /></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS">Vitamin D sebagai
hormon steroid serbaguna yang telah lama dikenal sebagai salah satu unsur penting
untuk kesehatan, punya keterlibatan dalam patologi dari penyakit mental dan
kesadaran. Vitamin D juga dilibatkan dalam beberapa proses fisiologis tubuh,
antara lain fungsi otot, pencegahan kanker, kesehatan kardiovaskuler dan
tulang, imunitas, serta metabolisme.</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS">Kadar konsentrasi
vitamin D yang rendah dalam serum (hipovitaminosis D) pada lansia dihubungkan
dengan meningkatnya angka kematian dan kemungkinan masuk ke panti jompo.
Keadaan hipovitaminosis D ini juga lebih lanjut dihubungkan dengan perbedaan
banyaknya sinar matahari yang terekspos pada manusia.Sinar matahari dibutuhkan
untuk mengubah provitamin D menjadi vitamin D.Hipovitaminosis D (HVD) ini
sebenarnya ialah suatu kondisi dimana kadar vitamin D dalam bentuk 25-OH vitamin
D dalam serum kurang dari 75 nM (30 ng/L) .</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS">Sebanyak 40% - 90%
lansia menderita HVD, tak terkecuali populasi lansia yang berada di wilayah
dengan sinar matahari yang berkelimpahan. Dengan demikian, dapat dipastikan bahwa studi
yang mengatakan bahwa perbedaan sinar matahari mempengaruhi kadar vitamin D
dalam serum tak sepenuhnya benar. </span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS"> Dalam beberapa studi, ditemukan
adanya hubungan antara HVD dan beberapa fungsi kognitif dasar, yakni perhatian,
ingatan, dan memori. Pada satu studi, ditemukan adanya hubungan antara kadar
vitamin D dalam serum dan tes Folstein/Mini-Mental Status (MMSE) dari 32 orang
lansia (rentang umur 61 â 92 tahun. Tes Folstein ataupun MMSE itu sendiri
adalah sebuah tes berisi 30 pertanyaan kuesioner untuk mengukur tingkat
kerusakan kognitif seseorang.</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS">Pada studi lain,
pada 225 pasien dengan diagnosis Alzheimerâs disease (AD), didapatkan adanya
korelasi antara rendahnya kadar vitamin D dalam serum serta hasil tes MMSE yang
buruk.</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS">Ada satu studi lagi,
pada 69 pasien sehat yang dipilih secara acak di Italia, diberi diet kaya
vitamin D, dan mereka mendapat skor MMSE yang lebih tinggi.</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS">Meskipun demikian,
berdasarkan fakta â fakta yang ada, belum bisa ditentukan apakah hubungan
antara vitamin D dan fungsi â fungsi kognitif dasar itu. Dengan evaluasi yang
lebih mendetail dan pemeriksaan â pemeriksaan kognitif dasar yang lebih
komprehensif mungkin akan ditemukan asosiasi yang lebih pasti antara keduanya.</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS"> Selain hubungan antara HVD dan
fungsi kognitif dasar, diadakan juga beberapa studi yang ingin menunjukkan
asosiasi antara HVD dan fungsi kognitif eksekutif. Adapun fungsi kognitif
eksekutif ini mengintegrasikan dan mengontrol fungsi â fungsi kognitif dasar
tadi. Fungsi kognitif eksekutif mencakup merencanakan sesuatu, menyelesaikan
permasalahan, mengatur respon emosi, juga memulai suatu aktivitas. Adapun
pemeriksaan â pemeriksaan untuk fungsi eksekutif ini ialah <i>Stroop test</i>, <i>Wisconsin Card Sorting
test</i>, <i>verbal fluency test</i>, dan <i>Tower and Trail Making test</i>.</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS">Meskipun demikian,
asosiasi antara HVD dan fungsi kognitif eksekutif belumlah didapatkan dengan
pasti.</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS"> HVD juga ternyata mempunyai peranan
dalam beberapa penyakit seperti <i>Dementia</i>
(Scott et al., McGrath et al.), <i>Depresi </i>(Hoogendijk
et al., Harris and Dawson-Hughes), <i>Bipolar
disorder</i> (Berk et al., Pasco et al.), <i>Schizophrenia</i> (McGrath et al., Torrey et al.)</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS"> Dalam sistem saraf pusat, vitamin D
juga mempunyai peranan. Vitamin D-lah yang mengaktifkan reseptor yang mengatur
perilaku, seperti sistem limbik, korteks cerebri, dan juga cerebellum. Vitamin
D juga menstimulasi sekresi neurothropin, suatu protein yang bertanggung jawab
untuk kelangsungan hidup, perkembangan, dan mempertahankan fungsi dari
neuron/sel saraf. Vitamin D dalam bentuk 1, 25-dihydroxy-vitamin D (kalsitriol)
meningkatkan sekresi neurothropins, termasuk neurothropins-3 , yang mempercepat
transmisi impuls melalui sinaps di hippocampus, bagian dari sistem limbik.
Neurothropins-3 juga bertanggung jawab atas perkembangan <i>dopaminergic neurons</i>, sel saraf di substansi nigra, yang
menghasilkan dopamin. Gangguan pada <i>dopaminergic
neurons</i> bisa menyebabkan penyakit Parkinson. </span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS">Reseptor vitamin D pada
tikus percobaan hasil rekayasa genetik, telah menurunkan tingkat faktor
perkembangan saraf, menyebabkan bentuk otak yang abnormal, dan juga
memperlihatkan gangguan perilaku seperti perubahan dalam interaksi sosial.</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS">Kerja antara vitamin
D dan reseptornya (VDR) bisa berperan dalam patogenesis penyakit demensia. Beberapa penelitian sudah dilakukan untuk
menemukan hubungan antara polimorfisme gen VDR dengan kelemahan kognitif.
Hasilnya ditemukan bahwa pada orang-orang dengan satu dari polimerfisme BsmI, TaqI, dan Bat, memiliki hasil yang buruk
pada uji neuropsikologis. Studi lain menunjukkan bahwa orang-orang dengan
polimerfisme ApaI 2,3 kali lebih rentan
terhadap Alzhaimer Deseases daripada mereka
yang memiliki gen polimerfisme Apa dan TaqI secara bersamaan.</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS"> Di luar sistem saraf pusat, vitamin
D meregulasi produksi antioksidan GDNF dan glutation. Pada percobaan yang
dilakukan terhadap tikus â tikus tua yang masih sehat, pemberian vitamin D
mengurangi rusaknya neuron hippocampal, neuron yang mengalami atrofi pada
penyakit Alzheimer. Vitamin D juga menghambat sekresi sitokinin dan
metalloprotein yang menimbulkan peradangan vaskular dan kalsifikasi pada
jaringan. </span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS">Pada saat manusia
menjadi sampel percobaan, kadar vitamin D diasosiasikan secara terbalik dengan
metalloproteinase MMP9 dan <i>C-reactive</i>
protein, yang menyebabkan peradangan vaskular. Suplementasi yang tepat pada
sampel â sampel yang mengalami defisiensi dapat menurunkan kadar MMP9 dan <i>C-reactive</i> protein dalam serum.</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS">Hipovitaminosis
dalam darah juga menyebabkan gangguan pada otak yang memberi efek domino pada
kinerja insulin. Karena kekurangan vitamin D, sensitivitas dan sinyal untuk
membuat insulin bekerja secara efektif berkurang, karena hal itu kadar glukosa
darah pun meningkat dan pada akhirnya menyebabkan penyakit diabetes. Kekurangan
vitamin D juga menyebabkan obesitas.</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS">Kadar vitamin D yang
rendah juga punya korelasi dengan hipertensi dan gagal jantung
kongestif/kardiomyopati, yang mana lebih jauh menyebabkan gangguan pada aliran
darah dalam otak. Dengan suplementasi
vitamin D sebanyak 800-IU dapat menurunkan tekanan darah sebesar 9.3% setelah 2
bulan. Pada penyakit vaskular, efek
anti-inflamasi, metabolisme, dan vaskuloprotektif yang dimiliki vitamin D ini lah yang dapat memelihara
kesadaran dengan mempertahankan kinerja dari pembuluh darah di otak.</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS">Vitamin D penting
diberikan tidak kurang dari 75 nM terutama bagi lansia untuk mencegah efek
buruk HVD. Untuk keamanan dari suplementasi vitamin D ini tidak perlu
diragukan, sampai batas dosis 10,000 U/d masih dapat diberikan tanpa efek
buruk, kecuali untuk pasien hiperparathirod. Biasanya untuk pasien-pasien HVD
diberikan terapi suplementasi vitamin D sesuai dengan kadar vitamin D dalam
darahnya.</span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<span lang="MS">Jadi, secara garis
besar, vitamin D mempunyai beberapa fungsi yakni menstimulasi neurothropin
dengan mengaktivasi reseptor vitamin D (Kuningas et al., Gezen-Ak et al.),
sebagai antioksidan (Wion et al., Naveilhan et al.), anti-inflamasi lewat
sitokinin dan metalloprotein (Zitterman et al., Timms et al.), mempertahankan
kerja insulin dan lemak (Cherniack and Troen), dan juga mempunyai efek
perlindungan terhadap kardiovaskular (Judd et al., Zitterman et al.)<a href="https://www.blogger.com/blogger.g?blogID=7294540944450239332" name="_GoBack"></a></span></div>
<div class="MsoNormal" style="line-height: 150%; margin-bottom: .0001pt; margin-bottom: 0in; text-align: justify; text-indent: 45.0pt;">
<br /></div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-37190104913954961292013-04-28T22:13:00.001-07:002013-04-28T22:13:56.905-07:00Vaksin MMR Tidak Mempengaruhi Autisme<br />
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span style="font-size: 14.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Vaksin MMR Tidak Mempengaruhi Autisme<o:p></o:p></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 14.0pt; mso-bidi-theme-font: minor-latin;">Oleh:<o:p></o:p></span></div>
<div align="center" class="MsoListParagraph" style="margin-bottom: .0001pt; margin: 0in; mso-add-space: auto; text-align: center;">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 14.0pt; mso-bidi-theme-font: minor-latin;">Julius
Candra / 2012060032<o:p></o:p></span></div>
<div align="center" class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: center;">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 14.0pt; mso-bidi-theme-font: minor-latin;">Otto
Tanujaya / 2012060033<o:p></o:p></span></div>
<div align="center" class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: center;">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 14.0pt; mso-bidi-theme-font: minor-latin;">Pricilia
Donna Esperansa Sea / 2012060106<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"> Autisme adalah suatu gangguan
perkembangan pada anak yang membatasi perilaku dan gangguan dalam berkomunikasi
sehingga ikut mempengaruhi kehidupan sosialnya </span><!--[if supportFields]><span
style='font-size:12.0pt;line-height:115%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"1n5vajun91","properties":{"formattedCitation":"(1)","plainCitation":"(1)"},"citationItems":[{"id":174,"uris":["http://zotero.org/users/local/oHr7X5O3/items/J4TST4VX"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/J4TST4VX"]}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">(1)</span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">.
Penyakit ini biasanya terjadi pada dua samapai tiga tahun awal setelah
kelahiran </span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"2qtptjpksh","properties":{"formattedCitation":"(2)","plainCitation":"(2)"},"citationItems":[{"id":172,"uris":["http://zotero.org/users/local/oHr7X5O3/items/TD3F4HTV"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/TD3F4HTV"]}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">(2)</span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">.
Salah satu faktor yang mempengaruhi autisme atau <i>Autism Spectrum Disorder</i>
(ASD) yaitu faktor genetika </span><!--[if supportFields]><span
style='font-size:12.0pt;line-height:115%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"uftu7kd9j","properties":{"formattedCitation":"(3)","plainCitation":"(3)"},"citationItems":[{"id":134,"uris":["http://zotero.org/users/local/oHr7X5O3/items/T86QIN65"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/T86QIN65"]}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">(3)</span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">.
Biasanya yang terkena autime adalah anak laki-laki. Ini bisa disebabkan karena
faktor ayah yaitu latar belakang ayah, ibu yaitu faktor stres selama mengandung
dan melahirkan, serta faktor lingkungan yaitu lingkungan yang banyak asap
rokoknya dan tidak diberikan nya imunisasi ketika masih anak-anak.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"> Sedangkan vaksin MMR sendiri
merupakan gabungan dari tiga jenis vaksin yakni gondongan, campak dan Rubella</span><!--[if supportFields]><span
style='font-size:12.0pt;line-height:115%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-element:field-begin'></span>
ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"em4kddsa0","properties":{"formattedCitation":"(4)","plainCitation":"(4)"},"citationItems":[{"id":114,"uris":["http://zotero.org/users/local/oHr7X5O3/items/VTKXIDR4"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/VTKXIDR4"]}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">(4)</span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">
. Penyakit tersebut dapat terinfeksi dengan cepat dan bisa sembuh dalam relatif
singkat. Akan tetapi, penyakit tersebut dapat kembali lagi dan berdampak serius
pada anak-anak sehingga pemberian vaksin MMR sangatlah penting.</span><!--[if supportFields]><span
style='font-size:12.0pt;line-height:115%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-element:field-begin'></span>
ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"7slda62dh","properties":{"formattedCitation":"(5)","plainCitation":"(5)"},"citationItems":[{"id":19,"uris":["http://zotero.org/users/local/oHr7X5O3/items/TDTNJMSI"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/TDTNJMSI"]}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">(5)</span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"> Ada banyak perbedaan mengenai apakah
vaksin MMR mempengaruhi Autisme? Setelah banyak dilakukan penelitian-penelitian
dari luar negeri disimpulkan bahwa vaksin MMR tidak mempengaruhi Autisme </span><!--[if supportFields]><span
style='font-size:12.0pt;line-height:115%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"242cj344pq","properties":{"formattedCitation":"(6)","plainCitation":"(6)"},"citationItems":[{"id":143,"uris":["http://zotero.org/users/local/oHr7X5O3/items/RFIHZ38J"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/RFIHZ38J"]}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">(6)</span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
style='font-size:12.0pt;line-height:115%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-element:field-begin'></span>
ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"2cq26s98la","properties":{"formattedCitation":"(7)","plainCitation":"(7)"},"citationItems":[{"id":113,"uris":["http://zotero.org/users/local/oHr7X5O3/items/5WIDXVS6"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/5WIDXVS6"]}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">(7)</span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
style='font-size:12.0pt;line-height:115%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-element:field-begin'></span>
ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"22avq3qs3a","properties":{"formattedCitation":"(8)","plainCitation":"(8)"},"citationItems":[{"id":131,"uris":["http://zotero.org/users/local/oHr7X5O3/items/I72PAW26"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/I72PAW26"]}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">(8)</span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">.
WHO sendiri badan kesehatan dunia sudah menyelidiki kebenaran kasus tersebut
melalui pemantauan </span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"1jqjmbscvj","properties":{"formattedCitation":"(9)","plainCitation":"(9)"},"citationItems":[{"id":110,"uris":["http://zotero.org/users/local/oHr7X5O3/items/US5X5A6N"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/US5X5A6N"]}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">(9)</span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
style='font-size:12.0pt;line-height:115%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-element:field-begin'></span>
ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"1jcdv9hdjr","properties":{"formattedCitation":"(10)","plainCitation":"(10)"},"citationItems":[{"id":144,"uris":["http://zotero.org/users/local/oHr7X5O3/items/KUDTB2ZD"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/KUDTB2ZD"]}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">(10)</span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">.
Di Indonesia sendiri Ikatan Dokter Anak Indonesia (IDAI) menyatakan bahwa
vaksin MMR tidak mempengaruhi Autisme dan merekomendasikannya sebagai vaksin
dasar anak-anak </span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"2i2fnpvo0d","properties":{"formattedCitation":"(11)","plainCitation":"(11)"},"citationItems":[{"id":178,"uris":["http://zotero.org/users/local/oHr7X5O3/items/MBP6WR9B"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/MBP6WR9B"],"itemData":{"id":178,"type":"webpage","title":"IDAI
- Ikatan Dokter Anak
Indonesia","URL":"http://www.idai.or.id/imunisasi/artikel.asp?q=20112494757","accessed":{"year":2012,"month":8,"day":28}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">(11)</span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"> Salah satu penelitian terbesar di
Denmark yang diikuti 537.303 anak yang 82% di antaranya menggunakan vaksin MMR
menunjukkan tidak ada laporan terjadi autisme yang berhubungan penggunaan
vaksin MMR </span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"16ecf6li3t","properties":{"formattedCitation":"(12)","plainCitation":"(12)"},"citationItems":[{"id":147,"uris":["http://zotero.org/users/local/oHr7X5O3/items/HA94VFFH"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/HA94VFFH"]}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">(12)</span><!--[if supportFields]><span style='font-size:12.0pt;
line-height:115%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><span
style='mso-element:field-end'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">.
Sampai sekarang masih dipantau perkembangan anak yang memakai vaksin MMR dan
belum terbukti positif terkena Autisme sama sesuai dengan hasil data sebelumnya.
<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"> Dengan bukti-bukti di atas dapat
disimpulkan bahwa tidak ada hubungan sama sekali antara Vaksin MMR dengan
Autisme. Oleh karena itu, dianjurkan kepada seluruh masyarakat agar tetap
menggunakan vaksin MMR, karena vaksin ini sangat berguna dan penting untuk
anak-anak dalam masa pertumbuhan daripada mereka terkena ketiga penyakit
berbahaya yakni, gondongan, campak, dan Rubella.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpFirst" style="margin-left: 0in; mso-add-space: auto; text-indent: .5in;">
<br /></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: 0in; mso-add-space: auto; text-indent: .5in;">
<span style="font-size: 14.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 12.0pt; mso-bidi-theme-font: minor-latin;">DAFTAR
PUSTAKA</span><span style="font-size: 14.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoBibliography">
<!--[if supportFields]><span style='mso-bidi-font-family:
Calibri;mso-bidi-theme-font:minor-latin'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_BIBL {"custom":[]}
CSL_BIBLIOGRAPHY <span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">1. Watson LR, Roberts JE,
Baranek GT, Mandulak KC, Dalton JC. Behavioral and physiological responses to
child-directed speech of children with autism spectrum disorders or typical
development. J Autism Dev Disord. 2012 Aug;42(8):1616â29. <o:p></o:p></span></div>
<div class="MsoBibliography">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">2. What Is Autism? [Internet]. Autism Speaks. [cited 2012 Aug
27]. Available from: http://www.autismspeaks.org/what-autism<o:p></o:p></span></div>
<div class="MsoBibliography">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">3. Richler J, Luyster R, Risi S, Hsu W-L, Dawson G, Bernier R,
et al. Is there a âregressive phenotypeâ of Autism Spectrum Disorder associated
with the measles-mumps-rubella vaccine? A CPEA Study. J Autism Dev Disord. 2006
Apr;36(3):299â316. <o:p></o:p></span></div>
<div class="MsoBibliography">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">4. Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C.
Vaccines for measles, mumps and rubella in children. Cochrane Database Syst
Rev. 2012 Feb 15;2:CD004407. <o:p></o:p></span></div>
<div class="MsoBibliography">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">5. CDC - Measles, Mumps, and Rubella (MMR Vaccine - [Internet].
[cited 2012 Aug 14]. Available from:
http://www.cdc.gov/vaccinesafety/Vaccines/MMR/MMR.html<o:p></o:p></span></div>
<div class="MsoBibliography">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">6. Uno Y, Uchiyama T, Kurosawa M, Aleksic B, Ozaki N. The
combined measles, mumps, and rubella vaccines and the total number of vaccines
are not associated with development of autism spectrum disorder: the first
case-control study in Asia. Vaccine. 2012 Jun 13;30(28):4292â8. <o:p></o:p></span></div>
<div class="MsoBibliography">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">7. Libbey J, Coon H, Kirkman N, Sweeten T, Miller J, Lainhart J,
et al. Are there altered antibody responses to measles, mumps, or rubella
viruses in autism? Journal of NeuroVirology. 2007;13(3):252â9. <o:p></o:p></span></div>
<div class="MsoBibliography">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">8. Peltola H, Jokinen S, Paunio M, Hovi T, Davidkin I. Measles,
mumps, and rubella in Finland: 25 years of a nationwide elimination programme.
The Lancet Infectious Diseases. 2008 Dec;8(12):796â803. <o:p></o:p></span></div>
<div class="MsoBibliography">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">9. Hensley E, Briars L. Closer look at autism and the
measles-mumps-rubella vaccine. J Am Pharm Assoc (2003). 2010 Dec;50(6):736â41. <o:p></o:p></span></div>
<div class="MsoBibliography">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">10. Menyikapi Kontroversi Autisme dan Imunisasi MMR [Internet].
[cited 2012 Aug 17]. Available from: http://puterakembara.org/rm/Alergi4.shtml<o:p></o:p></span></div>
<div class="MsoBibliography">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">11. IDAI - Ikatan Dokter Anak Indonesia [Internet]. [cited 2012 Aug
28]. Available from: http://www.idai.or.id/imunisasi/artikel.asp?q=20112494757<o:p></o:p></span></div>
<div class="MsoBibliography">
<span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 11.0pt;">12. Tidak Sebabkan Autis, Vaksin MMR Masih Dipermasalahkan
[Internet]. [cited 2012 Aug 17]. Available from:
http://www.autis.info/index.php/artikel-makalah/artikel/324-tidak-sebabkan-autis-vaksin-mmr-masih-dipermasalahkan</span><!--[if supportFields]><span
style='font-size:12.0pt;line-height:115%;mso-bidi-font-family:Calibri;
mso-bidi-theme-font:minor-latin'><span style='mso-element:field-end'></span></span><![endif]--> <span style="font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><o:p></o:p></span></div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-4626451026084881112013-04-04T08:44:00.001-07:002013-04-04T08:48:14.723-07:00Peran dan Sintesis Eikosanoid<br />
<div align="center" class="MsoNormal" style="text-align: center;">
</div>
<div align="center" class="MsoNormal">
<b><span style="line-height: 115%;"><span style="font-family: Verdana, sans-serif;">Tugas Biokimia Metabolisme Lipid (Jigsaw)<span style="font-size: small;"><o:p></o:p></span></span></span></b></div>
<div align="center" class="MsoNormal">
<span style="font-family: Verdana, sans-serif;">(dr. Maria Dara, M. Biomed)</span></div>
<div align="center" class="MsoNormal">
<b><span style="font-family: Verdana, sans-serif;">Peran dan Sintesis Eikosanoid<o:p></o:p></span></b></div>
<div align="center" class="MsoNormal">
<b><span style="font-family: Verdana, sans-serif;"><br /></span></b></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgtUqcu3MKcZwwrlsw8mygAItt6U9c_JspcyiG1DLMCOwPVeKmuABAp0bP3mjIA8lvnGu6yHNrzoCORhhawSIKu3nWvRqO9-vstxnpXUAYWlbUznHyjjEndEVlVtKB6hYzKFk3A0Lm2rhA/s1600/Atmajaya_logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><span style="font-family: Verdana, sans-serif;"><img border="0" height="200" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgtUqcu3MKcZwwrlsw8mygAItt6U9c_JspcyiG1DLMCOwPVeKmuABAp0bP3mjIA8lvnGu6yHNrzoCORhhawSIKu3nWvRqO9-vstxnpXUAYWlbUznHyjjEndEVlVtKB6hYzKFk3A0Lm2rhA/s200/Atmajaya_logo.jpg" width="116" /></span></a></div>
<div class="separator" style="clear: both; text-align: center;">
<span style="font-family: Verdana, sans-serif;"><br /></span></div>
<div class="separator" style="clear: both; text-align: center;">
<span style="font-family: Verdana, sans-serif;">oleh:</span></div>
<div class="separator" style="clear: both; text-align: center;">
<span style="font-family: Verdana, sans-serif;">Pricilia Donna Esperansa Sea</span></div>
<div class="separator" style="clear: both; text-align: center;">
<span style="font-family: Verdana, sans-serif;">2012-060-106</span></div>
<div align="center" class="MsoNormal">
<span style="font-family: Verdana, sans-serif;"><br /></span></div>
<br />
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;"><br /></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">Peran dan Sintesis Eikosanoid<o:p></o:p></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;"><br /></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Verdana, sans-serif;"><span style="line-height: 115%;">Eikosanoid merupakan senyawa yang
disintesis dari arakidonat dan beberapa asam lemak-tak jenuh ganda C20
(eikosanoat) lainnya yang umumnya terdapat dalam bentuk teresterfikasi dalam membrane
sel (fosfolipid). Eikosanoid yang terdiri atas Prostaglandin, tromboksan,
leukotrien, dan lipoksin merupakan salah
satu pengatur fungsi sel paling kuat di alam dan dihasilkan oleh hampir setiap
sel tubuh. Zat- zat ini aktif secara
fisiologis maupun farmakologis. </span><span style="background-color: #fefdfa; background-position: initial initial; background-repeat: initial initial; line-height: 115%;">Secara fisiologis senyawa eikosanoid dapat berfungsi
sebagai hormon lokal yang terikat dengan protein-G untuk menghasilkan efek
biokimianya.</span><span style="line-height: 115%;"><o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="line-height: 115%;"><span style="font-family: Verdana, sans-serif;">Eiosanoid berperan penting dalam beberapa proses penting
dalam tubuh, seperti respon peradangan setelah cidera atau infeksi. Respon ini
mencakup pengontrolan pendarahan dengan pembentukan bekuan darah. Dalam pengontrolan
peradangan juga dihasilkan beberapa efek seperti nyeri, pembengkakan dan demam.
Respon berlebihan dapat terjadi pada orang yang memiliki respon alergi.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="line-height: 115%;"><span style="font-family: Verdana, sans-serif;">Eikosanoid juga berperan dalam
proses kontraksi otot polos, terutama di usus dan rahim. Zat ini berperan dalam
pengaturan absorbsi air dan natrium di ginjal, juga dalam proses pengaturan
tekanan darah. Sebagian eikosanoid dapat memicu terjadinya vasokontriksi,
sedangkan yang lainnya memicu masodilatasi. Eikosanoid juga berperan dalam bronkodilatasi
dan bronkokontriksi.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="line-height: 115%;"><span style="font-family: Verdana, sans-serif;">Prostaglandin memerantarai
peradangan, nyeri dan memicu tidur serta mengatur koagulasi darah dan
reproduksi. Obat anti-inflamasi nonsteroid seperti aspirin bekerja menghambat
prostaglandin. Tromboksan berperan dalam pembekuan darah. Leukotrien berefek
dalam kontraksi otot dan bersifat kemotaktik serta penting dalam reaksi alergi
dan peradangan. <o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="line-height: 115%;"><span style="font-family: Verdana, sans-serif;">Teradapat tiga kelompok eikosanoid
yang disintesis dari asam eikosanoat C<sub>20</sub> yang berasal dari asam
lemak esensial linoleat dan α-linoleat, atau secara langsung dari
eikosapentaenoat dan arakidonat. Arakidonat bisa diperoleh dari makanan maupun
sintesis asam linoleat. Pembentukan senyawa eikosanoid dapat terjadi melalui 2
jalur.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpFirst" style="mso-list: l0 level1 lfo1; text-align: justify; text-indent: -.25in;">
<!--[if !supportLists]--><span style="font-family: Verdana, sans-serif;"><span style="line-height: 115%;">1.<span style="line-height: normal;"> </span></span><!--[endif]--><span style="line-height: 115%;">Jalur siklo-oksigenase
</span><span style="line-height: 115%;">Ă </span><span style="line-height: 115%;"> PG (prostaglandin) dan seri
TX<sub>2 </sub>(tromboksan) = (prostanoid)<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpLast" style="mso-list: l0 level1 lfo1; text-align: justify; text-indent: -.25in;">
<!--[if !supportLists]--><span style="font-family: Verdana, sans-serif;"><span style="line-height: 115%;">2.<span style="line-height: normal;"> </span></span><!--[endif]--><span style="line-height: 115%;">Jalur
lipoksigenase </span><span style="line-height: 115%;">Ă </span><span style="line-height: 115%;"> LT<sub>4</sub>
(leukotrien) dan LX<sub>4</sub> (lipoxin)<o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="line-height: 115%;"><span style="font-family: Verdana, sans-serif;">Kedua jalur ini bersaing dalam
memperebutkan substrat arakidonat. Ada juga jalur sitokrom P450 yang belum
diketahui fungsinya secara pasti. Waktu paruh zat ini sangat cepat sehingga cepat
mengalami inaktivasi dan diekskresikan.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpFirst" style="text-align: justify;">
<br /></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .25in; mso-add-space: auto; mso-list: l1 level1 lfo2; text-align: justify; text-indent: -.25in;">
<!--[if !supportLists]--><span style="font-family: Verdana, sans-serif;"><span style="line-height: 115%;">1.<span style="line-height: normal;"> </span></span><!--[endif]--><span style="line-height: 115%;">Jalur
siklo-oksigenase berperan dalam sintesis prostanoid<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="font-family: Verdana, sans-serif;"><span style="background-color: #fefdfa; background-position: initial initial; background-repeat: initial initial; line-height: 115%;">Dari jalur
siklooksigenase dihasilkan senyawa prostanoid. senyawa prostanoid memerlukan
dua molekul O2 yang dikatalisis oleh enzim Prostaglandin H sintetase (PGHS)
yang mempunya dua aktivitas enzim, yaitu siklooksigenase dan peroksidase. PGHS
mempunyai dua bentuk isoenzim, yaitu PGHS-1 dan PGHS-2. Produk lintasan
siklooksidase yang berupa endoperoksida (PGH) dikonversi menjadi Prostaglandin
D, E dan F serta tromboksan (TXA2) dan prostasiklin (PGI2).</span>
Masing-masing sel hanya menghasilkan satu jenis prostanoid.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="background-color: #fefdfa; background-position: initial initial; background-repeat: initial initial; line-height: 115%;"><span style="font-family: Verdana, sans-serif;">Aspirin,
merupakan obat anti-inflamasi nonsteroid (OAINS), menghambat COX-1 dan COX-2.
OAINS lain seperti indometasin dan ibuprofen, dan biasanya mengahambat
siklo-oksigenase dengan bersaing dengan arakidonat. <o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="line-height: 115%;"><span style="font-family: Verdana, sans-serif;">Inhibitor klasik ini bersifat non selektif yang akan menginhibisi semua
tipe COX sehingga menimbulkan efek samping yang nyata pada ulkus peptikum dan
dispepsia. OAINS yang bersifat asam juga akan secara langsung mengiritasi
lambung dan menghambat sisntesis prostaglandin oleh COX-1. Prostaglanding
berperan dalam melindungi saluran gastrointestinal dan mencegah pengaruh asam
pada mukosa.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="line-height: 115%;"><span style="font-family: Verdana, sans-serif;">OAINS baru bersifat selektif pada COX-2. Selektivitas ini mampu
mengurangi efek samping berupa ulkus peptikum. Celecoxib dan rofecoxib adalah
contoh OAINS yang selektif ini. Namun selektivitas pada COX-2 ini tidak
mempengarhi efek-efek merugikan lain dari OAINS, seperti resiko gagal ginjal,
dan bahkan berpotensi meningkatkan resiko serangan jantung dan stroke akibat
peningkatan kadar tromboksan. Transkripsi COX 2 dihambat sepenuhnya oleh
kortikosteroid anti-inflamatorik.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="line-height: 115%;"><span style="font-family: Verdana, sans-serif;">Peran asam lemak esensial dalam membentuk membrane tidak berkaitan
dengan pembentukan prostaglandin. Prostaglandin tidak menghilangkan gejala-gejala
defisiensi asam lemak esensial, dan defisiensi asam lemak esensial tidak
disebabkan inhibisi sintesis prostaglandin.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="line-height: 115%;"><span style="font-family: Verdana, sans-serif;">Sikloooksigenase sendiri adalah âenzim bunuh-diriâ karena menginaktivasi
prostaglandin, inilah sifat luar biasa enzim ini. Inaktivasi prostaglandin
15-hidroksiprostaglandin dehidrogenase berlangsung cepat. Penghambatan terhadap
kerja enzim oleh sulfalazin atau indometasin dapat memperlama waktu-paruh
prostaglandin dalam tubuh.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<br /></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .25in; mso-add-space: auto; mso-list: l1 level1 lfo2; text-align: justify; text-indent: -.25in;">
<!--[if !supportLists]--><span style="font-family: Verdana, sans-serif;"><span style="line-height: 115%;">2.<span style="line-height: normal;"> </span></span><!--[endif]--><span style="background-color: #fefdfa; background-position: initial initial; background-repeat: initial initial; line-height: 115%;">Jalur Lipoksiganenase membentuk leukotrien & lipoksin<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="background-color: white; background-position: initial initial; background-repeat: initial initial; color: #262626; line-height: 115%;"><span style="font-family: Verdana, sans-serif;">Leukotrien
merupakan kelompok senyawa triena terkonjugasi yang dibentuk dari asam
eikosanoat dalam leukosit, sel mastositoma, trombosit dan makrofag melalui
lintasan lipoksigenase sebagai respon terhadap rangsangan baik imunologis
maupun nonimunologis. Ketiga enzim lipoksigenase (dioksigenase) yang berbeda
menyisipkan atom oksigen ke posisi 5, 12, dan 15 pada asam arakhidonat sehingga
memberikan senyawa hidroperoksida (HPETE).<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<!--[if gte vml 1]><v:shapetype id="_x0000_t75"
coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
filled="f" stroked="f">
<v:stroke joinstyle="miter"/>
<v:formulas>
<v:f eqn="if lineDrawn pixelLineWidth 0"/>
<v:f eqn="sum @0 1 0"/>
<v:f eqn="sum 0 0 @1"/>
<v:f eqn="prod @2 1 2"/>
<v:f eqn="prod @3 21600 pixelWidth"/>
<v:f eqn="prod @3 21600 pixelHeight"/>
<v:f eqn="sum @0 0 1"/>
<v:f eqn="prod @6 1 2"/>
<v:f eqn="prod @7 21600 pixelWidth"/>
<v:f eqn="sum @8 21600 0"/>
<v:f eqn="prod @7 21600 pixelHeight"/>
<v:f eqn="sum @10 21600 0"/>
</v:formulas>
<v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
<o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_10" o:spid="_x0000_s1026" type="#_x0000_t75"
alt="http://www.pinnaclefitness-online.com/Fitness-research/prostaglandin_pathway.JPG"
style='position:absolute;left:0;text-align:left;margin-left:266.5pt;
margin-top:107.9pt;width:201.7pt;height:260.15pt;z-index:-1;visibility:visible;
mso-wrap-style:square;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
mso-position-vertical:absolute;mso-position-vertical-relative:text' stroked="t"
strokecolor="#a6a6a6">
<v:imagedata src="file:///C:\Users\GILVYON\AppData\Local\Temp\msohtmlclip1\01\clip_image001.jpg"
o:title="prostaglandin_pathway"/>
</v:shape><![endif]--><!--[if !vml]--><span style="height: 349px; left: 0px; margin-left: 354px; margin-top: 143px; mso-ignore: vglayout; position: absolute; width: 271px; z-index: -1;"><span style="font-family: Verdana, sans-serif;"><img alt="http://www.pinnaclefitness-online.com/Fitness-research/prostaglandin_pathway.JPG" height="349" src="file:///C:/Users/GILVYON/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" v:shapes="Picture_x0020_10" width="271" /></span></span><!--[endif]--><span style="font-family: Verdana, sans-serif;"><span style="background-color: white; background-position: initial initial; background-repeat: initial initial; color: #262626; line-height: 115%;">Hanya 5-lipoksigenase yang yang membentuk
leukotrien. Senyawa yang pertama terbentuk adalah leukotrien A4 yang
selanjutnya dimetabolisasi menjadi leukotrien B4 atau leukotrien C4. Leukotrien
C4 dibentuk melalui penambahan glutation peptida lewat ikatan tioeter.
Pengeluaran selanjutnya glutamate dan glisin akan menghasilkan secara berurutan
leukotrien D4 dan leukotrien E4.</span> <span style="color: #262626; line-height: 115%;"><br />
<span style="background: white;"><span style="text-align: start;">Lipoksin merupakan kelompok senyawa tetraena
terkonjugasi yang muncul di dalam leukosit. Kelompok senyawa ini terbentuk
lewat kerja kombinasi lebih dari satu lipoksigenase dengan menyisipkan lebih
banyak atom oksigen ke dalam molekul. Beberapa lipoksin (LXA4 hingga LX E4)
terbentuk dengan cara serupa seperti pada leukotrien.</span><o:p></o:p></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhJ3h4b7Qg6IJETXDC_MrjruWwWJaiCkCbkDKgUy1ECLTw18TzwFjTSt5hl7h2ag2QSnK6w3F0iu2lHYdom9wbG1B0JN1M_FauKs6Hpb3vMytjR4aaQxNmRvW9CvWC4rnLJQL9jhsTk_sc/s1600/Eicosanoid_synthesis.svg.png" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><span style="font-family: Verdana, sans-serif;"><img border="0" height="284" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhJ3h4b7Qg6IJETXDC_MrjruWwWJaiCkCbkDKgUy1ECLTw18TzwFjTSt5hl7h2ag2QSnK6w3F0iu2lHYdom9wbG1B0JN1M_FauKs6Hpb3vMytjR4aaQxNmRvW9CvWC4rnLJQL9jhsTk_sc/s320/Eicosanoid_synthesis.svg.png" width="320" /></span></a></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgk4JAgic_ndzmjCYqM83uoDR65OII-SdadfsyLOGmnIjanDQEC_SMOmLdmiJc2WTW520pQZU2beFt6Fy-CvD088ENpFHqE2rWcUDQu6gJRjpKEvPQt5cJAdyDPWe8PmjtPbi36JdDDst8/s1600/prostaglandin_+pathway.JPG" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><span style="font-family: Verdana, sans-serif;"><img border="0" height="400" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgk4JAgic_ndzmjCYqM83uoDR65OII-SdadfsyLOGmnIjanDQEC_SMOmLdmiJc2WTW520pQZU2beFt6Fy-CvD088ENpFHqE2rWcUDQu6gJRjpKEvPQt5cJAdyDPWe8PmjtPbi36JdDDst8/s400/prostaglandin_+pathway.JPG" width="272" /></span></a><span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .25in; mso-add-space: auto; text-align: justify;">
<span style="color: #262626; line-height: 115%;"><span style="background: white;"><span style="text-align: start;"><span style="font-family: Verdana, sans-serif;"><br /></span></span></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: 0.25in; text-align: start;">
<span style="color: #262626; font-family: Verdana, sans-serif;"><span style="line-height: 14px;">Daftar Pustaka:</span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: 0.25in; text-align: start;">
<span style="font-family: Verdana, sans-serif;"><span style="color: #262626;"><span style="line-height: 14px;">1. </span></span><span style="line-height: 115%;">Murray
RK, Granner DK, Mayes PA, Rodwell VW. Biokimia Harper. 27th ed. Jakarta: EGC; 2006.</span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: 0.25in; text-align: start;">
</div>
<div class="MsoBibliography">
<span style="line-height: 115%; mso-ascii-font-family: Calibri; mso-bidi-font-family: "Times New Roman"; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Calibri;"><span style="font-family: Verdana, sans-serif;">2. Klinis S. Biokimia Kedokteran Dasar.
EGC; <o:p></o:p></span></span></div>
<div class="MsoBibliography">
<span style="line-height: 115%; mso-ascii-font-family: Calibri; mso-bidi-font-family: "Times New Roman"; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Calibri;"><span style="font-family: Verdana, sans-serif;">3. Teratai
P. PEMBENTUKKAN SENYAWA EIKOSANOID [Internet]. PEMBENTUKKAN SENYAWA EIKOSANOID.
2012 [cited April 4, 2013]. Retrieved from:
http://ruangdiskusiapoteker.blogspot.com/2012/05/pembentukkan-senyawa-eikosanoid.html<o:p></o:p></span></span></div>
<div class="MsoBibliography">
<span style="line-height: 115%; mso-ascii-font-family: Calibri; mso-bidi-font-family: "Times New Roman"; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Calibri;"><span style="font-family: Verdana, sans-serif;">4. Laporan
Jurnal Bahaya dari NSAID [Internet]. prmob.net. [cited April 4, 2013].
Retrieved from: http://WEB-INF.prmob.net/views/ltr/article.jspx<o:p></o:p></span></span></div>
<!--[if supportFields]><span style='font-size:11.0pt;line-height:115%;
font-family:"Calibri","sans-serif";mso-ascii-theme-font:minor-latin;mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><span
style='mso-element:field-end'></span></span><![endif]--><br />
<div class="MsoListParagraphCxSpLast" style="margin-left: 0.25in; text-align: start;">
<span style="color: #262626; font-size: x-small;"><span style="line-height: 14px;"><br /></span></span></div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com2tag:blogger.com,1999:blog-7294540944450239332.post-18217090379960059762013-02-28T06:11:00.000-08:002013-02-28T06:11:29.046-08:00Anorexia Nervosa Pada Remaja<br />
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span style="font-size: 16pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;">Blok IV â Humaniora (MAC 102)<o:p></o:p></span></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span style="font-size: 16pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;">Makalah Filsafat Budaya<o:p></o:p></span></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span style="font-size: 14pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;">âKonsep Tubuh Ideal yang Salah Sebagai Penyebab
Anorexia Nervosa Remajaâ<o:p></o:p></span></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span style="font-size: 14pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;">Dosen Pembimbing: Yeremias Jena, M. Hum, M. Sc<o:p></o:p></span></span></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span style="font-size: 14pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;"><br /></span></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjneUtQxlO4PQNt2Sq4huMwBdgxxopaRoH86dn9pvID5F5x_5J5pvE_MrSHfo7gsZPyetJHedXK6KMZcaUVKVV3OveACVweYI8YwThQ6NNF3oWejpGy3nk1sz5jt96zi1MrT8ps_5ekwso/s1600/Atmajaya_logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><span style="font-family: Times, Times New Roman, serif;"><img border="0" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjneUtQxlO4PQNt2Sq4huMwBdgxxopaRoH86dn9pvID5F5x_5J5pvE_MrSHfo7gsZPyetJHedXK6KMZcaUVKVV3OveACVweYI8YwThQ6NNF3oWejpGy3nk1sz5jt96zi1MrT8ps_5ekwso/s320/Atmajaya_logo.jpg" width="186" /></span></a></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span style="font-size: 14pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;"><br /></span></span></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<br /></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span style="font-family: Times, Times New Roman, serif;"><span style="font-size: 14pt; line-height: 115%;"><v:shapetype coordsize="21600,21600" filled="f" id="_x0000_t75" o:preferrelative="t" o:spt="75" path="m@4@5l@4@11@9@11@9@5xe" stroked="f">
<v:stroke joinstyle="miter">
<v:formulas>
<v:f eqn="if lineDrawn pixelLineWidth 0">
<v:f eqn="sum @0 1 0">
<v:f eqn="sum 0 0 @1">
<v:f eqn="prod @2 1 2">
<v:f eqn="prod @3 21600 pixelWidth">
<v:f eqn="prod @3 21600 pixelHeight">
<v:f eqn="sum @0 0 1">
<v:f eqn="prod @6 1 2">
<v:f eqn="prod @7 21600 pixelWidth">
<v:f eqn="sum @8 21600 0">
<v:f eqn="prod @7 21600 pixelHeight">
<v:f eqn="sum @10 21600 0">
</v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:formulas>
<v:path gradientshapeok="t" o:connecttype="rect" o:extrusionok="f">
<o:lock aspectratio="t" v:ext="edit">
</o:lock></v:path></v:stroke></v:shapetype><v:shape alt="Atmajaya_logo.jpg" id="Picture_x0020_0" o:spid="_x0000_i1025" style="height: 243pt; mso-wrap-style: square; visibility: visible; width: 141pt;" type="#_x0000_t75">
<v:imagedata o:title="Atmajaya_logo" src="file:///C:\Users\GILVYON\AppData\Local\Temp\msohtmlclip1\01\clip_image001.jpg">
</v:imagedata></v:shape></span><span style="font-size: 14pt; line-height: 115%;"><o:p></o:p></span></span></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span style="font-size: 14pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;">Oleh:<o:p></o:p></span></span></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span style="font-size: 14pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;">Pricilia Donna Esperansa Sea<o:p></o:p></span></span></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span style="font-size: 14pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;">(2012-060-106)<o:p></o:p></span></span></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<br /></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span style="font-size: 14pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;">Fakultas Kedokteran<o:p></o:p></span></span></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span style="font-size: 14pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;">Universitas Katolik Indonesia Atma Jaya<o:p></o:p></span></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span style="font-size: 14pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;">Jakarta<o:p></o:p></span></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span style="font-family: Times, Times New Roman, serif;"><b><span style="font-size: 14pt; line-height: 115%;">2012/2013</span></b><span style="font-size: 12pt; line-height: 115%;"><br clear="all" style="mso-special-character: line-break; page-break-before: always;" />
<b><o:p></o:p></b></span></span></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span style="font-size: 14pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;"><br /></span></span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<b><span style="font-size: 14pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;"><br /></span></span></b></div>
<div align="center" class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;">
<span style="font-size: 14pt;"><span style="font-family: Times, Times New Roman, serif;">KONSEP TUBUH IDEAL YANG SALAH SEBAGAI
PENYEBAB<o:p></o:p></span></span></div>
<div align="center" class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;">
<span style="font-family: Times, Times New Roman, serif;"><span style="font-size: 14pt;">ANOREXIA NERVOSA REMAJA</span><span style="font-size: 12pt;"><o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt 0.25in; text-align: justify;">
<br /></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt 0.25in; text-align: justify;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<span style="font-family: Times, Times New Roman, serif;"><b><span style="font-size: 12pt;">Pendahuluan</span></b><b><o:p></o:p></b></span></div>
<div class="MsoListParagraphCxSpFirst" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Thomas Aquino
merumuskan keindahan sebagai â<em>id quod visum placet</em>â (that which
pleased upon being seen atau sesuatu yang menyenangkan ketika dilihat). Yang
menyenangkan untuk dilihat adalah yang serasi dan seimbang atau ideal. Maka
tubuh ideal adalah salah satu bentuk dari keindahan. Apabila Pria dianggap sebagai lambang kekuatan,
maka wanita sering diidetikkan dengan keindahan. Sebagian besar wanita memahami kodratnya ini
sehingga tak heran para wanita berlomba-lomba untuk mendapatkan tubuh ideal.
Tetapi konsep tubuh ideal ini agak samar-samar dan tidak ada batas jelasnya.<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-family: Times, Times New Roman, serif;"><i><span style="font-size: 12pt;">The Thin Ideal</span></i><span style="font-size: 12pt;"> adalah konsep dari
wanita langsing yang ideal. Persepsi umum keidealan ini adalah wanita langsing
dengan pinggang kecil dan sangat sedikit lemak. Hal ini dikarenakan salah satu
ukuran cantik selain hidung yang mancung dan kulit putih adalah tubuh yang
langsing dan tinggi. Konsepsi ini muncul dari banyaknya iklan-iklan di tv yang
menjadikan wanita dengan kriteria tersebut sebagai modelnya. Akhirnya setiap
wanita ingin menjadi seperti itu. Padahal gambaran seperti ini muncul karena
modelâmodel yang digunakan dalam iklan tersebut memang berasal dari barat,
sehingga sangat wajar jika mereka memiliki kulit yang putih, dan tubuh tinggi
semampai.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Sedangkan kebudayaan dan masyarakat punya persepsi masing-masing tentang
tubuh ideal. Masyarakat Afrika Selatan menganut semboyan âbig is betterâ.
Menurut mereka wanita yang ideal adalah yang gemuk karena menunjukkan
kemakmuran seseorang. Bahkan meskipun sekarang setelah kebudayaan barat sudah
mulai masuk pun, sebagian masyarakat Afrika masih mempertahankan slogan ini
dengan mengadakan kontes âMiss Fat South Africanâ. Sedangkan di Prancis, wanita
ideal adalah wanita yang langsing, anggun, cantik, dan berkelas.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Di Amerika gambaran tubuh ideal mengalami perubahan dari abad ke 18
hingga sekarang dipengaruhi oleh kondisi ekonomi dan politik, Cohen (2001).
Gambaran tubuh ideal wanita Amerika di abad 21 ini adalah tubuh kurus bak seorang model. Lihat saja
dari banyaknya film maupun iklan-iklan produk-produk Amerika yang menjadikan
wanita-wanita kurus sebagai modelnya. Gambaran seperti inilah yang akhirnya
mulai menjamur di kalangan wanita-wanita di seluruh dunia seiring dengan
semakin meluasnya efek globalisasi.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Di Indonesia sendiri konsep tubuh ideal saat ini telah dipengaruhi oleh
masuknya kebudayaan Eropa dan Amerika, yaitu langsing dan berkulit putih.
Padahal jika dilihat dari sejarah, buku maupun film-film yang mengambil setting
tahun 1950-1980an, tubuh wanita Indonesia umumnya pendek dan berisi.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-family: Times, Times New Roman, serif;"><span style="font-size: 12pt;">Media, masyarakat, dan kebudayaan memiliki peran dalam membentuk
pandangan wanita tentang citra tubuh mereka. </span><span style="font-size: 12pt;">Grogan
(1999) menyatakan bahwa citra tubuh merupakan persepsi, pikiran, dan perasaan
seseorang terhadap tubuhnya.</span><span style="font-size: 12pt;"> Pandangan ini dapat bersifat positif dan negatif. Citra
tubuh akan ikut membentuk kepribadian seseorang. Wanita yang memiliki pandangan
yang memandang positif tubuhnya akan memperlakukan tubuhnya dengan lebih baik.
Mereka akan lebih menghargai tubuhnya, memiliki percaya diri dan mudah bergaul.
Sedangkan wanita yang memandang negatif tubuhnya akan susah menerima tubuhnya
dan tidak menghargai tubuhnya. Mereka akan berusaha keras mengubah tubuhnya
sesuai dengan gambaran tubuh ideal yang ada dalam masyarakat. Mereka akan lebih
mudah marah dan tersinggung, menganggap diri rendah dan apabila terlalu ditekan
mereka akan mengalami depresi. Hal ini dapat menyebabkan gangguan pola makan
seperti Anorexia dan Bulimia.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-family: Times, Times New Roman, serif;"><span style="font-size: 12pt;">Menurut Renfrew Center Foundation for Eating
Disorders (2003), lebih dari 24 juta orang dari segala umur dan jenis kelamin
mengalami gangguan pola makan di Amerika Serikat</span><span style="font-size: 12pt;">. Pada umumnya penderita gangguan pola makan ini adalah para remaja.
Faktanya adalah perkembangan konsep diri pada remaja sangat dipengaruhi oleh
hubungan dengan orang-orang di sekitarnya (Breckenridge and Vincent, 1963).
Remaja Amerika umumnya mengalami gangguan makan akibat adanya trauma psikologis
maupun tekanan di lingkungan sekolahnya. Kasus bullyng yang sering terjadi di
sekolah-sekolah di Amerika dapat menjadi salah satu penyebab munculnya gangguan
pola makan. <o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-family: Times, Times New Roman, serif;"><span style="font-size: 12pt;">Gangguan pola makan ini akan menyebabkan
penderitanya mengalami malnutrisi dan
akhirnya mengakibatkan kematian. Meskipun beberapa pasien bisa sembuh tetapi
mereka tetap memiliki risiko komplikasi dan 20% di antaranya akan lebih cepat
meninggal daripada rekan â rekannya </span><span style="font-size: 12pt;"> (National</span><span style="font-size: 12pt;"> </span><span style="font-size: 12pt;">Association of Anorexia Nervosa and Associated Disorders,</span><span style="font-size: 12pt;"> </span><span style="font-size: 12pt;">2011)</span><span style="font-size: 12pt;">. Dalam sebuah penelitian disebutkan bahwa seorang
penderita Anorexia dapat mengalami masalah pada gigi, system endokrin,
ginekologi, system syaraf, dan self-injurious behavior (SIB). Mereka juga
rentan mengalami penyakit lambung, dan pelaggra. Kematian akibat Anorexia
merupakan dampak akhir dari adanya komplikasi yang dialami oleh penderita
Anorexia.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-family: Times, Times New Roman, serif;"><span style="font-size: 12pt;">Di Indonesia memang belum banyak dilakukan
penelitian tentang Anorexia pada remaja. Akan tetapi beberapa studi kuantitatif
menunjukan ada nya hubungan antara self body image dan gangguan makan pada
remaja. Penelitian oleh Kartika (2010) pada remaja kelas X dan XI di sebuah SMA
di Seamarang menunjukkan ada hubungan antara self body image dan gangguan
makan. </span><span style="font-size: 12pt;">Sebagian
besar (87,1 %) remaja putri belum menjalankan perilaku makan yang baik, 12,9 %
sudah menjalankan perilaku makan yang baik. Perilaku ini karena ketidakpuasan
atas bentuk tubuh mereka. Penelitian lain yang dilakukan oleh Tantiani (2007),
menunjukkan bahwa 34,8 % remaja Jakarta mengalami gangguan perilaku makan
dengan 11, 6% merupakan penderita Anorexia. Sedangkan Ai Nurhayanti dalam
artikelnya âStatus, Kebiasaan dan Gangguan Makan pada Remaja Sekolah Favorit
dan Non-favorit di Bogorâ, beberapa siswi mengalami gangguan perilaku makan.
Bagaimanapun remaja merupakan korban yang sangat rentan terkena Anorexia. </span><span style="font-size: 12pt;">Agar
bisa dicegah, para remaja harus memiliki pengetahuan tentang penyakit ini dan
menanamkan citra diri yang positif dalam diri mereka.</span><span style="font-size: 12pt;"><o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<b><span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Pembahasan<o:p></o:p></span></span></b></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Anorexia Nervosa merupakan salah satu
penyakit berbahaya yang rentan di derita oleh remaja. Para penderita Anorexia
tidak menolak untuk makan dan melakukan olahraga keras untuk menurunkan berat
badan mereka. Mereka tidak dapat menerima tubuh sendiri dan berusaha
merubahnya. Padahal untuk mendapatkan tubuh yang ideal tidak bisa dilakukan
dalam waktu singkat. Lagipula yang penting tubuh ideal adalah tubuh yang sehat.
Tapi para remaja cenderung mengambil model tubuh kurus sebagai tubuh ideal.
Konsep tubuh ini tidak lain berasal dari media yang secara tidak langsung ikut
mengkampanyekan diet dan tubuh kurus dalam setiap iklannya. Ketika remaja tidak
bisa menerima tubuhnya dan mengalami tekanan maka akan timbul gangguan perilaku
makan yaitu Anorexia Nervosa. Ketiga artikel dalam makalah saya ini akan
menunjukkan adanya hubungan antara body image sebagai penyebab Anorexia Nervosa
pada remaja.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<span style="font-family: Times, Times New Roman, serif;"><b><span style="font-size: 12pt;">1. âThe Other Side of
Well-being â What Makes a Young Woman Become an Anorectic?â</span></b><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-family:
TimesNewRomanPSMT;color:black;mso-themecolor:text1'><span style='mso-element:
field-begin'></span> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"2j8n5u263i","properties":{"formattedCitation":"(1)","plainCitation":"(1)"},"citationItems":[{"id":294,"uris":["http://zotero.org/users/local/oHr7X5O3/items/29TD7N37"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/29TD7N37"],"itemData":{"id":294,"type":"article-journal","title":"The
Other Side of Well-being - What Makes a Young Woman Become an
Anorectic?","container-title":"International Journal of
Psychological Studies","page":"76-86","volume":"3","issue":"2","source":"ProQuest","abstract":"The
aim of this research is to reveal those factors that make an individual enter
an anorectic world in adolescence. Why does a young woman develop anorexia?
What makes one go to a journey to that \"Wonderland\"? The causes of
anorexia were collected from the narratives of 11 Finnish women who survived
their own anorexic trip as winners. Anorexia is a serious psychiatric condition
that can lead to death at its worst. The causes of anorexia have not been
clearly evidenced which makes it difficult to draw a distinct insight of the
problems of anorexia. This article reveals the reasons and factors that make
usually good and dutiful girls destroy themselves and their lives hooked by
anorexia. Furthermore, the complex nature of eating disorder is discussed from
an educational perspective because when pursuing toward the ideal of education,
one performs to excess. [PUBLICATION
ABSTRACT]","ISSN":"19187211","language":"English","author":[{"family":"Savukoski","given":"Marika"},{"family":"MÀÀttÀ","given":"Kaarina"},{"family":"Uusiautti","given":"Satu"}],"issued":{"date-parts":[["2011",12]]},"accessed":{"date-parts":[[2013,2,3]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span></b><![endif]--><span style="font-size: 12pt;">(1)</span><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;mso-bidi-font-family:TimesNewRomanPSMT;color:black;
mso-themecolor:text1'><span style='mso-element:field-end'></span></span></b><![endif]--><b><span style="font-size: 12pt;"><o:p></o:p></span></b></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-family: Times, Times New Roman, serif;"><span style="font-size: 12pt;">Penghargaan atas kecantikaan dan kelangsingan merupakan ciri khas
kebudayaan barat di awal abad ke 21. Wanita diidetikan dengan langsing dan
tinggi. Model ini lalu disebarkankan melalui media-media seperti televisi,
majalah, dan iklan-iklan. Menjadi langsing dan tinggi seperti menjadi sebuah
keharusan. Diet sebagai sebuah kata ada di bibir setiap orang dan itu
muncul khusunya untuk masyarakat di mana
terlalu banyak makan dan sedikit olahraga.
</span><span style="font-size: 12pt;">(Bordo, 1993; Fay & Price, 1994.) Dalam
diri para penderita Anorexia tertanam prinsip: âAnda menjadi sesuatu hanya jika
anda kurus dan memiliki ukuran sangat kecilâ. Anorexia adalah penyakit serius
yang sangat berbahaya karena dapat menyebabkan kematian. Penyakit ini sudah
lama ada, tetapi baru terkenal di tahun 1990-an ketika sebagian besar public
figure diketahui mengalami sakit parah karena Anorexia.</span><span style="font-size: 12pt;"><o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Masyarakat umum
mengagungkan kelangsingan/slimmness dan menghubungkannya dengan seksualitas.
Tanpa tubuh yang kurus langsing, seseorang dianggap tidak menggairahkan dan
tidak bisa sukses. Meskipun begitu belum ada faktor fundamental penyebab
Anorexia, karena banyak factor yang dapat menyebabkan Anorexia.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Perilaku dalam mengahadapi
makanan sudah menjadi topic yang umum dibicarakan. Misalnya tentang rekomendasi
pengaturan nutrisi dan pola makan di Finlandia pada abad ke-20. Tetapi
pengaturan nutrisi ini oleh penderita Anorexia menjadi sebuah panduan umum dan
wajib, dan akhirnya menjadi gangguan pola makan serius.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Pandangan orang-orang dalam
kebudayaan barat tentang tubuh ideal pada umumnya sama karena media. Media menyediakan
model tubuh langsing bahkan kurus sebagai, memunculkan citra tubuh indah cuma
didapat kerena penampilan yang kurus. Menurut Orbach (1989), Anorexia dimulai
ketika seseorang mengejar mendapatkan tubuh kurus sesuai dengan apa yang
digambarkan oleh media dan didukung oleh masyarakat. Kelangsingan dan diet
telah mulai muncul hampir sama seperti agama-konsep khususnya dalam kehidupan
perempuan (Freedman, 1986). Kegemukan dianggap sebagai dosa besar. Kekhawatiran
utama tentang histeria kelangsingan ini adalah bahwa gambaran tubuh ideal dan
tekanan untuk menjadi sukses sebagai bagian dari anak muda dan remaja, akan
menyebabkan mereka menjadi Anorectic di tengah gempuran makanan.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Menurut Claude-Pierre
(2000), keinginan untuk menjadi langsing bukan satu-satunya penyebab Anorexia.
Anorexia merupakan penyakit yang lebih rumit. Masalah yang sama sekali berbeda
apakah seseorang adalah diet dalam rangka memenuhi masyarakat harapan pada
kelangsingan atau apakah dia ingin menurunkan berat badan untuk mati.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Salah satu penelitian
dengan melibatkan 11 partisipan di Finlandia ingin mengungkapkan penyebab
Anorexia pada remaja. Dalam penelitian ini para peneliti menggelompokan
penyebab Anorexia menjadi, a.problem dalam keluarga, b.ketidakmampuan
menyelesaikan konflik, c.kehilangan kendali atas kehidupan, d.pemujaan social
terhadap kecantikan ideal, e.pengalaman traumatis.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-family: Times, Times New Roman, serif;"><span style="font-size: 12pt;">Masalah keluarga ternyata
memberi efek negatif pada citra diri anak-anak muda yang sedang mencari
identitas diri. Selain itu beberapa faktor social dapat menyebabkan Anorexia
seperti tekanan terus-menerus, pengalaman kekurangan,</span><span style="font-size: 12pt;"> </span><span class="hps"><span lang="IN" style="font-size: 12pt;">terus</span></span><span class="hps"><span lang="IN" style="font-size: 12pt;"> </span></span><span class="hps"><span lang="IN" style="font-size: 12pt;">meningkat</span></span><span lang="IN" style="font-size: 12pt;"> <span class="hps">tuntutan</span> <span class="hps">baik dalam</span> <span class="hps">kehidupan kerja</span> <span class="hps">dan sekolah</span></span><span lang="IN" style="font-size: 12pt;"> </span><span class="hps"><span lang="IN" style="font-size: 12pt;">atau beberapa</span></span><span lang="IN" style="font-size: 12pt;"> <span class="hps">kejadian</span> <span class="hps">traumatis</span></span><span style="font-size: 12pt;">.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Anorexia sebagai suatu
penyakit sebagian mencerminkan penderitaan yang dimiliki individu dalam situasi
konflik tuntutan masyarakat yang semakin meningkat dan harapan: ketika hanya
normal, Anda tidak lain hanyalah hanya melalui over-performing Anda dapat
mencapai sesuatu dalam hidup Anda. Anorexia muncul sebagai akibat dari tekanan
social dan perasaan yang buruk. Sebagian besar perasaan ini terkait dengan
obsesi untuk menurunkan berat badan dan ketakutan terbesar bertambah berat
badan.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<br /></div>
<div class="Default" style="text-align: justify;">
<span style="font-family: Times, Times New Roman, serif;"><b>2.</b> <b>â</b><span class="A7"><b>The Psychological Characteristics and Health Related
Behavior of dolescents: The Possible Roles of Social Physique Anxiety and
Genderâ</b></span><span class="A7">
</span><!--[if supportFields]><span class=A15><span style='font-size:
7.0pt;font-family:"Calibri","sans-serif";mso-ascii-theme-font:minor-latin;
mso-hansi-theme-font:minor-latin;color:black;mso-themecolor:text1'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"2hjnvrn7f4","properties":{"formattedCitation":"(2)","plainCitation":"(2)"},"citationItems":[{"id":355,"uris":["http://zotero.org/users/local/oHr7X5O3/items/M94C7BF4"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/M94C7BF4"],"itemData":{"id":355,"type":"article-journal","title":"The
Psychological Characteristics and Health Related Behavior of Adolescents: The
Possible Roles of Social Physique Anxiety and
Gender","container-title":"The Spanish Journal of Psychology","page":"741-50","volume":"13","issue":"2","source":"ProQuest","abstract":"The
purpose of this study was to examine whether or not the social physique anxiety
level and gender have an influence on psychological characteristics and health
related behavior of adolescents. Five hundred and ninety eight female (M(age) =
14.95, SD = .70 years) and three hundred and eighty four male (M(age) = 15.08,
SD = .76 years) adolescents voluntarily participated in this study. The Social
Physique Anxiety Scale (SPAS), three subscales of the Physical Self-Description
Questionnaire, and the Multidimensional Perfectionism Scale as indicators of
psychological characteristics were administered to all participants. The Eating
Attitude Test and Physical Activity Assessment Questionnaire were used to
determine health related behavior. It was found that adolescents with high
levels of SPA (HSPA) had more unfavourable eating attitudes, higher scores in
socially-prescribed perfectionism, negative global physical self-worth and
negative body related perceptions than those with low levels of SPA (LSPA).
Physical activity levels of adolescents did not differ in the two SPA groups
(high/low level). In addition, male adolescents in the present study were more
physically active and had favorable eating attitudes and more positive
self-perceptions of body fat and general physical self-worth than their female
counterparts.","ISSN":"1138-7416","shortTitle":"The
Psychological Characteristics and Health Related Behavior of
Adolescents","language":"English","author":[{"family":"Caglar","given":"Emine"},{"family":"Bilgili","given":"Naile"},{"family":"Karaca","given":"Ayda"},{"family":"Ayaz","given":"Sultan"},{"family":"Asçi","given":"F.
HĂŒlya"}],"issued":{"date-parts":[[2010]]},"accessed":{"date-parts":[[2013,2,3]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span></span><![endif]-->(2)<!--[if supportFields]><span
class=A15><span style='font-size:7.0pt;font-family:"Calibri","sans-serif";
mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;color:black;
mso-themecolor:text1'><span style='mso-element:field-end'></span></span></span><![endif]--><o:p></o:p></span></div>
<div class="Default" style="text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Social physique anxiety atau gejala fisik
kecemasan sosial ini penting bagi pembentukan presentasi diri pada remaja.
Kekhawatiran terhadap bentuk fisik menjadi ciri khas pada masa remaja sehingga
sangat rentan pada gangguan citra tubuh karena menjadi fokus utama pada masa
ini. Pada masa ini remaja mengalami pembentukan identitas diri, remaja asyik
untuk membentuk tubuh mereka untuk mencapai fisik yang ideal sesuai dengan
perkembangan zaman. Fisik yang kurus dan ideal memberi perubahan pada diet dan
perilaku makan.<o:p></o:p></span></div>
<div class="Default" style="text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Norma sosial dan budaya, diperkuat oleh pesan
media, menempatkan pertanyaan tentang berat badan di antara faktor-faktor yang
menentukan daya tarik penampilan mereka. Perhatian terhadap Self-presentasi terkait
dengan tubuh juga dapat menjadi pemicu utama untuk adopsi dan pemeliharaan
perilaku seperti olahraga, diet, dan merokok, serta pengalaman emosional
termasuk kecemasan dan rendah diri.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Remaja dengan kecemasan
kecemasan fisik sosial yang tinggi sangat mungkin untuk mengatur pola makannya
agar dapat dianggap positif. Kecemasan fisik sosial biasa diidentikan dengan
latihan keras dan rutin, perfeksionisme negatif, dan pengaturan perfeksionisme
sosial yang buruk.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Jurnal ini ingin
memfokuskan pada penelitian bagaimana kecemasan fisik social yang dikonstruksi
oleh media dapat mempengaruhi perilaku remaja khususnya perilaku makan.
Thompson dan Chad (2002) menemukan bahwa kecemasan fisik sosial adalah
prediktor kuat sikap makan pada remaja.
Gambaran tubuh ideal yang disebarkan oleh media saat itu mengikuti
gambaran menurut kebudayaan barat yaitu kurus dan langsing. Hal ini menjadi
salah satu pemicu gangguan pola makan pada remaja.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Setelah dibuat perbandingan
antara remaja yang memiliki kecemasan fisik sosial tinggi dan remaja yang
kecemasan fisik sosialnya rendah, ternyata remaja yang kecemasan fisik
sosialnya tinggi cenderung memiliki citra tubuh yang negative, memiliki
gangguan perilaku makan, dan bersikap sangat perfeksionis. Tingginya kecemasan
fisik soisal mereka mempengaruhi aktivitas fisik mereka yang semakin tinggi
juga. Remaja yang memiliki kekhawatiran tinggi cenderung menganggap diri mereka
tidak berharga, mereka akan meragukan kemampuan mereka untuk membuat orang lain
tertarik karena penampilan mereka yang tidak menarik. Mereka akan terus
memperhatikan tubuh mereka dan mengevaluasi tubuh mereka agar sesuai dengan
konstruksi budaya yang ada di sekitar mereka.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Remaja sering tertekan
tentang penampilan fisik mereka dan berusaha untuk memperbaiki bentuk tubuh dan
ukurannya dengan diet, berpuasa, makan sangat sedikit, atau perilaku negatif
lainnya. Penjelasan lain untuk temuan ini mungkin dilakukan dalam konteks
sosio-budaya teori.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Tekanan sosial seringkali
berawal dari lingkungan eksternal dari media (film, iklan), individu ditekan untuk membentuk citra diri
mereka berdasarkan idealitas masayarakat. Media massa selain menggambarkan
tubuh ideal yaitu tubuh yang langsing dan kurus juga ikut mengkampanyekan diet
secara tidak langsung. Kondisi inilah yang mendorong gangguan makan yang parah
dan perspektif negatif atas tubuh pada remaja. Salah satu gangguan makan yang
paling berbahaya dan umum diderita oleh remaja ini lah yang disebut Anorexia.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<span style="font-family: Times, Times New Roman, serif;"><span style="font-size: 12pt;">3. â</span><b><span style="font-size: 12pt;">Relationship
Between Self-Acceptance on the Physical Condition of the Tendency of Anorexia
Nervosa on Girls Adolescents in SMAN 1 Banjarmasinâ</span></b><!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-family:Constantia-Italic;color:black;
mso-themecolor:text1;mso-bidi-font-style:italic'><span style='mso-element:field-begin'></span>
ADDIN ZOTERO_ITEM CSL_CITATION
{"citationID":"15r56mdotn","properties":{"formattedCitation":"(3)","plainCitation":"(3)"},"citationItems":[{"id":488,"uris":["http://zotero.org/users/local/oHr7X5O3/items/RV6ZRK2C"],"uri":["http://zotero.org/users/local/oHr7X5O3/items/RV6ZRK2C"],"itemData":{"id":488,"type":"article-journal","title":"Relationship
Between Self-Acceptance on the Physical Condition of the Tendency of Anorexia
Nervosa on Girls Adolescents in SMAN 1
Banjarmasin)","container-title":"Jurnal Psikologi Klinis
dan Kesehatan Mental","page":"130-137","volume":"1","issue":"2","abstract":"This
research aims to determine whether there is relationship between
self-acceptance on the\nphysical condition of the tendency of anorexia nervosa
among girls adolescent in SMAN 1\nBanjarmasin. According to Havighurst
(Hurlock, 1994), one developmental task of adolescence\nis to accept their
physical condition and use it effectively. But if teens are not able to accept
their\nphysical condition, it allows for the emergence of eating disorders, one
of which is anorexia\nnervosa (Grigg, Bowman, Redman, 1996). The research was
conducted in girl adolescence who\nattend school in SMAN 1 Banjarmasin. The
amounts of subjects are 100 people. The result of this\nresearch that there is
a negative relationship between the acceptance (self-acceptance) on
the\nphysical condition of the tendency of anorexia nervosa among girl
adolescence in SMAN
1\nBanjarmasin.","author":[{"family":"Permatasari","given":"Bunga"}],"issued":{"date-parts":[["2012",6]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"}
<span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12pt;">(3)</span><!--[if supportFields]><span style='font-size:12.0pt;
mso-bidi-font-family:Constantia-Italic;color:black;mso-themecolor:text1;
mso-bidi-font-style:italic'><span style='mso-element:field-end'></span></span><![endif]--><span style="font-size: 12pt;">.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-family: Times, Times New Roman, serif;"><span style="font-size: 12pt;">Dalam penelitian ini ditemukan adanya
hubungan negatif antara penerimaan diri dan kasus Anorexia nervosa pada remaja.
Semakin rendah penerimaan diri maka semakin tinggi kemungkinan mengidap
Anorexia. </span><i><span style="font-size: 16pt;"><o:p></o:p></span></i></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Masa remaja merupakan masa
transisi dari masa anak-anak dan masa dewasa. Dalam masa transisi ini terjadi
perubahan-perubahan biologis, kognitif dan sosio emosional. Kondisi fisik
merupakan bagian dari konsep remaja yang mulanya merupakan citra tubuh.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Penerimaan diri terhadap
kondisi fisik merupakan kondisi di mana sesorang dapat mencintai dirinya
sendiri dan dapat menerima kondisi fisiknya dalam batas apapun tanpa
mengkritiknya terus menerus. Konsep ini didapat dari hubungan dengan orang
sekitar maupun dari dari media massa. Konsep diri yang buruk akan membuat
remaja sulit menerima keadaaan dirinya dan mengupayakan segala cara untuk
melakukan perubahan. Remaja akan melakukan usaha-usaha untuk mengontrol berat
badan mereka agar bisa mendapatkan tubuh ideal seperti yang mereka inginkan.
Usaha-usaha ini antara lain dengan minum obat pencahar, tidak sarapan, tidak
makan salah satu jenis makanan tertentu, merokok, dan lain-lain.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Menurut salah satu remaja
yang pernah menderita Anorexia di sekolah tersebut mengatakan bahwa dia sendiri
mengalami kesulitan dalam mengikuti pelajaran di sekolah. Pihak sekolah tidak
mendata khusus anak-anak yang melakukan diet. Tetapi akan kelihatan sendiri
ketika upacara bendera pada hari Senin di sekolah. Beberapa siswi akan pingsan
karena sengaja tidak sarapan pagi dan anemia. Mereka sengaja tidak sarapan agar
bisa menjadi kurus. <o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Rendahnya level penerimaan
diri dapat menjadi faktor utama terbentuknya Anorexia dan gangguan perilaku
makan yang lain. Anorexia nervosa dapat
diartikan sebagai aktivitas untuk menguruskan badan dengan melakukan pembatasan makan secara sengaja
melalui control yang ketat. Para penderita Anorexia sadar bahwa mereka lapar
tetapi berusaha menekan rasa lapar tersebut dan tidak memenuhi kebutuhan
makannya. Peresepsi mereka tentang rasa kenyang akan terganggu sehingga setelah
mengkonsumsi makanan meskipun hanya
sedikit sekalipun mereka akan merasa sangat kenyang dan bahkan merasa mual.
Mereka akan melakukan segala upaya untuk berdiet dan menjadi kurus. Anorexia terutama
menimpa remaja perempuan di awal dewasa.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-family: Times, Times New Roman, serif;"><span style="font-size: 12pt;">Dari hasil penelitian yang dilakukan ada
beberapa subjek yang memiliki nilai penerimaan diri yang rendah dan nilai
kecenderungan Anorexia nervosa yang tinggi. Jika seorang remaja sering
melakukan diet ekstrim berarti dia sangat berpotensi atau bahakan sudah
mengidap anorexia. </span><span style="font-size: 12pt;">Jika aktivitas yang dilakukan
subjek yang mana merujuk pada aktivitas apa saja yang dilakukan oleh penderita
anorexia nervosa pada </span><i><span style="font-size: 12pt;">Diagnostic and Statistic </span></i><span style="font-size: 12pt;">Manual of Mental Disorder IV TR (4th Ed) (American Psychiatric Association,
2000), maka beberapa subjek tersebut bisa dikatakan mengarah atau mengalami
kecenderungan anorexia nervosa. <o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Ketiga jurnal ini secara
jelas mengungkapkan bahwa konsep tubuh ideal dari media yang menyebabkan citra
buruk negatif pada remaja dapat menjadi faktor utama penyebab Anorexia pada
remaja. Remaja perempuan dapat menjadi penilai sendiri untuk tubuhnya.
Penilaian ini terbentuk dari hubungannya dengan teman-temannya maupun dari
model atau contoh dijadikan pembanding. Remaja sering menjadikan artis atau
model iklan di TV sebagai contoh. Hasil penilaian diri ini yang menentukan
apakah dia bisa menerima keadaan tubuhnya sendiri. Penerimaan diri yang
negative dapat menjadi mendorong perilaku Anorexia pada remaja.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Jurnal terakhir ini memang
khusus saya ambil sebagai salah satu jurnal utama. Memang jurnal ini berskala
kecil karena hanya memfokuskan di salah satu tempat yaitu di SMAN 1 Banjarmasin
tetapi saya pikir sudah cukup untuk mewakilkan keadaan sebenarnya yang terjadi
di Indonesia. Bahwa remaja wanita di Indonesia pun rentan mengalami Anorexia
karena tidak bisa menerima dirinya. Tentu saja penerimaan diri ini dipengaruhi
oleh konsepsi tubuh ideal bentukan media seiring dengan masuknya kebudayaan
barat di Indonesia. Kebudayaan yang masuk ini termasuk di antaranya tentang
bagaimana perspektif cantik yaitu langsing dan kurus dari kebudayaan barat.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<b><span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Penutup<o:p></o:p></span></span></b></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Konsep tubuh ideal sebagai penyebab Anorexia merupakan kadang
kala tidak disadari dan bahkan masyarakat terkesan setuju dengan konsep tubuh
ideal yang dibuat oleh media ini. Tanpa menyadari bahwa remaja sangat rentan
menjadi Anorectic karena konsep tubuh ideal yang salah ini. Salah satu public
figure Holiwood yang pernah menderita Anorexia adalah Lady Gaga yang setelah
sembuh menyuarakan perang melawan Anorexia dan Bulimia. Pevita Pierce, salah
satu artis remaja di Indonesia yang cukup terkenal pun mengakui bahwa dirinya
pernah mengalami Anorexia ketika berusia 15tahun.<o:p></o:p></span></span></div>
<div class="MsoListParagraph" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Citra
tubuh yang positif dapat menjadikan seseorang lebih percaya diri dan dapat menerima
diri apa adanya. Citra diri yang negative akan membuat setiap sesorang berusaha
mengubah dirinya sendiri. Salah satu yang membentuk citra diri adalah keadaan
social masyarakat. Konsepsi tubuh yang berlebihan dari media akan mempengaruhi
bagaimana sesorang memaknai tubuhnya. Remaja adalah komunitas yang paling
rentan akan hal ini karena sedang dalam proses transisi menuju kedewasaan dan
mencari jati diri. Citra tubuh yang negative dapat mengakibatkan Anorexia.
Padahal Anorexia merupakan penyakit yang sangat berbahaya karena dapat
menyebabkan kematian.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-family: Times, Times New Roman, serif;"><span style="font-size: 12pt;">Remaja wanita setelah mencapai masa purbetas
akan menyadari ada perubahan dalam tubuh mereka. Mereka wanita </span><span class="hps"><span style="font-size: 12pt;">biasanya
akan</span></span><span style="font-size: 12pt;"> <span class="hps"><span lang="IN">membandingkan diri
mereka</span></span><span lang="IN"> </span></span><span style="font-size: 12pt;">dengan </span><span class="hps"><span lang="IN" style="font-size: 12pt;">model dalam</span></span><span lang="IN" style="font-size: 12pt;"> <span class="hps">iklan</span>, <span class="hps">dalam hal</span> <span class="hps">daya tarik</span> <span class="hps">fisik
mereka</span></span><span class="hps"><span style="font-size: 12pt;">. </span></span><span style="font-size: 12pt;">Bertolak dari apa yang
sering mereka lihat di media massa, akan muncul konsep cantik itu langsing dan
kurus dalam diri mereka. Keinginan untuk memiliki tubuh langsing seperti
artis-artis dan model-model di televisi yang sebagian besar mengalami Anorexia
memebuat mereka melakukan diet gila-gilaan untuk menurunkan berat badan mereka.
Diet dan olahraga ini akhirnya menjadi tak terkontrol. Segala gambaran yang
mereka lihat tentang dirinya adalah gemuk dan jelek meskipun kenyataannya
mereka kekurangan berat badan. Sampai
titik inilah seorang remaja dapat dikatakan mengalami Anorexia. Sayangnya
keluarga jarang menyadari gangguan pola makan putri mereka dan tidak bisa
menolongnya.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Pemerintah tidak dapat
membungkam media, sehingga sangat tidak mungkin melarang media untuk
menampilkan model-model kurus. Butuh kesadaran dari masing-masing pihak untuk
membentuk konsep tubuh dan kecantikan yang benar. Maka yang dibisa dilakukan
adalah menanamkan konsep diri yang positif pada remaja sejak masih anak-anak.
Oleh karena itu dukungan keluarga, teman dan lingkungan sekitar tidak dapat
diabaikan.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">Anorexia Nervosa masih bisa disembuhkan
meskipun hanya sedikit kemungkinan nya dan tetap membawa resiko nantinya.
Keluarga harus bisa mengembalikan kepercayaan diri penderita Anorexia. Kerja
sama antara dokter, keluarga dan penderita Anorexia sendiri sangat dibutuhkan
untuk mendukung kesembuhan. Dengan menanamkan konsep diri melalui citra diri
yang positif sejak masih anak-anak dapat mencegah seorang remaja terkena
Anorexia. <o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify; text-indent: 0.5in;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<br /></div>
<span style="font-family: Times, Times New Roman, serif;"><b><span style="font-size: 12pt; line-height: 115%;"><br clear="all" style="mso-special-character: line-break; page-break-before: always;" />
</span></b>
</span><div class="MsoNormal">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<b><span style="font-size: 12pt;"><span style="font-family: Times, Times New Roman, serif;">RUJUKAN<o:p></o:p></span></span></b></div>
<div class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;">
<br /></div>
<div class="MsoBibliography" style="text-align: justify;">
<!--[if supportFields]><span
style='mso-bidi-font-family:"Microsoft Sans Serif";color:black;mso-themecolor:
text1'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>Â </span>ADDIN ZOTERO_BIBL {"custom":[]}
CSL_BIBLIOGRAPHY <span style='mso-element:field-separator'></span></span><![endif]--><span style="font-size: 12pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;">1. Savukoski
M, MÀÀttÀ K, Uusiautti S. The Other Side of Well-being - What Makes a Young
Woman Become an Anorectic? International Journal of Psychological Studies.
December 2011;3(2):76â86. <o:p></o:p></span></span></div>
<div class="MsoBibliography" style="text-align: justify;">
<span style="font-size: 12pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;">2. Caglar E, Bilgili N,
Karaca A, Ayaz S, Asçi FH. The Psychological Characteristics and Health Related
Behavior of Adolescents: The Possible Roles of Social Physique Anxiety and
Gender. The Spanish Journal of Psychology. 2010;13(2):741â50. <o:p></o:p></span></span></div>
<div class="MsoBibliography" style="text-align: justify;">
<span style="font-size: 12pt; line-height: 115%;"><span style="font-family: Times, Times New Roman, serif;">3. Permatasari B.
Relationship Between Self-Acceptance on the Physical Condition of the Tendency
of Anorexia Nervosa on Girls Adolescents in SMAN 1 Banjarmasin). Jurnal
Psikologi Klinis dan Kesehatan Mental. June 2012;1(2):130â7. <o:p></o:p></span></span></div>
<span style="font-family: Times, Times New Roman, serif;"><span style="font-size: 11pt; line-height: 115%;"><br clear="all" style="mso-special-character: line-break; page-break-before: always;" />
</span>
</span><div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<!--[if supportFields]><span
style='font-size:12.0pt;line-height:115%;mso-bidi-font-family:"Microsoft Sans Serif";
color:black;mso-themecolor:text1'><span style='mso-element:field-end'></span></span><![endif]--><span style="font-size: 12pt; line-height: 115%;"><b><span style="font-family: Times, Times New Roman, serif;">DAFTAR
PUSTAKA<o:p></o:p></span></b></span></div>
<div class="MsoNormal" style="margin-bottom: 3pt; text-align: justify; text-indent: 0.5in;">
<span style="font-family: Times, Times New Roman, serif;">Anonymous. Bigger is better at âMiss
Fat South Africaâ beauty pageant. Jet. 2002;101(22):55â6.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 3.0pt; text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Breckenridge, Vincent.
Child Development: Physical and Psychologic Growth Through Adolescence.
Saunders: 1963<o:p></o:p></span></div>
<div class="MsoBibliography" style="margin-bottom: 3.0pt; text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Caglar E,
Bilgili N, Karaca A, Ayaz S, Asçi FH. The Psychological Characteristics and
Health Related Behavior of Adolescents: The Possible Roles of Social Physique
Anxiety and Gender. The Spanish Journal of Psychology. 2010;13(2):741â50. <o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 3.0pt; text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Cohn L. Eating Disorders:
A Reference Sourcebook. Greenwood Publishing Group; 1999.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 3.0pt; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Eating Disorders; Studies from
University Medical Center Provide New Data on Anorexia. Food Weekly News
[Internet]. Retrieved from: <a href="http://search.proquest.com/docview/1284356299/13C2483D00B7DAB0510/11?accountid=48149"><span style="color: black; mso-themecolor: text1;">http://search.proquest.com/docview/1284356299/13C2483D00B7DAB0510/11?accountid=48149</span></a><o:p></o:p></span></div>
<div class="MsoBibliography" style="margin-bottom: 3.0pt; tab-stops: 0in; text-align: justify; text-indent: .5in;">
<span class="reference-text"><span style="font-family: Times, Times New Roman, serif;">Hannah Jones, et al.
"INTERNALIZATION OF THE THIN IDEAL, WEIGHT AND BODY IMAGE CONCERNS."
Social Behavior & Personality: An International Journal 31.1 (2003): 81.<o:p></o:p></span></span></div>
<div class="MsoBibliography" style="margin-bottom: 3.0pt; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Jay S. Cardiac Effects of Anorexia
Nervosa: Itâs More than Being Too Thin! Journal Watch. Psychiatry [Internet].
October 8, 2003; Retrieved from: <a href="http://search.proquest.com/docview/1284330487/13C313C7D9838D122E7/19?accountid=48149"><span style="color: black; mso-themecolor: text1;">http://search.proquest.com/docview/1284330487/13C313C7D9838D122E7/19?accountid=48149</span></a><o:p></o:p></span></div>
<div class="MsoBibliography" style="margin-bottom: 3.0pt; text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Kartika
Setyorini KS, Wirawanni Y. Hubungan Body Image dan Pengetahuan Gizi dengan
Perilaku Makan Remaja Putri (Studi Kasus di Kelas X dan XI SMAN 4 Semarang)
[Internet]. 2010. Retrieved from: http://eprints.undip.ac.id/24907/<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 3.0pt; text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Lady Gaga Pernah Menderita
Bulimia dan Anoreksia [Internet]. KOMPAS.com. Retrieved from: <a href="http://entertainment.kompas.com/read/2012/09/26/09095828/Lady.Gaga.Pernah.Menderita.Bulimia.dan.Anoreksia"><span style="color: black; mso-themecolor: text1;">http://entertainment.kompas.com/read/2012/09/26/09095828/Lady.Gaga.Pernah.Menderita.Bulimia.dan.Anoreksia</span></a><o:p></o:p></span></div>
<div class="MsoBibliography" style="margin-bottom: 3.0pt; text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">MD CD, Watkins
JB, Walker WA. Nutrition in Pediatrics: Basic Science, Clinical Applications.
PMPH-USA; 2008. <o:p></o:p></span></div>
<div class="MsoBibliography" style="margin-bottom: 3.0pt; text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Navone, Jhon.
Toward a Theology of Beauty. Kanisius; 2006<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 3.0pt; text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Permatasari B.
Relationship Between Self-Acceptance on the Physical Condition of the Tendency
of Anorexia Nervosa on Girls Adolescents in SMAN 1 Banjarmasin). Jurnal
Psikologi Klinis dan Kesehatan Mental. June 2012;1(2):130â7.</span></div>
<div class="MsoBibliography" style="margin-bottom: 3.0pt; text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Pevita Pearce
[Internet]. Retrieved from: <a href="http://pevitapearce.blogdetik.com/"><span style="color: black; mso-themecolor: text1;">http://pevitapearce.blogdetik.com/</span></a><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 3.0pt; text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Savukoski M, MÀÀttÀ K,
Uusiautti S. The Other Side of Well-being - What Makes a Young Woman Become an
Anorectic? International Journal of Psychological Studies. December
2011;3(2):76â86.</span></div>
<div class="MsoBibliography" style="margin-bottom: 3.0pt; text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Silber TJ,
Lyster-Mensh LC, DuVal J. Anorexia Nervosa: Patient and Family-Centered Care.
Pediatric Nursing. December 2011;37(6):331â3. <o:p></o:p></span></div>
<div class="MsoBibliography" style="margin-bottom: 3.0pt; text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Stearns PN.
Fat History: Bodies and Beauty in the Modern West. NYU Press; 2002. <o:p></o:p></span></div>
<div class="MsoBibliography" style="margin-bottom: 3.0pt; text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Suleiman SR.
The Female Body in Western Culture: Contemporary Perspective. Harvard
University Press; 1986. <o:p></o:p></span></div>
<div class="MsoBibliography" style="margin-bottom: 3.0pt; text-align: justify; text-indent: .5in;">
<span style="font-family: Times, Times New Roman, serif;">Wentz E,
Gillberg IC, AnckarsÀter H, Gillberg C, RÄstam M. Somatic problems and
self-injurious behaviour 18 years after teenage-onset anorexia nervosa.
European Child & Adolescent Psychiatry. August 2012;21(8):421â32. <o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: 3.0pt;">
<br /></div>
luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com2tag:blogger.com,1999:blog-7294540944450239332.post-72941639450731084292011-02-14T05:48:00.000-08:002011-02-14T05:48:28.734-08:00Valentine Day...<span style="font-family: Arial,Helvetica,sans-serif;">hmmm... Hari ini kita merayakan hari kasih sayang atau lebih dikenal dengan Valentine day, oleh karena itu sebelum mengupas lebih lanjut, saya mau bilang met valentine semuanya...hehehehehe</span><br />
<br />
<span style="font-family: Arial,Helvetica,sans-serif;">okelah, yuki mari lanjut...</span><br />
<div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Beberapa para ahli mengatakan bahwa asal mula Valentine itu berkaitan dengan St. Valentine. Ia adalah seorang pria Roma yang menolak melepaskan agama Kristen yang diyakininya.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Ia meninggal pada 14 Februari 269 Masehi, bertepatan dengan hari yang dipilih sebagai pelaksanaan 'undian cinta'. Legenda juga mengatakan bahwa St. Valentine sempat meninggalkan ucapan selamat tinggal kepada putri seorang narapidana yang bersahabat dengannya. Di akhir pesan itu, ia menuliskan : "Dari Valentinemu". </span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Sementara itu, ada cerita lain yang mengatakan bahwa <b>Saint Valentine</b> adalah seorang pria yang membaktikan hidupnya untuk melayani Tuhan di sebuah kuil pada masa pemerintahan Kaisar Claudius. Ia dipenjarakan atas kelancangannya membantah titah sang kaisar. Baru pada tahun 496 Masehi, pendeta Gelasius menetapkan 14 Februari sebagai hari penghormatan bagi Valentine.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Akhirnya secara bertahap 14 Februari menjadi hari khusus untuk bertukar surat cinta dan St. Valentine menjadi idola para pecinta. Datangnya tanggal itu ditandai dengan pengiriman puisi cinta dan hadiah sederhana, semisal bunga. Sering juga untuk merayakan hari kasih sayang ini dilakukan acara pertemuan besar atau bahkan permainan bola.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Di AS, <b>Miss Esther Howland</b> tercatat sebagai orang pertama yang mengirimkan kartu valentine pertama. Acara Valentine mulai dirayakan besar-besaran semenjak tahun 1800 dan pada perkembangannya, kini acara ini menjadi sebuah ajang bisnis yang menguntungkan. </span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Perlahan semarak hari kasih sayang ini merebak keluar dan menular pada masyarakat di seluruh dunia dibumbui dengan versi sentimental tentang makna valentine itu sendiri. Bahkan anak-anak kecil pun tertular dengan wabah ini, mereka saling berkirim kartu dengan teman-temannya di sekolah untuk menunjukkan rasa sayang mereka.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;"><b>Sejarah Hari Valentine</b></span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Asal mula hari Valentine tercipta pada jaman kerajaan Romawi. Menurut adat Romawi, 14 Februari adalah hari untuk menghormati <b>Juno</b>. Ia adalah ratu para dewa dewi Romawi. Rakyat Romawi juga menyebutnya sebagai dewi pernikahan. Di hari berikutnya, 15 Februari dimulailah perayaan 'Feast of Lupercalia.'</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Pada masa itu, kehidupan belum seperti sekarang ini, para gadis dilarang berhubungan dengan para pria. Pada malam menjelang festival Lupercalia berlangsung, nama-nama para gadis ditulis di selembar kertas dan kemudian dimasukkan ke dalam gelas kaca. Nantinya para pria harus mengambil satu kertas yang berisikan nama seorang gadis yang akan menjadi teman kencannya di festival itu.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Tak jarang pasangan ini akhirnya saling jatuh cinta satu sama lain, berpacaran selama beberapa tahun sebelum akhirnya menikah. Di bawah pemerintahan Kaisar Claudius II, Romawi terlibat dalam peperangan. Claudius yang dijuluki si kaisar kejam kesulitan merekrut pemuda untuk memperkuat armada perangnya. </span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Ia yakin bahwa para pria Romawi enggan masuk tentara karena berat meninggalkan keluarga dan kekasihnya. Akhirnya ia memerintahkan untuk membatalkan semua pernikahan dan pertunangan di Romawi. Saint Valentine yang saat itu menjadi pendeta terkenal di Romawi menolak perintah ini.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Ia bersama Saint Marius secara sembunyi-sembunyi menikahkan para pasangan yang sedang jatuh cinta. Namun aksi mereka diketahui sang kaisar yang segera memerintahkan pengawalnya untuk menyeret dan memenggal pendeta baik hati tersebut.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Ia meninggal tepat pada hari keempat belas di bulan Februari pada tahun 270 Masehi. Saat itu rakyat Romawi telah mengenal Februari sebagai festival Lupercalia, tradisi untuk memuja para dewa. Dalam tradisi ini para pria diperbolehkan memilih gadis untuk pasangan sehari.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Dan karena Lupercalia mulai pada pertengahan bulan Februari, para pastor memilih nama Hari Santo Valentinus untuk menggantikan nama perayaan itu. Sejak itu mulailah para pria memilih gadis yang diinginkannya bertepatan pada hari Valentine. </span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;"><b>Kisah St. Valentine</b></span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Valentine adalah seorang pendeta yang hidup di Roma pada abad ketiga. Ia hidup di kerajaan yang saat itu dipimpin oleh Kaisar Claudius yang terkenal kejam. Ia sangat membenci kaisar tersebut, dan ia bukan satu-satunya. Claudius berambisi memiliki pasukan militer yang besar, ia ingin semua pria di kerajaannya bergabung di dalamya. </span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Namun sayangnya keinginan ini bertepuk sebelah tangan. Para pria enggan terlibat dalam perang. Karena mereka tak ingin meninggalkan keluarga dan kekasihnya. Hal ini membuat Claudius sangat marah, ia pun segera memerintahkan pejabatnya untuk melakukan sebuah ide gila.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Ia berpikir bahwa jika pria tak menikah, mereka akan dengan senang hati bergabung dengan militer. Lalu Claudius melarang adanya pernikahan. Para pasangan muda menganggap keputusan ini sangat tidak manusiawi. Karena menganggap ini adalah ide aneh, St. Valentine menolak untuk melaksanakannya.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Ia tetap melaksanakan tugasnya sebagai pendeta, yaitu menikahkan para pasangan yang tengah jatuh cinta meskipun secara rahasia. Aksi ini diketahui kaisar yang segera memberinya peringatan, namun ia tak bergeming dan tetap memberkati pernikahan dalam sebuah kapel kecil yang hanya diterangi cahaya lilin, tanpa bunga, tanpa kidung pernikahan.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Hingga suatu malam, ia tertangkap basah memberkati sebuah pasangan. Pasangan itu berhasil melarikan diri, namun malang ia tertangkap. Ia dijebloskan ke dalam penjara dan divonis mati. Bukannya dihina, ia malah dikunjungi banyak orang yang mendukung aksinya. Mereka melemparkan bunga dan pesan berisi dukungan di jendela penjara.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Salah satu dari orang-orang yang percaya pada cinta itu adalah putri penjaga penjara. Sang ayah mengijinkannya untuk mengunjungi St. Valentine di penjara. Tak jarang mereka berbicara selama berjam-jam. Gadis itu menumbuhkan kembali semangat sang pendeta itu. Ia setuju bahwa St. Valentine telah melakukan hal yang benar. </span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Di hari saat ia dipenggal,14 Februari, ia menyempatkan diri menuliskan sebuah pesan untuk gadis itu atas semua perhatian, dukungan dan bantuannya selama ia dipenjara. Diakhir pesan itu, ia menuliskan: "Dengan Cinta dari Valentinemu."</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">Pesan itulah yang kemudian merubah segalanya. Kini setiap tanggal 14 Februari orang di berbagai belahan dunia merayakannya sebagai hari kasih sayang. Orang-orang yang merayakan hari itu mengingat St. Valentine sebagai pejuang cinta, sementara kaisar Claudius dikenang sebagai seseorang yang berusaha mengenyahkan cinta.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;"><b>Tradisi Valentine</b></span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">-- Selama beberapa tahun di Inggris, banyak anak kecil didandani layaknya orang dewasa pada hari Valentine. Mereka berkeliling dari rumah ke rumah sambil bernyanyi. </span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">-- Di Wales, para pemuda akan menghadiahkan sendok kayu pada kekasihnya pada hari kasih sayang itu. Bentuk hati dan kunci adalah hiasan paling favorit untuk diukir di atas sendok kayu tersebut. </span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">-- Pada jaman Romawi kuno, para gadis menuliskan namanya di kertas dan memasukkan ke dalam botol. lalu para pria akan mengambil sah satu kertas tersebut untuk melihat siapakan yang akan menjadi pasangan mereka dalam festifal tersebut.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">-- Di Negara yang sama, para gadis akan menerima hadiah berupa busana dari para pria. Jika ia menerima hadiah tersebut, ini pertanda ia bersedia dinikahi pria tersebut.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">-- Beberapa orang meyakini bahwa jika mereka melihat robin melayang di udara saat hari Valentine, ini berarti ia akan menikah dengan seorang pelaut. Sementara jika seorang wanita melihat burung pipit, maka mereka akan menikah dengan seorang pria miskin. Namun mereka akan hidup bahagia. Sementara jika mereka melihat burung gereja maka mereka akan menikah dengan jutawan.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">-- Sebuah kursi cinta adalah kursi yang lebar. Awalnya kursi ini dibuat untuk tempat duduk seorang wanita (jaman dahulu wanita mengenakan busana yang sangat lebar). Belakangan kursi cinta dibuat untuk tempat duduk dua orang. dengan cara ini sepasang kekasih bisa duduk berdampingan.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">-- Pikirkan lima atau enam nama pria (jika Anda wanita) atau lima atau enam nama wanita (jika Anda pria) yang ingin Anda nikahi. Lalu putralah setangkai apel sambil menyebut nama tersebut satu per satu. Anda akan menikah dengan nama yang anda sebut saat tangkai tersebut lepas dari buahnya.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">-- Petiklah sekuntum bungan dandelion yang tengah mengembang. Tiuplah putik-putik pada bunga tersebut, lalu hitunglah putik yang tersisa. Itu adalah jumlah anak yang akan Anda miliki setelah menikah.</span></div><div style="font-family: Arial,Helvetica,sans-serif;"><span style="font-size: small;">-- Jika Anda memotong sebuah apel pada tengahnya dan menghitung jumlah biji di dalamnya, ini juga bisa menunjukkan jumlah anak yang akan Anda miliki setelah menikah. </span></div><span style="font-size: small;"><span style="font-family: Arial,Helvetica,sans-serif;">Terlepas dari semua tradisi dan mitos Valentine tersebut, hari Valentine tetap jadi hari yang dinanti sebagian orang. Meski untuk menunjukkan rasa sayang tak perlu harus menunggu sampai 14 Februari dan tak harus selalu membanjiri yang tersayang dengan hadiah, karena perhatian dan kasih sayang bisa kita wujudkan setiap hari. Semoga kasih sayang selalu melimpahi kita setiap hari! </span></span>luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0tag:blogger.com,1999:blog-7294540944450239332.post-77610518938330121982011-02-14T00:24:00.000-08:002011-02-14T00:24:53.283-08:00Postingan Pertama<span style="font-family: Arial,Helvetica,sans-serif;">wow......</span><br />
<span style="font-family: Arial,Helvetica,sans-serif;">ini bog pertama ku....</span><br />
<span style="font-family: Arial,Helvetica,sans-serif;">dengan postingan pertamaku di hari valentine......</span><br />
<span style="font-family: Arial,Helvetica,sans-serif;">hehehehhehe...</span><br />
<span style="font-family: Arial,Helvetica,sans-serif;">nulis apa ya???</span><br />
<span style="font-family: Arial,Helvetica,sans-serif;">belum terbayang kan.... </span><br />
<span style="font-family: Arial,Helvetica,sans-serif;">ntar baru lanjut deh......</span><br />
<span style="font-family: Arial,Helvetica,sans-serif;">hahahahahhaha</span><br />
<br />
<span><span style="background-color: #ffe599;"><span style="background-color: white;"></span></span></span>luphharrypotterhttp://www.blogger.com/profile/11465611080168675053noreply@blogger.com0